




Facultad de Química  




Programa de Doctorado en Química  
con Mención de Excelencia  
 
Synthesis of novel fluorinated building blocks and 
α-helix peptidomimetics 
 
Tesis Doctoral  
Daniel Mark Sedgwick 
 
Dirigida por:  
Prof. Santos Fustero Lardiés                    Valencia  









































D. Santos Fustero Lardiés, Catedrático de Química Orgánica de la Universitat de València, y 

















Que la presente Tesis Doctoral, titulada “Synthesis of novel 
fluorinated building blocks and α-helix peptidomimetics”, ha 
sido realizada bajo su dirección en el Departamento de Química 
Orgánica de la Universitat de València, por el licenciado en 
Química D. Daniel Mark Sedgwick, y autorizan su presentación 
para que sea calificada como Tesis Doctoral.  
 
 
































































































































































[M]   metal complex  
[O]   oxidant  
Å   ångströms  
Ac   acetyl  
AIBN  azobisisobutyronitrile 
AIDS  acquired immunodeficiency 
syndrome 
aq   aqueous  
Ar   aryl  
atm   atmospheres  
AZT  azidothymidine 
B2(pin)2  bis(pinacolato)diboron  
Bn   benzyl  
Boc   tert-butyloxycarbonyl  
br   broad  
Bu   butyl  
Bz   benzoyl  
ca.  circa 
CAN   cerium ammonium nitrate  
cat.   catalytic amount  
CC50  half maximal cytotoxic conce-
ntration 
CM   cross metathesis  
CNS  central nervous system 
COD  cyclooctadiene 
Conv.  conversion 
Cy   cyclohexyl  
δ  chemical shift  
d   doublet  
dba   dibenzylideneacetone  
DBU  1,8-diazobicyclo[5.4.0]undec-
7-ene 
DCE   1,2-dichloroethane  
DCM   dichloromethane  
DFT   density functional theory  
DHQ  dihydroquinine 
DHQD  dihydroquinidine 
DIBAL-H  diisobutyl aluminium hydride  
DMAP   4-dimethylaminopyridine  
DME  1,2-dimethoxyethane 
DMF   N,N-dimethyl formamide  
DMPU  N,N’-dimethylpropyleneurea 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DOS   diversity-oriented synthesis  
dppf  1,1’-bis(diphenylphosphino)-
ferrocene 
dr   diastereomeric ratio  
DTBM  3,5-di-tert-butyl-4-methoxy 
phenyl 
e.g.   for example  
EC50  half maximal effective concen-
tration 
ee   enantiomeric excess  
equiv   equivalents  
er   enantiomeric ratio  
ESI   electrospray ionisation  
Et   ethyl  
EWG   electron-withdrawing group  
FDA   food and drug administration  
FG   functional group  
g   grams  
gem   geminal  
h   hours  
HAART highly active antiretroviral the-
rapy 
HBTU hexafluorophosphate benzo-









HPLC   high-performance liquid chro-
matography  
HRMS   high-resolution mass spectro-
metry  
hν photon of light 
Hz   Hertz  
i.e.   in other words  
i-Pr   isopropyl  
IC50  half maximal inhibitory conce-
ntration 
IR  infrared 
L   ligand  
LA  lewis acid 
LDA  lithium diisopropylamide 
LRMS   low-resolution mass spectro-
metry  
m   meta  
M   molar  
m   multiplet 
m-CPBA meta-chloroperoxybenzoic 
acid  
MALDI   matrix-assisted laser desorp-
tion/ionisation 
Me   methyl  
mg  milligram 
min   minutes  
mmol  millimole 
ml  millilitre 
mp   melting point  
Ms   mesyl, methanesulfonyl  
MS   molecular sieves  
MTBE   methyl tert-butyl ether  
MTIP  myosin-tail domain interact-
ing protein 
mw   microwave irradiation  
MyoA  myosin A 
N   normal  
NBS  N-bromosuccinimide 
NFSI   N-fluorobenzenesulfonimide  
NME  new molecular entity 
NMO  N-methylmorpholine N-oxide 
NMR   nuclear magnetic resonance  
NNRTI non-nucleoside reverse transc-
riptase inhibitor 
NRTI  nucleoside reverse transcript-
ase inhibitor 
NtRTI nucleotide reverse transcript-
ase inhibitor 
Nu   nucleophile  
o   ortho  
°C   degrees Celsius  
p   para  
PCC  pyridinium chlorochromate 
PDB  protein database 
PET   positron emission tomography  
Ph  phenyl 
PMB  para-methoxybenzyl 
PMP   para-methoxyphenyl  
ppm   parts per million  
Py   pyridine  
q   quartet  
QTOF  quadrupole time-of-flight  
v 
 
r.t.   room temperature  
RCEYM  ring-closing enyne metathesis 
RCM   ring-closing metathesis  
Rev  regulator of expression of vir-
ion proteins 
RF   fluorine-containing substitute-
nt  
Rf  retention factor 
RNA  ribonucleic acid 
RRE  Rev response element 
RT  retention time 
s   singlet  
sat   saturated  
SM   starting material  
t   triplet  
t-Bu   tert-butyl  
TBAF  tetrabutylammonium fluoride 
TBS   tert-butyl dimethyl silyl  
Tf   trifluoromethanesulfonyl  
TFA   trifluoroacetic acid  
THF   tetrahydrofuran  
TLC   thin-layer chromatography  
TMS   trimethyl silyl  
TOCSY  total correlation spectroscopy 
TOF   time of flight  
Tol   p-tolyl  
Ts   tosyl, toluenesulfonyl  
TS   transition state  
TXCA  trihaloisocyanuric acid 
UV   ultraviolet  
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At its heart, the present PhD thesis is based on the premise of two important areas in modern organic 
chemistry: firstly, the development of new methodologies to incorporate fluorine into organic 
molecules; and secondly, the design and synthesis of small molecules with high therapeutic potential 
(Scheme 0.0). 
The work presented in the first three chapters will therefore focus on the incorporation of fluorine into 
organic molecules and the synthesis of fluorinated building blocks. In each chapter, we aim to obtain 
biologically relevant small molecules containing fluorine atoms or fluorinated groupings. The 
introduction of fluorine is a commonly used method in drug discovery to fine-tune the properties of 
drug candidates and therefore, given the scarcity of fluorine-containing molecules in natural sources, 
new synthetic methods towards new fluorinated scaffolds represent an important goal for organic 
chemists. On the other hand, the fourth and final chapter will explore the possibilities of novel p-
terphenyl structures as peptidomimetics to exploit important biological targets. 
In this context, the present PhD thesis will have the following structure. 
Chapter 1. Synthesis of enantioenriched 1-amino-1,2-dihydronaphthalenes. 
This work builds upon past efforts in our research group in the area of diversity oriented 
synthesis, utilising ortho-bromobenzaldehyde as a common precursor. In this study, we will 
synthesise an unprecedented fluorinated scaffold containing a trifluoromethyl group, during 
which we will explore the effect of fluorinated groups during the ring-closing metathesis 
reaction (RCM). 
Chapter 2. Synthesis of 1,2-fluorohydrins via 1,2-difunctionalisation of olefins. 
This chapter focuses on simplicity and practicality. Fluorohydrins are an important class of 
fluorinated organic molecules; fludrocortisone was the first fluorinated drug to obtain FDA 
approval. Their synthesis has traditionally relied on the opening of epoxides, but in this chapter 
we will bypass this intermediate to form fluorohydrins directly from olefins, one of the most 
widely available and inexpensive classes of chemical. 
Chapter 3. Synthesis and reactivity of β-fluorovinyl sulfones. 
In this chapter we will develop methodologies for the stereodivergent synthesis of both (E)- and 
(Z)-β-fluorovinyl sulfones, a scarcely studied structure with potential as a fluorinated building 
block. We will also explore the reactivity of these structures. 
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Chapter 4. Synthesis and biological evaluation of novel p-terphenyls as α-helix mimetics. 
The work described in this chapter is part of a long-term project within our research group, in 
collaboration with J. Gallego (UCV) and J. Alcamí (ISCIII). We found that p-terphenyls can be 
used to mimic the α-helix in the Rev protein of HIV-1. In this way, these small molecules are 
able to inhibit the replication of the virus. This chapter will build upon this work, exploring 
different structures and substitution patterns in order to learn more about the structure-
activity relationship of these compounds, as well as designing a new derivative to tackle a 
protein-protein interaction that is key in the parasitic cycle of malaria. 
 
 
Scheme 0.0. General objectives. 





La present tesi doctoral està basada en dues 
àrees importants de la química orgánica 
moderna: en primer lloc, el desenvolupament 
de noves metodologies per la incorporació de 
flúor a molècules orgàniques; i en segon lloc, 
el disseny i síntesi de molècules menudes 
amb un gran potencial terapèutic (Esquema 
0.0). 
 
El treball presentat en els capítols 1 al 3 
s’enfocarà a la incorporació del flúor en 
molècules orgàniques i la síntesi de building 
blocks fluorats. Cada capítol té com a objectiu 
l’obtenció d’una classe de molècula orgánica 
fluorada diferent. La introducció del flúor és 
un mètode utilitzat sovint per modificar les 
propietats de candidats a nous fàrmacs. Per 
tant, i degut a la manca de fonts naturals que 
continguen àtoms de flúor, el 
desenvolupament de noves metodologies per 
l’obtenció d’estructures fluorades representa 
una meta important per als químics orgànics. 
D’una altra banda, al quart capítol 
s’exploraran les possibilitats de noves 
estructures terfeníliques com 
peptidomimètics que interaccionen amb 
dianes biològiques importants. 
 
En aquest context, el present document 
tindrà la següent estructura. 
 
 
 0.0. Resumen. 
 
La presente tesis doctoral está basada en dos 
áreas importantes de la química orgánica 
moderna: en primer lugar, el desarrollo de 
nuevas metodologías para la incorporación de 
flúor en moléculas orgánicas; y en segundo 
lugar, el diseño y síntesis de moléculas 
pequeñas con un gran potencial terapéutico 
(Esquema 0.0).  
 
El trabajo presentado en los capítulos 1 al 3 se 
basará en la incorporación del flúor en 
moléculas orgánicas y la síntesis de building 
blocks fluorados. Cada capítulo tiene como 
objetivo la síntesis de una clase de molécula 
orgánica fluorada diferente. La introducción del 
flúor es un método utilizado habitualmente 
para modificar las propiedades de candidatos 
de nuevos fármacos. Por tanto, y dada la 
escasez de fuentes naturales que contienen 
átomos de flúor, el desarrollo de nuevas 
metodologías para la obtención de estructuras 
fluoradas representa una meta importante para 
los químicos orgánicos. Por otro lado, en el 
cuarto capítulo se explorarán las posibilidades 
de nuevas estructuras terfenílicas como 
peptidomiméticos que interactúan con dianas 
biológicas importantes. 
 
En este contexto, el presente documento 
tendrá la siguiente estructura. 
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Capítol 1. Síntesi d’1-amino-1,2-
dihidronaftalens enantioenriquits. 
Aquest treball és una extensió d’esforços 
previs del nostre grup d’investigació a l’àrea 
de la síntesi orientada a la diversitat, a la qual 
s’utilitza orto-brombenzaldehíd com a 
precursor comú. Més epecíficament, en 
aquest estudi se sintetitzaran molècules 
fluorades sense precedent a la literatura 
química, i a més s’exploraran els efectes dels 
grups fluorats durant les reaccions de 
metàtesi de tancament d’anell. 
 
Capítol 2. Síntesi de 1,2-fluorhidrines 
mitjançant la 1,2-difunctionalització 
d’olefines. 
Aquest capítol té com a objectiu la practicitat. 
Les fluorhidrines representen una classe de 
compostos orgànics importants; la 
Fludrocortisona va ser el primer fàrmac 
fluorat aprovat per la FDA. Tradicionalment, la 
síntesi d’aquesta estructura s’ha basat en 
l’obertura d’epòxids, però en aquest treball es 
tindrà com a objectiu l’obtenció de 
l’estructura desitjada directament a partir 
d’olefines, una de les classes de compostos 
químics més abundants i barats. 
 
Capítol 3. Síntesi i reactivitat de β-
fluorovinilsulfones. 
Dins d’aquest capítol es desenvoluparan 
metodologies per a la síntesi estereodivergent 
d’(E)- i (Z)-β-fluorovinilsulfones, una 
estructura poc estudiada amb potencial com a 
Capítulo 1. Síntesis de 1-amino-1,2-
dihidronaftalenos enantioenriquecidos. 
Este trabajo es una extensión de esfuerzos 
previos en nuestro grupo de investigación en el 
área de la síntesis orientada a la diversidad, en 
la que se utiliza el orto-bromobenzaldehído 
como precursor común. Más específicamente, 
este estudio se centrará en la síntesis de 
moléculas fluoradas inéditas en la literatura 
química, y además se explorarán los efectos de 
los grupos fluorados durante las reacciones de 
metátesis de cierre de anillo. 
 
Capítulo 2. Síntesis de 1,2-fluorhidrinas 
mediante 1,2-difuncionalización de olefinas. 
Este capítulo tiene como meta la practicidad. 
Las fluorhidrinas representan una clase de 
compuestos orgánicos importantes; la 
Fludrocortisona fue el primero fármaco 
fluorado aprobado por la FDA. 
Tradicionalmente, la síntesis de esta estructura 
ha sido dominada por la apertura de epóxidos, 
pero en este estudio se tendrá como objetivo la 
obtención del producto deseado directamente 
a partir de olefinas, una de las clases de 
compuestos químicos más abundantes y 
baratos. 
 
Capítulo 3. Síntesis y reactividad de β-
fluorovinilsulfonas. 
Dentro de este capítulo se desarrollarán 
métodos para la síntesis estereodivergente de 
(E)- y (Z)-β-fluorovinilsulfonas, una estructura 
muy poca estudiada con potencial como 
Resum(en)  D. M. Sedgwick, Tesis Doctoral 
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precursor de molècules fluorades més 
complexes. A més a més, s’explorarà la 
reactivitat d’aquests nous derivats. 
 
Capítol 4. Síntesi i avaluació biológica de nous 
p-terfenils com mimètics de proteïnes amb 
forma d’α-hèlix.  
El treball descrit a aquest capítol forma part 
d’un projecte de llarg termini dins del nostre 
grup d’investigació, en col·laboració amb els 
profesors J. Gallego (UCV) i J. Alcamí (ISCIII). 
S’ha descobert que els p-terfenils es poden 
utilitzar per mimetitzar l’α-hèlix de la proteína 
Rev del VIH-1. D’aquesta manera els terfenils 
són capaços d’inhibir la replicació del virus. 
Aquest capítol aprofundeix en l’esmentat 
estudi, i explora noves estructures i patrons 
de substitució per tal d’aclarir més quant a la 
relació estructura-activitat d’aquests derivats. 
A més a més, es durà a terme la síntesi d’un 
nou terfenil amb la fi d’inhibir una interacció 
proteïna-proteïna clau en el cicle vital de la 
malaltia parasitària de la malària. 
 
precursor de moléculas fluoradas más 
complejas. Además, se explorará la reactividad 
de estos nuevos derivados. 
 
Capítulo 4. Síntesis y evaluación biológica de 
nuevos p-terfenilos como miméticos de 
proteínas con forma de α-hélice. 
El trabajo descrito en este capítulo forma parte 
de un proyecto de largo plazo dentro de 
nuestro grupo de investigación, en 
colaboración con los profesores J. Gallego 
(UCV) y J. Alcamí (ISCIII). Se ha descubierto que 
los p-terfenilos se pueden utilizar para 
mimetizar la α-hélice de la proteína Rev del 
VIH-1. De esta manera, los terfenilos son 
capaces de inhibir la replicación del virus. Este 
capítulo profundiza en dicho estudio, y explora 
nuevas estructuras y patrones de sustitución 
para esclarecer más acerca de la relación 
estructura-actividad de estos derivados. 
Además, se llevará a cabo la síntesis de un 
nuevo terfenilo con el fin de inhibir una 
interacción proteína-proteína clave en el ciclo 
vital de la enfermedad parasitaria de la malaria. 
 
  





Synthesis of fluorinated benzo-fused bicyclic 
homoallylic amines 









Given the background of our research group in the asymmetric allylation of tert-butanesulfinyl imines 
and the synthesis of di- and tetrahydronaphthalene scaffolds, in this work we aimed to study the effects 
of different fluorinated groups in this synthetic route.  
This would include the synthesis of a variety of benzaldehyde-derived sulfinimines with a fluorinated 
olefin in the ortho position, which would serve as a handle to then carry out the ring-closing metathesis 
reaction. The main fluorinated group on which this chapter will focus is the trifluoromethyl group. 
Given the scarcity of this class of fluorinated dihydronaphthalenes in the literature, and the importance 
of both fluorine chemistry and the dihydronaphthalene skeleton in industrial settings, the resulting 









1.1.1. The use of N-tert-butanesulfinyl imines in the synthesis of 
enantioenriched homoallylic amines. 
 
Asymmetric synthesis has become a fundamental area of organic chemistry in recent years since the 
realisation that chemistry is three-dimensional, just like the world around us.1 Although the concept of 
chirality has been understood for more than a century, its underlying importance in many fields was not 
fully appreciated until the infamous thalidomide disaster in the 1960s.2 Of course, in this specific 
example the teratogenic side-effects could not have been avoided even administering the enantiopure 
drug due to racemisation in vivo. However, we as chemists are now aware of the drastic differences in 
biological activity that a pair of enantiomers can have, and there are now many more restrictions and 
requirements that new drugs must pass in order to gain approval.  
This has led to a global research effort to develop methods of obtaining a single enantiomer in organic 
synthesis; so-called asymmetric synthesis. There are currently several viable ways to achieve this: 1) use 
of chiral catalysts; 2) use of diastereomeric resolving agents to preferentially crystallise one enantiomer 
over the other; 3) use of the “chiral pool”; and the most relevant to this work, 4) use of chiral 
auxiliaries. 
The use of chiral auxiliaries depends on the facile addition of a chiral group, which can then be used to 
infer chirality into a different part of the molecule, and its subsequent removal. This essentially allows 
the introduction of a wide variety of functional groups in an enantioselective manner, without leaving a 
trace on the final product.3 
One such example is the use of tert-butylsulfinamide 1.1, a chiral auxiliary developed by Ellman and co-
workers in 19974 that has seen increased use in the past decade for a number of reasons: its simple 
synthesis has permitted wide commercial availability at accessible prices; easy preparation of versatile 
N-tert-butanesulfinyl imines 1.2 via condensation of 1.1 with the corresponding aldehyde or ketone 
(Scheme 1.1); the formal positive charge on the sulphur atom augments the electrophilicity of the 
resulting imines, increasing their reactivity towards a range of nucleophiles; the N-tert-butanesulfinyl 
group is a potent directing group, due to its bulk and coordinating ability; and lastly, the sulfinyl moiety 
can be quantitatively removed in acidic conditions. These chiral imine intermediates have been used to 
                                                          
1
 U. Meierhenrich, Amino acids and the Asymmetry of Life, Springer, Berlin, 2008. 
2
 S. W. Smith, Toxicol. Sci., 2009, 110, 4-30. 
3
 Y. Gnas and F. Glorius, Synthesis, 2006, 12, 1899-1930. 
4
 G. Liu, D. A. Cogan and J. A. Ellman, J. Am. Chem. Soc., 1997, 119, 9913-9914. 
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synthesise a wide range of enantioenriched amines, which represent important motifs in the 




Scheme 1.1. The use of tert-butylsulfinamide in the asymmetric synthesis of amines. 
 
Despite the wide variety of nucleophiles that have been successfully added to sulfinyl imines 1.2,5 this 
chapter will focus specifically on the 1,2-allylation of N-tert-butanesulfinyl imines. The first examples 
were disclosed by Ellman et al. in 1999 in a report dealing with the addition of organolithium and 
Grignard reagents to N-tert-butanesulfinyl aldimines and ketimines, including the addition of 
allylmagnesium bromide 1.3; the addition took place with high yields and diastereoselectivities using 
DCM at -78 °C (Scheme 1.2).6 
 
 
Scheme 1.2. The first addition of allylmagnesium bromide 1.3 to N-tert-butanesulfinyl ketimines. 
                                                          
5
 M. T. Robak, M. A. Herbage and J. A. Ellman, Chem. Rev., 2010, 110, 3600-3740. 
6
 D. A. Cogan, G. Liu and J. Ellman, Tetrahedron, 1999, 55, 8883-8904. 
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Since then a plethora of reports have surfaced utilising variants of the allylation reaction: in the 
asymmetric synthesis of natural products7 and biologically relevant compounds;8 with different metals 
such as boron,9 zinc,7d, 10 and indium;11 and even in cascade reactions.12 
In terms of the mechanism, the results obtained by Ellman et al. in the above example support a closed 
chair-like transition state (Scheme 1.2), such as those proposed by Hua and co-workers in their study 
with the related N-p-toluenesulfinyl imines.13 In this way, the metal centre interacts with both the 
nitrogen atom of the imine and the oxygen atom of the sulfinyl group, activating the imine as well as 
forcing the sulfinyl group into a rigid conformation, thereby improving the directing ability of the bulky 
tert-butyl substituent. The superior results observed in the allylation reaction compared to the addition 
of other organometallic species have been attributed to the formation of this rigid six-membered 
transition state. This was later reinforced by studies carried out by Xu, Lin and co-workers, who 
observed different stereochemistry in the products depending on the conditions used in the reaction 
(Table 1.1).10 These authors used zinc as the metal of choice, stating that the higher reactivity compared 
with indium-based reagents allowed milder reaction conditions—the reactions were all carried out at 
room temperature.  
 
  
                                                          
7
 a) M. B. Bertrand and J. P. Wolfe, Org. Lett., 2006, 8, 2353-2356. b) Y. Nishikawa, M. Kitajima, N. Kogure and H. 
Takayama, Tetrahedron, 2009, 65, 1608-1617. c) R. S. Grainger and E. J. Welsh, Angew. Chem. Int. Ed., 2007, 46, 
5377-5380. d) M. Liu, X.-W. Sun, M.-H. Xu and G.-Q. Lin, Chem. Eur. J., 2009, 15, 10217-10224. 
8
 X.-Z. Wang and T. R. Burke Jr., Synlett, 2004, 3, 0469-0472. 
9
 a) S.-W. Li and R. A. Batey, Chem. Commun., 2004, 1382-1383. b) Y.-S. Zhao, Q. Liu, P. Tian, J.-C. Tao and G.-Q. 
Lin, Org. Biomol. Chem., 2015, 13, 4174-4178. 
10
 X.-W. Sun, M.-H. Xu and G.-Q. Lin, Org. Lett., 2006, 8, 4979-4982.   
11
 a) F. Foubelo and M. Yus, Tetrahedron: Asymmetry, 2004, 15, 3823-3825. b) X.-W. Sun, M. Liu, M.-H. Xu and G.-
Q. Lin, Org. Lett., 2008, 10, 1259-1262. c) J. C. González-Gómez, F. Foubelo and M. Yus, Synlett, 2008, 18, 2777-
2780. d) M. Medjahdi, J. C. González-Gómez, F. Foubelo and M. Yus, J. Org. Chem., 2009, 74, 7859-7865. 
12
 a) I. R. Cooper, R. Grigg, W.-S. MacLachlan, M. Thornton-Pett and V. Sridharan, Chem. Commun., 2002, 1372-
1373. b) I. R. Cooper, R. Grigg, M.-J. Hardie, W.-S. MacLachlan, M. Thornton-Pett, V. Sridharan and W. A. Thomas, 
Tetrahedron Lett., 2003, 44, 2283-2285. 
13
 D. H. Hua, S. W. Miao, J. S. Chen and S. Iguchi, J. Org. Chem., 1991, 56, 4-6.  
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Table 1.1. Condition-controlled stereoselectivity inversion. 
 
Entry Solvent Additive (equiv) Time (h) Yield 1.6 (%) dr  
1 THF None 0.5 99 90:10 
2 THF In(OTf)3 (1.3) 10 93 98:2 
3 THF HMPA (2) 1 99 53:47 
4 HMPA None 1 99 26:74 
5 HMPA H2O (10 μL) 12 97 1:99 
Standard reaction conditions: Reactions carried out with 0.25 mmol 1.5 and 0.5 mmol Zn and allyl bromide at r.t. 
in 5 ml solvent. 
 
The result obtained with THF as a solvent and no additive (entry 1, Table 1.1) is also consistent with si-
face allylation—resulting in the (S)-amine product—through the closed transition state described by 
Ellman and Hua (Scheme 1.3, TS-1). When indium(III) triflate is used as an additive, however, the 
authors proposed a slightly different transition state (Scheme 1.3, TS-2). In this case, the addition of a 
stronger Lewis acid disrupts the six-membered transition state and forces it open. Nevertheless, the 
additive binds the sulfinyl oxygen and the imine nitrogen atoms just as in TS-1, once again promoting si-
face addition. On the other hand, when hexamethylphosphoramide (HMPA) was used as a solvent, the 
opposite diastereoisomer was obtained. HMPA is strongly coordinating due to the highly polarised P=O 
bond, and as such is thought to interrupt the coordination of the sulfinyl group to the zinc metal centre 
by solvating the zinc cation (Scheme 1.3, TS-3). With no Lewis acid present, the uncoordinated sulfinyl 
group would adopt a synperiplanar conformation, this time promoting re-face allylation and resulting in 
the (R)-amine product.  
 








A similar study was published in 2009 by the same authors, in which the group studied the asymmetric 
benzoyloxyallylation of N-tert-butanesulfinyl imines and used this as the key step in the synthesis of 
natural product (-)-Cytoxazone.7d 
 
  
Chapter 1  D. M. Sedgwick, Tesis Doctoral 
15 
 
1.1.2. The ring-closing metathesis reaction and the use of fluorinated 
olefins. 
 
The term “olefin metathesis” was first used by Calderon, and comes from the Greek word μεταθεση 
meaning “change of position”, reflecting exactly the way a metathesis reaction works; the double bond 
effectively switches between pairs of carbon atoms during the reaction (Figure 1.1).14 
 
 
Figure 1.1. A simple view of metathesis reactions. 
 
The reaction was discovered accidentally in 1955 by a DuPont research group,15 but it was not until 
later that the reaction took hold as a useful transformation in a synthetic chemist’s toolbox due to the 
impractical catalysts involved: early catalysts based on nickel, tin or molybdenum displaying this activity 
were neither bench-stable nor viable for large-scale synthesis or commercialisation. Robert Grubbs 
solved these problems using ruthenium-based catalysts in the 1990s, and was later awarded the Nobel 
Prize in 2005—along with Yves Chauvin and Richard Schrock—for “the development of the metathesis 
method in organic synthesis”.16 The first-generation Grubbs catalyst was first described in 1995. The 
second-generation catalyst, developed in 1999, boasts improved stability towards air and moisture, due 
to the replacement of one tricyclohexylphosphine ligand for an N-heterocyclic carbene. Also developed 
in 1999 were the Hoveyda-Grubbs catalysts, which incorporated an ortho-isopropoxy group into the 
benzylidene ligand, replacing the second phosphine ligand. These catalysts offer greater thermal 
stability, despite being slower to initiate the reaction (Figure 1.2).17 
 
                                                          
14
 N. Calderon, H. Y. Chen and K. W. Scott, Tetrahedron, 1967, 34, 3327-3329. 
15
 a) A. W. Anderson and N. G. Merckling, U. S. Patent 2721198, October 18, 1955. b) W. L. Truett, D. R. Johnson, I. 
M. Robinson and B. A. Montague, J. Am. Chem. Soc., 1960, 82, 2337-2340. 
16
 a) Y. Chauvin, Angew. Chem. Int. Ed., 2006, 45, 3741-3747. b) R. R. Schrock, Angew. Chem. Int. Ed., 2006, 45, 
3748-3759. c) R. H. Grubbs, Angew. Chem. Int. Ed., 2006, 45, 3760-3765. 
17
 For an extensive review on metathesis catalysts, see: G. C. Vougioukalakis and R. H. Grubbs, Chem. Rev., 2010, 
110, 1746-1787. 




Figure 1.2. Selected ruthenium-based metathesis catalysts. 
 
In the past 20 years, since the mass commercialisation of these catalysts, metathesis reactions have 
become fundamental to synthetic chemists. Several classes of the reaction have been described: a) 
ring-opening metathesis (ROM); b) ring-opening metathesis polymerisation (ROMP); c) ring-closing 
metathesis (RCM); d) cross metathesis (CM); e) acyclic diene metathesis (ADMET); and other variations 
including alkynes (Scheme 1.4).  
 
 
Scheme 1.4. Summary of metathesis reactions. 
 
In terms of this chapter, the most important of these is ring-closing metathesis. RCM reactions have 
gained popularity due to their potential to provide easy access to medium and large-sized rings,18 as 
well as heterocycles,19 motifs that feature heavily in natural products, pharmaceuticals, and medically 
relevant compounds. For example, in 2005 a group from Boehringer Ingelheim described the scale-up 
of the synthesis of 15-membered macrocyclic protease inhibitor 1.9 active against hepatitis C, in which 
they obtained an 83% yield and 90% purity on a 400 kg scale (Scheme 1.5).20 
 
                                                          
18
 L. Yet, Chem. Rev., 2000, 100, 2963-3007. 
19
 a) A. Deiters and S. F. Martin, Chem. Rev., 2004, 104, 2199-2238. b) I. Nakamura and Y. Yamamoto, Chem. Rev., 
2004, 104, 2127-2198. 
20
 T. Nicola, M. Brenner, K. Donsbach and P. Kreye, Org. Process Res. Dev., 2005, 27, 513-515. 




Scheme 1.5. Industrial application of the ring-closing metathesis reaction. 
 
On a more relevant note, various forms of metathesis reaction have also been applied successfully to 
fluorinated substrates containing fluorinated groups both away from and directly attached to the olefin 
in question.21 The first examples were described just a few months apart in 2003-2004 by the groups of 
Brown,22 Haufe,23 and Rutjes.24 In the vast majority of cases, the reactions required high temperatures 
in order to take place, immediately differentiating them from analogous reactions involving non-
fluorinated substrates.  
Brown and co-workers described the synthesis of a range of fluorinated cyclic sulfamides 1.11 that bear 
a resemblance to known HIV protease inhibitors, obtaining high yields in all cases (Scheme 1.6). 
 
 
Scheme 1.6. RCM strategy to synthesise HIV protease-like fluoroalkene containing sulfamides. 
                                                          
21
 For an extensive review on metathesis reactions using fluorinated substrates, see: S. Fustero, A. Simón-Fuentes, 
P. Barrio and G. Haufe, Chem. Rev., 2015, 115, 871-930. 
22
 S. S. Salim, R. K. Bellingham, V. Satcharoen and R. C. D. Brown, Org. Lett., 2003, 5, 3403-3406. 
23
 M. Marhold, A. Buer, H. Hiemstra, J. H. van Maarseveen and G. Haufe, Tetrahedron Lett., 2004, 45, 57-60. 
24
 V. de Matteis, F. L. van Delft, R. de Gelder, J. Tiebes and F. P. J. T. Rutjes, Tetrahedron Lett., 2004, 959-963. 
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Haufe et al. found that fluorinated acrylate derivatives 1.12 and related compounds were the most 
suitable substrates due to the more electron-deficient nature of the double bond. The authors 
therefore focused their efforts on the synthesis of fluorinated unsaturated lactams 1.13 (Scheme 1.7). 
 
 
Scheme 1.7. Synthesis of fluorinated γ- and δ-lactams via RCM of fluoroalkenes. 
 
Rutjes and co-workers, on the other hand, explored a more diverse scope of the reaction, including 
trifluoromethylated olefins. Several interesting observations arise when comparing the results of the 
three reports, in that many substrates that were unsuccessful for trifluoromethyl-containing olefins 
were in fact successful for fluoroolefins, and vice versa. Various unsaturated chloro- and 
trifluoromethylated five-membered rings could be obtained in high yields with this strategy, whereas 
the synthesis of trifluoromethylated unsaturated γ-lactams was unsuccessful; the opposite was true for 
the related monofluorinated substrates. Similarly, the synthesis of trifluoromethylated piperidines 
failed using this method, whilst their monofluorinated analogues could be obtained in high yields 
(Scheme 1.8). However, this could be due to the incompatibility of the more basic benzyl protecting 
group with the catalyst, since a later publication by Rutjes detailed the successful synthesis of other 
trifluoromethylated piperidines with less basic nitrogen functionalities.25 
 
                                                          
25
 V. de Matteis, F. L. van Delft, H. Jakobi, S. Lindell, J. Tiebes and F. P. J. T. Rutjes, J. Org. Chem., 2006, 71, 7527-
7532. 










 showcasing the differences in 
reactivity between trifluoromethyl and fluoroalkenes. 
 
The RCM reaction has also seen other advances in recent years: Haufe et al. later applied this 
methodology to the synthesis of a selection of bicyclic lactams and lactones;26  and Marquez et al. 
applied it to the synthesis of fluorinated pyrroles;27 and Couve-Bonnaire et al. applied the reaction to 




                                                          
26
 M. Marhold, C. Stillig, R. Fröhlich and G. Haufe, Chem. Eur. J., 2014, 20, 5777-5785. 
27
 T. J. Cogswell, C. S. Donald and R. Marquez, Org. Biomol. Chem., 2016, 14, 183-190. 
28
 D. Guérin, I. Dez, A.-C. Gaumont, X. Pannecoucke and S. Couve-Bonnaire, C. R. Chimie, 2018, 21, 740-748.  
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1.1.3. The asymmetric allylation/RCM strategy towards enantioenriched 
cyclic homoallylic amines. 
 
In 2007, Grainger and Welsh described the synthesis of a natural product, (-)-Aphanorphine 1.21,7c 
using the allylation of N-tert-butanesulfinyl imines as the key step to introduce the desired chiral 
information. In this example, the authors used an interesting strategy involving the asymmetric 
allylation followed by a ring-closing metathesis (RCM) reaction between the newly added allyl group 
and a second double bond that was already present in the substrate (Scheme 1.9).  
The authors achieved an elegant synthesis of the natural product, starting with the condensation of (R)-
tert-butylsulfinamide (R)-1.1 with the simple aldehyde 1.14 to form the corresponding imine 1.15 in a 
high yield. Following this, the authors added Grignard reagent 1.16 to the imine, affording the resulting 
enantioenriched sulfinylamine 1.17. Here, the authors state that they were unable to separate the 
diastereoisomers and so continued with the synthesis using the mixture. After N-methylation, the 
authors carried out a RCM reaction to construct the six-membered ring present in the final product. 
Acid-catalysed methanolysis of the sulfinyl protecting group gave the free amine 1.20, which could be 
recrystallised to furnish the enantiomerically pure (R)-1.20. From there, the desired product 1.21 was 
synthesised in 9 more steps, giving a total of 15 steps.  
 
 
Scheme 1.9. Total synthesis of (-)-Aphanorphine by Grainger and Welsh.
7c
 
Chapter 1  D. M. Sedgwick, Tesis Doctoral 
21 
 
This same allylation/RCM strategy has been employed by our group in several other publications. The 
first of these dealt with the asymmetric synthesis of fluorinated cyclic α-aminoesters.29 In this case, 
imines 1.22 were used, bearing the methyl ether of (R)-phenylglycinol as the chiral auxiliary rather than 
N-tert-butylsulfinamide (Scheme 1.10). The allylation with the corresponding allylzinc bromide took 
place with high diastereoselectivity, due to the cyclic transition state in which the methoxy group of the 
chiral auxiliary coordinates to the zinc metal centre.  
 
 
Scheme 1.10. Synthesis of fluorinated cyclic α-aminoesters via allylation/RCM strategy. 
 
A second example in 2013 saw the asymmetric synthesis of pyrazole-based bicyclic peptidomimetics.30 
In this case the N-tert-butanesulfinyl imine 1.25 was used for the diastereoselective allylation reaction, 
affording both diastereoisomers by using the suitable conditions: indium-based addition to obtain the 
(S)-amine product (conditions i, Scheme 1.11);11d and zinc-based addition in HMPA/water for the 
opposite (R)-amine (conditions ii, Scheme 1.11).10 Unfortunately, following the allylation step, the ring-
closing metathesis was unsuccessful with the sulfinyl protecting group on the amine. Therefore, given 
that an alanine residue was present in the desired final products, the sulfinyl protecting group was 
exchanged for the Boc-protected alanine chain. The resulting product 1.27 was a suitable substrate for 
the key ring-closing metathesis reaction, paving the way to potential peptidomimetics 1.29. 
 
                                                          
29
 S. Fustero, M. Sánchez-Roselló, V. Rodrigo, C. del Pozo, J. F. Sanz-Carvera and A. Simón, Org. Lett., 2006, 8, 
4129-4132. 
30
 S. Fustero, R. Román, A. Asensio, M. A. Maestro, J. L. Aceña and A. Simón-Fuentes, Eur. J. Org. Chem., 2013, 
7164-7174. 




Scheme 1.11. Synthesis of both diastereoisomers of bicyclic homoallylic amines through the use of varying 
asymmetric allylation conditions. 
 
Marquez and co-workers also reported the use of the allylation/RCM strategy in the synthesis of α,β-
unsaturated-δ-lactams (Scheme 1.12).31 However, these authors used a p-methoxybenzyl protecting 
group on the starting imine 1.30, resulting in racemic products. Following this, the unsaturated lactams 
1.33 were successfully hydrogenated to 1.34 with almost complete diastereoselectivity. 
 
 
Scheme 1.12. Construction of fluorinated δ-lactams. 
                                                          
31
 T. J. Cogswell, C. S. Donald, D.-L. Long and R. Marquez, Org. Biomol. Chem., 2015, 13, 717-728. 
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1.1.4. Di- and tetrahydronaphthalenes; a privileged class of compounds. 
 
Dihydronaphthalenes are often used as precursors for the related tetrahydronaphthalene—or 
tetralin—scaffold, and therefore represent interesting synthetic targets. Tetralins are a privileged 
substructure in pharmaceuticals and natural products; many FDA-approved drugs contain the tetralin 
core or are derived from tetralin-based natural products (Figure 1.3).32 
 
 
Figure 1.3. Tetralin-derived drugs and natural products. 
 
The dihydronaphthalene scaffold itself is extremely scarce in FDA-approved drugs, although some 
examples of bioactive compounds do exist that are based on this structure. For example, a 
conformationally restricted analogue of amphetamine, 2-amino-1,2-dihydronaphthalene (2-ADN), was 
proven to be a potent CNS stimulant (Figure 1.4, a).33 In contrast, the corresponding 
tetrahydronaphthalene analogue was shown to be much less active. 
In addition, several dihydronaphthalene derivatives of podophyllotoxin have been proven to have 
potent anticancer activity. In particular, I and II display high cytotoxicity and selectivity against HT-29 
cancer cell lines (Figure 1.4, b).34 
 
                                                          
32
 a) K. Huhl, Climacteric, 2005, 8, 3-63. b) M. Waldhoer, S. E. Bartlett and J. L. Whistler, Annu. Rev. Biochem., 
2004, 73, 953-990. c) A. Janecka, J. Fichna and T. Janecki, Curr. Top. Med. Chem., 2004, 4, 1-17. d) H. Xu, M. Lv and 
X. Tian, Curr. Med. Chem., 2009, 16, 327-349. e) G. Macqueen, L. Born and M. Steiner, CNS Drug Rev., 2001, 7, 1-
24. 
33
 B. A. Hathaway, D. E. Nichols, M. B. Nichols and G. K. W. Yim, J. Med. Chem., 1982, 25, 535-538. 
34
 M. A. Castro, J. M. M. del Corral, M. Gordaliza, P. A. Garcia, M. A. Gomez-Zurita, M. D. Garcia-Gravalos, J. de la 
Iglesia-Vicente, C. Gajate, F. An, F. Mollinedo and A. S. Feliciano, J. Med. Chem., 2004, 47, 1214-1222. 




Figure 1.4. a) Structure of amphetamine and derivatives. b) Structure of dihydronaphthalene-based derivatives 
of podophyllotoxin with anticancer activity. 
 
Furthermore, dihydronaphthalenes have proved key intermediates in the synthesis of opioid derivatives 
codeine and dihydroisocodeine (Figure 1.5).35 
 
 
Figure 1.5. Dihydronaphthalene intermediates used in the synthesis of opioids. 
 
                                                          
35
 L. Quilin and Z. Hongbin, Chin. J. Org. Chem., 2017, 37, 1629-1652. 
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Examples of dihydronaphthalenes containing an amine substituent mainly consist of those with the 
amine in the C2 position; the related 1-amino-1,2-dihydronaphthalenes are much less common, 
especially enantioenriched versions. However, there are several examples of their synthesis using the 
asymmetric catalytic ring opening of azabenzonorbornadienes 1.35. This strategy was originally 
developed by Lautens,36 and has since been used to synthesise 1,2-aminoalcohols 1.36, 1,2-diamines 
1.37,36, 37 1-amino38 1.38 and 1-amino-2-alkyl-1,2-dihydronaphthalenes 1.39 (Scheme 1.13).39 
 
 
Scheme 1.13. Synthesis of 1-amino-1,2-dihydronaphthalenes using the catalytic ring opening of 
azabenzonorbornadienes.  
  
                                                          
36
 M. Lautens, K. Fagnou and T. Rovis, J. Am. Chem. Soc., 2000, 122, 5650-5651. 
37
 a) Y.-H. Cho, V. Zunic, H. Senboku, M. Olsen and M. Lautens, J. Am. Chem. Soc., 2006, 128, 6837-6846. b) Y.-H. 
Cho, A. Fayol and M. Lautens, Tetrahedron: Asymmetry, 2006, 17, 416-427. 
38
 F. Yang, J. Chen, J. Xu, F. Ma, Y. Zhou, M. V. Shinde and B. Fan, Org. Lett., 2016, 18, 4832-4835. 
39
 S. Cabrera, R. Gómez Arrayás and J. C. Carretero, Angew. Chem. Int. Ed., 2004, 43, 3944-3947. 





Our research group has been active in this field of research over the past decade, as seen previously. As 
well as cyclohexenes29 and pyrazole-based bicycles,30 we have also studied the synthesis of di- and 
tetrahydronaphthalenes using the asymmetric allylation/RCM strategy.  
The first example explored the application of this protocol to obtain a range of 1-amino-1,2-
dihydronaphthalene products, as well as its use in the synthesis of Sertraline and its derivatives: an 
antidepressant originally developed by Pfizer under the trade name Zoloft (Scheme 1.14).32e, 40 
In this study, our group studied the possibility of combining these reactions into a one-pot process. This 
type of method has become popular in recent years, since in an industrial setting, synthetic chemists 
must deal with environmental and economic issues to make the process as cheap and sustainable as 
possible; the use of one-pot processes is one way to help alleviate these problems, since there is no 
need to purify after each reaction and therefore the added waste from chromatography or solvents is 
not generated.  
The one-pot process developed included three steps: condensation, allylation, and ring-closing 
metathesis. Since all three reactions were fairly clean and produced few by-products, the main 
challenge was finding a suitable solvent and the compatibility between allylzinc bromide and the 
ruthenium-based catalyst used in the RCM step. Fortunately, the one-pot procedure proceeded well in 
THF, affording the corresponding dihydronaphthalene in an 85% yield and excellent diastereoselectivity 
starting from 2-vinylbenzaldehyde 1.40 (Scheme 1.14). Dihydronaphthalene 1.41 was then taken 
forward to synthesise 1.42, an intermediate in Chandrasekhar’s total synthesis of Sertraline.41 
 
 
Scheme 1.14. One-pot procedure towards the synthesis of Sertraline.  
                                                          
40
 S. Fustero, R. Lázaro, L. Herrera, E. Rodríguez, N. Mateu and P. Barrio, Org. Lett., 2013, 15, 3770-3773.  
41
 S. Chandrasekhar and M. V. Reddy, Tetrahedron, 2000, 56, 1111-1114. 
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The ring closing metathesis reaction is not limited to the simple coupling of two olefins; ring-closing 
enyne metathesis (RCEYM) is also a well-established transformation involving the coupling of an alkene 
and an alkyne, resulting in 1,3-dienes. This process was also explored by our group in the context of the 
synthesis of dihydronaphthalene derivatives, giving rise to a related allylation/RCEYM procedure 




Scheme 1.15. RCEYM strategy towards functionalised dihydronaphthalenes. 
 
In a separate study, our group also studied the same methodology on substrates with an ortho-(α-
fluoro)vinyl group.43 In accordance to the previous examples involving RCM of fluorinated olefins, this 
reaction required high temperatures to proceed. Nonetheless, both the allylation and RCM reactions 




Scheme 1.16. Allylation/RCM sequence using pendant vinyl fluorides. 
 
                                                          
42
 R. Lázaro, P. Barrio, C. Finamore, R. Román and S. Fustero, Struct. Chem., 2017, 28, 445-452. 
43
 R. Lázaro, R. Román, D. M. Sedgwick, G. Haufe, P. Barrio and S. Fustero, Org. Lett., 2016, 18, 948-951. 
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1.3. Results and discussion.  
 
In accordance with the objectives described in Section 1.0, the first step would be the construction of 
ortho-trifluoromethylvinyl benzaldehyde and related substrates with other fluorinated groups in the 
same position, in order to proceed to the condensation/allylation/RCM procedure and obtain the 
desired enantioenriched amino dihydronaphthalenes. 
In this context, in 2014 Valdés and co-workers described a fairly general method to add the 1,1,1-
trifluoropropene group onto aromatic rings via palladium-catalysed coupling between aryl bromides 
and trifluoromethylated tosylhydrazone 1.49 (Scheme 1.17).44 
 
 
Scheme 1.17. Synthesis of trifluoromethyl styrenes via coupling of tosylhydrazones and aryl bromides. 
 
With regards to the mechanism, the authors proposed a catalytic cycle that starts with the oxidative 
addition of the aryl bromide to the palladium to give intermediate I (Scheme 1.18). Following this, the 
carbene species formed by the liberation of elemental nitrogen from diazo intermediate II coordinates 
to the palladium metal centre to form intermediate III. From there, migratory insertion of the carbene 
ligand and β-hydride elimination from the methyl group originating from 1.49 affords 1.51.  
This method represented a step forward with regards to the introduction of this fluorinated group in 
aromatic substrates; although other methods did exist they usually required harsher conditions and 
more complex starting materials.45 
 
                                                          
44
 A. Jiménez-Aquino, J. A. Vega, A. A. Trabanco and C. Valdés, Adv. Synth. Catal., 2014, 356, 1079-1084. 
45
 a) B. Jiang and Y. Xu, J. Org. Chem., 1991, 56, 7336-7340. b) G.-Q. Shi, X.-H. Huang and F. Hong, J. Org. Chem., 
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Scheme 1.18. Proposed mechanism for the formation of α-trifluoromethyl styrenes. 
 
The reaction was shown to be functional group tolerant, and the authors obtained α-trifluoromethyl 
styrenes containing an array of functionalities on the aromatic ring. However, the reaction had never 
been carried out with an aldehyde in the ortho position, as we required for our planned synthetic route.  
Nonetheless, we first proceeded to synthesise trifluoromethylated tosylhydrazone 1.49 through 
condensation between 1,1,1-trifluoromethylacetone 1.52 and tosylhydrazine 1.53, giving a good yield 
of the corresponding bench-stable tosylhydrazone after recrystallisation (Scheme 1.19). 
 
 
Scheme 1.19. Synthesis of trifluoromethylated building block tosylhydrazone 1.49. 
 
We then attempted the coupling of 1.49 with ortho-bromobenzaldehyde 1.54, but found that this 
substrate was incompatible with the conditions described by Valdés et al. Nevertheless, after a short 
optimisation we were able to obtain the desired aldehyde 1.55 in a good 73% yield by changing the 
solvent to THF and using a lower temperature in a microwave oven (Scheme 1.20). 
 




Scheme 1.20. Synthesis of trifluoromethylated ortho-vinyl benzaldehydes 1.55. 
 
Using this method, we were able to synthesise a small library of trifluoromethylated substrates (Table 
1.2). Here, it was important for the reaction to proceed to completion; the starting benzaldehydes and 
the products had a very similar retention factor on silica gel, making the separation very difficult. 
Furthermore, the products were unstable and relatively volatile, so purification had to be carried out in 
solvents with low boiling points—mixtures of hexane and diethyl ether—and the products were used 
immediately in the next step. 
 
Table 1.2. Scope of the palladium-catalysed coupling reaction to introduce the trifluoromethylvinyl moiety. 
 
 
After obtaining a range of trifluoromethylated substrates, we then decided to synthesise derivatives 
with other fluorinated groups. Given that we had now optimised the coupling reaction using 
trifluoromethylated tosylhydrazones, we decided to apply the same strategy to the synthesis of other 
fluorinated derivatives. Therefore, starting with the corresponding fluorinated ketones we planned to 
form the tosylhydrazones and couple them with o-bromobenzaldehyde 1.54. However, we found that 
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mono-fluoroacetone was far too expensive to be used as a starting material, and so we turned to the 
corresponding sulfonyl derivatives—since the sulfone group could be removed through treatment with 
magnesium leaving the free (di)fluoromethyl group, as described by Gouverneur et al.46  
In this context, we found that such tosylhydrazones could be prepared with a two-step reaction 
sequence: the addition of (di)fluoromethyl phenyl sulfone 1.56 to ethyl acetate, followed by 
condensation of the resulting ketone 1.57 with tosylhydrazide 1.53 (Scheme 1.21). We found that the 
addition of difluoromethyl phenyl sulfone 1.56a to ethyl acetate had to be carried out at -98 °C (in a 
bath of ethanol/liquid nitrogen) rather than the standard -78 °C, potentially due to the instability of the 
intermediate anion. Furthermore, these addition reactions were more successful when the base was 
added to the mixture of ethyl acetate and the sulfone (Barbier-like conditions), rather than first forming 
the intermediate anion and then adding the electrophile. Again, this was most likely due to the 
instability of the intermediate anions. 
After preparing the fluorinated tosylhydrazones, we attempted the coupling reaction. Unfortunately, 
we did not observe the desired derivatives 1.55 in any case; the result was generally a complex mixture, 
and the crude NMR spectra contained no sign of the desired products. Changing the reaction conditions 
(lower temperatures and reaction times due to possible decomposition, higher catalyst loading etc.) 
was also unsuccessful. 
 
 
Scheme 1.21. Synthesis of fluorinated tosylhydrazones 1.58 and failed couplings towards 1.55. 
 
Therefore, we decided to follow Gouverneur et al., taking their report as a starting point to synthesise 
the other products we had in mind. In this context, we first attempted a palladium-catalysed cross-
coupling between boronic acid 1.59 and vinyl bromide 1.60 to introduce the pentafluoroethyl group. 
Here, it is worth mentioning that this reaction has not been carried out before, and other studies often 
                                                          
46
 J. Walkowiak, T. Martinez del Campo, B. Ameduri and V. Gouverneur, Synthesis, 2010, 11, 1883-1890. 
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lack the pentafluoroethyl group, instead focusing on the related and more common trifluoromethyl 
substituent. Fortunately, the reaction was a success, and we obtained the desired pentafluoroethyl-
bearing compound 1.55g, although we found this compound to be even more unstable than the 
trifluoromethylated analogues (1.55a-f) and were unfortunately unable to obtain acceptable NMR 
spectra (Scheme 1.22). However, using the compound in the next reaction immediately after 
purification we were able to continue the synthesis. 
 
 
Scheme 1.22. Synthesis of pentafluoroethyl-containing substrate 1.55g. 
 
Following this, we turned our attention to the (di)fluoromethyl-bearing aldehydes. Given that 
Gouverneur and co-workers had described a route to synthesise α-difluoromethylstyrene, we started 
with an analogous route with an acetal-protected aldehyde in the ortho position—we reasoned that a 
reactive aldehyde in the ortho position could interfere with several steps in the synthetic sequence. This 
route started with the introduction of a ketone group into the commercial substrate 1.61, followed by 
the addition of the corresponding sulfone to form alcohol intermediate 1.63.47 From there, we 
attempted the dehydration to give the final acetal-protected aldehyde 1.64, but the reaction was 
unsuccessful in all conditions tested, resulting in complex mixtures (Scheme 1.23). 
 
 
Scheme 1.23. First attempted synthetic route towards (di)fluoromethanesulfonyl-bearing substrates. 
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In light of these results, a second route was designed in which the aldehyde group was to be 
incorporated in the final step. This route started with the direct addition of difluoromethyl phenyl 
sulfone 1.56a to o-bromobenzaldehyde 1.54 to form alcohol 1.65, which was then oxidised to ketone 
1.66. The oxidation step caused certain problems. Reaction with pyridinium di- and chlorochromate, as 
well as with manganese(II) oxide all failed to proceed to completion, which was problematic given the 
difficulty in separating the ketone product from the alcohol starting material by column 
chromatography. Eventually, we found that using Jones’ reagent (CrO3·H2SO4) in dichloroethane in the 
microwave oven at 70 °C forced the reaction to complete, and afforded desired ketone 1.66 in high 
yields. This intermediate was then used in a Wittig reaction to form the C—C double bond. 
Interestingly, when t-BuOK was used as the base in this step, the Wittig product was not formed. 
Instead, we observed a cleavage of the ketone—CF2SO2Ph bond. The final step was then the 
introduction of the aldehyde in the ortho position, but unfortunately this reaction did not take place in 
any of the conditions tested (Scheme 1.24). 
  
 
Scheme 1.24. Second attempted route towards (di)fluoromethanesulfonyl-bearing substrates. 
 
We therefore resorted to a longer reaction sequence starting with the formylation of commercial 
compound 1.61 using n-BuLi and DMF (Scheme 1.25). From there, the desired fluoroalkyl phenyl 
sulfone—we attempted this route with both the mono- and difluoro derivatives—was introduced via 
nucleophilic addition to the aldehyde to form alcohol 1.69, which was then oxidised to the 
corresponding ketone. In this case, this was carried out with Dess-Martin periodinane, due to the 
suspected sensitivity of the acetal protecting group to acidic conditions, such as those arising from the 
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use of Jones’ reagent. Nonetheless, the separation of alcohol and ketone was much more simple here 
than in the previous route, and therefore it was less important for the reaction to proceed to 
completion. A simple Wittig reaction with methyltriphenylphosphonium bromide produced the desired 
C—C double bond, and subsequent deprotection of the aldehyde group provided 1.55h. 
The synthesis of the monofluorinated derivative was unsuccessful using this synthetic route; 1.70b was 
incompatible with the Wittig reaction to form 1.71b, likely due to the acidic proton in the α-position 
with respect to the sulfone group.  
 
 
Scheme 1.25. Synthesis of difluoromethyl-containing substrate 1.55h. 
 
Furthermore, in order to later study the effect of the fluorinated groups on the reaction sequence, we 
synthesised two non-fluorinated derivatives containing the methyl and ethyl ester substituents. To this 
end, we first chose to study α-methyl analogue 1.55i since this was the simplest change we could make 
to remove fluorine. Secondly, we chose the ethyl ester 1.55j given the electron-withdrawing nature of 
this substituent, which would mimic the electronic properties of the trifluoromethylated olefins without 
containing fluorine atoms in the structure. These were synthesised via analogous routes to those 
already seen for the synthesis of the fluorinated derivatives. Methyl-bearing 1.55i was synthesised by 
palladium-catalysed cross-coupling between 2-bromobenzaldehyde 1.54 and boronate 1.72 (Scheme 
1.26, a). On the other hand, ethyl ester-bearing 1.55j was synthesised by a three-step sequence, 
starting with the addition of the organolithiate derived from 1.61 to diethyl oxalate. Wittig 
methylenation of the thus obtained ketoester and deprotection of the acetal rendered the final product 
in an overall moderate yield (Scheme 1.26, b). 
 




Scheme 1.26. Synthesis of non-fluorinated derivatives for comparison. 
 
With the 2-vinylbenzaldehyde derivatives in hand, we formed the corresponding N-tert-butanesulfinyl 
imines uneventfully, despite obtaining only moderate yields in several cases, potentially due to the 
instability of the aldehyde starting materials. In the case of 1.75g (see Scheme 1.22), it is worth noting 
that the yield represents both the coupling and the condensation steps, due to the difficulties in 
isolating the aldehyde starting material (Table 1.3). 
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Table 1.3. Results of the condensation reaction to form the corresponding N-tert-butanesulfinyl imines 
 
a
 Yield corresponds to the total yield including both the synthesis of 1.55g and the condensation depicted here. 
 
From there, the next step was the diastereoselective allylation reaction using allylzinc bromide 1.7. For 
this step, we used the same conditions that had been previously developed in our group.43 The yield of 
the allylation (or crotylation) reaction was high in all cases, except the slightly lower yield observed for 
thiophene-based 1.76f (Table 1.4). Additionally, excellent diastereoselectivity was observed in all cases, 
although incidentally the two non-fluorinated substrates gave slightly lower diastereoselectivities (dr = 
10:1 vs. >20:1). The reactions were carried out with both racemic and enantiopure N-tert-butanesulfinyl 
imines, in order to reliably analyse the diastereoisomeric ratio via chiral HPLC. 
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Table 1.4. Diastereoselective allylation and crotylation reaction with N-tert-butanesulfinyl imines 1.75.  
  
a
 Yields correspond to both the condensation and allylation steps. 
 
The reaction was assumed to take place via the same six-membered chair-like transition state 
demonstrated earlier, resulting in the (S)-amine products (Scheme 1.27).  This was extrapolated from an 
earlier study carried out in our research group, in which the absolute stereochemistry of the secondary 
amine was elucidated via X-ray crystallography.40 
 




Scheme 1.27. Transition state explaining the stereochemical outcome of the allylation reaction. 
 
In terms of the final step in the sequence, the RCM, we found it necessary to first exchange the N-
sulfinyl protecting group for the fluorinated substrates to react (as seen previously).43 Treatment of 
1.76 with HCl in methanol quickly and efficiently removed the N-tert-butanesulfinyl group. Following 
this, we chose tert-butyloxycarbonyl (Boc) and acetyl (Ac) as the new protecting groups due to their 
ease of introduction (Table 1.5). Fortunately, we observed no decay in optical purity during the 
exchange of the protecting group. 
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Yields correspond to the total yield over both deprotection and reprotection steps. 
 
Once the protecting groups had been exchanged, we tackled the RCM reaction again. Even without the 
deactivating N-tert-butanesulfinyl group, the reaction was not as straightforward as one may think; this 
was to be expected in part, given the past examples dealing with the RCM of trifluoromethylated 
olefins.22-25 The reaction mixture had to be heated to high temperatures for the reaction to take place 
(Table 1.6). Though the yields were generally low to moderate, the optical purity of the products was 
maintained, with the exception of the slight decay observed in the thiophene-based products 1.79f and 
1.80b (er = >20:1 to 18:1) (Table 1.6). 
 
Chapter 1  D. M. Sedgwick, Tesis Doctoral 
40 
 
Table 1.6. RCM reaction with stryrenes bearing fluorinated substituents to form dihydronaphthalenes. 
 
 
We then carried out the final ring closing metathesis step with the non-fluorinated derivatives 1.76i and 
1.76j, revealing the dramatic effect of the vinyl substituent. While fluorinated substrates 1.76a-h 
bearing the tert-butanesulfinyl protecting group had proven unreactive even when forcing the reaction 
in toluene at high temperatures, non-fluorinated derivatives 1.76i and 1.76j were suitable substrates in 
standard RCM conditions at room temperature, even with the sulfinyl protecting group intact (Scheme 
1.28). In particular, it is worth noting the stark difference observed between substrates 1.76a and 1.76j; 
both compounds contain an electron-withdrawing substituent on the olefin and therefore are 
electronically similar, yet the non-fluorinated 1.76j was far more reactive than 1.76a. 




Scheme 1.28. Dramatic effect of fluorinated groups on the RCM reaction. 
 
In summary, a new approach to the synthesis of 1-amino-4-fluoroalkyl-1,2-dihydronaphthalene 
derivatives from readily available ortho-fluoroalkylvinyl benzaldehydes has been developed, with a 
particular emphasis on those bearing trifluoromethyl substituents. Additionally, we have studied the 
deactivating effect of such fluoroalkyl substitution on RCM reactions. We can conclude that α-
fluoroalkylated styrenes are much less reactive than their corresponding non-fluorinated α- substituted 
counterparts, and this deactivation is much more pronounced than for common electron-withdrawing 
groups, such as esters.  
 
  





We have successfully carried out an asymmetric allylation/RCM sequence to synthesise 
enantioenriched fluorinated 1-amino-1,2-dihydronaphthalenes, using N-tert-butylsulfinamide as a chiral 
auxiliary in order to achieve high diastereoselectivities in the allylation step. 
Furthermore, we have studied substituent effects in the RCM reaction; olefins containing fluorinated 
groups are highly deactivated and must be forced to react at high temperatures, in contrast to 
comparable non-fluorinated substituents.  
The dihydronaphthalene products may find uses in pharmaceutical sciences given the prominence of 
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1.5. Experimental section. 
 
Reactions were carried out under a nitrogen atmosphere unless otherwise indicated. Solvents were 
purified prior to use: THF and toluene were distilled from sodium and DCM from calcium hydride. The 
reactions were monitored with the aid of TLC on 0.25 mm pre-coated silica-gel plates. The TLC plates 
were revealed with with UV light and aqueous ceric ammonium molybdate solution or potassium 
permanganate stain. Flash column chromatography was performed with the indicated solvents on silica 
gel 60 (particle size: 0.040–0.063 mm). 1H, 13C and 19F NMR spectra were recorded on a 300 MHz 
spectrometer. Chemical shifts are given in ppm (δ), referenced to the residual proton resonances of the 
solvents. Coupling constants (J) are given in Hertz (Hz). The letters s, d, t, q and m stand for singlet, 
doublet, triplet, quartet and multiplet respectively. The letters br indicate that the signal is broad.  
 




A 5-mL microwave glass vial was charged with Pd2(dba)3 (4 mol%, 0.07 mmol), Xphos (8 mol%, 0.09 
mmol), Na2CO3 (2.2 equiv, 2.37 mmol) and N-tosylhydrazone 1.49 (1.40 mmol, 1.3 equiv), which was 
previously prepared from 1,1,1- trifluoromethyl ketone (1 equiv, 22 mmol)  and tosylhydrazide  (1 
equiv, 22 mmol) by heating  at 70 °C in EtOH (0.5 M) for 5h and then filtering the precipitate solid at 
room temperature as a crystalline white solid. The solid reagents were dried together under reduced 
pressure before being used. THF (0.3 M) and the corresponding o-bromobenzaldehyde 1.54 (1.08 
mmol) were added. The vial was sealed and the mixture was heated by microwave irradiation at 100 °C 
for 90 minutes. The reaction mixture was cooled to room temperature, opened, filtered through Celite 
and concentrated under reduced pressure. The residue obtained was purified by flash column 
chromatography and used immediately for the next condensation reaction. Due to the instability of the 
aldehyde products, we were unable to obtain HRMS measurements for some derivatives. 





Flash chromatography of the crude reaction product [n-hexane-Et2O (30:1)] afforded 1.55a as a yellow 





Flash chromatography of the crude reaction product [n-hexane-Et2O (30:1)] afforded 1.55b as a yellow 
oil (69%, 250 mg).  
1H NMR (CDCl3, 300 MHz): δ 5.64 (q, J= 3.0 Hz, 1H), 6.32 (q, J= 3.0 Hz, 1H), 7.36 (dd, J= 3.0, 1.5 Hz, 1H), 
7.59 (dd, J= 8.4, 2.4 Hz, 1H), 7.97 (d, J= 3.0 Hz, 1H), 10.07 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 122.3 (q, J= 273.9 Hz, CF3), 125.6 (q, J= 4.7 Hz, C), 128.2 (CH), 132.1 (CH), 
133.6 (CH), 134.4 (q, J= 30.2 Hz, C), 134.4 (q, J= 30.2 Hz, C), 134.7 (C), 136.0 (C), 136.3 (C), 189.4 (C) 
ppm.  




Flash chromatography of the crude reaction product [n-hexane-Et2O (30:1)] afforded 1.55c as a 
colourless oil (59%, 220 mg).  
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1H NMR (CDCl3, 300 MHz): δ 5.67 (q, J= 2.7 Hz, 1H), 6.32 (q, J= 3.0 Hz, 1H), 7.12 (dd, J= 8.7, 2.4 Hz, 1H), 
7.28-7.21 (m, 2H), 8.05 (dd, J= 8.7, 5.7 Hz, 1H), 10.05 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 117.1 (d, J= 21.7 Hz, CH), 117.8 (d, J= 23.0 Hz, CH), 122.1 (q, J=273.8 Hz, 
CF3), 125.7 (q, J= 4.8 Hz, C), 131.2 (d, J= 9.9 Hz, CH), 131.5 (d, J= 2.8 Hz, CH), 134.4 (q, J= 32.5 Hz, C), 
139.1 (d, J= 9.4 Hz, CH), 165.2 (d, J= 264.2 Hz, CF), 189.0 (C) ppm.  




Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.55d as a yellow 
solid (71%, 200 mg), with a melting point of 74-76 °C.  
1H NMR (CDCl3, 300 MHz): δ 4.74 (q, J= 1.2 Hz, 1H), 5.22 (s, 2H), 5.41 (q, J= 1.5 Hz, 1H), 5.94 (s, 1H), 6.56 
(s, 1H), 9.06 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 102.4 (CH2), 106.7 (CH), 110.6 (CH), 125.3 (q, J= 273.8 Hz, CF3), 125.7 (q, J= 
4.8 Hz, C), 130.4 (C), 133.5 (C), 134.6 (q, J= 31.9 Hz, CH2), 149.0 (C), 152.1 (C), 189.0 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.6 (s, 3F) ppm.  
HRMS (EI) calcd. for C11H8F3O3 [M+H




Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.55e as a yellow 
oil (73%, 300 mg).  
1H NMR (CDCl3, 300 MHz): δ 3.88 (s, 3H), 5.58 (q, J= 1.2 Hz, 1H), 6.37 (q, J= 1.5 Hz, 1H), 7.16 (dd, J= 8.7, 
3.0 Hz, 1H), 7.32 (d, J= 8.7 Hz, 1H), 7.48 (d, J= 3.0 Hz, 1H), 10.08 (s, 1H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 55.6 (CH3), 111.0 (CH), 120.9 (CH), 122.5 (q, J= 273.9 Hz, CF3), 125.3 (q, J= 
4.8 Hz, CH2), 129.3 (CH), 131.9 (CH), 134.9 (q, J= 32.1 Hz, C), 136.1 (C), 160.3 (C), 190.7 (C) ppm.  




Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.55f as a yellow 
oil (94%, 500 mg).  
1H NMR (CDCl3, 300 MHz): δ 5.74 (q, J= 1.5 Hz, 1H), 6.27 (q, J= 1.5 Hz, 1H), 7.16-7.19 (m, 1H), 7.72 (dd, 
J= 4.8, 1.2 Hz, 1H), 9.85 (d, J= 1.5 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 122.1 (q, J= 273.8 Hz, CF3), 126.1 (q, J= 5.1 Hz, CH2), 129.5 (C), 131.9 (q, J= 
32.5 Hz, C), 134.1 (C), 141.4 (C), 142.2 (C), 182.9 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.0 (s, 3F) ppm.  
HRMS (EI) calcd. for C8H6F3OS [M+H
+]: 207.0086, found: 207.0081. 
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To a solution of 1.60 (1.3 equiv, 0.87 mmol) in THF:DME (1:1, 2 ml) and aq. 2 M KOH (1.3 ml), 
phenylboronic acid 1.59 (1 equiv, 0.67 mmol), PdCl2(PPh3)2 (3 mol%, 0.02 mmol), and AsPh3 (15 mol% 
equiv, 0.1 mmol) were added  under an inert atmosphere in a sealed tube. The mixture was stirred at 
75 °C for 12h. The mixture was cooled to room temperature, water (5 ml) was added, and the mixture 
was extracted with Et2O (2 × 10 ml). The combined organic layers were washed with brine and dried 
over anhydrous sodium sulphate. The solvent was removed and the crude residue was used 
immediately in the next condensation reaction. 
 





i. Formylation reaction. In a round-bottomed flask, 2-bromobenzaldehyde ethylene acetal 1.61 
(5 mmol, 1 equiv) was dissolved in anhydrous THF (25 ml) and cooled to -78 °C. Then a solution of n-
BuLi (2.6 M in hexane, 7.5 mmol, 1.5 equiv) was added dropwise and stirred for 1h at the same 
temperature. Then, N,N-dimethyl formamide (7.5 mmol, 1.5 equiv) was added dropwise and the 
reaction mixture was allowed to warm up to 0 °C. The reaction was quenched with a saturated solution 
of ammonium chloride and the mixture was extracted with diethyl ether. The organic phase was 
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subsequently washed with brine, dried over anhydrous sodium sulfate, and the solvent was evaporated 
in vacuo. No further purification was necessary. 
ii. Sulfone addition. The crude reaction mixture from the previous step (883 mg, 4.96 mmol) 
was dissolved in THF (24 ml), and PhSO2CF2H (0.9 ml, 5.95 mmol) was added, and the mixture was 
cooled to -78 °C. At this temperature, LiHMDS (1M in THF, 6.5 ml, 6.5 mmol) was added dropwise and 
the mixture was stirred for 15h. Saturated aqueous ammonium chloride was then added at -78 °C and 
the residue was brought to room temperature and extracted with diethyl ether. The combined organic 
layers were dried over MgSO4 and the solvent was evaporated under reduced pressure. Flash 
chromatography of the crude reaction mixture [n-hexane-EtOAc (4:1)] afforded 1.69a as a colourless oil 




1H NMR (CDCl3, 300 MHz): δ 3.63 (br, 1H), 4.00-4.07 (m, 2H), 4.12-4.20 (m, 2H), 5.95 (s, 1H), 6.22 (d, J= 
22.5 Hz, 1H), 7.35-7.42 (m, 2H), 7.55-7.62 (m, 3H), 7.71-7.76 (m, 2H), 8.02 (d, J= 7.5 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 65.1 (CH2), 65.2 (CH2), 66.2 (dd, J= 27.2, 18.4 Hz, CH), 102.1 (CH), 120.7 
(dd, J= 299.9, 289.4 Hz, CF2), 126.9 (CH), 128.8 (CH), 128.9 (CH), 129.2 (CH), 129.5 (CH), 130.7 (CH), 
132.9 (C), 139.0 (C),  135.4 (CH), 135.8 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -119.1 (ddd, J= 238.3 Hz, 22.6, 1.9 Hz, 1F), -103.0 (d, J= 238.3 Hz, 1F).  
HRMS (EI) calcd. for C17H20F2NO5S [M+NH4
+]: 388.1025, found: 388.1025. 
 
iii. Oxidation reaction. To a solution of 1.69a (626 mg, 1.69 mmol) in DCM (17 ml), NaHCO3 (20 
mg) and Dess-Martin periodinane were added (907 mg, 2.03 mmol) at room temperature. The reaction 
mixture was stirred at room temperature for 2h and was then filtered through Celite and the filtrate 
was washed with water and saturated aq. NaHCO3. The combined organic layers were dried over 
anhydrous sodium sulphate and the solvent was evaporated under reduced pressure. The crude 
product was purified by column chromatography [hexane:EtOAc (4:1)] to afford 1.70a as a colourless oil 
(82%, 520 mg). 





1H NMR (CDCl3, 300 MHz): δ 3.74-3.82 (m, 2H), 3.85-3.93 (m, 2H), 6.12 (s, 1H), 7.50-7.55 (m, 3H), 7.60-
7.69 (m, 3H), 7.76-7.81 (m, 1H), 7.99-8.02 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 64.5 (CH2), 101.5 (CH), 114.7 (t, J= 303.4 Hz, CF2), 126.9 (CH), 127.9 (CH), 
129.0 (CH), 129.3 (CH), 130.9 (CH), 131.5 (CH), 132.8 (C), 133.1 (C), 135.8 (CH), 138.6 (C), 190.2 (t, J= 
25.2 Hz, C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -105.5 (s, 2F) ppm.  
HRMS (EI) calcd. for C17H18F2O5SN [M+NH4
+]: 386.0874, found: 386.0870. 
 
iv. Wittig methylenation. Ketone 1.70a was subjected to the same conditions as described 




Flash chromatography [n-hexane-EtOAc (6:1)] afforded 1.71a as a colourless oil (67%, 235 mg). 
1H NMR (CDCl3, 300 MHz): δ 3.97-4.16 (m, 4H), 5.88 (s, 1H), 5.96 (t, J= 0.9 Hz, 1H), 6.37 (t, J= 1.5 Hz, 1H), 
7.37-7.46 (m, 3H), 7.55-7.60 (m, 2H), 7.65-7.75 (m, 2H), 7.97 (d, J= 7.20 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 65.4 (CH2), 101.5 (CH), 120.4 (t, J= 288.3 Hz, CF2), 126.8 (CH), 128.7 (CH), 
128.9 (CH), 129.1 (CH), 129.95 (t, J= 6.8 Hz, CH2), 130.3 (CH), 130.8 (CH), 132.9 (C), 133.8 (C), 134.6 (t, J= 
22.1 Hz, C), 135.1 (CH), 136.7 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -97.7 (br, 2F; CF2) ppm.  
HRMS (EI) calcd. for C18H20F2O4SN [M+NH4
+]: 384.1081, found: 384.1076. 




 v. Acetal deprotection. Wittig product 1.71a was subjected to the same conditions as described 




Flash chromatography [n-hexane-EtOAc (7:1)] afforded 1.55h as a white solid (95%, 260 mg) with a 
melting point of 120-122 °C.  
1H NMR (CDCl3, 300 MHz): δ 5.91 (t, J= 0.9 Hz, 1H), 6.42 (t, J= 1.5 Hz, 1H), 7.54-7.60 (m, 5H), 7.72-7.78 
(m, 1H), 7.94-7.99 (m, 3H), 10.18 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 120.1 (t, J= 288.9 Hz, CF2), 129.1 (CH), 129.3 (CH), 129.4 (CH), 130.2 (t, J= 
6.8 Hz, CH2), 130.8 (CH), 131.7 (CH), 132.6 (C), 133.5 (CH), 134.4 (t, J= 22.3 Hz, C), 135.0 (C), 135.4 (CH), 
136.9 (C), 191.3 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -99.3 (s, 2F) ppm.  
HRMS (EI) calcd. for C16H16F2O3SN [M+NH4
+]: 340.0819, found: 340.0814. 
 




A solution of potassium isopropenyltrifluoroborate 1.72 (237 mg, 1.6 mmol), PdCl2(dppf).CH2Cl2 (21 mg, 
0.03 mmol), o-bromobenzaldehyde 1.54 (237 mg, 1.28 mmol), and Et3N (0.2 ml, 1.4 mmol) in n-PrOH 
(20 ml) was heated at 100 °C under a N2 atmosphere for 13h. Then the mixture was cooled to room 
temperature, and diluted with water (10 ml) followed by extraction with diethyl ether (20 ml). The 
ethereal layer was washed with brine (10 ml) and dried over anhydrous sodium sulphate. The solvent 
was removed in vacuo, and the crude product was purified by flash column chromatography 
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(hexane/DCM 30:1) affording 2-(1-propen-2-yl)benzaldehyde 1.55i (130 mg, 0.9 mmol, 70%), whose 
spectroscopic data were consistent with those described in the literature.49 This product was used 
immediately for the next condensation reaction. 
 




i. Addition of diethyl oxalate. n-BuLi (2.5 M in n-hexane, 1.24 mmol, 0.5 ml) was added slowly 
to a solution of 2-bromobenzaldehyde ethylene acetal 1.61 (1.12 mmol, 0.2 ml) in anhydrous THF (10 
ml) at -78 °C. After stirring for 1h, diethyloxalate (1.24 mmol, 0.17 ml) was added to the mixture at -78 
°C. The mixture was stirred for 3h, and was subsequently quenched through addition of saturated 
aqueous NH4Cl. The mixture was extracted with Et2O and the combined organic layers were washed 
with brine, dried over anhydrous sodium sulphate, and concentrated under vacuum. The residue was 
purified by flash chromatography [n-hexane: Et2O (7:1)] to afford 1.73 (188 mg, 70%), whose 
spectroscopic data are consistent with those described in the literature.50 
ii. Wittig methylenation. NaHMDS (1 M in toluene, 1.4 ml, 0.822 mmol) was added dropwise to 
a suspension of methyl triphenylphosphonium chloride (294 mg, 0.822 mmol) in THF (4 ml) at 0 °C 
under nitrogen atmosphere. The resulting mixture was stirred at this temperature for 45 mins, after 
which a solution of 1.73 (525 mg, 0.685 mmol) in THF (4 ml) was slowly added. The reaction mixture 
was stirred at room temperature until 1.73 was no longer detectable by TLC (approximately 12h). The 
reaction mixture was then hydrolysed with a saturated solution of NH4Cl (3 ml) and extracted with 
EtOAc (3 × 10 mL). The organic layer was washed with brine (2 × 5 ml), dried over anhydrous sodium 
sulphate, and concentrated in vacuo to give a yellow oil, which was purified by means of column 
chromatography on silica gel [n-hexane-EtOAc (10:1)] to afford ethyl 2-[2-(1,3-dioxolan-2-
yl)phenyl]acrylate as a colourless oil (60%, 120 mg). 
 
                                                          
49
 S. Basak, D. Mal, Tetrahedron, 2016, 72, 1758-1772. 
50
 K. Tanaka, M.  Katsurada, F. Ohno, Y. Shiga and M. Oda, J. Org. Chem., 2000, 65, 432-437. 





Ethyl 2-[2-(1,3-dioxolan-2-yl)phenyl]acrylate, 1.74 
1H NMR (CD3OD, 300 MHz): δ 1.24 (t, J= 7.2 Hz, 3H), 3.91-3.93 (m, 2H), 4.00-4.03 (m, 2H), 4.19 (q, J= 7.2 
Hz, 2H), 5.70 (d, J= 2.0 Hz, 1H), 5.71 (s, 1H), 6.45 (d, J= 2.0 Hz, 1H), 7.15-7.18 (m, 1H), 7.35-7.38 (m, 2H), 
7.53-7.56 (m, 1H) ppm.  
13C NMR (CD3OD, 75.5 MHz): δ 14.5 (CH3), 62.2 (CH2), 64.4 (CH2), 102.9 (CH), 127.7 (CH), 128.1 (CH2), 
128.9 (CH), 129.4 (CH), 131.4 (CH), 137.4 (C), 138.0 (C), 143.1 (C), 168.2 (C) ppm.  
HRMS (EI) calcd. for C14H17O4 [M+H
+]: 249.1121, found: 249.1114. 
 
iii. Acetal deprotection. To a solution of the previous product (420 mg, 1.15 mmol) in acetone 
(6 ml) at 0 °C, I2 (one bead) was added and the mixture was stirred at this temperature for 5h. After this 
time, the solvent was removed under reduced pressure and the residue was purified by flash 
chromatography [n-hexane-EtOAc (7:1)] affording 1.55j as a colourless oil (77%, 150 mg), whose 
spectroscopic data are consistent with those described in the literature.51 
 
  
                                                          
51
 a) S. W. Youn, H. S. Song and J. H. Park, Org. Lett., 2014, 16, 1028. b) T. Minami, T. Isonaka and Y. Okada, J. 
Ichikawa, J. Org. Chem., 1993, 58, 7009-7015. 
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A solution of the corresponding aldehyde 1.55 (5 mmol, 1.0 equiv) and Ti(OEt)4 (5.0 equiv) in anhydrous 
DCM (0.1 M) was stirred for 5 minutes at room temperature. To the resulting solution, (R)-N-tert-
butanesulfinamide 1.1 was added, and the mixture was stirred at room temperature for 12h. After this 
time, saturated aqueous NaHCO3 was added until white titanium salts precipitated. The suspension was 
filtered through a short pad of Celite, washing with small portions of DCM. The filtrate was extracted 
with ethyl acetate and the combined organic layers were washed with brine, dried over anhydrous 
sodium sulphate, and concentrated under vacuum. The residue was purified by flash chromatography 
to afford imines 1.75. Neither of the non-fluorinated products 1.75i or 1.75j required further 
purification and were used immediately in the following allylation step. 
 
 
(RS-E)-2-Methyl-N-[2-(3,3,3-trifluoro-1-propen-2-yl)benzylidene]propane-2-sulfinamide, 1.75a  
Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.75a as a yellow 
oil (98%, 525 mg). [α]D
25 = -13.9 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.25 (s, 9H), 5.56 (q, J= 1.2 Hz, 1H), 6.25 (q, J= 1.5 Hz, 1H), 7.36-7.39 (m, 
1H), 7.50-7.53 (m, 2H), 8.10-8.13 (m, 1H), 8.71 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.6 (CH3), 57.9 (C), 122.5 (q, J= 274.3 Hz, CF3), 124.9 (q, J= 5.0 Hz, CH2), 
128.4 (CH), 129.3 (CH), 130.5 (CH), 131.6 (CH), 132.9 (C), 135.6 (C), 135.9 (q, J= 31.7 Hz, C), 160.8 (CH) 
ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.3 (s, 3F) ppm.  
HRMS (EI) calcd. for C14H17F3NOS [M+H
+]: 304.0977, found: 304.0982. 






Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.75b as a pale 
yellow solid (81%, 400 mg), with a melting point of 49-51 °C. [α]D
25 = -85.1 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.25 (s, 9H), 5.57 (q, J= 3.0 Hz, 1H), 6.28 (q, J= 3.0 Hz, 1H), 7.33 (d, J= 9.0 
Hz, 1H), 7.48 (dd, J= 8.4, 2.4 Hz, 1H), 8.08 (d, J= 3.0 Hz, 1H), 8.63 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.6 (CH3), 58.2 (C), 122.3 (q, J= 271.8 Hz, CF3), 125.7 (q, J= 4.0 Hz, CH2), 
125.7 (C), 128.1 (CH), 131.6 (CH), 131.8 (CH), 133.7 (C), 134.4 (C), 135.8 (C), 134.9 (q, J =31.9 Hz, C), 
159.6 (CH) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.4 (s, 3F) ppm.  
HRMS (EI) calcd. for C14H16F3NOS [M+H





Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.75c as a white 
solid (87%, 425 mg) with a melting point of 46-48 °C. [α]D
25 = -116.94 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.24 (s, 9H), 5.60 (q, J= 1.20 Hz, 1H), 6.29 (q, J= 1.5 Hz, 1H), 7.09 (dd, J= 8.7, 
2.4 Hz, 1H), 7.18-7.25 (m, 1H), 8.14 (dd, J= 9.0, 6.0 Hz, 1H), 8.64 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.4 (CH3), 57.8 (C), 117.0 (d, J= 21.7 Hz, CH), 117.8 (d, J= 20.7 Hz, CH), 
122.2 (q, J= 273.8 Hz, CF3), 125.6 (q, J= 5.1 Hz, CH2), 129.4 (q, J= 5.0 Hz, C), 131.3 (d, J= 9.9 Hz, CH), 131.5 
(d, J= 2.8 Hz, CH), 134.6 (q, J= 31.9 Hz, C), 137.6 (d, J= 8.9 Hz, C), 159.5 (CH), 164.1 (d, J= 256.7 Hz, CF) 
ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.3 (s, 3F), -106.7 (s, 1F) ppm.  
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HRMS (EI) calcd. for C14H16F4NOS [M+H





Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 4d as a white solid 
(96%, 300 mg) with a melting point of 58-60 °C. [α]D
25 = -50.3 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.23 (s, 9H), 5.55 (q, J= 1.5 Hz, 1H), 6.07 (d, J= 1.2 Hz, 1H), 6.08 (d, J= 1.2 
Hz, 1H), 6.25 (q, J= 1.2 Hz, 1H), 6.81 (s, 1H), 7.58 (s, 1H), 8.57 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 57.7 (C), 102.1 (CH2), 107.0 (CH), 109.7 (CH), 122.4 (q, J= 274.0 
Hz, CF3), 125.5 (q, J= 4.7 Hz, CH2), 128.0 (C), 131.4 (C), 134.9 (q, J= 31.5 Hz, C), 148.8 (C), 150.6 (C), 159.8 
(C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.4 (s, 3F) ppm.  
HRMS (EI) calcd. for C15H17F3NO3S [M+H





Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.75e as a 
colourless oil (91%, 350 mg). [α]D
25 = -80.1 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.21 (s, 9H), 3.83 (s, 3H), 5.48 (d, J= 1.5 Hz, 1H), 6.19 (d, J= 1.5 Hz, 1H), 7.02 
(dd, J= 8.4, 2.7 Hz, 1H), 7.26 (d, J= 8.7 Hz, 1H), 7.58 (d, J= 2.7 Hz, 1H), 8.64 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.4 (CH3), 55.3 (CH3), 57.8 (C), 112.0 (CH), 118.1 (CH), 122.5 (q, J= 274.0 
Hz, CF3), 120.7 (C), 125.0 (q, J= 4.7 Hz, CH2), 131.5 (CH), 134.0 (C), 134.0 (q, J= 31.5 Hz, C), 135.4 (q, J= 
31.5 Hz, C), 159.5 (C), 160.0 (C), 160.7 (C) ppm.  
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19F NMR (CDCl3, 282.4 MHz): δ -67.0 (s, 3F) ppm.  
HRMS (EI) calcd. for C15H19F3NO2S [M+H





Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.75f as a yellow oil 
(88%, 315 mg). [α]D
25 = -55.0 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.24 (s, 9H), 5.64 (q, J= 1.5 Hz, 1H), 6.22 (q, J= 1.5 Hz, 1H), 7.13-7.16 (m, 
1H), 7.55 (dd, J= 5.4, 1.2 Hz, 1H), 8.63 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 58.2 (C), 120.4 (C), 125.7 (q, J= 5.1 Hz, CH2), 129.1 (CH), 131.4 
(CH), 131.9 (q, J= 32.2 Hz, C), 138.5 (C), 139.2 (C), 154.2 (CH) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -66.9 (s, 3F) ppm.  
HRMS (EI) calcd. for C12H15F3NOS2 [M+H





Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.75g as a 
colourless oil (66%, 100 mg). [α]D
25 = - 60.2 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.23 (s, 9H), 5.71 (br, 1H), 6.28 (br, 1H), 7.30-7.33 (m, 1H), 7.47-7.50 (m, 
2H), 8.09-8.12 (m, 1H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 57.8 (C), 113.1 (tq, J= 255.4, 38.1 Hz, CF2), 119.1 (qt, J= 286.9, 
38.1 Hz, CF3), 127.9 (t, J= 7.6 Hz, CH2), 128.4 (CH), 129.3 (CH), 130.8 (CH), 131.5 (CH), 132.9 (C), 135.4 (t, 
J= 23.1 Hz, C), 139.9 (C), 160.8 (CH) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -114.4 (q, J= 57.8 Hz, 2F), -83.0 (t, J= 2.0 Hz, 3F) ppm.  
HRMS (EI) calcd. for C15H17F5NOS [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded 1.75h as a 
colourless oil (52%, 120 mg). [α]D
25 = - 16.3 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.21 (s, 9H), 5.86 (t, J= 0.9 Hz, 1H), 6.32 (t, J= 1.5 Hz, 1H), 7.47-7.61 (m, 5H), 
7.70-7.76 (m, 1H), 7.95-8.06 (m, 3H), 8.71 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 57.8 (C), 120.18 (t, J= 289.1 Hz, CF2), 128.7 (CH), 129.2 (CH), 
129.3 (CH), 129.9 (t, J= 6.7 Hz, CH2), 130.8 (CH), 131.7 (CH), 132.7 (C), 133.0 (C), 135.2 (t, J= 22.3 Hz, C), 
135.3 (CH), 136.1 (C), 161.3 (CH) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -99.8 (br s, 1F), -98.3 (br s, 1F) ppm.  
HRMS (EI) calcd. For C20H22F2NO3S2 [M+H
+]: 426.1005, found: 426.1000. 
 
  
Chapter 1  D. M. Sedgwick, Tesis Doctoral 
58 
 





A 1 M solution of allylzinc/crotylzinc bromide in THF was prepared by stirring allyl/crotyl bromide (1.0 
equiv) and activated Zn (3.0 equiv) in anhydrous THF (1 M) at 55 °C. This freshly prepared solution (1.1 
equiv, 0.55 mmol) was then added to a solution of imine 1.75 (1.0 equiv, 0.5 mmol) in THF (0.1 M) at -
60 °C. After stirring for 3h at -60 °C the reaction mixture was quenched with saturated aqueous NH4Cl 





Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded 1.76a as a 
colourless oil (95%, 250 mg). [α]D
25 = - 225.8 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.09 (s, 9H), 2.24-2.50 (m, 2H), 3.69 (br, 1H), 4.54-4.59 (m, 1H), 5.10-5.16 
(m, 2H), 5.66 (d, J= 3.0 Hz, 1H), 5.62-5.76 (m, 1H), 6.14 (q, J= 3.0 Hz, 1H), 7.17-7.22 (m, 2H), 7.33-7.41 
(m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.6 (CH3), 43.1 (CH2), 52.4 (CH), 55.6 (C), 119.4 (CH2), 122.8 (q, J= 271.8 
Hz, CF3), 124.2 (q, J= 4.9 Hz, CH2), 127.2 (CH), 127.7 (CH), 129.1 (CH), 129.9 (CH), 133.3 (C), 134.5 (CH), 
136.6 (q, J= 31.1 Hz, C), 140.8 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.5 (s, 3F) ppm.  
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HRMS (EI) calcd. for C17H23F3NOS [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded 1.76b as a 
colourless oil (99%, 230 mg). [α]D
25 = - 57.5 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.18 (s, 9H), 2.27-2.36 (m, 1H), 2.49-2.57(m, 1H), 3.76 (s, 1H), 4.60 (ddd, J= 
6.0, 3.0, 0.5 Hz, 1H), 5.19-5.25 (m, 2H), 5.68-5.81 (m, 2H), 6.23 (dd, J= 3.0, 3.0 Hz, 1H), 7.18 (d, J= 9.0 Hz, 
1H), 7.26-7.29 (m, 1H), 7.45 (d, J= 3.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 42.9 (CH2), 52.2 (CH), 55.8 (C), 119.8 (CH2), 122.5 (q, J= 203.8 
Hz, CF3), 124.8 (q, J= 4.8 Hz, CH2), 127.5 (CH), 128.1 (CH), 131.3 (CH), 131.6 (C), 133.9 (CH), 135.7 (q, J= 
31.5 Hz, C), 142.9 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.5 (s, 3F) ppm.  
HRMS (EI) calcd. for C17H22ClF3NOS [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (4:1)] afforded 1.76c as 
colourless oil (94%, 265 mg). [α]D
25 = - 103.4 (c 1.0; CHCl3).
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1H NMR (CDCl3, 300 MHz): δ 1.15 (s, 9H), 2.27-2.38 (m, 1H), 2.46-2.52 (m, 1H), 3.75 (s, 1H), 4.57 (ddd, J= 
5.7, 3.9, 1.5 Hz, 1H), 5.16-5.21 (m, 2H), 5.66-5.80 (m, 2H), 6.22 (q, J= 1.2 Hz, 1H), 6.93 (dd, J= 9.3, 2.7 Hz, 
1H), 7.09 (dt, J= 8.4, 3.0 Hz, 1H), 7.43 (dd, J= 5.7, 2.2 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 43.1 (CH2), 51.8 (CH), 55.6 (C), 116.4 (d, J= 10.1 Hz, CH), 116.7 
(d, J= 11.0 Hz, CH), 119.5 (CH2), 122.6 (q, J= 273.6 Hz, CF3), 124.7 (q, J= 4.8 Hz, CH2), 129.7 (q, J= 8.4 Hz, 
CH), 134.16 (CH), 135.0 (d, J= 8.0 Hz, C), 135.4 (q, J= 31.3 Hz, C), 136.6 (d, J= 3.1 Hz, C), 161.1 (d, J= 
249.1 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -114.8 (ddd, J= 9.0, 8.2, 5.6 Hz, 1F), -67.5 (s, 3F) ppm.  
HRMS (EI) calcd. for C17H22F4NOS [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (4:1)] afforded 1.76d as a 
colourless oil (89%, 225 mg). [α]D
25 = -61.6 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.17 (s, 9H), 2.24-2.38 (m, 1H), 2.44-2.51 (m, 3H), 3.72 (s, 1H), 4.54 (ddd, J= 
9.6, 3.9, 1.5 Hz, 1H), 5.15-5.21 (m, 2H), 5.67-5.77 (m, 2H), 5.98 (dd, J= 6.0, 1.2 Hz, 2H), 6.18 (q, J= 1.2 Hz, 
1H), 6.67 (s, 1H), 6.88 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 43.1 (CH2), 52.3 (CH), 55.5 (C), 101.4 (CH2), 107.2 (CH), 109.4 
(CH), 119.3 (CH2), 122.8 (q, J= 273.3 Hz, CF3), 124.6 (q, J= 4.6 Hz, CH2), 134.4 (C), 134.6 (CH), 135.0 (q, J= 
31.2 Hz, C), 136.6 (C), 145.6 (C), 148.5 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.6 (s, 3F) ppm.  
HRMS (EI) calcd. for C18H23F3NO3S [M+H
+]: 390.1345, found: 390.1356. 
 






Flash chromatography of the crude reaction product [n-hexane-EtOAc (4:1)] afforded 1.76e as a white 
solid (92%, 280 mg), with a melting point of 60-62 °C. [α]D
25 = - 91.7 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.18 (s, 9H), 2.28-2.40 (m, 1H), 2.50-2.57 (m, 1H), 3.73 (br, 1H), 3.81 (s, 3H), 
4.60 (ddd, J= 9.6, 3.9, 1.8 Hz, 1H), 5.17-5.23 (m, 2H), 5.69 (q, J= 1.5 Hz, 1H), 5.71-5.83 (m, 1H), 6.19 (q, 
J= 1.2 Hz, 1H), 6.84 (dd, J= 8.4, 2.7 Hz, 1H), 6.98 (d, J= 2.7 Hz, 1H), 7.16 (d, J= 9.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 43.1 (CH), 52.5 (CH2), 55.1 (CH3), 55.6 (C), 112.9 (CH), 112.8 
(CH), 119.4 (CH2), 122.9 (q, J= 273.8 Hz, CF3), 124.4 (q, J= 4.0 Hz, CH2), 125.5 (C), 131.1 (CH), 134.4 (CH), 
135.9 (q, J= 31.1 Hz, C), 142.4 (C), 160.0 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.7 (s, 3F) ppm.  
HRMS (EI) calcd. for C18H25F3NO2S [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (4:1)] afforded 1.76f as a 
colourless oil (58%, 450 mg). [α]D
25 = - 75.7 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.20 (s, 9H), 2.42-2.53 (m, 1H), 2.57-2.64 (m, 1H), 3.79 (s, 1H), 4.78-4.83 
(m, 1H), 5.16-5.22 (m, 2H), 5.78-5.80 (m, 1H), 5.64-5.77 (m, 1H),  6.12 (q, J= 1.5 Hz, 1H), 6.93 (dd, J= 5.4, 
1.2 Hz, 1H), 7.28 (d, J= 4.8 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.9 (CH3), 44.9 (CH2), 50.9 (CH), 55.8 (C), 117.2 (C), 119.8 (C), 120.2 (CH2), 
124.3 (q, J= 5.1 Hz, CH2), 125.2 (CH), 128.2 (CH), 132.5 (q, J= 31.6 Hz, C), 133.9 (CH), 145.2 (C) ppm.  
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19F NMR (CDCl3, 282.4 MHz): δ -67.3 (s, 3F) ppm.  
HRMS (EI) calcd. for C15H21F3NOS2  [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded 1.76g as a white 
solid (90%, 180 mg), with a melting point of 59-61 °C. [α]D
25 = - 90.2 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.15 (s, 9H), 2.32-2.40 (m, 1H), 2.51-2.58 (m, 1H), 3.78 (br, 1H), 4.56-4.61 
(m, 1H), 5.17-5.24 (m, 2H), 5.50-5.83 (m, 1H), 5.88 (s, 1H), 6.23 (s, 1H), 7.17-7.19 (m, 1H), 7.24-7.30 (m, 
1H), 7.36-7.47 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 42.9 (CH2), 52.6 (CH), 55.6 (C), 108.8-125.0 (C2F5), 119.4 (CH2), 
127.1 (CH), 127.6 (t, J= 7.7 Hz, CH2), 127.7 (CH), 129.1 (CH), 130.1 (CH), 133.8 (C), 134.5 (CH), 140.9 (C) 
ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -112.8 (d, J= 181.3 Hz, 2F), -82.7 (s, 3F) ppm.  
HRMS (EI) calcd. for C18H23F5OSN [M+H




methylpropane-2-sulfinamide , 1.76h 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (2:1)] afforded 1.76h as a 
colourless oil (95%, 100 mg). [α]D
25 = - 66.1 (c 1.0; CHCl3).
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1H NMR (CDCl3, 300 MHz): δ 1.16 (s, 9H), 2.30-2.41 (m, 1H), 2.61-2.65 (m, 1H), 3.79 (br s, 1H), 4.64-4.68 
(m, 1H), 5.14-5.21 (m, 2H), 5.69-5.83 (m, 1H), 6.06 (br, 1H), 6.42 (t, J= 1.5 Hz, 1H), 7.18-7.47 (m, 4H), 
7.57-7.62 (m, 2H), 7.72-7.77 (m, 1H), 7.99 (d, J= 7.5 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.6 (CH3), 42.9 (CH2), 52.8 (CH), 55.6 (C), 119.2 (CH2), 120.5 (t, J= 287.7 
Hz, CF2), 125.3 (C), 127.1 (CH), 127.5 (CH), 128.2 (CH), 129.0 (CH), 129.2 (CH), 130.5 (t, J= 6.2 Hz, CH2), 
130.6 (CH), 130.9 (CH), 132.9 (C), 134.8 (CH), 135.2 (CH), 140.8 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -99.9 (d, J= 219.1 Hz, 1F; CFF), -94.8 (d, J= 205.6 Hz, 1F; CFF) ppm.  
HRMS (EI) calcd. for C23H28F2NO3S2 [M+H
+]: 468.1469, found: 468.1468. 
 
 
(RS)-2-Methyl-N-{(S)-1-[2-(1-propen-2-yl)phenyl] -3-buten-1-yl}propane-2-sulfinamide, 1.76i 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (8:1)] afforded 1.76i as a 
colourless oil (74% from 1.55i, 100 mg). [α]D
25 = - 88.8 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.11 (s, 9H), 2.04 (s, 3H), 2.27-2.55 (m, 2H), 3.59 (br, 1H), 4.66 (br, 1H), 4.81 
(s, 1H), 5.08-5.12 (m, 2H), 5.18 (s, 1H), 5.59-5.74 (m, 1H), 7.04 (d, J= 7.0 Hz, 1H), 7.16-7.19 (m, 2H), 7.30 
(d, J= 7.1 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.5 (CH3), 25.7 (CH3), 43.8 (CH2), 52.5 (CH), 55.5 (C), 115.8 (CH2), 118.9 
(CH2), 127.0 (CH), 127.1 (CH), 128.1 (C), 134.6 (CH), 138.2 (C), 143.9 (C), 144.7 (C) ppm.  
HRMS (EI) calcd. for C17H26NOS [M+H
+]: 292.1730, found: 292.1722. 
 
 
(RS)-Ethyl 2-{2-[(1S)-1-[(tert-butylsulfinyl)amino]-3-buten-1-yl]phenyl}acrylate, 1.76j 
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Flash chromatography of the crude reaction product [n-hexane-EtOAc (3:1)] afforded 1.76j as colourless 
oil (78% from 1.55j, 39 mg). [α]D
25 = - 99.8 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.16 (s, 9H), 1.27 (t, J= 8.5 Hz, 3H), 2.29-2.40 (m, 1H), 2.56-2.63 (m, 1H), 
3.70 (br, 1H), 4.18-4.29 (m, 2H), 4.47-4.52 (m, 1H), 5.13-5.18 (m, 2H), 5.63-5.77 (m, 1H), 5.81 (d, J= 1.5 
Hz, 1H), 6.61 (d, J= 1.5 Hz, 1H), 7.12 (dd, J= 7.5, 1.7 Hz, 1H), 7.27-7.28 (m, 1H), 7.31-7.37 (m, 1H), 7.44 
(dd, J= 8.0, 1.7 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 14.1 (CH3), 22.6 (3CH3), 42.8 (CH2), 52.9 (CH), 55.6 (C), 61.3 (CH2), 119.1 
(CH2), 126.9 (CH), 127.1 (CH), 128.2 (CH), 129.8 (CH), 129.9 (CH2), 134.5 (CH), 137.0 (C), 139.9 (C), 140.4 
(C), 166.4 (C) ppm.  
HRMS (EI) calcd. for C19H28F3NO3S [M+H





Flash chromatography of the crude reaction product [n-hexane-EtOAc (3:1)] afforded 1.76k as a 
colourless oil (82%, 133 mg). [α]D
25 = - 71.1 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 0.75 (d, J= 6.9 Hz, 3H), 1.15 (s, 9H), 2.28-2.41 (m, 1H), 3.98 (s, 1H), 4.21 (dd, 
J= 9.3, 0.9 Hz, 1H), 5.17-5.25 (m, 2H), 5.63-5.75 (m, 1H), 5.93 (d, J= 1.2 Hz, 1H), 5.99 (dd, J= 4.5, 1.5 Hz, 
2H), 6.21 (q, J= 1.5 Hz, 1H), 6.72 (d, J= 0.9 Hz, 1H), 6.82 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 16.9(CH3), 22.6 (3CH3), 47.5 (CH), 55.6 (C), 56.4 (CH), 101.5 (CH2), 107.4 
(CH), 108.9(CH), 117.7(CH2), 121.1 (q, J= 273.3 Hz, CF3), 124.6 (C), 125.6 (q, J= 4.9 Hz, CH2), 132.9 (C), 
135.6 (q, J= 30.7 Hz, C), 146.7 (C), 141.6 (CH), 148.5 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -65.5 (s, 3F) ppm.  
HRMS (EI) calcd. for C19H25F3NO3S [M+H
+]: 404.1502, found: 404.1523. 
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i. Removal of the chiral auxiliary. Hydrogen chloride (2.9 mmol, 4.0 equiv, 4M in 1,4-dioxane) 
was added to a solution of the corresponding sulfinyl amine (0.73 mmol, 1.0 equiv) in MeOH (1 M) at 
room temperature. After 45 minutes the deprotection was complete and the solution was concentrated 
to dryness. The residue was re-dissolved in DCM (5 ml) and 2M NaOH was added and extracted three 
times with DCM. The combined organic layers were dried over anhydrous sodium sulphate. Solvents 
were removed under reduced pressure and the crude reaction mixture was used in the next protection 
step without further purification. 
ii. N-Boc-protection. The crude deprotection product was dissolved in anhydrous 1,4-dioxane 
(0.2 M) and treated with K2CO3 (1.8 mmol, 2.5 equiv) and di-tert-butyl dicarbonate (Boc2O) (0.9 mmol, 
1.1 equiv), and the resulting mixture was stirred at 50 °C overnight. The suspension was then filtered 
through a short pad of Celite and washed with small portions of ethyl acetate. Solvents were removed 
under reduced pressure and the residue was purified by means of flash chromatography on silica gel 
affording the desired product. 
 
 
tert-Butyl (S)-{1-[2-(3,3,3-trifluoro-1-propen-2-yl)phenyl]-3-buten-1-yl}carbamate, 1.77a 
Flash chromatography of the crude reaction product [n-hexane-Et2O (30:1)] afforded 1.77a as a white 
solid (83%, 100 mg), with a melting point of 30-32 °C. [α]D
25 = - 18.5 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.39 (s, 9H), 2.41-2.47 (m, 2H), 4.78 (br, 1H), 4.92 (br, 1H), 5.04- 5.12 (m, 
2H), 5.60-5.74 (m, 2H), 6.20 (d, J= 3.0 Hz, 1H), 7.25-7.38 (m, 2H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 41.0 (CH2), 50.4 (CH), 50.5 (CH), 79.4 (C), 118.8 (CH2), 122.9 (q, 
J= 271.8 Hz, CF3), 124.4 (q, J= 2.2 Hz, CH2), 125.9 (CH), 126.8 (CH), 129.2 (CH), 130.1 (CH), 132.5 (C), 
134.0 (CH), 141.5 (C), 154.7 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.0 (s, 3F) ppm.  
HRMS (EI) calcd. for C18H23F3NO2 [M+H
+]: 342.1675, found: 342.1673.  




tert-Butyl (S)-{1-[5-chloro-2-(3,3,3-trifluoro-1-propen-2-yl)phenyl]-3-buten-1-yl} carbamate, 
1.77b 
Flash chromatography of the crude reaction product [n-hexane-Et2O (30:1)] afforded 1.77b as a 
colourless oil (55%, 90 mg). [α]D
25 = - 38.2 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.40 (s, 9H), 2.30-2.48 (m, 2H), 4.83-4.89 (m, 2H), 5.09-5.14 (m, 2H), 5.60-
5.71 (m, 1H), 5.74 (br, 1H), 6.23 (d, J= 1.5 Hz, 1H), 7.18 (d, J= 9.0 Hz, 1H), 7.23 (dd, J= 9.0, 3.0 Hz, 1H), 
7.35 (d, J= 3.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 40.9 (CH2), 50.5 (d, J= 1.4 Hz, CH), 79.7 (C), 118.6 (CH2), 122.7 
(q, J= 273.8 Hz, CF3), 125.2 (q, J= 4.7 Hz, CH2), 126.3 (CH), 127.0 (CH), 130.7 (C), 131.3 (CH), 133.5 (CH), 
135.2 (C), 135.7 (C), 143.9 (C), 154.7 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -66.9 (s, 3F) ppm.  
HRMS (EI) calcd. for C14H15ClF3NO2 [M-(t-Bu)+H
+]: 320.0660, found: 320.0658.  
HPLC (Chiralcel OD-H, 98:2 hexane/i-PrOH, 1 ml min‐1, 240 nm) RT (major) = 4.01 min, RT (minor) = 4.24 
min. 
 




tert-Butyl (S)-{1-[4-fluoro-2-(3,3,3-trifluoro-1-propen-2-yl)phenyl]-3-buten-1-yl} carbamate, 
1.77c 
Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.77c as a pale 
yellow oil (68%, 105 mg). [α]D
25 = - 12.2 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.38 (s, 9H), 2.37-2.46 (m, 2H), 4.81-4.89 (m, 2H), 5.04-5.11 (m, 2H), 5.58-
5.22 (m, 1H), 5.78 (br, 1H), 6.23 (d, J= 1.5 Hz, 1H), 6.95 (dd, J= 9.3, 2.7 Hz, 1H), 7.07 (dd, J= 8.1, 2.7 Hz, 
1H), 7.33 (dd, J= 8.7, 3.4 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 41.0 (CH2), 50.1 (CH), 75.5 (C), 116.2 (d, J= 21.0 Hz, CH), 116.7 
(d, J= 22.1 Hz, CH), 118.3 (CH2), 122.7 (q, J= 273.9 Hz, CF3), 125.0 (d, J= 2.0 Hz, CH), 127.7 (d, J= 83.3 Hz, 
CH), 133.7 (CH), 134.2 (C), 135.5 (d, J= 31.5 Hz, C), 137.6 (d, J= 3.1 Hz, C), 154.7 (C), 160.9 (d, J= 271.8 
Hz, CH) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -115.7 (ddd, J= 14.4, 8.5, 5.6 Hz, 1F), -66.9 (s, 3F) ppm.  
HRMS (EI) calcd. for C18H22F4NO2 [M+H
+]: 360.1581, found: 360.1573.  






Flash chromatography of the crude reaction product [n-hexane-Et2O (10:1)] afforded 1.77d as a 
colourless oil (67%, 120 mg). [α]D
25 = - 19.2 (c 1.0; CHCl3).
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1H NMR (CDCl3, 300 MHz): δ 1.25 (s, 9H), 2.25 (t, J= 6.9 Hz, 2H), 4.63-4.70 (m, 2H), 4.89-4.97 (m, 2H), 
5.45-5.57 (m, 2H), 5.83 (s, 2H), 6.04 (d, J= 1.5 Hz, 1H), 6.55 (s, 1H), 6.68 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 41.1 (CH2), 50.7 (CH), 79.4 (C), 101.4 (CH2), 105.9 (CH), 109.7 
(CH), 118.0 (CH2), 122.9 (q, J= 279.3 Hz, CF3), 124.7 (q, J= 2.3 Hz, CH2), 124.7 (C), 125.6 (C), 133.9 (CH), 
135.8 (C), 136.3 (C), 146.7 (C), 148.4 (C), 154.7 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -66.1 (s, 3F) ppm.  
HRMS (EI) calcd. for C19H23F3NO4 [M+H
+]: 386.1574, found: 386.1580.  




tert-Butyl (S)-{1-[5-methoxy-2-(3,3,3-trifluoro-1-propen-2-yl)phenyl]-3-buten-1-yl} carbamate, 
1.77e 
Flash chromatography of the crude reaction product [n-hexane-Et2O (10:1)] afforded 1.77e as a 
colourless oil (84%, 105 mg). [α]D
25 = - 26.3 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.39 (s, 9H), 2.34- 2.50 (m, 2H), 3.81 (s, 3H), 4.81-4.90 (m, 2H), 5.04-5.12 
(m, 2H), 5.60-5.74 (m, 2H), 6.17 (d, J= 1.5 Hz, 1H), 6.79 (dd, J= 8.4, 2.7 Hz, 1H), 6.88 (d, J= 2.7 Hz, 1H), 
7.16 (d, J= 8.1 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3),  40.9 (CH2), 50.7 (CH), 55.2 (CH3), 79.4 (C), 111.8 (CH), 118.0 
(CH2), 122.9 (q, J= 268.8 Hz, CF3), 124.5 (q, J= 3.5 Hz, CH2), 124.7 (C), 131.2 (CH), 134.0 (CH), 136.2 (d, J= 
28.8 Hz, C), 143.1 (C), 154.7 (C), 160.1 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -66.1 (s, 3F) ppm.  
HRMS (EI) calcd. for C19H25F3NO3 [M+H
+]: 372.1781, found: 372.1783.  
HPLC (Chiralpak IC, 98:2 hexane/i-PrOH, 1 ml min‐1, 240 nm) RT (major) = 6.67 min, RT (minor) = 5.74 
min. 
 




tert-Butyl (S)-{1-[3-(3,3,3-trifluoro-1-propen-2-yl)thiophen-2-yl]-3-but-3-en-1-yl} carbamate, 
1.77f 
Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.77f as a 
colourless oil (64%, 160 mg). [α]D
25 = - 4.5 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.41 (s, 3H), 2.47-2.58 (m, 2H), 4.82 (s, 1H), 5.07-5.13 (m, 3H), 5.63-5.72 
(m, 1H), 5.76 (s,1H), 6.12 (d, J= 1.2 Hz), 6.96 (dd, J= 5.1, 0.9 Hz, 1H), 7.20 (d, J= 5.4 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 42.0 (CH2), 48.6 (CH), 79.8 (C), 118.6 (CH2), 122.1 (q, J= 267.0 
Hz, CF3), 123.1 (CH), 123.8 (CH2), 128.2 (CH), 130.7 (C), 133.2 (CH), 146.1 (C), 154.6 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -66.7 (s, 3F) ppm.  
HRMS (EI) calcd. for C16H21F3NO2S  [M+H
+]: 348.1240, found: 348.1249.  




tert-Butyl (S)-{1-[2-(3,3,4,4,4-pentafluoro-1-buten-2-yl)phenyl]-3-buten-1-yl} carbamate, 
1.77g 
Flash chromatography of the crude reaction product [n-hexane-Et2O (10:1)] afforded 1.77g as a 
colourless oil (80%, 80 mg). [α]D
25 = - 19.0 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.32 (s, 9H), 2.38-2.40 (m, 2H), 4.69 (br, 1H), 4.79 (br, 1H), 4.96-5.02 (m, 
2H), 5.56-5.64 (m, 1H), 5.75 (s, 1H), 6.14 (s, 1H), 7.11-7.13 (m, 1H), 7.16-7.20 (m, 1H), 7.28-7.33 (m, 2H) 
ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 41.1 (CH2), 50.8 (CH), 79.3 (C), 112.5 (tq, J= 251.1, 39.4 Hz, 
CF2), 117.9 (CH2), 119.4 (qt, J= 287.7, 36.6 Hz, CF3), 125.9 (CH), 126.8 (CH), 127.7 (CH2), 129.2 (CH), 
130.3 (CH), 133.1 (C), 134.1 (CH), 135.9 (C), 154.6 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -112.7 (br, 2F), -82.9 (s, 3F) ppm.  
HRMS (EI) calcd. for C19H23F5NO2 [M+H
+]: 392.1643, found: 392.1637.  






Flash chromatography of the crude reaction product [n-hexane-Et2O (10:1)] afforded 1.77h as a 
colourless oil (74%, 95 mg). [α]D
25 = - 39.8 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 0.89 (d, J= 6.9 Hz, 3H), 1.38 (s, 9H), 2.44 (dd, J= 21.0, 13.8 Hz, 1H), 4.7 (s, 
2H), 5.11-5.04 (m, 2H), 5.83-5.71 (m, 2H), 5.96 (dd, J= 3.3, 1.2 Hz, 2H), 6.19 (s, 1H), 6.72 (s, 1H), 6.76 (s, 
1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 17.2 (CH3),  21.5 (CH), 28.3 (CH3), 43.9 (CH), 54.7 (CH), 79.2 (C), 101.4 
(CH2), 106.2 (CH), 109.5 (CH), 116.4 (CH2), 122.9 (q, J= 274.3 Hz, CF3), 124.7 (C), 125.4 (CH2), 128.4 (C), 
135.3 (C), 146.2 (C), 148.3 (C), 154.7 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -66.4 (s, 3F) ppm.  
HRMS (EI) calcd. for NaC20H24F3NO4 [M+Na
+]: 422.1550, found: 422.1561.  
HPLC (Chiralpak IC, 98:2 hexane/i-PrOH, 1 ml min‐1, 240 nm) RT (major) = 6.50 min, RT (minor) = 5.97 
min. 
 
iii. N-Acetyl-protection. The crude residue from the chiral auxiliary deprotection was re-
dissolved in anhydrous DCM (8 ml), and Ac2O (1.2 mmol, 1.5 equiv), Et3N (1.62 mmol, 2 equiv) and 
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DMAP (0.162 mmol, 0.8 equiv) were successively added at room temperature. The mixture was stirred 
at room temperature for 16h. At this time, the reaction was quenched with aqueous NH4Cl and 
extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulphate. 
The solvent was removed under reduced pressure and the residue was purified by means of flash 




Flash chromatography of the crude reaction product [n-hexane-EtOAc (2:1)] afforded 1.78a as a 
colourless oil (74%, 90 mg). [α]D
25 = - 41.7 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.90 (s, 3H), 2.43-2.48 (m, 2H), 5.02-5.09 (m, 2H), 5.15-5.22 (m, 1H), 5.60-
5.73 (m, 1H), 5.76 (dd, J= 1.3, 1.3 Hz, 1H), 5.98 (d, J= 7.3 Hz, 1H), 6.19 (dd, J= 1.5, 1.5 Hz, 1H), 7.23-7.28 
(m, 2H), 7.32-7.37 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 23.1 (CH3), 40.5 (CH2), 49.5 (CH), 118.0 (CH2), 123.2 (q, J= 275.5 Hz, CF3), 
124.6 (q, J= 6.0 Hz, CH2), 126.0 (CH), 126.9 (CH), 129.1 (CH), 130.1 (CH), 132.7 (C), 134.1 (CH), 136.1 (q, 
J= 34.0 Hz, C), 141.1 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -67.0 (s, 3F) ppm.  
HRMS (EI) calcd. for C15H17F3NO [M+H
+]: 284.1257, found: 284.1253.  
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Flash chromatography of the crude reaction product [n-hexane-EtOAc (2:1)] afforded 1.78b as a 
colourless oil (80%, 190 mg). [α]D
25 = - 28.7 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 7.18 (d, J= 5.2 Hz, 1H), 6.93 (dd, J= 5.2, 1.1 Hz, 1H), 6.26 (d, J= 6.9 Hz, 1H), 
6.09 (dd, J= 1.5, 1.3 Hz, 1H), 5.77 (dd, J= 1.5, 1.3 Hz), 5.59-5.73 (m, 1H), 5.4 (q, J= 7.5 Hz, 1H), 5.11-5.03 
(m, 2H), 2.62-2.44 (m, 2H), 1.02 (s, 3H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 22.9 (CH3), 41.6 (CH2), 47.7 (CH), 118.5 (CH2), 122.8 (q, J= 275.5 Hz, CF3), 
123.2 (CH), 123.9 (q, J= 5.5 Hz, CH2), 128.1 (CH), 131.0 (C), 132.8 (q, J= 32.9 Hz, C), 133.2 (CH), 145.1 (C), 
169.1 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -67.2 (s, 3F) ppm.  
HRMS (EI) calcd. for C13H15F3NOS [M+H
+]: 290.0821, found: 290.0831.  




(S)-N-(1-{2-[3,3-Difluoro-3-(phenylsulfonyl) -1-propen-2-yl]phenyl}-3-buten-1-yl) acetamide, 
1.78c 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (1:1)] afforded 1.78c as a 
colourless oil (72%, 90 mg). [α]D
25 = - 14.5 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.90 (s, 3H), 2.49-2.54 (m, 2H), 5.02-5.19 (m, 3H), 5.61-5.74 (m, 2H), 6.06 
(br, 1H), 6.41 (br, 1H), 7.27-7.42 (m, 3H), 7.47-7.49 (m, 1H), 7.57-7.62 (m, 2H), 7.71-7.77 (m, 1H), 7.99 
(d, J= 7.8 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 23.2 (CH3), 31.5 (CH2), 40.6 (CH2), 50.0 (CH), 117.9 (CH2), 120.5 (t, J= 172.8 
Hz, CF2), 125.8 (CH), 127.0 (CH), 129.1 (CH), 129.2 (CH), 130.7 (C), 130.9 (CH), 132.9 (C), 133.6 (C), 134.2 
(CH), 135.2 (CH), 141.2 (C), 169.0 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -99.7 (s, 1F), -93.1 (s, 1F) ppm.  
HRMS (EI) calcd. for C21H22F2NO3S [M+H
+]: 406.1288, found: 406.1284.  
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Unfortunately, we were unable to separate the enantiomers of this compound using chiral HPLC. 
However, the final compound in the reaction sequence (1.80c) was successfully analysed and was found 
to have an er of >20:1.  
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To a solution of the corresponding homoallylamine (0.4 mmol, 1.0 equiv) in toluene (for R’= RF) or DCM 
(for R’= CH3, CO2Et) (8 ml, 0.05M), 2
nd generation Grubbs catalyst (Grubbs II) (0.02 mmol, 5 mol%) (for 
1.77) or 2nd generation Hoveyda-Grubbs catalyst [Hoveyda-Grubbs II] (0.02 mmol, 5 mol%) (for 1.78 and 
1.55i-j) was added. The reaction mixture was stirred approximately 4h at 100 °C (for R’= RF) or room 
temperature (for R’= CH3, CO2Et). After that time, the reaction mixture was concentrated under vacuum 
and purified by means of flash chromatography on silica gel. 
 
 
tert-Butyl (S)-[4-(trifluoromethyl)-1,2-dihydronaphthalen-1-yl] carbamate, 1.79a 
Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.79a as a white 
solid (67%, 80 mg), with a melting point of 39-41 °C. [α]D
25 = - 16.3 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.45 (s, 9H), 2.66 (br, 2H), 4.79-4.94 (m, 2H), 6.64-6.67 (m, 1H), 7.32-7.35 
(m, 2H), 7.37-7.40 (m, 1H), 7.45-7.47 (m, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.5 (CH3), 29.6 (CH2), 47.2 (CH), 79.8 (C), 123.3 (q, J= 273.1 Hz, CF3), 
124.6 (CH), 127.4 (C), 127.6 (CH), 128.3 (CH), 129.6 (q, J= 5.8 Hz, CH), 125.6 (C), 135.3 (C), 154.9 (C) 
ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -64.3 (s, 3F) ppm.  
HRMS (EI) calcd. for C16H19F3NO2 [M+H
+]: 314.1362, found: 314.1347.  
Chapter 1  D. M. Sedgwick, Tesis Doctoral 
75 
 




tert-Butyl (S)-[7-chloro-4-(trifluoromethyl)-1,2-dihydronaphthalen-1-yl] carbamate, 1.79b 
Flash chromatography of the crude reaction product [n-hexane- Et2O (20:1)] afforded 1.79b as a white 
solid (74%, 75 mg), with a melting point 85-87 °C. [α]D
25 = - 3.43 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.46 (s, 9H),  2.60-2.65 (m, 2H), 4.80-4.92 (m, 2H), 6.64-6.68 (m, 2H), 7.27-
7.31 (m, 1H), 7.36 (d, J= 1.8 Hz, 1H), 7.39 (d, J= 2.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 29.5 (CH2), 47.1 (CH), 80.1 (C), 123.1 (q, J= 277.8 Hz, CF3), 
125.9 (CH), 127.4 (CH), 127.7 (C), 128.3 (CH), 129.9 (q, J= 5.0 Hz, CH), 134.7 (C), 137.4 (C), 154.9 (C) 
ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -64.5 (s, 3F) ppm.  
HRMS (EI) calcd. for C16H18ClF3NO2 [M+H
+]: 348.0973, found: 348.0975.  




tert-Butyl (S)-[6-fluoro-4-(trifluoromethyl)-1,2-dihydronaphthalen-1-yl] carbamate, 1.79c 
Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.79c as a 
colourless oil (66%, 60 mg). [α]D
25 = - 16.2 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.44 (s, 9H), 2.57-2.74 (m, 2H), 4.76-4.91 (m, 2H), 6.72 (t, J= 3.3 Hz, 2H), 
7.01 (ddd, J= 10.8, 8.4, 2.7 Hz, 1H), 7.15-7.19 (m, 1H), 7.40 (dd, J= 8.4, 5.7 Hz, 1H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 28.3 (CH3), 29.8 (CH2), 46.5 (CH), 79.9 (C), 111.8 (d, J= 2.2 Hz, CH), 112.2 
(CH), 115.4 (CH), 115.7 (CH), 123.0 (q, J= 277.8 Hz, CF3), 127.9 (q, J= 24.5 Hz, C), 129.2 (q, J= 7.6 Hz, C), 
131.0 (C), 154.8 (C), 162.4 (d, J= 241.6 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -64.6 (s, 3F), -113.2 (dd, J= -15.2, 9.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H18F4NO2 [M+H
+]: 332.1312, found: 332.1310.  




tert-Butyl (S)-[8-(trifluoromethyl)-5,6-dihydronaphtho[2,3-d][1,3]dioxol-5-yl] carbamate, 
1.79d 
Flash chromatography of the crude reaction product [n-hexane-Et2O (5:1)] afforded 1.79d as a 
colourless oil (80%, 58 mg). [α]D
25 = - 2.05 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.44 (s, 9H), 2.54-2.68 (m, 2H), 4.62-4.64 (m, 1H), 4.77 (s, 1H), 5.97 (s, 2H), 
6.53-6.56 (m, 1H), 6.89 (s, 1H), 6.96 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.4 (CH3), 29.6 (CH2), 47.3 (CH), 79.8 (CH), 101.4 (CH2), 105.4 (CH), 108.5 
(C), 123.3 (q, J= 277.8 Hz, CF3), 127.5 (q, J= 5.7 Hz, CH), 128.0 (C), 128.4 (C), 130.1 (C), 147.5 (C), 147.6 
(C), 154.8 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -63.9 (s, 3F) ppm.  
HRMS (EI) calcd. for C17H19F3NO4 [M+H
+]: 358.1261, found: 258.1259.  
HPLC (Chiralpak IC, 98:2 hexane/i-PrOH, 1 ml min‐1, 240 nm) RT (major) = 12.93 min, RT (minor) = 9.66 
min. 
 




tert-Butyl (S)-[7-methoxy-4-(trifluoromethyl)-1,2-dihydronaphthalen-1-yl] carbamate, 1.79e 
Flash chromatography of the crude reaction product [n-hexane-Et2O (7:1)] afforded 1.79e as a white 
solid (77%, 53 mg), with a melting point of 80-82 °C. [α]D
25 = - 5.44 (c 1.0; CHCl3)
  
1H NMR (CDCl3, 300 MHz): δ 1.45 (s, 9H), 2.61 (br, 2H), 3.83 (s, 3H), 4.78-4.86 (m, 2H), 6.49-6.52 (m, 1H), 
6.84 (dd, J= 8.7, 2.7 Hz, 1H), 6.94 (d, J= 2.7 Hz, 1H), 7.40 (dd, J= 8.7, 1.8 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.4 (CH3), 29.6 (CH2), 47.6 (CH), 55.4 (CH3), 79.8 (C), 79.8 (C), 113.3 (CH), 
120.3 (C), 123.4 (q, J= 273.0 Hz, CF3), 126.1 (CH), 126.7 (C), 128.2 (d, J= 29.8 Hz, C), 137.4 (C), 154.9 (C), 
159.9 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -63.9 (s, 3F) ppm.  
HRMS (EI) calcd. for C17H21F3NO3 [M+H
+]: 344.1468, found: 344.1460.  




tert-Butyl (S)-[4-(trifluoromethyl)-6,7-dihydrobenzo[b]thiophen-7-yl] carbamate, 1.79f 
Flash chromatography of the crude reaction product [n-hexane-Et2O (12:1)] afforded 1.79f as a yellow 
solid (68%, 99 mg), with a melting point of 81-83 °C. [α]D
25 = - 35.4 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.44 (s, 9H), 2.74-2.84 (m, 2H), 4.90 (br, 1H), 5.17-5.94 (m, 1H), 6.38-6.42 
(m, 1H), 7.06 (dd, J= 5.4, 1.8 Hz), 7.24 (d, J= 5.1 Hz) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.7 (CH3), 31.5 (CH2), 44.1 (CH), 80.0 (C), 117.6 (C), 121.2 (C), 124.3 (CH), 
125.3 (CH), 125.5 (CH), 129.3 (C), 137.5 (C), 154.5 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -66.6 (s, 3F) ppm.  
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HRMS (EI) calcd. for C14H17F3NO2S [M+H
+]: 320.0927, found: 320.0922.  




tert-Butyl (S)-[4-(perfluoroethyl)-1,2-dihydronaphthalen-1-yl] carbamate, 1.79g 
Flash chromatography of the crude reaction product [n-hexane-Et2O (15:1)] afforded 1.79g as a 
colourless oil (80%, 20 mg). [α]D
25 = - 15.8 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.46 (s, 9H), 2.64-2.66 (m, 2H), 4.74-4.77 (m, 1H), 4.85-4.92 (m, 1H), 6.68 
(t, J= 6.03 Hz, 1H), 7.30-7.33 (m, 2H), 7.38-7.41 (m, 1H), 7.50-7.53 (m, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.4 (CH3), 29.9 (CH2), 47.4 (CH), 79.9 (C), 113.5-121.6 (C2F5), 125.4 (CH), 
127.4 (CH), 127.9 (C), 128.2 (CH), 128.9 (CH), 133.3 (t, J= 10.0 Hz, CH), 135.7 (C), 154.9 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz) δ -111.2 (q, J= 285 Hz, 2F), -83.3 (s, 3F) ppm.  
HRMS (EI) calcd. for NaC17H18F5NO2 [M+Na
+]: 386.1150, found: 386.1138.  




tert-Butyl [(5S,6S)-6-methyl-8-(trifluoromethyl)-5,6-dihydronaphtho[2,3-d][1,3] dioxol-5-yl] 
carbamate, 1.79h 
Flash chromatography of the crude reaction product [n-hexane-Et2O (20:1)] afforded 1.79h as a white 
solid (42%, 30 mg), with a melting point of 135-137 °C. [α]D
25 = - 32.5 (c 1.0; CHCl3).
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1H NMR (CDCl3, 300 MHz): δ 1.2 (d, J= 7.2 Hz), 1.44 (s, 9H), 2.74 (s, 1H), 4.62-4.64 (m, 1H), 4.77 (s, 1H), 
5.97 (s, 2H), 6.28-6.29 (m, 1H), 6.89 (s, 1H), 6.96 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 14.2 (CH3), 28.3 (CH3), 32.2 (CH), 51.5 (CH), 79.7 (C), 101.4 (CH2), 105.3 
(CH), 108.6 (CH), 120.6 (C), 123.3 (q, J= 277.8 Hz, CF3), 127.7 (q, J= 29.6 Hz, C), 131.2 (C), 133.8 (q, J= 8.2 
Hz, CH), 147.5 (C), 147.7 (C), 155.3 (C) ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -64.3 (s, 3F) ppm.  
HRMS (EI) calcd. for C18H21F3NO4 [M+H
+]: 372.1417, found: 372.1402.  





Flash chromatography of the crude reaction product [n-hexane-EtOAc (2:1)] afforded 1.80a as a 
colourless oil (42%, 54 mg). [α]D
25 = - 2.0 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.96 (s, 3H), 2.58-2.79 (m, 2H), 5.19-5.25 (m, 1H), 5.71 (br, 1H), 6.64-6.68 
(m, 1H), 7.32-7.39 (m, 3H), 7.48-7.51 (m, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 23.4 (CH3), 29.2 (CH2), 45.8 (CH), 123.5 (q, J= 271.1 Hz, CF3), 124.7 (q, J= 
2.2 Hz, CH), 127.4 (C), 128.1 (CH), 128.6 (CH), 129.1 (CH), 129.7 (q, J= 6.2 Hz, CH), 134.6 (C), 169.2 (C) 
ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -64.3 (s, 3F) ppm.  
HRMS (EI) calcd. for C13H13F3NO [M+H
+]: 256.0944, found: 256.0956.  
HPLC (Chiralcel OD-H, 95:5 hexane/i-PrOH, 1 ml min‐1, 240 nm) RT (major) = 19.70 min, RT (minor) = 
15.40 min. 
 





Flash chromatography of the crude reaction product [n-hexane-EtOAc (4:1)] afforded 1.80b as a white 
solid (44%, 65 mg), with a melting point of 133-135 °C. [α]D
25 = - 6.5 (c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.94 (s, 3H), 2.74-2.78 (m, 2H), 5.33-5.40 (m, 1H; CH), 5.96 (d, J= 9.3 Hz, 1H; 
NH), 6.39-6.42 (m, 1H; CH), 7.08 (dd, J= 5.1, 1.8 Hz, 1H; CH), 7.26 (d, J= 5.1 Hz, 1H; CH) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 23.1 (CH3), 30.7 (CH2), 42.1 (CH), 122.5 (q, J= 268.4 Hz, CF3), 123.9 (CH), 
124.7 (C), 125.1 (q, J= 4.4 Hz, CH), 125.2 (CH), 126.1 (q, J= 32.4 Hz, C), 129.6 (C), 136.6 (C), 169.1 (C) 
ppm.   
19F NMR (CDCl3, 282.4 MHz): δ -66.5 (s, 3F) ppm.  
HRMS (EI) calcd. for C11H11F3NOS [M+H
+]: 262.0508, found: 262.0505.  





Flash chromatography of the crude reaction product [n-hexane-EtOAc (3:1)] afforded 1.80c as a white 
solid (40%, 15 mg), with a melting point of 70-72 °C. [α]D
25 = - 7.45(c 1.0; CHCl3).  
1H NMR (CDCl3, 300 MHz): δ 1.94 (s, 3H), 2.57-2.63 (m, 1H), 2.79-2.86 (m, 1H), 5.19 (m, 1H), 6.13 (d, J= 
8.1 Hz, 1H), 6.75-6.77 (m, 1H), 7.32-7.35 (m, 3H), 7.63-7.81 (m, 4H), 7.99-8.02 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 23.3 (CH3), 29.9 (CH2), 46.2 (CH), 122.3 (t, J= 288.4 Hz, CF2), 126.1 (t, J= 
19.4 Hz, C) 126.3-126.4 (C+CH), 127.8 (CH), 128.4 (CH), 129.1 (CH), 129.3 (CH), 130.7 (2CH), 132.9 (C), 
135.1 (CH), 135.3 (CH), 136.5 (t, J= 10.0 Hz, C), 169.4 (C) ppm.  
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19F NMR (CDCl3, 282.4 MHz): δ 96.3 (dd, J= 229.0, 5.1 Hz), 99.2 (d, J= 228.7 Hz) ppm.  
HRMS (EI) calcd. for C19H18F2NO3S [M+H
+]: 378.0970, found: 378.0955.  





Flash chromatography of the crude reaction product [n-hexane-EtOAc (2:1)] afforded 1.81a as a 
colourless oil (72%, 25 mg). [α]D
25 = - 6.8 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.14 (s, 9H), 2.04 (s, 3H), 2.50-2.71 (m, 2H), 3.36 (d, J= 9.0 Hz, 1H), 4.37-
4.44 (m, 1H), 5.78 (br, 1H), 7.20-7.34 (m, 4H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 19.1 (CH3), 22.6 (CH3), 32.6 (CH2), 55.0 (CH), 56.1 (C), 122.1 (CH), 123.4 
(CH), 126.7 (CH), 127.2 (CH), 127.9 (CH), 132.2 (C), 134.9 (C), 135.9 (C) ppm.  
HRMS (EI) calcd. for C15H22NOS [M+H




Flash chromatography of the crude reaction product [n-hexane-EtOAc (1:1)] afforded 1.81b as a 
colourless oil (87%, 15 mg). [α]D
25 = - 4.2 (c 1.0; CHCl3).
  
1H NMR (CDCl3, 300 MHz): δ 1.18 (s, 9H), 1.40 (t, J= 7.0 Hz, 3H), 2.78-2.83 (m, 2H), 3.34 (d, J= 9.2 Hz, 
1H), 4.32 (q, J= 7.0 Hz, 2H), 4.44-4.51 (m, 1H), 7.07-7.10 (m, 1H), 7.29-7.40 (m, 3H), 7.89 (d, J= 7.5 Hz, 
1H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 14.2 (CH3), 22.6 (3CH3), 32.6 (CH2), 54.1 (CH), 56.3 (C), 60.8 (CH2), 126.7 
(CH), 126.9 (CH), 128.1 (CH), 128.2 (CH), 130.0 (C), 130.7 (C), 135.6 (CH), 135.8 (C), 165.9 (C) ppm.  
HRMS (EI) calcd. for C17H24NO3S [M+H
+]: 322.1471, found: 322.1473. 
  











A simple route to 1,2-fluorohydrins via 
1,2-difunctionalisation of olefins 









In this chapter we will study the possibility of a one-pot procedure for the synthesis of fluorohydrins 
from olefin starting materials, whereby the epoxidation and subsequent opening with HF is carried out 
in the same reaction sequence. To this end, the compatibility of m-CPBA and HF·amine reagents will 
need to be assured in terms of this transformation. The regioselectivity will also be studied. 
This work was developed in collaboration with the group of G.B. Hammond, and a part of the scope of 












2.1.1. Olefin 1,2-difunctionalisation. 
 
The 2001 Nobel Prize in Chemistry was partly awarded to Barry Sharpless “for his work on chirally 
catalysed oxidation reactions”; a testament to his emblematic asymmetric epoxidation and 1,2-
dihydroxylation of olefins, and to the utility of olefin 1,2-difunctionalisation in general.52 The 1,2-
difunctionalisation of olefins is a powerful transformation in organic chemistry, allowing us to rapidly 
build molecular complexity at the expense of a double bond. Not only that, but olefins are ideal starting 
blocks for many organic synthetic routes, due to the following characteristics. 
 
 They are among the cheapest and most abundant organic starting material containing useful 
functional groups. 
 They are often tolerant of a great variety of transformations throughout a synthetic route, and 
can be “revealed” at will through the addition of heteroatoms. 
 They are usually prochiral, providing an escape from “flatland” as well as facile access to the 
chiral world.53 
 
Aside from hydrogenation or halogenation processes—which in themselves could be classed as formal 
1,2-difunctionalisation of olefins—perhaps the first example of this illustrious transformation was the 
dihydroxylation of olefins reported in the 1930s by Criegee.54 This osmium-based transformation was 
for years a purely stoichiometric transformation due to a lack of viable catalytic alternatives. This was 
clearly not ideal, given the toxicity and cost of osmium tetroxide. Criegee did, however, observe an 
accelerating effect when pyridine was added to the reaction media—this would later be crucial to 
Sharpless’ studies into this transformation (Scheme 2.1, a).  
Later, in the 1970s, VanRheenen and co-workers at the Upjohn Company developed the so-called 
Upjohn dihydroxylation, in which a tertiary amine oxide additive permitted the use of catalytic amounts 
of osmium tetroxide (Scheme 2.1, b).55 
                                                          
52
 K. B. Sharpless, Angew. Chem. Int. Ed., 2002, 41, 2024-2032.  
53
 F. Lovering, J. Bikker and C. Humblet, J. Med. Chem., 2009, 52, 6752-6756. 
54
 a) R. Criegee, Justus Liebigs Ann. Chem., 1936, 522, 75-96. b) R. Criegee, Angew. Chem., 1937, 50, 153-155. c) R. 
Criegee, Angew. Chem., 1938, 51, 519-520.  
55
 V. VanRheenen, R. C. Kelly and D. Y. Cha, Tetrahedron Lett., 1976, 23, 1973-1976. 
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These studies formed the basis of Sharpless’ seminal advances in the 1980s, when the group 
successfully developed an asymmetric version of the cis-dihydroxylation of alkenes using catalytic 
osmium tetroxide in conjunction with a cinchona alkaloid ligand to induce chirality and N-
methylmorpholine N-oxide (NMO) as a terminal oxidant to regenerate the active osmium tetroxide 
(Scheme 2.1, c).56  
 
 
Scheme 2.1. a) The first dihydroxylation sequence developed by Criegee, highlighting the rate-enhancing effect 
observed when pyridine was present in the reaction media. b) The Upjohn dihydroxylation, the first efficient 
catalytic version of the transformation. c) Sharpless’ first asymmetric catalytic variant, the rate of which is also 
enhanced by the quinuclidine-based ligand. 
 
Interestingly, the cinchona alkaloid chiral ligands granted the perfect balance between binding strength 
of the two species present in the catalytic cycle; it binds strongly enough to osmium tetroxide to 
                                                          
56
 a) S. G. Hentges and K. B. Sharpless, J. Am. Chem. Soc., 1980, 102, 4263-4265. b) E. N. Jacobsen, I. Markó, W. S. 
Mungall, G. Schröder and K. B. Sharpless, J. Am. Chem. Soc., 1988, 110, 1968-1970. 
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accelerate the rate of the asymmetric reaction, and is labile enough to be cleaved from the osmate 
ester for the catalytic cycle to continue at a fast rate. This phenomenon, termed “ligand-accelerated 
catalysis” by Sharpless himself, is also responsible for negating the uncatalysed reaction which leads to 
the racemic product. However, another catalytic cycle was later found to be acting in unison with the 
NMO co-oxidant. This was later rectified and a refined version was developed using the solid potassium 
osmate salt along with potassium ferricyanide as the co-oxidant. This advance allowed the group to 
develop the so-called AD-mix (AD being an abbreviation of asymmetric dihydroxylation), a commercially 
available mixture containing all the required components—that is, potassium osmate, potassium 
ferricyanide, potassium carbonate and the corresponding cinchona alkaloid present as a phthalazine 
adduct—in the correct ratio, permitting scientists around the world to carry out this sophisticated 
transformation by simply adding 1.4 g of AD-mix to 1 mmol of olefin.57  
This transformation was also extended to the 1,2-hydroxylamination of olefins, again by Sharpless and 
co-workers.58 This can be achieved through the addition of an imide precursor, usually a mixture of an 
N-chlorosodiocarbamate or an N-halosulfonamide such as chloramine-T, and of course the osmium 
catalyst and ligand (Scheme 2.2).  
 
 
Scheme 2.2. Representative examples of olefin 1,2-hydroxyamination developed by Sharpless.
 
 
Since these early examples, there have been many advances in this field including 1,2-
dicarbofunctionalisations, 59  1,2-carboheterofunctionalisations, 60  and new 1,2-
                                                          
57
 H. C. Kolb, M. S. VanNieuwenhze and K. B. Sharpless, Chem. Rev., 1994, 94, 2483-2547.  
58
 a) K. B. Sharpless, D. W. Patrick, L. K. Truesdale and S. A. Biller, J. Am. Chem. Soc., 1975, 97, 2305-2307. b) E. 
Herranz, S. A. Biller and K. B. Sharpless, J. Am. Chem. Soc., 1978, 100, 3596-3598. For a review on the 1,2-
hydroxyamination of alkenes see: J. A. Bodkin and M. D. McLeod, J. Chem. Soc., Perkin Trans. 1., 2002, 2733-2746. 
59
 For selected recent examples see: a) X. Tang and A. Studer, Angew. Chem. Int. Ed., 2018, 57, 814-817. b) Z. 
Kuang, K. Yang and Q. Song, Org. Lett., 2017, 19, 2702-2705. c) R. K. Dhungana, B. Shrestha, R. Thapa-Magar, P. 
Basnet and R. Giri, Org. Lett., 2017, 19, 2154-2157.  
60
 For selected recent examples see: a) J. Cheng, Y. Cheng, J. Xie and C. Zhu, Org. Lett., 2018, 19, 6452-6455. b) Y.-
Y. Liu, X.-H. Yang, R.-J. Song, S. Luo and J.-H. Li, Nature Commun., 2017, 8, Article number: 14720, DOI: 
10.1038/ncomms14720. 
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diheterofunctionalisations.61 Thus, given the large volume of work available in this area, this section will 
focus on selected examples that incorporate fluorine into the final product. Of course, one of the 
earliest and most emblematic examples of this class of difunctionalisation is the halofluorination 
reaction first described by Olah and co-workers, using N-halosuccinimide in conjunction with their own 
HF·pyridine reagent (Scheme 2.3).62 This reaction can also be carried out using other halogen sources, 
such as elemental bromine or iodine with a silver nitrate additive, or trihaloisocyanuric acids—the latter 
proving the most sustainable and atom economical, since the cyanuric acid precipitate can be 
halogenated and reused.63 In terms of the mechanism, the reaction first involves the formation of a 
halonium cation intermediate, which is then opened by the nucleophilic fluoride present in the 
HF·pyridine solution in a regioselective manner to form the Markovnikov product.64  
 
 
Scheme 2.3. Halofluorination using electrophilic halogen sources and Olah’s reagent. 
 
More recent examples of olefin 1,2-difunctionalisations incorporating a fluorine substituent into the 
final product were reported by Liu et al. through the years 2009-2016.65 This group developed a high-
valent palladium catalytic cycle using strong iodine(III) oxidant 2.1 combined with silver(I) fluoride as 
the source of nucleophilic fluorine. In this context, the authors suggest a mechanism by which the 5-
aminopent-1-ene starting materials undergo aminopalladation to form six-membered ring I. From 
there, the palladium(II) centre is oxidised to palladium(IV) by 2.1 and AgF. The R—F bond in the final 
piperidine product is then formed via reductive elimination from II (Scheme 2.4, a).66 Curiously, when 
                                                          
61
 For selected recent examples see: a) Y. Yang, R.-J. Song, X.-H. Ouyang, C.-Y. Wang, J.-H. Li and S. Luo, Angew. 
Chem. Int. Ed., 2017, 56, 7916-7919. b) X. Sun, X. Li, S. Song, Y. Zhu, Y.-F. Liang and N. Jiao, J. Am. Chem. Soc., 
2015, 137, 6059-6066. c) J. L. Jat, M. P. Paudyal, H. Gao, Q.-L. Xu, M. Yousufuddin, D. Devarajan, D. H. Ess, L. Kürti 
and J. R. Falck, Science, 2014, 343, 61-65. 
62
 a) G. A. Olah, M. Nojima and I. Kerekes, Synthesis, 1973, 1973, 780-783. b) G. A. Olah, J. T. Welch, Y. D. Vankar, 
M. Nojima, I. Kerekes and J. A. Olah, J. Org. Chem., 1979, 44, 3872-3881. 
63
 L. T. C. Crespo, R. da S. Ribeiro, M. C. S. de Mattos and P. M. Esteves, Synthesis, 2010, 14, 2379-2382. 
64
 M. Lübke, R. Skupin and G. Haufe, J. Fluorine Chem., 2000, 102, 125-133. 
65
 G. Yin, X. Mu and G. Liu, Acc. Chem. Res., 2016, 49, 2413-2423. 
66
 T. Wu, G. Yin and G. Liu, J. Am. Chem. Soc., 2009, 131, 16354-16355. 
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N-tosyl amines were used the six-membered endo product was observed, whereas when the amine 
protecting group was changed to a strongly-chelating carbamate the 5-exo product was observed 
(Scheme 2.4, b).67  This methodology was also applied to the total synthesis of fluorinated derivatives of 
both Swainsonine and Febrifugine by the same authors in 2016, highlighting the usefulness of this 
practical procedure in the preparation of 2.2, a common intermediate towards both natural product 
analogues (Scheme 2.4, c).68 In 2012, the same transformation was reported by Meng, Li et al. using 
metal-free reaction conditions.69  
 
 
Scheme 2.4. a) Intramolecular 1,2-aminofluorination mechanism. b) Stereodivergent products depending on the 
amine protecting group. c) 1,2-Aminofluorination in the synthesis of natural product analogues. 
 
Similar transformations have been described using carboxylic acids with an unactivated olefin in a 
remote position, mainly based on electrophilic lactonisations without requiring a metal promoter.70 For 
example, in 2014 Rueping et al. described the use of 2-vinylbenzoic acids as substrates for this type of 
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 T. Wu, J. Cheng, P. Chen and G. Liu, Chem. Commun., 2013, 49, 8707-8709. 
68
 L. Wu, P. Chen and G. Liu, Org. Lett., 2016, 18, 960-963. 
69
 Q. Wang, W. Zhong, X. Wei, M. Ning, X. Meng and Z. Li, Org. Biomol. Chem., 2012, 10, 8566-8569. 
70
 a) M. Sawaguchi, S. Hara, T. Fukuhara and N. Yoneda, J. Fluorine Chem., 2000, 104, 277-280. b) L. F. Lourie, Y. A. 
Serguche, G. V. Shevchenko, M. V. Ponomarenko, A. N. Chernega, E. B. Rusanov and J. A. K. Howard, J. Fluorine 
Chem., 2006, 127, 377-385. c) Y. A. Serguchev, L. F. Lourie, M. V. Ponomarenko, E. B. Rusanov and N. V. Ignat’ev, 
Tetrahedron Lett., 2011, 52, 5166-5169.  
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transformation (Scheme 2.5).71 To this end, they employed a phase-transfer strategy by which 
Selectfluor was gradually introduced into the apolar media by anion exchange with a sodium carbonate 
additive. Stuart and co-workers then developed another version of this transformation using a 
hypervalent fluoroiodine reagent, in this case not limited to 2-vinylbenzoic acid derivatives.72  
 
 
Scheme 2.5. Selectfluor-mediated fluorolactonisation of 2-vinylbenzoic acids derivatives.  
 
All previous examples of this approach with electrophilic fluorine sources afforded exclusively the 5-exo 
lactonisation, however, in 2016 Jacobsen reported the first example of this transformation using a 
nucleophilic fluoride source to afford the 6-endo lactones, and in an enantioselective manner.73 To this 
end, the authors employed aryl iodide 2.3 bearing a chiral C2 axis as the catalyst—this species would 
undergo oxidation by m-CPBA and subsequent fluorination by HF·pyridine would produce the active 
hypervalent fluoroiodine complex responsible for the fluorolactonisation (Scheme 2.6). These 
conditions were first reported by Shibata et al. in the development of an aminofluorination protocol.74 
 
 
Scheme 2.6. Enantioselective fluorolactonisation developed by Jacobsen et al. 
 
However, many of the aforementioned transformations are intramolecular, and are therefore limited to 
defined substrate classes. Therefore, searching for ways to improve the scope of 1,2-
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 D. Parmar, M. Sudan Maji and M. Rueping, Chem. Eur. J., 2014, 20, 83-86. 
72
 G. C. Geary, E. G. Hope and A. M. Stuart, Angew. Chem. Int. Ed., 2015, 54, 14911-14914. 
73
 E. M. Woerly, S. M. Banik and E. N. Jacobsen, J. Am. Chem. Soc., 2016, 138, 13858-13861. 
74
 S. Suzuki, T. Kamo, K. Fukushi, T. Hiramatsu, E. Tokunaga, T. Dohi, Y. Kita and N. Shibata, Chem. Sci., 2014, 5, 
2754-2760.  
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difunctionalisations involving the introduction of fluorine into the final product—and based on their 
own observations that iodonium species formed between iodine(III) reagents and olefins undergo 
oxidative addition with palladium species75—in 2017 Liu and co-workers described the palladium-
catalysed fluorocarbonylation of unactivated olefins, affording β-fluorocarboxylic acid derivatives 
(Scheme 2.7).76 Interestingly, the palladium catalysed process ends with either the acyl fluoride or the 
carboxylic acid from adventitious acetate or fluoride ions in the media. Therefore, the authors 
quenched with a nucleophile such as methanol, water or amine to converge the two intermediate 
products into the single desired ester, carboxylic acid or amide respectively. 
 
 
Scheme 2.7. Synthesis of β-fluorocarbonyl derivatives via 1,2-difunctionalisation of olefins. 
 
More recently, in 2016 several advances in 1,2-difluorination reactions were described. Building on the 
stoichiometric procedure reported by Hara, Yoneda and co-workers using iodoarene difluorides in 
combination with 5HF·Et3N,
77 Jacobsen78 and Gilmour79 presented protocols in which the iodoarene can 
be used catalytically to provide high yields and, in Jacobsen’s examples, high enantioselectivities 
(Scheme 2.8, a). Furthermore, Jacobsen and co-workers were able to obtain different products 
depending on whether the favoured reaction pathway involved anchimeric assistance from a 
neighbouring amide group (affording 1,2-difluorinated products 2.5) or migration of the aryl substituent 
(affording 1,1-difluorinated products 2.6). Gilmour also provided a similar protocol using the simple p-
iodotoluene as the catalyst, giving rise to racemic 1,2-difluorinated products (Scheme 2.8, b). 
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 M. Li, F. Yu, X. Qi, P. Chen and G. Liu, Angew. Chem. Int. Ed., 2016, 55, 13843-13848. 
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 X. Qi, F. Yu, P. Chen and G. Liu, Angew. Chem. Int. Ed., 2017, 56, 12692-12696. 
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 S. Hara, J. Nakahigashi, K. Ishi-i, M. Sawaguchi, H. Sakai, T. Fukuhara and N. Yoneda, Synlett., 1998, 495-496. 
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 a) S. M. Banik, J. W. Medley and E. N. Jacobsen, J. Am. Chem. Soc., 2016, 138, 5000-5003. b) S. M. Banik, J. W. 
Medley and E. N. Jacobsen, Science, 2016, 353, 51-54. 
79
 I. G. Molnár and R. Gilmour, J. Am. Chem. Soc., 2016, 138, 5004-5007. 




Scheme 2.8. Difluorinations developed by Jacobsen and Gilmour. 
 
  





The first fluorine-containing drug to reach the market, Fludrocortisone, contains a fluorohydrin moiety 
and resulted in a decisive drive for research in this field (Figure 2.1). The discovery of this compound 
came about when in the 1950s Fried and Sabo observed that the introduction of a halogen into the 
cortisol skeleton increased its bioactivity, and that the activity was inversely proportional to the size of 
the halogen.80 In this sense, the presence of the fluorine atom was shown to increase the activity 10-
fold for glucocorticoid and up to 800-fold for mineralocorticoid receptors. Fludrocortisone is primarily 
administered as the acetate prodrug which is hydrolysed in vivo, and is generally used to replace 
aldosterone (the main compound in the mineralocorticoid class of hormones) in patients suffering 
maladies that cause hormone imbalances. 
Other fluorinated steroid-based drugs have also been approved for use as anti-inflammatories, such as 
Fluticasone propionate and Difluprednate (Figure 2.1).81 The latter was proven to have increased topical 
potency due to the fluorine substituents in positions C6 and C9, whereas the C21 acetate and C17 
butyrate groups improve the lipophilicity and anti-inflammatory activity, respectively.82 
Since then, other drugs containing the fluorohydrin subunit have been introduced into the market with 
varying therapeutic uses. For example, Sofosbuvir is an anti-viral drug that was approved by the FDA in 
2013 for use in the treatment of hepatitis C (Figure 2.1).83 This compound is also a prodrug, first 
requiring metabolism in the liver to hydrolyse the ester and the phosphoramide groups, as well as 
subsequent phosphorylation to afford the active triphosphate form. 
 
 
Figure 2.1. Steroid-based drugs containing a fluorohydrin moiety, and Sofosbuvir, a more recent anti-viral agent 
used against hepatitis C. 
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 J. Fried and E. F. Sabo, J. Am. Chem. Soc., 1954, 76, 1455-1456. 
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 K. N. Jamal and D. G. Callanan, Clin. Opthal., 2009, 3, 381-390.  
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 M. Korenfeld, Expert Rev. Ophthamol., 2008, 3, 619-625. 
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 a) A. Yancey, A. Armbruster and S. Tackett, J. Pharm. Tech., 2015, 31, 29-37. b) A. Fung, Z. Jin, N. Dyatkina, G. 
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The synthesis of fluorohydrins has been dominated by the opening of epoxides with nucleophilic 
fluoride sources, among which HF·amine reagents stand out for their atom economy and practicality.  
The synthesis of fluorohydrins has been described at length in the chemical literature.84  
The opening of terminal epoxides with fluoride sources generally follows the standard rules for this 
type of transformation: the fluoride attacks the most substituted carbon in acidic reaction conditions 
due to an SN1 type mechanism, resulting in the terminal alcohol; and the least substituted carbon in 
basic reaction conditions due to an SN2 type mechanism, resulting in the terminal fluoride. However, 
with HF·amine reagents the situation is not always as straightforward as it may seem, given the 
competing nature of the acidic HF and the basic hydrogen-bond donor. Haufe and Sattler studied the 
regioselectivity of this opening using 2.7 as the model substrate, finding that 9HF·pyridine typically 
favours the formation of 2.8 through an SN1 type mechanism whereas 3HF·Et3N shows little selectivity 
(Scheme 2.9). 85 These results can be shifted towards the formation of the opposite regioisomer 
through the addition of extra base, essentially lowering the concentration of HF and leading to more 
basic reaction conditions. Nevertheless, this seems slightly unnecessary since similar results are 
obtained through the simple treatment of the epoxide with an inorganic fluoride salt, such as KHF2 
(Scheme 2.9, a). Furthermore, since the reaction between the epoxide and Olah’s reagent generally 
takes place via an SN1 type mechanism, the presence of proximal heteroatoms can alter the 
regioselectivity of the process (Scheme 2.9, b) 
 
 
Scheme 2.9. Regioselectivity observed with the opening of epoxides with varying fluoride sources. 
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 For an extensive review on the synthesis of fluorohydrins, see: a) G. Haufe, J. Fluorine Chem., 2004, 125, 875-
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85
 A. Sattler and G. Haufe, J. Fluorine Chem., 1994, 69, 185-190. 





Several reports have been published regarding the 1,2-hydroxyfluorination of olefins. However, to the 
best of our knowledge, none of these have involved the use of HF·amine reagents—although 
Jouannetaud et al. employed HF·SBF5 superacid to produce cinchona-derived fluorohydrins in 2006.
86 
This reaction, however, was unselective and the authors obtained complex mixtures of products in 
most cases. 
In this context, the vast majority use Selectfluor as an electrophilic fluorine source. For example, in the 
years 2004 and 2013 the groups of Stavber87 and Singh,88 respectively, reported facile procedures 
involving the use of Selectfluor in an aqueous medium for the 1,2-hydroxyfluorination of alkenes. 
However, these were both limited to aromatic derivatives, and both afforded the corresponding 
terminal fluorides (Scheme 2.10). 
 
 
Scheme 2.10. The use of Selectfluor and water in the 1,2-hydroxyfluorination of olefins. 
 
Furthermore, in 2012 Davies and co-workers achieved the regio- and diastereoselective synthesis of 
fluorohydrins starting from allylamines 2.13.89 The authors developed a one-pot epoxidation-ring 
opening sequence using m-CPBA and HBF4 as the fluoride source, obtaining moderate yields and high 
diastereomeric excesses in almost all cases (99:1 dr in most cases). In addition, they were able to 
selectively produce one diastereoisomer or the other depending on the amount of tetrafluoroboric acid 
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87
 G. Stavber, M. Zupan, M. Jereb and S. Stavber, Org. Lett., 2004, 6, 4973-4976. 
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(Scheme 2.11). With just two equivalents of tetrafluoroboric acid, a hydrogen bond is established 
between the amine group and the m-CPBA during the epoxidation step, delivering the epoxide group to 
the same face as the amine to afford 2.14. However, when excess tetrafluoroboric acid is used, this is 
disrupted since the amine is completely protonated throughout the reaction, and the epoxide is 
delivered to the other face due to steric interactions, affording 2.15 instead. 
 
 
Scheme 2.11. Diastereodivergent synthesis of fluorohydrins using allylic amine starting materials. 
 
Most recently, in 2017 Xu, Tang and co-workers reported a silver-catalysed hydroxyfluorination 
procedure.90 The authors employed a mixture of AgOTf and Sm(OTf)3 as the catalyst and promoter, a 
complex PhNO2/H2O/MeNO2 solvent mixture and Selectfluor as the fluorine source (Scheme 2.12). The 
reaction is limited to the use of styrenes 2.16 as substrates, due to the radical pathway proposed by the 
authors. Nonetheless, for styrenes the reaction shows a wide scope and functional group compatibility, 
as well as being the first to selectively achieve the fluoride substituent in an internal position from a 
procedure of this kind. 
 
 
Scheme 2.12. Ag-catalysed radical 1,2-hydroxyfluorination of styrenes. 
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In addition, the authors carried out a number of experiments to shed some light on the reaction 
mechanism. These included the use of a radical inhibitor, a radical trapping agent, performing the 
reaction under strict oxygen exclusion and isotopic labelling. All of these experiments suggested that a 
radical chain or a single-electron transfer mechanism may be operating. Supported by DFT calculations, 
the following reaction mechanism was proposed (Scheme 2.13). After complexation to styrene 2.16, 
the corresponding silver species II is oxidised by Selectfluor rendering a silver(II) intermediate complex 
III, which in turn oxidises the styrene ligand to the corresponding radical cation IV, regenerating the 
silver(I) active catalyst I. The styrene radical cation IV then reacts with water affording the key benzylic 
radical V, which is subsequently fluorinated by Selectfluor affording products 2.17. Interestingly, 
theoretical calculations showed that radical cation VI obtained as a by-product may preferentially 
promote the Ag(I)/Ag(II) oxidation step over Selectfluor. Hence, after the first catalytic cycle using 
Selectfluor as the oxidant (Route A), Route B would be operating (Scheme 2.13). 
 
 
Scheme 2.13. Mechanism of 1,2-hydroxyfluorination of styrenes described by Xu, Tang et al. 
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2.3. Results and discussion.  
2.3.1. Development of a one-pot hydroxyfluorination procedure. 
 
To begin this work, we first analysed the possibility of the one pot procedure using styrene as the 
model substrate with a combination of m-CPBA and HF·amine, given that these were decided to be the 
most standard and practical reagents for both of the necessary transformations (Table 2.1). To our 
delight, the desired fluorohydrin was obtained in a decent yield and regioselectivity. This showed that 
the reagents were indeed compatible; the epoxidation was possible in acidic conditions in the presence 
of HF, and the subsequent opening took place without complications.  
We first studied the necessary equivalents of the two reagents, and quickly found that a large excess of 
HF compared to m-CPBA was necessary for the reaction to proceed to completion (entries 1-5, Table 
2.1). We also studied the delay in HF addition, first allowing a period of time for the epoxidation step 
before the subsequent ring opening (entries 5-8, Table 2.1). However, we observed no significant 
advantage to this. Therefore, we opted to add all the reactants at the beginning in the search for 
maximum simplicity and practicality. 
Oddly, no reaction was obtained when using 3HF·Et3N as the fluoride source (entry 10, Table 2.1). This 
could perhaps be due to incompatibility of m-CPBA with triethylamine, since the intermediate epoxide 
was not observed and only the starting styrene was recuperated.  
No significant difference was observed between HF·pyridine and HF·DMPU (entries 8-9 and 13-14, 
Table 2.1) and so we decided to continue the study using HF·pyridine, given the lower cost of this 
reagent. Similarly, dichloromethane was preferred to chloroform due to the lower environmental cost 
(entry 9 vs. 14, Table 2.1).  
A small amount of the regioisomer with the fluorine in the terminal position was observed in all cases, 
although the major product was the desired 2.19; all conditions tested showed a selectivity of around 
5:1 - 7:1 (2.19:2.20) (Table 2.1). 
Hence, the optimum conditions taken forward were the use of two equivalents of m-CPBA, seven 
equivalents of HF·pyridine, in dichloromethane at 0 °C and with simultaneous addition of all reagents 
from the onset (entry 14, Table 2.1). 
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Table 2.1. Optimisation of our one-pot 1,2-difunctionalisation procedure towards fluorohydrins. 
 
Entry Solvent x y t1 (h) t2 (h) amine Yield 2.19 (%)
a, b 
1 CHCl3 1.1 2.2 1 5 DMPU 32 
2 CHCl3 1.2 2.4 1 5 DMPU 44 
3 CHCl3 1.5 3 1 5 DMPU 48 
4 CHCl3 2 4 1 5 DMPU 55 
5 CHCl3 2 7 1 5 DMPU 76 
6 CHCl3 2 7 4 18 DMPU 77 
7 CHCl3 2 7 0.5 5 DMPU 75 
8 CHCl3 2 7 0 5 DMPU 75 
9 CHCl3 2 7 0 5 pyridine 74 
10 CHCl3 2 7 0 5 Et3N - 
c 
11 DCM 1.1 7 0.5 6 DMPU 40 
12 DCM 2 7 1 4 DMPU 75 
13 DCM 2 7 0 5 DMPU 76 
14 DCM 2 7 0 5 pyridine 75 
a
 Determined through 
1
F NMR using fluorobenzene as an internal standard. 
b
 Yield is given as a mixture of 





A slight inconvenience was the formation of small amounts of 2.21 resulting from the opening of the 
intermediate epoxide with m-chlorobenzoic acid, although this could be separated by simple flash 
column chromatography. The acidic media presumably activates the epoxide to a state in which this 
relatively poor nucleophile is able to open the epoxide ring (Scheme 2.14). Of course, given the 
situations seen previously, the exact reaction mechanism might be far more complex and will be 
studied in more detail in turn. The formation of this side product could be avoided in a stepwise 
synthesis; however, any economic loss resulting from the small drop in product yield would presumably 
be offset by the practicality of the one pot procedure. 
 




Scheme 2.14. The origin of side product 2.21. 
 
With the optimum conditions in hand, we selected a range of olefins to study the scope of our one-pot 
1,2-hydroxyfluorination protocol. We first studied several styrene derivatives with varying substituents 
on the aromatic ring (Table 2.2). 
 




 Isolated yields. 
b
 The reaction was also carried out on a 10 mmol scale with a yield of 53%. 
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The reaction proved to be fairly tolerant of electron-withdrawing substituents: styrene derivatives 
bearing trifluoromethyl, nitro, nitrile, ester, fluorine and chlorine substituents in the para position 
(2.19a-g, Table 2.2) all resulted in moderate to good yields, bearing in mind that these yields take into 
account two steps (a global yield of 50% corresponds to roughly 70% yield in each of the two reactions).  
Electron-donating substituents such as methoxy groups in the para position hampered the reaction and 
the main species identified in the crude mixture was the intermediate epoxide, possibly due to its lower 
electrophilicity (2.19i, Table 2.2). Interestingly, m-methoxystyrene gave rise to the desired fluorohydrin 
in a moderate yield (2.19k, Table 2.2), confirming that electronic effects were hampering the formation 
of the products in the case of 2.19i—the negative inductive effect of the methoxy group overrides the 
resonance effect when in the meta position, acting as an electron-withdrawing group although the 
aromatic ring itself is electron-rich. Oddly, neither p-methylstyrene nor p-tert-butyl styrene resulted in 
the corresponding fluorohydrin products 2.19h and 2.19j, despite being only slightly electron-donating.  
We next decided to explore aliphatic alkenes to set our methodology apart from those seen in 
previously reported 1,2-hydroxyfluorinations of alkenes, which have all been limited to aromatic 
derivatives. To this end, we chose allylbenzene derivatives, dodecene and cycloalkenes as suitable 
substrates. In order to begin to explore the reaction mechanism, we selected methylcyclohexene 2.18r 
and 1,2-dimethylcyclohexene 2.18s as substrates; if the reaction were to proceed through the prior 
opening of the epoxide and formation of a carbocation intermediate, the more substituted derivatives 
could give rise to higher yields and/or regioselectivities due to the facile opening of the epoxide and 
stabilisation of the positively-charged intermediate. 
Therefore, we first had to synthesise 2.18s. This was done via addition of methyllithium to 2-
methylcyclohexanone to form alcohol 2.22 and subsequent iodine-mediated dehydration (Scheme 
2.15). 91 This strategy afforded the isomeric olefins 2.18s and 2.23 in a 5:1 ratio. Since we were unable 
to separate these two isomers by neither column chromatography nor distillation, we used the 5:1 
mixture in the hydroxyfluorination reaction. 
 
 
Scheme 2.15. Synthesis of dimethylcyclohexene 2.18s. 
                                                          
91
 N. G. Léonard and P. J. Chirik, ACS Catal., 2018, 8, 342-348. 
Chapter 2  D. M. Sedgwick, Tesis Doctoral 
105 
 





 Isolated yields. 
b
 Inseparable 3:1 cis:trans mixture. 
c
 5:1 mixture of 2.18s and 2.23 used as the starting material. 
 
The results were generally good: the desired fluorohydrins were formed in moderate yields in most 
cases. In contrast to our expected results, the more substituted alkenes 2.18r and 2.18s gave lower 
yields. However, in the crude mixture we were able to identify mostly the starting alkene, and therefore 
we concluded that the problem arose due to the first epoxidation step rather than the opening with HF. 
On the other hand, allylbenzene and derivatives 2.18l-n all gave rise to desired fluorohydrins 2.19l-n in 
moderate to good yields (a global yield of 60% corresponds with an average of 77% yield for both 
steps), concordant with the assumption that electronic effects had hampered the reaction in the case 
of certain styrene derivatives. Fluorohydrin 2.19o derived from dodecene gave excellent results, and 
unsubstituted cyclopentene 2.18p and cyclohexene 2.18q also resulted in good yields. 
Encouraged by these results, we turned our attention to more challenging substrates that could be 
useful in the life sciences (Table 2.4). In this sense, we decided that cholesterol could be an interesting 
substrate choice, given that the fluorohydrin product would bear a certain resemblance to 
Fludrocortisone and Difluprednate (fluorohydrin-containing drugs currently on the market, refer to 
Section 2.1.2). The reaction proceeded well, and the product 2.19t was formed in high selectivity to 
give a high 76% yield as a 3.5:1 mixture of inseparable diastereoisomers. We were able to speculate the 
major product in this mixture since cholesterol is reported to undergo epoxidation with m-CPBA in a 4:1 
isomeric ratio, favouring the α isomer.92 
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Chapter 2  D. M. Sedgwick, Tesis Doctoral 
106 
 
Similarly, the use of glucal 2.18u in our protocol could result an analogue of fluorodeoxyglucose—the 
F18 version of which is a commonly used radiopharmaceutical in PET imaging.93 Unfortunately, glucal did 
not react under the reaction conditions, possibly due to the hydroxyl groups—we had not confirmed 
the compatibility with hydroxyl groups in the previous studies of the reaction scope—or due to the 
enol-ether nature of the double bond. We therefore tested tri-O-benzyl-D-glucal 2.18v but, 
disappointingly, this also resulted in no reaction. 
 




                                                          
93
 a) P. Som, H. L. Atkins, D. Bandoypadhyay, J. S. Fowler, A. R. MacGregor, K. Matsui, Z. H. Oster, D. F. Sacker, C. Y. 
Shlue, H. Turner, C.-N. Wan, A. P. Wolf and S. V. Zabinski, J. Nucl. Med., 1980, 21, 670-675. b) A. Newberg, A. Alavi 
and M. Reivich, Sem. Nucl. Med., 2002, 32, 13-34. 
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2.3.2. Stereochemical studies. 
 
The ultimate goal for this strategy would be the development of an enantioselective version. However, 
the development of such a protocol would require us to first understand the reaction mechanism 
entirely, and given the previously discussed background of this transformation we were aware of the 
complex situation that could arise. Despite giving rise to the product of an SN1 type reaction pathway, it 
seemed unlikely that the epoxide fully opens to form the carbocation intermediate.  
In a recent report, Hammond, Xu et al. described the regio- and stereoselective ring-opening of 
aziridines 2.24 with HF·DMPU which, incidentally, was developed by the same group a few years 
earlier.94, 95 They originally reasoned that the increased acidity of HF·DMPU compared to other 
HF·amine reagents may be beneficial both for controlling the regioselectivity of the opening by 
favouring the nucleophilic attack at the most substituted carbon (Markovnikov regioselectivity) and for 
increasing the reactivity. Hence, they found that the treatment of N-tosylaziridines 2.24 with 7.5 
equivalents of HF·DMPU in DCE at room temperature for 18-24 hours led to the formation of the 
corresponding β-fluoroamines 2.25 in good to excellent yields and excellent regioselectivities in most 
cases (Scheme 2.16).  
 
 
Scheme 2.16. Regio- and stereoselective ring-opening of N-tosylaziridines by HF·DMPU. 
 
In addition, the authors studied the stereochemical outcome when bicyclic 2.24a and, more 
interestingly, chiral non-racemic aziridines 2.24b-d were used as substrates (Scheme 2.17). Firstly, 
complete inversion was observed for bicyclic aziridines 2.24a, affording exclusively the corresponding 
trans-products 2.25a (Scheme 2.17, Eq. a). On the other hand, the study with chiral non-racemic 
substrates shed more light onto the complex stereochemical scenario observed (Scheme 2.17, Eq. b-d). 
Purely aliphatic aziridine 2.24b afforded the corresponding fluoroamine 2.25b with complete inversion 
                                                          
94
 O. E. Okoromoba, Z. Li, N. Robertson, M. S. Mashuta, U. R. Couto, C. F. Tormena, B. Xu and G. B. Hammond, 
Chem. Commun., 2016, 52, 13353-13356. 
95
 O. E. Okoromoba, J. Han, G. B. Hammond and B. Xu, J. Am. Chem. Soc., 2014, 136, 14381-14384. 
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of configuration, similar to that observed in equation a, supporting an SN2 mechanism. A similar 
proposal had been made by Schlosser et al. in 1990, referencing a “conveyer-belt” type mechanism to 
explain the contradictory results observed in the opening of epoxides with Olah’s reagent—the reaction 
appeared to take neither an SN1 nor SN2 pathway, given the inversion of stereochemistry yet the 
internal attack of the fluoride ion. Given the polymer-like structure of HF·pyridine even in solution, 
Schlosser and co-workers suggested that a chain of H—F hydrogen bonds formed a ring around the 




Figure 2.2. Conveyer-belt like transition state proposed by Schlosser et al. 
 
On the other hand, phenyl substituted aziridine 2.24c racemised upon opening. The authors 
rationalised this result with the extra stabilisation of the positive charge in the benzylic position (TS-1, 
Scheme 2.17), resulting in a quasi-SN1 type mechanism. Finally, the most striking result was obtained 
when benzyl substituted substrate 2.24d was used; fluoroamine 2.25d was obtained in high ee, 
although with almost complete retention of configuration. The authors explain this unexpected 
stereochemical outcome with neighbouring group participation, by which the adjacent phenyl ring 
would stabilise the intermediate carbocation, following an SNi type mechanism. DFT calculations 
support this proposal and suggest a hydrogen bond directed delivery of the fluoride anion from the 
same face the nitrogen atom is placed, resulting in a quasi-SNi transition state (TS-2, Scheme 2.17).  
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 H. Suga, T. Hamatani and M. Schlosser, Tetrahedron, 1990, 46, 4247-4254. 




Scheme 2.17. Study on the stereochemical outcome of the ring-opening of aziridines by HF·DMPU. 
 
Given these precedents, we first studied the use of cis- and trans-stilbene in our one pot 
hydroxyfluorination protocol. Since the two processes are stereospecific—that is, epoxidation is syn 
specific, and the opening usually takes place in an anti manner—well-defined products should be 
obtained.  
Unexpectedly, we found that although the trans isomer did indeed afford exclusively the anti 
fluorohydrin product, the cis isomer furnished a 1:1 ratio of syn and anti diastereoisomers. We 
attributed this observation to the fact that cis-stilbene oxide would be less stable due to steric 
repulsions between the two phenyl groups in close proximity, thereby promoting the prior opening of 
the epoxide, forming a carbocation intermediate and giving rise to a 1:1 mixture of products (Scheme 
2.18). 
 




Scheme 2.18. Stereochemical outcomes using cis- and trans-stilbene. 
 
These results made us question if the stereochemical outcome would be the same for epoxides as that 
obtained by Hammond, Xu et al. in the case of aziridines. Therefore, we next studied the opening of 
enantiomerically-enriched epoxides with both HF·DMPU and HF·pyridine. Given the poor UV-absorption 
spectra of the fluorohydrin products, we had to first convert the products to the corresponding 
naphthoyl esters to measure the enantiomeric excess via HPLC (Scheme 2.19). As we expected, we 
observed a large degree of racemisation upon treatment of the commercially available (R)-styrene 
oxide 2.28 with HF·pyridine and almost complete racemisation with HF·DMPU, concordant with the 
acidity of each of the two HF reagents. Furthermore, the addition of an external base did not improve 
the situation significantly. 
 
 
Scheme 2.19. Significant racemisation upon opening of styrene oxide with HF·amine reagents. 
 
We had expected this outcome, and refused to be disheartened by the poor enantiomeric excesses 
obtained. We then turned to aliphatic derivatives, since these should be opened by HF·amine reagents 
with inversion via an SN2 like pathway and, more importantly, conservation of the optical purity. 
Therefore, we synthesised (S)-dodecene oxide 2.30, treated it with HF·amine reagents, and formed the 
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2-naphthoyl ester for analysis by HPLC.97 To our delight, and as we hoped, we found that the product 
was formed in good yield and the enantioselectivity of the starting epoxide was maintained (Scheme 
2.20). 
 
Scheme 2.20. Synthesis and analysis of an aliphatic enantioenriched epoxide in the ring-opening reaction with 
HF·pyridine. 
 
These results must be taken into account for the development of an enantioselective version of this 
protocol. Furthermore, we would also need to study the compatibility of enantioselective epoxidation 
conditions with the HF·amine reagents; some options include the Sharpless asymmetric epoxidation,52 
or the use of the Jacobsen98 or Shi catalysts.99 
 
  
                                                          
97
 F. Derosa, S. Karve and M. Heartlein, Int. Pat., 2015200465, 2015. 
98
 W. Zhang, J. L. Loebach, S. R. Wilson and E. N. Jacobson, J. Am. Chem. Soc., 1990, 112, 2801-2803. 
99
 Y. Shi, Acc. Chem. Res., 2004, 37, 488-496. 





We have developed a simple, metal-free and practical one pot protocol for the 1,2-hydroxyfluorination 
of olefins. The procedure is robust, showing compatibility with a variety of functional groups and 
proceeding in good yields and regioselectivities even under air and used-as-received solvents.  
Furthermore, we have built upon past examples of this type of transformations, opening up the 
possibility of one pot procedures from aliphatic alkenes. This class of substrates was lacking from the 
previously reported hydroxyfluorination reactions. 
Finally, we have studied the stereoselective implications of the opening of epoxides with HF·amine 
reagents, and we have found that an enantioselective one pot procedure could be possible for aliphatic 
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2.5. Experimental section. 
 
Reactions were carried out under atmospheric conditions. DCM was used without further purification. 
The reactions were monitored with the aid of TLC on 0.25 mm pre-coated silica-gel plates. Visualization 
was carried out with UV light and aqueous ceric ammonium molybdate solution or potassium 
permanganate stain. Flash column chromatography was performed with the indicated solvents on silica 
gel 60 (particle size: 0.040–0.063 mm). 1H, 13C and 19F NMR spectra were recorded on a 300 MHz 
spectrometer. Chemical shifts are given in ppm (δ), referenced to the residual proton resonances of the 
solvents. Coupling constants (J) are given in Hertz (Hz). The letters m, s, d, t, and q stand for multiplet, 
singlet, doublet, triplet, and quartet respectively. The letters br indicate that the signal is broad. HPLC 
analyses were performed using either a JASCO PU-2089 Plus chromatographer equipped with an MD-
2010 detector or an Agilent 1100 series instrument equipped with a refraction index detector using 
chiral stationary columns from Daicel. IR spectra were recorded in a Thermo Scientific FTIR 
spectrometer Nicolet iS10. 
 




A 5-ml polypropylene vial was charged with m-CPBA 77% w/w (90 mg, 0.4 mmol, 2 equiv). DCM (2 ml) 
was added and the resulting suspension was cooled in an ice bath. The corresponding olefin (0.2 mmol) 
was then added followed by HF·pyridine 70% w/w (36 µL, 1.4 mmol, 7 equiv). The reaction mixture was 
stirred for 5h, then quenched by the addition of ice and a spatula tip of KHSO3, and stirred for a further 
30 minutes whilst warming to room temperature. The reaction mixture was then extracted with DCM (3 
x 5 ml), and the combined organic layers dried over anhydrous sodium sulphate, filtered and 
concentrated under reduced pressure. The crude mixture was purified by flash chromatography using 
appropriate mixtures of hexanes and ethyl acetate as the eluent (for low molecular weight derivatives 
pentane/diethyl ether mixtures were used due to their high volatility). 
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Compounds 2.19a-g, 2.19l-r and both anti- and syn-2.27 have been previously described, and their 




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19a as a 
colourless oil (68%, 19 mg). This reaction was also carried out on a 10 mmol scale (1.04 g styrene) 




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19b as a 
colourless oil (43%, 18 mg).  
1H NMR (300 MHz, CDCl3): δ 1.96 (dd, J= 7.7, 5.5 Hz, 1H), 3.95–3.74 (m, 2H), 5.56 (ddd, J= 48.3, 6.2, 3.8 
Hz, 1H), 7.40 (d, J= 8.0 Hz, 1H), 7.59 (d, J= 8.4 Hz, 2H) ppm.  
13C NMR (75.5 MHz, CDCl3): δ 66.3 (d, J= 24.1 Hz), 93.9 (d, J= 174.0 Hz), 123.9 (q, J= 272.2 Hz), 125.6 (q, 
J= 3.6 Hz), 125.9 (d, J= 7.5 Hz), 130.9 (q, J= 32.3 Hz), 140.3, (d, J= 20.0 Hz) ppm.  
19F NMR (282 MHz, CDCl3): δ -62.74 (s, 3F), -189.98 (ddd, 1F, J= 48.6, 27.0, 21.8 Hz). 
HRMS (EI) calcd. for NaC9H8F4O [M+Na
+]: 231.0403, found: 231.0396.  
IR (neat, νmax, cm
-1): 3338, 2360, 1623, 1418, 1323, 1256, 1164, 1113, 1066, 1017, 880, 841, 765, 698. 
 
 





Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19c as a 




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19d as a 
colourless oil (67%, 22 mg).90 
 
 
Methyl 4-(1-fluoro-2-hydroxyethyl)benzoate, 2.19e 
Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19e as a 




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19f as a 
colourless oil (38%, 12 mg).90 






Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19g as a 




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19k as a 
colourless oil (40%, 14 mg).   
1H NMR (CDCl3, 300 MHz): δ 1.92 (br s, OH), 3.75 (s, 3H), 3.93–3.77 (m, 2H), 5.47 (ddd, J= 48.7, 7.5, 3.3 
Hz, 1H), 6.86–6.72 (m, 3H), 7.30–7.19 (m, 1H) ppm.  
13C NMR (75.5 MHz , CDCl3): δ 55.2, 66.5 (d, J= 24.4 Hz), 94.6 (d, J= 172.8 Hz), 111.2 (d, J= 7.7 Hz), 114.2, 
117.8 (d, J= 7.1 Hz), 129.7, 137.8 (d, J= 19.8 Hz), 159.7 ppm.  
19F NMR (282 MHz, CDCl3): δ -187.89 (ddd, J= 48.9, 29.4, 19.5 Hz).   
HRMS (EI) calcd. for NaC9H11FO2 [M+Na
+]: 193.0635, found: 193.0637.  
IR (neat, νmax, cm












Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19l as a 
colourless oil (60%, 19 mg).100 
IR (neat, νmax, cm




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19m as a 
colourless oil (57%, 20 mg).100 
IR (neat, νmax, cm




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19n as a white 
solid (41%, 15 mg).100 
IR (neat, νmax, cm
-1): 3358, 2916, 2838, 1717, 1614, 1587, 1511, 1436, 1302, 1244, 1176, 1111, 1091, 




                                                          
100
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Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19o as a waxy 
solid (93%, 38 mg).101 
HPLC (Chiralcel AY-H, 95:5 hexane/i-PrOH, 1 mL min‐1, 240 nm) RT (major) = 10.41 min, RT (minor) = 
11.27 min.  
IR (neat, νmax, cm





Flash chromatography of the crude reaction product [n-pentane-Et2O (1:1)] afforded 2.19p as a 
colourless oil (72%, 15 mg).102 
IR (neat, νmax, cm
-1): 3331, 2963, 1084, 1035, 877.  
This reaction was also conducted at the 2 mmol scale using the following procedure: A 5-mL 
polypropylene vial was charged with m-CPBA 77% w/w (900 mg, 4 mmol, 2 equiv). DCM (20 ml) was 
added and the resulting suspension was cooled in an ice bath. Finally, cyclopentene (2 mmol) was 
added followed by HF·pyridine 70% w/w (360 µL, 14 mmol, 7 equiv). The reaction mixture was stirred 
for 5h, then quenched by the addition of ice and a spatula of KHSO3 and stirred for a further 30 minutes 
whilst warming to room temperature. The reaction mixture was then extracted with DCM (3 x 20 ml), 
and the combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated 
under reduced pressure with the bath of the rotary evaporator at 0 °C. The residue was purified by 
kugelrohr distillation (35 °C, 15 mmHg), affording 2.19p as a colourless liquid (126 mg, 61%). 
 
                                                          
101
 H. Yoshino, K. Nomura, S. Matsubara, K. Oshima, K. Matsumoto, R. Hagiwara and Y. Ito, J. Fluorine Chem. 2004, 
125, 1127-1129. 
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 D. F. Shellhamer, A. A. Briggs, B. M. Miller, J. M. Prince, D. H. Scott and V. L. Heasley, J. Chem. Soc. Perkin Trans. 
2 1996, 973-977. 





Flash chromatography of the crude reaction product [n-pentane-Et2O (1:1)] afforded 2.19q as a 
colourless oil (63%, 15 mg).101 
IR (νmax, cm




Flash chromatography of the crude reaction product [n-pentane-Et2O (1:1)] afforded 2.19r as a 
colourless oil (20%, 5 mg).101 
IR (neat, νmax, cm
-1): 3545, 2929, 2858, 2360, 1716, 1670, 1575, 1448, 1333, 1297, 1262, 1164, 1145, 





Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded 2.19t as a white 
solid (76%, 14 mg), with a melting point of 200-203 °C. 
1H NMR (300 MHz, CDCl3): δ 0.79 (d, J= 6.6 Hz, 3H), 0.80 (d, J= 6.6 Hz, 3H), 0.83 (d, J= 6.5 Hz, 3H), 1.83 – 
0.95 (m, 34H), 2.12 – 1.87 (m, 2H), 4.00 (tt, J= 10.6, 5.4 Hz, 1H), 4.18 (dt, J= 49.2, 2.8 Hz, 1H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 15.9 (s), 16.0 (s), 18.6 (s), 21.0 (s), 22.5 (s), 22.8 (s), 23.8 (s), 23.9 (s), 27.9 
(s), 28.1 (s), 30.3 (s), 30.7 (s), 31.7 (s), 32.0 (s), 34.8 (s), 35.7 (s), 36.1 (s), 38.1 (d, J= 2.0 Hz), 39.4 (s), 39.8 
(s), 40.3 (s), 42.7 (s), 45.3 (s), 56.0 (d, J= 23.2 Hz), 67.2 (s), 74.6 (d, J= 21.1 Hz), 95.3 (d, J= 178.9 Hz) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -184.8 (m).  
HRMS (EI) calcd. for C27H50NO2 [M-HF+NH4
+]: 420.3836, found: 420.3829.  
IR (neat, νmax, cm




Flash chromatography of the crude reaction product [n-hexane-AcOEt (2:1)] afforded anti-2.27 as a 
white solid (76%, 33 mg).90 
  










The synthesis and reactivity of 
fluorovinyl sulfones 









The main objective of this project was to synthesise the scarcely studied β-fluorovinyl sulfones. Basing 
our objectives on the literature available at the time, we proposed their synthesis should be relatively 
straightforward taking advantage of the intrinsic electrophilicity of the corresponding alkynyl sulfones. 
Furthermore, given that this class of compounds had not been described in the literature, we planned 
to study the reactivity of such compounds; nucleophilic additions, cycloadditions, hydrogenations and 
coupling reactions were all potentially well-suited to this class of compounds. In this way, the 
synthesised β-fluorovinyl sulfones could be used as fluorinated building blocks to produce more 








3.1.1. Previous syntheses of fluorovinyl sulfones and related compounds. 
 
We began this venture after finding that this class of compounds was scarce in the chemical literature; 
although several methods had been described for the synthesis of α-fluorovinyl sulfones,103, 104 still 
none existed with the fluorine in the β position. We therefore decided to focus on the β isomers. 
However, during the preparation of this work in mid-2017, two separate reports were published 
detailing the synthesis of β-fluorovinyl sulfones.105, 106 
Related compounds with electron withdrawing groups, such as esters and ketones, had been 
described—although still overwhelmingly in their α-fluorinated isomer. Traditionally, the formation of 
compounds of this type has been dominated by the elimination of HX from carefully chosen starting 
materials (Scheme 3.1).107 However, this approach is hindered by the availability of the specific starting 
materials for each desired product. It is also worth noting that early examples are often limited to 
compounds arising from either fluoroethylenes or polyfluorinated starting materials, for lack of 
selective and practical fluorinating agents; this is somewhat less of a problem nowadays. Nonetheless, 
both mono- and difluorinated acrylates and ketones have been synthesised in this way (Scheme 3.1). 
Archibald and co-workers reported an interesting example in 1990, consisting in the addition of 1,1-
difluoroethene 3.1 to acyl chlorides 3.2, followed by triethylamine-mediated elimination of HCl from 
intermediate 3.3, finally furnishing the desired Friedel-Crafts like products 2,2-difluorovinyl ketones 3.4, 
as well as acrylates 3.6 after the regioselective Baeyer-Villiger oxidation (Scheme 3.1).105 
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Scheme 3.1. Synthesis of β,β-difluoro-α,β-unsaturated ketones and acrylates via HX elimination. 
 
Nguyen and Wakselman were particularly active in this area in the 1980s and 90s, and successfully 
synthesised β-fluoro-α,β-unsaturated esters 3.10 (Scheme 3.2) and carboxylic acids 3.14, as well as 
related α-fluoro-α,β-ketones and allylic alcohols.108 
 
 
Scheme 3.2. Past examples of fluorinated α,β-unsaturated carbonyl compounds. 
 
The development of new fluorinating reagents in turn resulted in several new—or perhaps better said, 
updated—methodologies for the synthesis of conjugated vinyl fluorides, using more sophisticated 
fluorinated starting materials or reagents to give access to a wider scope of target compounds. For 
                                                          
108
 a) H. Molines, and C. Wakselman, J. Fluorine Chem., 1984, 25, 447-451. b) T. Nguyen, J. Leroy and C. 
Wakselman, J. Org. Chem., 1993, 58, 3772-3774. c) T. Nguyen and C. Wakselman, J. Org. Chem., 1989, 54, 5640-
5642. d) A. Ohmori, S. Takaki, T. Kitahara, Eur. Pat. 136668, 1985. e) H. Molines, T. Nguyen and C. Wakselman, 
Synthesis, 1985, 8, 755-756. 
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example, in 1985, McCarthy, Peet et al. described the first fluoro-Pummerer rearrangement, utilising 
DAST as an alternative to acetic anhydride in the traditional Pummerer rearrangement (Scheme 3.3).109a 
They later applied this to the synthesis of vinyl fluoride-containing nucleoside mechanism-based 
inhibitors of S-adenosyl-L-homocysteine hydrolase, an enzyme responsible for the hydrolysis of S-
adenosylhomocysteine into L-homocysteine and adenosine.109b In 1990, Krishnan and Sampson applied 
this new methodology to the synthesis of β-fluoroacrylonitriles 3.19 and acrylates 3.20 (Scheme 3.3).109c 
 
 
Scheme 3.3. The fluoro-Pummerer rearrangement and its application to the synthesis of β-fluoroacrylonitriles 
and acrylates. 
 
The wider availability of fluorinated small molecules permitted the application of more traditional olefin 
syntheses to obtain fluorinated analogues. Many of these have been successfully applied or adapted 
accordingly to the synthesis of α-fluoro-α,β-unsaturated carbonyls and related compounds. These are 
the Wittig, Julia, Peterson and related olefinations,104, 110, 111, 112, 113, 114 as well as Knoevenagel-like 
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4902-4923.  
113
 a) A. K. Ghosh, S. Banerjee, S. Sinha, S. B. Kang and B. Zajc, J. Org. Chem., 2009, 74, 3689-3697. b) E. Pfund, C. 
Lebargy, J. Rouden and T. Lequeux, J. Org. Chem., 2007, 72, 7871-7877. c) B. Zajc and R. Kumar, Synthesis, 2010, 
11, 1822-1836. 
114
 a) N. Asakura, Y. Usuki and H. Iio, J. Fluorine Chem., 2003, 124, 81-88. b) J. T. Welch and R. W. Herbert, J. Org. 
Chem., 1990, 55, 4782-4784. 
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reactions,103, 115 which all formally involve the addition of a fluoromethylene anion to a carbonyl 
compound followed by an elimination to form the double bond. Of these methods, the Peterson, Julia, 
Knoevenagel-like and Horner-Wadsworth-Emmons (HWE) methods have been used to synthesise α-
fluorovinyl sulfones (Scheme 3.4).116 
Unfortunately, many of these procedures suffer from poor stereoselectivity,110, 114 the need for metal 
catalysts,112a, 116 or the use of complex or expensive starting materials. Furthermore, all of these only 
provide access to the vinyl fluorides with the fluorine in the α position relative to the functional group.  
 
 
Scheme 3.4. Compilation of reactions involving a fluorinated carbon-acid/carbonyl addition-elimination for the 
synthesis of α-fluorovinyl sulfones. 
 
Methods to synthesise the related β isomers are much less common. In this context, the vast majority 
of the literature deals with the addition of the fluoride ion to electron-deficient alkynes. Nevertheless, 
the simplest ester of this type, ethyl (Z)-3-fluoropropenoate (Z)-3.22, can be synthesised via Wittig 
reaction with ethyl oxylate 3.21 as shown by Patrick et al. in 2011,117 following the methodology 
described by Burton et al. back in 1985 (Scheme 3.5).118 For the opposite stereoisomer however, the 
authors did use the nucleophilic addition of fluoride to ethyl propiolate 3.23, obtaining the desired 
ethyl (E)-3-fluoropropenoate (E)-3.22, albeit in a low yield. 
                                                          
115
 a) J. Qian, W. Yi, M. Lv and C. Cai, Synlett, 2015, 26, 127–132. b) T. Kitazume and N. Ishikawa, Chem. Lett., 1981, 
1259-1260. 
116
 For other examples of addition-elimination procedures to form the desired compounds, see: a) M. 
Inbasekaran, N. P. Peet, J. R. McCarthy and M. E. LeTourneau, J. Chem. Soc., Chem. Commun., 1985, 678-679. b) T. 
Ishihara and M. Kuroboshi, Chem. Lett., 1987, 1145-1148. c) G. Lemonnier, L. Zoute, G. Dupas, J.-C. Quirion and P. 
Jubault, J. Org. Chem., 2009, 74, 4124-4131. 
117
 T. B. Patrick, J. Neumann and A. Tatro, J. Fluorine Chem., 2011, 132, 779–782. 
118
 D. G. Cox, N. Gurusamy and D. J. Burton, J. Am. Chem. Soc., 1985, 107, 2811-2812. 




Scheme 3.5. Synthesis of ethyl (E)- and (Z)-3-fluoropropenoate 3.22. 
 
There are several precedents for the addition of fluoride to electron-deficient alkynes such as these, 
although many suffer from low yields or low/uncontrollable stereoselectivity.119 Interestingly, Cousseau 
et al. saw a reverse in selectivity with 2-decynenitrile 3.24 when using a polymer-bound version of the 
fluoride nucleophile (Scheme 3.6). Nonetheless, the Z isomers were the major product in the vast 
majority of cases. This can be explained by considering the reaction mechanism; after addition of the 
fluoride ion, the negative charge on the intermediate species would be most stable the furthest 




Scheme 3.6. Reverse in selectivity when using the polymer-bound dihydrogen trifluoride reagent with 2-
decynenitrile.  
 
Later, in 2012 Jiang et al. described an efficient method for the hydrofluorination of electron deficient 
alkynes, albeit using a relatively expensive nucleophilic fluoride reagent: silver(I) fluoride.120 To achieve 
this, the authors simply heated a mixture of the alkyne and AgF in MeCN:H2O (20:1) at 80 °C for ten 
hours, obtaining the desired compounds in good to excellent yields (Scheme 3.7). The 
                                                          
119
 a) P. Albert and J. Cousseau, J. Chem. Soc., Chem. Commun., 1985, 961-962. b) A. Gorgues, D. Stéphan and J. 
Cousseau, J. Chem. Soc., Chem. Commun., 1989, 1493-1493. 
120
 Y. Li, X. Liu, D. Ma, B. Liu and H. Jiang, Adv. Synth. Catal., 2012, 354, 2683-2688. 
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Scheme 3.7. Hydrofluorination of electon-deficient alkynes to form (Z)-β-fluorochalcones. 
 
Following this, in 2017 Sun, Gong and co-workers described the synthesis of the same β-fluoroalkenyl 
carbonyl products starting from the corresponding β-chloro derivatives.121 This reaction consists in the 
elimination of HCl to form the corresponding alkynyl carbonyl compound, and from there the same 
addition of nucleophilic fluoride.  
The remainder of this section will look specifically at the synthesis of fluorovinyl sulfones. The fluoro-
Pummerer rearrangement following the development of DAST permitted the facile synthesis of a simple 
fluorinated sulfone building block, fluoromethyl phenyl sulfone 3.30, which the McCarthy group 
exploited throughout the 1980s and 90s.116a, 122, 123 The α-protons are fairly acidic in this compound; 
sulfones are strongly electron-withdrawing, and the resulting anion is stabilised through resonance. 
Therefore, treatment of 3.30 with n-BuLi forms the corresponding carbanion, which then reacts with an 
aldehyde to give the corresponding α-fluoro-β-hydroxy sulfone 3.31. Upon treatment with 
methanesulfonyl chloride, elimination of H2O from the molecule results in the desired α-fluorovinyl 
sulfone, 3.32 (Scheme 3.8).  
 
                                                          
121
 J. Zhang, L. Liu, J. Duan, L. Gu, B. Chen, T. Sun and Y. Gong, Adv. Synth. Catal., 2017, 359, 4348-4358. 
122
 J. R. McCarthy, D. P. Matthews, M. L. Edwards, D. M. Stemerick and E. T. Jarvi, Tetrahedron Lett., 1990, 31, 
5449-5452. 
123
 a) J. R. McCarthy, E. W. Huber, T.-B. Le, F. M. Laskovics and D. P. Matthews, Tetrahedron, 1996, 52, 45-58. b) J. 
R. McCarthy, D. P. Matthews, D. M. Stemerick, E. W. Huber, P. Bey, B. J. Lippert, R. D. Snyder and P. S. Sunkara, J. 
Am. Chem. Soc., 1991, 113, 7439-7440. 




Scheme 3.8. The use of fluorinated building block fluoromethyl phenyl sulfone in the synthesis of α-fluorovinyl 
sulfones 3.32 via HWE reactions reported by McCarthy et al.,
116a, 122, 123





The group later turned to modified Horner-Wadsworth-Emmons reactions, again starting from 
fluorinated building block 3.30 (Scheme 3.8).122 Treatment of 3.30 with diethyl chlorophosphate 3.33 
and base forms 3.34, a suitable reagent for the HWE reaction. Reaction of 3.34 with base and a 
carbonyl compound then results in the corresponding α-fluorovinyl sulfone, albeit in relatively poor E/Z 
selectivity. The same authors have used this method to introduce a terminal vinyl fluoride moiety into 
nucleoside mechanism-based inhibitors of ribonuclease diphosphate reductase, an enzyme which 
transforms ribonucleotides into deoxyribonucleotides.123 Berkowitz et al. also used the HWE approach 
to synthesise and develop terminal vinyl fluoride containing amino acids as mechanism-based inhibitors 
of pyridoxal phosphate dependent enzymes, such as amino acid decarboxylases.124 
Usuki and co-workers disclosed the synthesis of various α-fluorovinyl sulfones using a Peterson 
olefination in 2003 (Scheme 3.8).114a This reaction showed higher E/Z selectivity than the previous 
examples, although still moderate. The preference for the formation of the E isomer is thought to be 
due to no more than steric effects in the intermediate. It is worth noting that these reactions resulted 
in slightly higher yields when carried out in a one-pot manner without isolating the intermediate 3.35. 
Furthermore, the E/Z selectivities were mostly unaffected. 
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Wnuk and co-workers also used this same approach but with the addition of slightly more sophisticated 
versions of 3.34, using a 2-pyridinyl or 2-pyrimidinyl sulfone rather than the simpler phenyl.125 This was 
synthesised by mixing 2-mercaptopyridine with diethyl (chloromethyl)phosphonate followed by 
oxidation of the resulting sulphide, and subsequent fluorination with Selectfluor to give 3.38. The actual 
Horner-Wadsworth-Emmons reaction was carried out in the standard manner, resulting in high yields of 
3.39 and high E/Z selectivities when aromatic aldehydes were used (>19:1). Unfortunately, for aliphatic 
aldehydes the E/Z selectivity was a meagre 2:1 (Scheme 3.9). 
 
 
Scheme 3.9. Synthesis of α-fluorovinyl 2-pyridyl and 2-pyrimidinyl sulfones via HWE reaction. 
 
The Julia olefination was applied to the synthesis of α-fluorovinyl sulfones in 2008 by Zajc and co-
workers.104a This procedure relied on the successful synthesis of fluorinated disulfone 3.43, during 
which the authors encountered certain problems with chemoselectivity; the fluorination of the central 
methylene group can result in both the mono- and difluorinated product (Scheme 3.10). Interestingly, 
this method resulted in the opposite E/Z selectivity for the products, in most cases giving the Z isomer 
as the major product. 
 
                                                          
125
 S. F. Wnuk, P. I. Garcia Jr. and Z. Wang, Org. Lett., 2004, 6, 2047-2049. 




Scheme 3.10. The application of the Julia olefination to the synthesis of α-fluorovinyl sulfones. 
 
Prakash and co-workers also described a simple and effective route to α-fluorovinyl sulfones starting 
from the simple and commercially available compound fluorobis(phenylsulfonyl)methane 3.45 (Scheme 
3.13).103 In this reaction, 3.45 is alkylated using a simple mixture of caesium carbonate and a benzyl, 
propargyl or allyl halide. The subsequent elimination of PhSO2X provides the corresponding (E)-α-
fluorovinyl sulfones 3.46. 
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3.1.2. The chemistry of vinyl sulfones. 
 
The synthetic utility of vinyl sulfones in organic chemistry is well-established. The strongly electron-
withdrawing character of the sulfone group renders the double bond highly electron deficient, allowing 
it to react in a wide array of chemical processes. Traditionally, vinyl sulfones have been viewed as 
excellent substrates for Michael additions and cycloaddition reactions, although over the past few 
decades the rapidly advancing field of organic chemistry has given rise to ever more sophisticated 
processes. A brief overview of earlier reactions covered in the literature can be seen below (Scheme 
3.12).126 However, the reactions covered in more detail in this section will be limited to those deemed 








                                                          
126
 For earlier reviews on the chemistry of vinyl sulfones, see: a) N. S. Simpkins, Tetrahedron, 1990, 46, 6951-6984. 
b) D. C. Meadows and J. Gervay-Hague, Med. Res. Rev., 2006, 26, 793-814. c) A.-N. R. Alba, X. Companyó and R. 
Rios, Chem. Soc. Rev., 2010, 39, 2018-2033. For a review on their synthesis see: Y. Fang, Z. Luo and X. Xu, RSC Adv., 
2016, 6, 59661-59676. 
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3.1.2.1. Transition metal catalysed reactions. 
 
In 2004, Carretero and co-workers reported the first example of the asymmetric conjugate addition of 
carbon nucleophiles to α,β-unsaturated sulfones 3.47 (Scheme 3.13).127 However, the reaction heavily 
relied on the coordinating ability of the 2-pyridyl substitution on the sulfone; no reaction occurred with 
the standard phenyl substitution. The authors attributed this to the ability of the pyridine ring to 
coordinate to the metal catalysts used, thereby directing the reaction to take place at the double bond 
(Scheme 3.13). Furthermore, not only did no reaction occur with the phenyl substitution on the sulfone, 
but little to no reaction was observed for other nitrogen-based directing groups, highlighting the special 
geometry and electronic properties provided by the 2-pyridyl group. With the optimised conditions, the 
authors successfully added a range of arylboronic acids to α,β-unsaturated 2-pyridyl sulfones in high 
yields and good enantioselectivities, using the combination of a rhodium catalyst and the chiral ligand 
Chiraphos, 3.49. 
In subsequent studies Carretero et al. disclosed the application of the same catalytic system to the 
addition of alkenyl boronic acids to similar substrates,128, 129 and more recently a Fujiwara-Moritani / 
intramolecular Michael addition sequence rendering densely functionalised indanes.130 
 
 
Scheme 3.13. Addition of boronic acids to α,β-unsaturated 2-pyridyl sulfones by Carretero et al.
127-129 
 
Several other reports were published in the past decade involving 1,4-additions to vinyl 2-pyridyl 
sulfones, albeit using different conditions. Firstly, Charette, Bechara and co-workers reported the use of 
a copper-BINAP system to catalyse the addition of dialkyl zinc reagents to α,β-unsaturated 2-pyridyl 
                                                          
127
 P. Mauleón and J. C. Carretero, Org. Lett., 2004, 6, 3195-3198. 
128
 P. Mauleón and J. C. Carretero, Chem. Commun., 2005, 4961-4963. 
129
 P. Mauleón, I. Alonso, M. Rodríguez Rivero and J. C. Carretero, J. Org. Chem., 2007, 72, 9924-9935. 
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sulfones (Scheme 3.14, Method 1).131 This was followed by a publication from Feringa et al. just a few 
months later, in which they carried out the same transformation using Grignard reagents instead of 
zinc-based nucleophiles (Scheme 3.14, Method 2),132 and a second by Feringa in 2010 using very similar 
conditions to Charette, but with monodentate ligand 3.52 rather than BINAP 3.50 (Scheme 3.14, 
Method 3).133 All three procedures were fairly robust, resulting in high yields and high 
enantioselectivities in most cases.  
 
 
Scheme 3.14. Other methods for the addition of organometallics to α,β-unsaturated 2-pyridyl sulfones. 
 
Following this work with 2-pyridyl sulfones, there was still a lack of methods to carry out similar 
reactions in a more generic way, i.e. without relying on the coordinating ability of the pyridyl group. In 
2012, Nishimura, Hayashi and co-workers overcame this challenge using a rhodium-based catalyst in 
conjunction with a diferrocenyl ligand 3.56 (Scheme 3.15).134 This system showed excellent reactivity 
and successfully added a range of arylboronic acids to the β position of α,β-unsaturated sulfones in high 
enantioselectivites. Careful ligand choice was important here, as more common asymmetric ligands 
such as BINAP resulted in cine substitution; addition in β, followed by elimination of the adjacent 
sulfone group upon release of the rhodium catalyst to give the corresponding terminal olefin 3.54 
(Scheme 3.15). The same authors later showed that these same conditions can also be used for the 
                                                          
131
 J.-N. Desrosiers, W. S. Bechara and A. B. Charette, Org. Lett., 2008, 10, 2315-2318. 
132
 P. H. Bos, A. J. Minnaard and B. L. Feringa, Org. Lett., 2008, 10, 4219-4222. 
133
 P. H. Bos, B. Maciá, M. A. Fernández-Ibáñez, A. J. Minnaard and B. L. Feringa, Org. Biomol. Chem., 2010, 8, 47-
49. 
134
 T. Nishimura, Y. Takiguchi and T. Hayashi, J. Am. Chem. Soc., 2012, 134, 9086-9089. 
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addition of cyclopropyl boronic acids to afford β-cyclopropyl sulfones 3.55.135 The reaction could be 




Scheme 3.15. Asymmetric addition of aryl and cyclopropyl boronic acids to α,β-unsaturated sulfones. 
 
Additionally, other functionalities besides carbon nucleophiles have been introduced into the β position 
by means of transition metal catalysis. In 2011, Carretero et al. successfully carried out the borylation of 
vinyl sulfones that, after subsequent oxidation, afforded β-hydroxy sulfones 3.57 in high yields and 
enantioselectivities (Scheme 3.16).136 In this case, both phenyl and 2-pyridyl sulfones gave good results, 
and the most effective catalytic system was copper(I) chloride with either the Josiphos 3.58 or 
Taniaphos 3.59 ligands—both ferrocene-based diphosphine ligands—with relatively high catalytic 
loadings of 10 mol%. On the other hand, Duan and co-workers successfully described the 
enantioselective addition of diarylphosphines both to vinyl sulfonic esters and vinyl trifluoromethyl 
sulfones.137 
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 R. Takechi and T. Nishimura, Chem. Commun., 2015, 51, 8528-8531. 
136
 A. L. Moure, R. Gómez Arrayás and J. C. Carretero, Chem. Commun., 2011, 47, 6701-6703. 
137
 J. Lu, J. Ye and W.-L. Duan, Org. Lett., 2013, 15, 5016-5019. 








Vinyl sulfones, although originally deemed challenging coupling partners due to their strongly 
coordinating character, have also been used successfully in Heck reactions.138 Gillingham et al. 
demonstrated the use of sulfoxides, sulfides and sulfones as Heck-coupling partners to aryl halides and 
triflates, through the use of the exceptionally active and very bulky catalyst Pd[(Pt-Bu)3]2, resulting in 
high yields and stereoselectivities (Scheme 3.17). 
 
 
Scheme 3.17. Stereoselective Heck reactions using vinyl sulphides, sulfoxides and sulfones. 
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3.1.2.2. Organocatalytic reactions. 
 
In contrast to the examples seen thus far, vinyl sulfones have also been used successfully in 
organocatalytic processes. For instance, in 2013 Dou and Lu disclosed an thiourea-catalysed asymmetric 
addition of fluorinated oxindoles 3.63 to vinyl (bis)sulfones 3.62, to produce the corresponding 
fluorinated oxindole adducts 3.67 (Scheme 3.18).139 One year later, Jiang et al. published a report 
focusing on the addition of oxazolones 3.64 catalysed by related thiourea 3.66. The authors 
demonstrated how these products could be transformed into 3.69, a useful precursor towards 
enantioenriched monofluorinated bioactive molecules (Scheme 3.18).140 
 
 
Scheme 3.18. Organocatalysed nucleophilic additions to vinyl (bis)sulfones. 
 
Along with phenyl and pyridyl sulfones, recently a “second generation” class of sulfone substrates 
(3.70) has emerged carrying a substituted tetrazole group, which has been used to exert a greater 
degree of stereocontrol, as well as augmented reactivity. Cid and co-workers recently demonstrated 
the high reactivity of these new sulfones in Michael additions with a wide variety of nucleophiles 
including amines, malonates, alkoxides, thiols and more, as well as in cycloadditions with dienes, 
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nitrones, nitrile oxides and azides; the latter occurred with concomitant loss of the sulfone group as 
previously seen.141 
Simlandy and Mukherjee used this new class of sulfones in a thia-Michael/Julia-Kocienski cascade 
reaction to obtain enantioenriched 2H-thiochromenes 3.72 (Scheme 3.19).142 This reaction starts with 
the condensation of 2-mercaptobenzaldehyde 3.71 with Jørgensen’s diarylprolinol silyl ether catalyst. 
From there, the thiol group adds to the β position of the vinyl sulfone to form the sulfide intermediate 
in an enantioselective manner, and a Julia-Kocienski olefination between the α-carbon and the free 
aldehyde affords the final thiochromene.  
 
 
Scheme 3.19. Enantioselective cascade reaction to form 2H-thiochromenes 3.72. 
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3.1.2.3. Cycloaddition reactions. 
 
On the other hand, cycloadditions have also been a longstanding reaction for vinyl sulfones, due to 
their electron deficient-character making them excellent dienophiles.126 Aside from coupling with 
standard dienes,143 there are also many reports that utilise vinyl sulfones in other classes of 
cycloadditions. For example, Shanmugam and co-workers reported a [3+2]-1,3-dipolar cycloaddition 




Scheme 3.20. Cycloaddition between isatin-derived azomethine and vinyl sulfone dipolarophile. 
 
Azides have also been used, however in these cases the sulfone is often eliminated in situ in an  
aromatisation process after the cycloaddition has taken place.145 Pathak and co-workers have been very 
active in this area over the past few years, and have disclosed several cycloaddition reactions between 
azides and vinyl sulfones.145a-d In 2014, the group published two reports dealing with this area. Perhaps 
the most interesting is a three-component reaction involving a nucleophilic substitution between 
sodium azide and an alkyl halide, followed by a cycloaddition between the resulting azide and vinyl 
sulfone 3.76, affording triazoles 3.77 in high yields and regioselectivities (Scheme 3.21). The same 
authors have also carried out extensive studies into the potential of these cycloaddition reactions in 
carbohydrate chemistry, as a way to introduce triazole groups into sugar molecules, or to couple two 
sugar molecules together to produce triazole-linked disaccharides 3.78 (Scheme 3.21). 
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 a) V. Lysiak, A. Ratajczak, A. Mencel, K. Jarzembek and J. Polanski, Bioorg. Med. Chem., 2005, 13, 671-675. b) P. 
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 P. Shanmugam, B. Viswambharan, K. Selvakumar and S. Madhavan, Tetrahedron Lett., 2008, 49, 2611-2615. 
145
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Scheme 3.21. a) Cycloaddition reaction between azides and vinyl sulfones with concomitant loss of the sulfone 
group. b) Application to carbohydrate chemistry, where A and B are distinct sugar molecules functionalised 
with a vinyl sulfone and an azide respectively. 
 
In 2013, Wulff and co-workers reported the synthesis of complex tricyclic compounds 3.81 via 1,3-
dipolar cycloaddition between cyclic vinyl sulfones 3.79 and pyrazolidinone-derived azomethine imines 
3.80 (Scheme 3.22, a).146 Good yields were obtained, albeit with a relatively small scope; the authors 
found that certain combinations of bulkier substrates hindered the reaction. Following this, in 2014 
Namboothiri et al. reported another 1,3-dipolar cycloaddition, this time using diazosulfone dipoles 3.83 
(Scheme 3.22, b).147 In this case, the sulfone group in the dipolarophile 3.82 was also eliminated in situ, 
along with the ketone group originating from 3.83. The reactions proceeded in mild conditions—at 0 °C 
and 15 minutes of reaction time—to give pyrazoles 3.84 in high yields and regioselectivities. 
 
 
Scheme 3.22. Further examples of 1,3-dipolar cycloaddition reactions with vinyl sulfone dipolarophiles. 
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3.1.2.4. Hydrogenation reactions. 
 
Heterogeneous hydrogenation was discovered by Sabatier at the beginning of the 20th century,148 and 
later in the 1960s Wilkinson and co-workers at Monsanto developed the first homogeneous catalyst 
precursor, [(PPh3)3RhCl].
149 Since then, countless new catalysts and reactions have been developed, 
converting hydrogenation reactions into some of the most important in organic chemistry; they are 
highly atom economical, cheap, usually require very low catalyst loadings, and lend themselves well to 
industrial settings.150 Despite this, vinyl sulfones have lagged behind their ester or carboxylic acid 
counterparts.  
Since the first asymmetric homogeneous hydrogenation was described for the synthesis of L-DOPA in 
the 1970s151 there have been many reports on the homogeneous hydrogenation of plenty of other α,β-
unsaturated carbonyl compounds, although few examples exist for the related sulfones. Several 
standard heterogeneous methods have been described,152 including a recent patent and a report on the 
hydrogenation of an intermediate towards the synthesis of Eletriptan hydrobromide, a selective agonist 
of 5-HT1 receptors.
153 In addition, Alper and Cho described a homogeneous procedure using a palladium 
catalyst pre-activated with oxygen that was capable of hydrogenating a variety of vinyl sulfones,154 and 
Toru et al. reported a radical addition of alkyl halides followed by reduction by Bu3SnH.
155 Other older 
publications detailed the diastereoselective hydrogenation with a homogeneous rhodium catalyst,156 or 
the hydrogenation of vinyl sulfones containing a second coordinating group such as a carboxylic acid or 
an ester in the β position.157 Although important advances, they were still insufficient compared to the 
advances made in the asymmetric hydrogenation of other substrates, given that they still relied on 
specific substrates containing another functional group to direct the stereoselectivity. 
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In 1997, Pfaltz et al. described the first hydrogenation reaction using a chiral version of Crabtree’s 
homogeneous iridium-based catalyst using chiral phosphinooxazoline (PHOX) N,P-ligands (Figure 3.1),158 
increasing the visibility of iridium-based catalysts in hydrogenation contexts; until then, their rhodium-
based counterparts had seen far more use. 
 
 
Figure 3.1. Crabtree’s homogeneous Ir-based catalyst and Pfaltz’s asymmetric Ir-PHOX version. 
 
Over the past few decades, both the Pfaltz159 and Andersson160 groups have been active in developing 
new chiral iridium-based catalysts of this type to be used in enantioselective hydrogenation reactions, 
and in 2012 the Andersson group took up the challenge of developing a general catalytic system for the 
asymmetric hydrogenation of sulfone substrates.161 The authors focused on cyclic allylic sulfones, 
although they also successfully hydrogenated a variety of vinyl sulfones (E)-3.85 with high yields and 
enantioselectivities (Scheme 3.23). Several ligands were tested in order to achieve high 
enantioselectivities for all substrates, but eventually complex 3.87 was found to be the best performing 
and most general. Subsequently, these saturated products were subjected to the Ramberg-Bäcklund 
rearrangement—one of the most important transformations for this class of saturated sulfones—to 
produce chiral allylic compounds 3.88. Later, in 2014, the group published a second report on this 
reaction, this time comparing the reactivity of the E and Z isomers and different S-substitutions on the 
                                                          
158
 a) R. Crabtree, Acc. Chem. Res., 1979, 12, 331-337. b) P. Schnider, G. Koch, R. Prétôt, G. Wang, F. M. Bonen, C. 
Krüger and A. Pfaltz, Chem. Eur. J., 1997, 3, 887.  
159
 a) D. Rageot, D. H. Woodmansee, B. Pugin and A. Pfaltz, Angew. Chem. Int. Ed., 2011, 50, 9598-9601. b) B. 
Wüstenberg and A. Pfaltz, Adv. Synth. Catal., 2008, 350, 174-178. For a review, see: c) A. Pfaltz, J. Blankenstein, R. 
Hilgraf, E. Hörmann, S. McIntyre, F. Menges, M. Schönleber, S. P. Smidt, B. Wüstenberg and N. Zimmermann, Adv. 
Synth. Catal., 2003, 345, 33-43. 
160
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1356. b) J. J. Verendel, O. Pàmies, M. Diéguez and P. G. Andersson, Chem. Rev., 2014, 114, 2130-2169. c) T. L. 
Church, T. Rasmussen and P. G. Andersson, Organometallics, 2010, 29, 6769-6781. d) K. Källström, I. Muslow and 
P. G. Andersson, Chem. Eur. J., 2006, 12, 3194-3200. e) K. Källström, C. Hedberg, P. Brandt, A. Bayer and P. G. 
Andersson, J. Am. Chem. Soc., 2004, 126, 14308-14309. 
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vinyl sulfone starting materials with the same catalyst (Scheme 3.23).162 In this study, they found that 
the E and Z isomers performed differently under the reaction conditions: although the 
enantioselectivity remained high, the conversions dropped significantly. 
 
 
Scheme 3.23. Asymmetric hydrogenation of vinyl sulfones and subsequent Ramberg-Bäcklund rearrangement. 
 
Zhang and co-workers have also been working in this field over the past few years. In 2012, the group 
published a procedure for the enantioselective hydrogenation of β-amido-α,β-unsaturated sulfones, 
this time using a rhodium-based catalyst with the Tangphos ligand 3.91 (Scheme 3.24).163 The authors 
only used the Z-sulfones, perhaps due to the beneficial effects of having two coordinating groups in cis, 
and obtained high yields and enantioselectivities for all the compounds tested. 
 
 
Scheme 3.24. Asymmetric hydrogenation of β-amido-α,β-unsaturated sulfones. 
 
Following this, in 2017 the same authors published a second account of the enantioselective 
hydrogenation of α-substituted α,β-unsaturated sulfones 3.92 (Scheme 3.25).164 The authors screened 
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several families of ligands, including Josiphos 3.58 and Tangphos 3.91, with little success. They 
eventually found that the 3D structure of BINAP and related ligands gave the best enantioselectivities 
with these substrates, and among them DTBM-Segphos (3.94) was the best in generality. Aromatic 
groups with electron-donating and withdrawing, heteroaromatics, and aliphatic groups were all well 
tolerated, resulting in high enantioselectivities across the board.  
 
 
Scheme 3.25. Asymmetric hydrogenation of α-substituted α,β-unsaturated sulfones 3.92. 
 
Although not technically a hydrogenation, Carretero et al. also reported the enantioselective reduction 
of vinyl sulfones using phenylsilane in 2007.165 Yet again, the authors demonstrated the significance of 
the 2-pyridyl sulfones; no reaction occurred with substrates 3.95a lacking this group, whereas yields of 
>90% were obtained for substrates 3.95b. A small screening found that BINAP 3.50 or Segphos 3.97, in 
conjunction with a copper metal centre, was once again the most efficient system to promote this 
reaction (Scheme 3.26). With the optimised conditions in hand, the authors proceeded to explore the 
scope of the reaction and found that the reduction of vinyl sulfones 3.95b resulted in high yields and 
moderate to high enantioselectivities for a wide variety of substrates.  
 
 
Scheme 3.26. Asymmetric reduction of vinyl sulfones using phenylsilane as the reducing agent.   
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3.1.2.5. Reactions with fluorovinyl sulfones. 
 
Despite remaining a vastly underexplored field several examples of reactions carried out with 
fluorovinyl sulfones do exist, although the majority of these utilise the α-fluoro isomers. These are 
mainly desulfonylation reactions (given that fluorovinyl sulfones have been synthesised in the past 
generally with the intention of later removing the sulfonyl group), a transformation that has been 
successfully carried out in two ways: 1) prior transformation into the corresponding stannane, and 
subsequent hydrolysis (this is the only example of downstream chemistry with the β-fluoro derivatives) 
(Scheme 3.27, a);106, 124, 166 and 2) treatment with aluminium amalgam (Scheme 3.27, b).123, 116a 
 
 
Scheme 3.27. Desulfonylation of fluorovinyl sulfones. a) Prior transformation into stannanes followed by 
hydrolysis.
106, 124
 b) Direct reductive desulfonylation with aluminium amalgam.
116a 
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In another study, α-fluorovinyl sulfones 3.106 and sulfoxides were used as electrophiles with 
isocyanoacetates 3.107 with varying success.167 In very few cases the reactions proceeded to 
completion, and in many cases mixtures of starting material, addition product 3.108, fluorinated 
pyrrole 3.111, and sulfonyl pyrrole 3.112 were obtained (Scheme 3.28). These products are due to the 
cascade that is produced after the simple addition product 3.108 is formed. From there, the negative 
charge resulting from the first Michael addition attacks the carbon of the isocyanate, forming 
heterocyclic intermediate 3.109, which then isomerises to 3.110 and either eliminates the sulfonyl 
group or fluoride to produce 3.111 or 3.112 respectively. 
The highest yield of the desired fluorinated pyrrole 3.111 that was achieved was a meagre 35% which, 
interestingly, was obtained when a cryptand additive was present; in this case the desired fluoropyrrole 
was the only product. Nevertheless, in most cases the major product was either Michael addition 
product 3.108 or defluorinated pyrrole 3.112, along with various side products. 
 
 




Finally, α-fluorinated vinyl sulfones have been used in a few cycloaddition processes, with varying 
success. Fluorovinyl sulfone 3.113 was used in dipolar cycloaddition with sodium azide to afford 
fluorinated triazole 3.114—an intermediate towards 3.115 which was then used in biological studies as 
orally active antihypertensives—albeit in a low 15% yield (Scheme 3.29).168 
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Scheme 3.29. 1,3-Dipolar cycloaddition between sodium azide and fluorovinyl sulfone 3.113. 
 
More recently, in 2008 Haufe et al. described the Diels-Alder reaction with various α-fluoro-β-arylvinyl 
sulfones 3.117 as the dienophiles (Scheme 3.30).169 The reactions proceeded well, although the 
fluorovinyl sulfones were fairly unreactive without electron-withdrawing groups on the aryl substituent; 
the reaction times for the simple phenyl and 4-OMe containing sulfones were 23 and 54 hours 
respectively. Interestingly, when cyclopentadiene was used as the diene, the exo adduct was formed in 
slight excess, whereas when the diene used was diphenylisobenzofuran, the endo-fluoro adduct was 
formed in excess. Nevertheless, the products were formed in good yields and moderate selectivities.  
 
 
Scheme 3.30. Cycloaddition reactions with fluorovinyl sulfones. 
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As mentioned previously, when we embarked on this project, only the α isomers existed in the 
literature. The following examples of the synthesis of β-fluorovinyl sulfones were published just last 
year during the development of our own process. 
The first example of β-fluorovinyl sulfones came from Hammond, Xu et al.,105 with an elegant gold-
catalysed synthesis starting from the corresponding alkynyl sulfones that gave high yields and a wide 
scope (Scheme 3.31). The authors used a JohnPhos gold bistriflimide catalyst in conjunction with 
HF·pyridine as the fluoride source. This procedure was based on traditional gold catalysis, by which the 
gold catalyst activates the triple bond in 3.118, converting it into a suitable electrophile for attack by 
the nucleophilic fluoride ion. The catalytic cycle finishes with protodeauration, producing the 
corresponding β-fluorovinyl sulfone 3.119 and releasing the gold catalyst. The reaction was compatible 
with various functional groups, including carbonyls, halides and ethers, and gave exclusively the Z 
isomer in all cases. 
 
 




The second and last example was disclosed by Berkowitz and co-workers.106 In this report, the authors 
prepared amino acid derivatives 3.123 with the (1’-fluoro)vinyl group in the quaternary α position, with 
the same goal as in the aforementioned publication by the same authors: mechanism-based inhibitors 
for pyridoxal phosphate dependent enzymes. 
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Berkowitz et al. described the synthesis and isolation of the long-elusive β,β-difluorovinyl phenyl 
sulfone 3.121, and its use as a fluorinated building block; specifically a (1-fluoro)vinyl cation 
surrogate.106 Percy et al. had described a potential synthesis and use of 3.121 in 1996, trapping it as a 
dienophile in a Diels-Alder reaction, although they were unable to isolate it.170 Nonetheless, Berkowitz 
achieved the synthesis of this compound by treating β-chloro-β,β-difluoroethyl phenyl sulfone 3.120 
with a highly hindered amine base, 2,2,6,6-tetramethylpiperidine, for just 15-20 seconds before 
immediately isolating the desired β,β-difluorovinyl phenyl sulfone via acid work up and distillation. This 
was then used as an electrophile to synthesise masked amino acid derivatives 3.122 with the (1’-
fluoro)vinyl group in the quaternary α position (Scheme 3.32). 
 
 
Scheme 3.32. β,β-Difluorovinyl phenyl sulfone 3.121 as a (1-fluoro)vinyl cation surrogate in the synthesis of α-
(1’-fluoro)vinyl amino acids for use as mechanism-based inhibitors. 
 
  
                                                          
170
 P. J. Crowley, J. M. Percy and K. Stansfield, Tetrahedron Lett., 1996, 37, 8233-8236. 
Chapter 3  D. M. Sedgwick, Tesis Doctoral 
153 
 
3.3. Results and discussion.  
3.3.1. Synthesis of β-fluorovinyl sulfones. 
 
The starting alkynyl sulfones were synthesised using the methodology described by Nair and co-
workers, taking 3.125 as the model substrate.171 This synthetic route involves cerium(IV) ammonium 
nitrate (CAN) mediated iodosulfonylation of phenylacetylene to give 2-iodo-2-phenyl-1-tosylethene 
3.124, followed by treatment with K2CO3 to eliminate HI, resulting in the desired 3.125 (Scheme 3.33). 
 
 
Scheme 3.33. Synthesis of model alkynyl sulfone 3.125. 
 
From there we began to test fluoride sources, and found that treatment of 3.125 with TBAF—one of 
the most common and least expensive fluoride sources—produced 3.126 via addition of fluoride in the 
β position, albeit in a moderate 43% yield. It’s worth noting that the β-fluorovinyl sulfone was formed 
exclusively as the Z stereoisomer, as has been seen by other authors when adding fluoride to ynones or 
ynals.120, 121 However, a relatively high quantity of β-keto sulfone 3.127 was also formed in the reaction 
with TBAF (Scheme 3.34).  
 
 
Scheme 3.34. Preliminary tests with TBAF. 
 
Nevertheless, encouraged by the knowledge that it is in fact possible to obtain β-addition using nothing 
more than the intrinsic electrophilicity of the alkynyl sulfone moiety, we turned to other fluoride 
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sources in the hope of improving the yield and the chemoselectivity (Table 3.1). We attributed the 
formation of 3.127 to the addition of residual water present either in the THF, the glassware, or the 
TBAF solution itself (commercial TBAF solutions contain ca. 5% water). Unfortunately, other “drier” 
fluoride sources such as KF, KHF2, NaF, TMAF, TBAT, and ZnF2 all either failed to react or resulted in 
lower selectivity and yield than the commercial solution of TBAF. Practical elements such as the use of 
oven-dried glassware, molecular sieves, freshly distilled THF, or a new TBAF solution to ensure the 
minimum amount of residual water gave similarly disappointing results. Furthermore, the reaction was 
attempted with more equivalents of TBAF, in order to increase the rate of reaction and force the 
introduction of fluoride into the structure, but to no avail. On a positive note, neither the α-fluorovinyl 
sulfone nor the related (E)-β-fluorovinyl sulfone was observed in any case. 
 
Table 3.1. Optimisation studies with other sources of fluoride.
a 
 
Entry Equiv TBAF Additive T (°C) Time (h) Yield 3.126 (%)c 3.126:3.127d 
1 1.5 - 0 6 45 1:1 
2 1.5 - 60 3 38 1:1 
3b 1.5 - r.t. 3 31 1:2 
4 1.5 4 Å MS r.t. 3 37 1:1 
5 1.5 Na2SO4 (2 equiv) r.t. 3 39 1:1 
6 5 - r.t. 2 41 1:1 
a 
All glassware oven-dried and fresh THF and TBAF solution used.
 b 
Reaction carried out with TBAF (1M in THF) 




Ratio determined by 
1
H NMR of crude reaction mixture. 
 
Given that these attempts failed to improve the results, we decided to explore the possibility of a 
metal-catalysed reaction. In this context, Jiang et al. and Sun, Gong et al. described the use of silver(I) 
fluoride in the synthesis of β-fluorochalcones, although the silver species was used stoichiometrically in 
both cases.172 
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Zhu et al. also published a report on the hydrofluorination of ynamides using silver(I) fluoride as the 
fluorinating agent in 2014.173 However, the same authors published a second study in 2016 in which 
they were able to control the regioselectivity of the hydrofluorination of the same class of ynamide 
substrates, achieving α-fluoroenamides 3.129 with a silver catalyst (Scheme 3.35, a) and (Z)-β-
fluoroenamides 3.130 with a copper catalyst (Scheme 3.35, b).174 However, the regioselectivity seems 
to be somewhat substrate-dependent rather than purely catalyst-dependent. Submitting ynamides 
3.128a to the copper-catalysed conditions resulted in no reaction; the substitution at the nitrogen atom 
is critical for the success of the reaction. Curiously, the β-hydrofluorination procedure also resulted in 
high yields and selectivities when using the (Ph3P)3CuF stoichiometrically. 
 
 
Scheme 3.35. a) α-Hydrofluorination of ynamides using silver catalysis. b) β-Hydrofluorination of ynamides 
using copper catalysis. 
 
In terms of gold catalysis, the Hammond group recently disclosed a novel HF reagent—HF·DMPU (N,N-
dimethylpropyleneurea)—and described its use in the gold-catalysed hydrofluorination of alkynes 
(Scheme 3.36).175 Amongst the examples was ethyl phenylpropiolate 3.131, which when treated with 
JohnPhos gold phthalimide catalyst [Au]-I produced the β-fluorinated product, ethyl 3-fluoro-3-
phenylacrylate 3.132 in high yield, regioselectivity, and Z-stereoselectivity. 
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Scheme 3.36. Gold-catalysed hydrofluorination of alkynes reported by Hammond et al. 
 
We therefore looked into the reaction between alkynyl sulfone 3.125 and fluorine sources in the 
presence of a variety of metal catalysts, focusing on those seen in the previously mentioned examples 
(Table 3.2).  
To our surprise, we found that both the (E)-β-fluorovinyl sulfone—which is thus far unknown in the 
chemical literature—and the expected Z isomer were formed to a certain degree with both copper and 
silver catalysts. Interestingly, the E isomer was the major product formed only when 3HF·Et3N was used 
in conjunction with copper catalyst (PPh3)3CuF, whereas changing the HF source to Olah’s reagent 
(HF·pyridine) or HF·DMPU resulted in more of the Z isomer. In contrast, the use of both silver and gold 
resulted in the Z isomer as the major product, as seen in the uncatalysed reaction with TBAF (entry 18, 
Table 3.2). We identified the geometric isomers using the coupling constant in the 1H and 19F NMR 
spectra; trans H—F coupling constants, corresponding to the Z isomer, are larger. In this case, we 
observed coupling constants of 30 Hz and 18 Hz, accounting for the Z and E isomers respectively (Figure 
3.2). 
Chapter 3  D. M. Sedgwick, Tesis Doctoral 
157 
 
Figure 3.2. Identification of E and Z isomers based on the H-F coupling constant. 
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Table 3.2. Exploration of different metal catalysts and HF sources. 
 
Entry [cat.] F- source Solvent T (°C) Time (h) Yield 3.126 (%) Z:E 
1 (Ph3P)3CuF 3HF·Et3N THF 70 16 58% 1:2 
2 (Ph3P)3CuF HF·DMPU THF 70 16 51% 1:1 
3 (Ph3P)3CuF HF·Py THF 70 16 49% 3:1 
4 (Ph3P)3CuF 3HF·Et3N THF 55 20 63% 2:3 
5 (Ph3P)3CuF 3HF·Et3N Dioxane 55 20 58% 1:3 
6 (Ph3P)3CuF 3HF·Et3N Dioxane 70 6 42% 1:3 
7 (Ph3P)3CuF 3HF·Et3N Dioxane 70 20 90% 1:3 
8 Ag(NTf)2 3HF·Et3N DMF 70 16 55% 5:1 
9 - AgF MeCN (aq.) r.t. 16 - - 
10 Ph3PAuMe 3HF·Et3N THF 55 6 - - 
11 Ph3PAuMe HF·DMPU DCE 55 6 37% 19:1 
12 Ph3PAuMe HF·Py DCE 55 6 44% 12:1 
13 Ph3PAuMe HF·DMPU THF 70 16 51% 1:1 
14 Ph3PAuMe HF·DMPU DCE 55 20 53% 25:1 
15 Ph3PAuMe HF·DMPU DCE 70 6 44% 22:1 
16 SPhosAuOTf HF·DMPU DCE 55 20 37% 25:1 
17 JohnPhosAuCl HF·DMPU DCE 55 20 58% 3:1 
18 - TBAF THF r.t. 3 43% 99:1 
 
In the end, the best Z-selectivity was obtained with with TBAF in THF; although the gold-catalysed 
reactions gave slightly higher yields and acceptable selectivities (entry 14, Table 3.2), we decided that 
the metal-free treatment of alkynyl sulfones with just TBAF in THF far outweighed the gold-catalysed 
procedure in terms of practicality, cost, and sustainability. However, we still had the problem of the 
formation of β-keto sulfones 3.127. On the other hand, we had also discovered suitable reaction 
conditions to favour the formation of the corresponding E isomers—this will be developed further later 
in the chapter, given that these derivatives remain unprecedented in the chemical literature (vide 
infra). 
To this end, we decided to run some control experiments to determine the origin of this unwanted side-
product (Scheme 3.37). We first treated 3.125 with a mixture of THF:H2O (10:1), to see if water was a 
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strong enough nucleophile to add to the β position as we first suspected. However, we found that this 
was not the case, and no reaction took place. Therefore, we treated the product 3.126 with the same 
THF:H2O mixture, to see if the product was a better electrophile and an addition-elimination reaction 
was responsible for the formation of 3.127, although this also failed to give a reaction, even after 
addition of a small amount of TBAF. Finally, we found that addition of one equivalent of lithium 
hydroxide to the mixture of 3.126 in THF:H2O resulted in a 1:1:1 mixture of 3.125, 3.126, and 3.127. 
This suggested that the presence of hydroxide ions promoted both the elimination of HF from the 
product, as well as the formation of the β-keto sulfone through addition to the alkynyl sulfone starting 
material. We confirmed this by treating starting alkynyl sulfone 3.125 with lithium hydroxide in 
aqueous THF, and observing that the β-keto sulfone was indeed formed. 
 
 
Scheme 3.37. Control experiments to determine the origin of 3.127. 
 
In light of these results, we deduced that the reaction responsible for the formation of β-keto sulfone 
3.127 was the addition of the hydroxide ion, and that this species came from the commercial TBAF 
solution. Since THF-based solutions of TBAF often contain a small amount of water, the basic nature of 
TBAF means that there would be significant amounts of OH- present in the media. We therefore took a 
new approach, and explored the use of acidic additives to the reaction mixture in order to neutralise 
the hydroxide solution, thereby hindering the formation of the unwanted β-keto sulfones. To our 
delight, this approach was more successful than the last attempts, and both the yield and selectivity 
improved greatly with this addition. However, the reaction was also sensitive to the manner in which 
the TBAF solution was neutralised: the best results were obtained with just one equivalent of NH4Cl 
whereas saturated aqueous NH4Cl solution or stronger acids, such as TsOH, inhibited the reaction 
(Table 3.3).  
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Table 3.3. Optimisation using acids to neutralise the TBAF solution. 
 
Entry [AH] Equiv [AH] Time (h) Conv. (%) 3.126c 3.126:3.127e 
1 - - 3 100 43% 1:1 
2 NH4Cl 1 3 100 73% 13:1 
3 NH4Cl 1.5 20 70 N.D.
d 10:1 
4 NH4Cl 2 20 56 N.D.
d 10:1 
5 NH4Cl (sat.)
b - 8 0 - - 
6 TsOH 1 8 0 - - 
7a - - 5 90 N.D. 3:1 
a 
TBAF@SiO2 used instead of TBAF (1M in THF). 
b 




Given the difficulty in separating these compounds (starting 3.125, 3.126, and 3.127) by flash column 
chromatography, the yield was not determined for these reactions since they did not proceed to completion. 
e 
The 
ratio was determined using 
1
H NMR of the crude reaction mixture.  
 
The reaction was also attempted with TBAF supported on silica gel, since we hypothesised that the 
acidic nature of silica would offset the basicity of TBAF and prevent the formation of 3.127. Not only 
that, but it should contain far less water and therefore less hydroxide ions. Although the selectivity was 
slightly better than when the standard THF solution was used, the difference was not as drastic as we 
had hoped (entry 7, Table 3.3).  
With these optimised conditions in hand (entry 2, Table 3.3), we sought to explore the scope of the 
reaction. We therefore synthesised a range of alkynyl sulfones with varied substituents, such as 
electron-withdrawing and donating aromatic groups, heteroaromatics, and aliphatic groups (Table 3.4). 
Aside from 3.125g and 3.125p-u, these were all synthesised following the same CAN-mediated 
iodosulfonylation/HI elimination methodology described by Nair et al. (refer to Scheme 3.33, from now 
on referred to as method A), starting from the corresponding terminal alkynes.171 The remaining 
derivatives were synthesised via a second method (denominated method B, this will be discussed in 
more depth on page 163) based on the nucleophilic addition of the terminal alkyne to diphenyl or 
dimethyl disulphide. The majority of the terminal alkyne starting materials were commercially available, 
although given the high price of some derivatives we opted to synthesise them ourselves. 
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Terminal alkyne 3.133l containing the ortho-bromo substituent (Scheme 3.38) necessary for the 
synthesis of 3.125l (Table 3.4) was synthesised through the deprotection of the TMS protected 
derivative, which we found to be a far cheaper alternative to the expensive terminal alkyne. A simple 
treatment with potassium carbonate in methanol afforded the desired 3.133l in a 96% yield.  
 
 
Scheme 3.38. Synthesis of (2-bromophenyl)acetylene 3.133l. 
 
On the other hand, electron-rich alkynes 3.133p-r (Scheme 3.39) were synthesised using a Corey-Fuchs 
reaction, starting from the corresponding aldehyde. To this end, the aldehydes were reacted with 
tetrabromomethane and triphenylphosphine, resulting in the gem-dibromoalkene intermediates 3.134. 
This was then subjected to a DBU-mediated elimination reaction to afford the desired terminal alkynes 
3.133p-r in high yields.176  
 
 
Scheme 3.39. Synthesis of electron-rich terminal alkynes.  
 
After the synthesis of the non-commercial (or expensive) terminal alkynes, the alkynyl sulfones could 
then be synthesised. Method A (Scheme 3.33) was generally inadequate for terminal alkyne substrates 
bearing methoxy substituents on the aromatic ring; during the first attempt to synthesise compounds 
3.125h and 3.125i (Table 3.4) via method A we isolated a mixture consisting mostly of the vinyl iodide 
intermediate. Furthermore, the retention factors of the intermediate and the final product were very 
similar in all solvent mixtures tested, and we had to resort to different reaction conditions for the 
second step to proceed to completion. Eventually we achieved these compounds by using a longer 
reaction time and a higher temperature (75 °C rather than 60 °C). 
                                                          
176
 a) S. S. Ichake, A. Konala, V. Kavala, C.-W. Kuo and C. F. Yao, Org. Lett., 2017, 19, 54-57. b) A. K. Morri, Y. 
Thummala and V. R. Doddi, Org. Lett., 2015, 17, 4640-4643. 
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On the other hand, 3.125g, 3.125p-s and 3.125u (Table 3.4) were synthesised via method B: a two-step 
sequence consisting in n-BuLi mediated addition of the terminal alkyne to phenyl or methyl disulphide, 
followed by oxidation of the resulting methyl or phenyl sulphide to the corresponding sulfone.105 During 
the first step of this reaction with phenyl disulphide, thioanisole was formed as a side product. This was 
removed either by column chromatography or by high vacuum before the subsequent oxidation step, 
although this could often be ignored and extra equivalents of m-CPBA used in the oxidation step since 
the resulting phenyl methyl sulfone by-product could usually be separated from the desired alkynyl 
sulfone (Scheme 3.40).  
 
 
Scheme 3.40. Method B, n-BuLi mediated addition of terminal alkyne 3.133 to phenyl or methyl disulfide and 
subsequent oxidation with m-CPBA. 
 
Finally, ethynyl tosyl sulfone 3.125t was synthesised by aluminium chloride mediated coupling of 
(bis)trimethylsilylacetylene to afford the TMS-protected sulfone intermediate 3.135 and subsequent 
deprotection, although this step proved somewhat difficult. Standard procedures such as treatment 
with potassium carbonate in methanol afforded 3.136, resulting from the deprotection of the TMS 
group, followed by addition of two molecules of methanol to the terminal position. In the end, the 
deprotection was carried out by slowly adding an aqueous solution of sodium fluoride to a solution of 
3.135 in methanol at 0 °C (Scheme 3.41).177 Therefore, we reasoned that treatment of 3.135 with TBAF 
could proceed similarly, resulting in 2,2-difluoroethyl tosyl sulfone 3.137. However, this was not the 
case, although the likely high instability of this compound means that it could have been formed and 
lost during the course of the reaction. 
 
                                                          
177
 J. R. Sommer, A. H. Shelton, A. Parthasarathy, I. Ghiviriga, J. R. Reynolds and K. S. Schanze, Chem. Mater., 2011, 
23, 5296-5304.  




Scheme 3.41. Problems with the removal of the TMS protecting group; unexpected formation of 3.136 and 
attempts to form 3.137 under analogous conditions. 
 
After the successful synthesis of our library of alkynyl sulfones 3.125, we tested them with our metal-
free fluorination procedure (Table 3.5). To our delight, a range of neutral and electron-donating groups 
were well-tolerated (3.126a-i, Table 3.5). However, electron-withdrawing groups resulted in slightly 
lower yields and selectivities. Bromine-containing substrates 3.125j and 3.125k gave moderate yields 
and selectivities, and fluorinated substrates 3.125m and 3.125n resulted in lower yields and 
selectivities. Substrates 3.125h and 3.125l with substitutions in the ortho position failed to react (Table 
3.5), possibly due to steric effects.  
Interestingly, methyl sulfone 3.125s reacted well in just one hour and the corresponding ketone was 
not observed. This suggests that the less electrophilic methanesulfonyl alkyne was unreactive towards 
hydroxide ions in the reaction media, resulting purely in the desired fluorovinyl sulfone 3.126s (Table 
3.5).  
Unfortunately, terminal fluorovinyl sulfone 3.126t was not observed; in fact, when TBAF was added to 
ethynyl tolyl sulfone 3.125t the mixture fumed and a black paste was formed almost immediately, even 
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H NMR (see experimental section).
 c 
No reaction, starting material recuperated.   
d 
Violent exothermic reaction, product not detected (see text). 
e 
Corresponding allene formed (see text). 
f
 Reaction 
carried out at 60 °C over 16h. 
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Aliphatic substrates 3.125u and 3.125v were also unsuccessful, this time due to the rapid formation of 
the corresponding allenyl sulfone, 3.138.178 We attributed this to the presence of a hydrogen atom in 
the γ position, which could be deprotonated in the basic reaction conditions (Scheme 3.42). 
 
 
Scheme 3.42. Speculative mechanism for the formation of the sulfonyl allene derivative from aliphatic alkynyl 
sulfones. 
 
The related ethyl phenylpropiolate was also shown to be a suitable substrate, and the corresponding 
ethyl β-fluoro-β-phenylacrylate 3.132 was also obtained in moderate yield (Table 3.5).  The ester was 
less reactive in our optimised reaction conditions, and the mixture had to be heated for the reaction to 
proceed. Even after 24 hours at 60 °C full conversion was still not achieved, although the product was 
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 S. E. Denmark, M. A. Harmata and K. S. White, J. Org. Chem., 1987, 52, 4031-4042. 
Chapter 3  D. M. Sedgwick, Tesis Doctoral 
167 
 
We then turned our attention to the E isomers. Thankfully, the metal-catalysed processes that had given 
rise to this geometric isomer avoided the formation of the unwanted β-keto sulfone 3.127 and other 
side products; here, the main difficulty was improving the selectivity. Having previously obtained the 
best results with (PPh3)3CuF and 3HF·Et3N (entries 5-7, Table 3.2), we resumed our search for the 
optimum conditions here. Unfortunately, we had problems reproducing these reactions. The catalyst 
was originally prepared following a procedure described by Chaudhuri et al. in 2000, a somewhat 
awkward procedure containing several steps (Cat1) (Scheme 3.43, a).179 After several failed attempts to 
recreate an active catalyst using this method, we turned to a different solution and followed a simpler 
synthesis described by Szabó et al. (Cat2) (Scheme 3.43, b).180  
 
 
Scheme 3.43. Synthesis of the desired catalyst. 
 
In theory, both of these methods afforded the desired catalyst as a complex with methanol, although 
we later found via 1H NMR that the batch of catalyst that we had first used contained no methanol. We 
therefore decided to test the commercially available (PPh3)3CuF (CatCom), which contained no 
methanol, and found that this catalyst was also inactive in the reaction conditions. Furthermore, in 
contrast to our home-made catalyst batches, no signal was detected in the 19F NMR of the commercial 
catalyst; presumably due to different species in equilibrium or coupling with the neighbouring 
phosphorus atoms.181 
These results led us to believe that the true catalytic species responsible for the E isomer was in fact not 
(PPh3)3CuF as we first believed, but a different copper complex. Therefore, we tested the reaction with 
several other complexes, including both copper(I) and copper(II) metal species (CuI, CuCl, Cu(OTf)2, and 
CuF2), as well as mixtures of CuF2 and triphenylphosphine, but to no avail. What’s more, these tests all 
gave poor conversions and the same mixture of (E)- and (Z)-3.126, neither one in a significant majority.  
                                                          
179
 M. K. Chaudhuri, S. S. Dhar and N. Vijayashree, Trans. Met. Chem., 2000, 25, 559-561. 
180
 J. M. Larsson, S. R. Pathipati and K. J. Szabó, J. Org. Chem., 2013, 78, 7330-7336. 
181
 D. J. Gulliver, W. Levason and M. Webster, Inorg. Chim. Acta, 1981, 52, 153-159. 
Chapter 3  D. M. Sedgwick, Tesis Doctoral 
168 
 
Following this, we decided to investigate the batches of the synthesised catalyst as the fluoride donor in 
stoichiometric amounts, given that Zhu demonstrated that good results could also be obtained this 
way.173, 174 To our surprise the reactions took place to completion, albeit resulting in varying amounts of 
the E and Z isomers (Table 3.6). Frustratingly, the commercial catalyst was also active in Zhu’s 
stoichiometric conditions—erasing our doubts that fluorine was even present in the commercially 
bought batch—although it resulted in the opposite selectivity (entry 1, Table 3.6). In these tests we also 
found that toluene gave slightly higher E:Z selectivity.  
With renewed hope, we once again attempted the synthesis of the catalyst using the original procedure 
(Method a, Scheme 3.43). This time, adding less triphenylphosphine to the mixture resulted in an active 
species (Cat3)—leading us to believe that a species such as (PPh3)2CuF2 could be responsible for the 
reaction. We were unable to confirm this, however. 
 
Table 3.6. New optimisation of the metal-catalysed syn-hydrofluorination of 3.125g. 
 
Entry Catalyst [cat.] (mol%) [HF] Solvent T (°C) Conv. (%)a E:Zb 
1 Cat1 100 - THF 70 100 2:3 
2 Cat1 10 3HF·Et3N Dioxane 70 90 1:1 
3 Cat2 100 - THF 70 100 1:1 
4 CatCom 100 - THF 70 100 2:3 
5 Cat2 100 - Toluene 70 100 3:1 
6 Cat3 10 3HF·Et3N Dioxane 70 100 3:1 










F NMR (vide infra). 
 
Nonetheless, after a short optimisation we found that toluene was the best solvent, possibly due to its 
non-coordinating nature (entry 7, Table 3.6). 
We therefore took these conditions forward to study the scope of this reaction. We observed a clear 
trend with regards to the substrate nature and the selectivity of the reaction; substrates containing 
electron-donating groups with respect to the alkyne group resulted in the best E-selectivity, whereas 
more electron-poor alkynes resulted in poor selectivity, or even slight Z-selectivity. Despite this, the E 
and Z isomers were easily separable by flash column chromatography, and (E)-β-fluorovinyl sulfones 
were eventually obtained in synthetically useful yields (Table 3.7). The selectivity was easily determined 
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through 19F NMR; the doublet corresponding to the E isomer appeared at roughly -70 ppm, whereas the 
related Z isomer would appear at around -90 ppm (Figure 3.4). 
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 Isolated yield of (E)-3.126. 
b 
E:Z ratio determined by 
19
F NMR of crude reaction mixture. 
c
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3.3.2. Reactivity of β-fluorovinyl sulfones 
 
After carrying out the selective synthesis of both (E)- and (Z)-β-fluorovinyl sulfones, we began to 
explore their reactivity. Firstly, we tested some simple nucleophilic additions with a variety of 
nucleophiles. Unfortunately, as Berkowitz observed with his 2,2-difluorovinyl phenyl sulfone 3.121, 
many nucleophiles reacted with our model substrate (Z)-3.126a via an addition-elimination mechanism, 
in which the fluorine was lost each time. Nucleophiles that reacted in this way included amines 
(pyrrolidine, piperidine and benzylamine) and n-butyllithium resulting in 3.139 and 3.140 respectively 
(Scheme 3.44). Others such as diethyl malonate, nitromethane, allyl trimethylsilane, trifluoromethyl 
trimethylsilane (Prakash’s reagent), and trimethylsilyl acetylene failed to react at all. 
 
 
Scheme 3.44. Reaction of β-fluorovinyl sulfones with certain nucleophiles. Enamine 3.139 was highly 
susceptible to hydrolysis. 
 
After seeing these results, we realised that a fluorine atom in the β position would always be 
susceptible to elimination in this class of simple 1,4-addition reactions. We also explored metal-
catalysed addition reactions as demonstrated by Charette, Carretero and Nishimura.132-139 However, 
these reactions gave slightly different results in our case. Firstly, we tried the rhodium-catalysed 
addition of arylboronic acids as described by Nishimura and co-workers.138 In this reaction, we were 
able to detect addition-elimination product 3.141 (Scheme 3.45); this meant the substrate was indeed 
reactive in these reaction conditions. We first thought that the base, potassium phosphate, was too 
strong for the fluoride substituent, which resulted in effectively a double-benzylic position. We 
therefore attempted the reaction with different bases, and even in more acidic conditions using 
ammonium chloride, but to no avail. The result was always the same; around a 10% conversion and 
3.141 as the only product. This led us to believe that the actual mechanism was slightly different, and 
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the rhodium was actually responsible for the loss of fluorine via β-fluoride elimination. Since we used a 
5 mol% catalyst loading (therefore 10 mol% in terms of rhodium metal) and always saw around 10% 
conversion, we assumed that the reaction failed to proceed to completion due to the resulting 
rhodium-fluoride species being inactive as a catalyst in this reaction (Scheme 3.45).  
 
 
Scheme 3.45. Results of attempted rhodium-catalysed addition of arylboronic acids to (Z)-3.126a. 
 
In this field, we also attempted some of the reactions disclosed by Charette131 and Carretero,165 namely 
the addition of diethyl zinc and reduction with phenylsilane respectively. Our substrate was unreactive 
in these cases, which didn’t come as a total surprise given that the original reports detailed the 
dependency of the reactions on the 2-pyridyl sulfone moiety. With this is mind, we also attempted the 
synthesis of various alkynyl 2-pyridyl sulfones 3.142 in order to obtain the corresponding β-fluorovinyl 
2-pyridyl sulfones and confirm the different reactivity observed by other authors.127-133 However, all 
synthetic routes tested failed to yield the target 3.142 (Scheme 3.46). 
 
 
Scheme 3.46. Attempted syntheses of alkynyl 2-pyridyl sulfones 3.142. 
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After these failed reactions, we decided to move in a different direction with this study. Given the facile 
loss of fluorine in this type of addition reaction, we hypothesised that these substrates would benefit 
from more concerted processes, thereby avoiding the formation of negative charges during the 
reaction. To this end, we explored both Diels-Alder and cycloaddition reactions between various 
dipoles—such as nitrones, azides, and ylides182—and our fluorovinyl sulfones. Both the E and Z isomers 
were tested, and all reactions were followed by TLC and NMR analysis. Unfortunately, these reactions 
also failed to give any promising product, although in several cases E/Z isomerisation was observed 
when the starting fluorovinyl sulfones were subjected to high temperatures. 
We then started to look at hydrogenation reactions. This would surely be a challenging prospect; vinyl 
halides are generally considered to be poor substrates for hydrogenation reactions, given the tendency 
of C—X bonds to cleave under such reaction conditions. Despite this, the hydrogenation of vinyl 
fluorides—though still a fairly understudied subject—is perhaps the most common owing to the relative 
strength of the C—F bond compared to its chloride and bromide counterparts.183 
We began this study using standard hydrogenation conditions, and the reaction took place and 
proceeded to completion. However, the result was a mixture of the desired saturated β-fluoroalkyl 
sulfone 3.143a, along with a relatively high proportion of defluorinated product 3.144a (Scheme 3.47).  
 
 
Scheme 3.47. First attempt at the hydrogenation of model fluorovinyl sulfone (Z)-3.126a. 
 
We decided to try several other hydrogenation methodologies to obtain the resulting saturated β-
fluoroalkyl sulfones 3.143 in higher selectivities, including the use of other metal catalysts and some 
transfer hydrogenation procedures with ammonium formate or diimine as the hydrogen source (entries 
1-10, Table 3.8). Given the limited success of these tests, we decided to persist with the standard 
palladium over activated charcoal and attempt to improve the selectivity. Various studies have 
described the effect of solvents on hydrodehalogenation processes—the related hydrodechlorination 
has been more widely studied due to environmental issues—and usually conclude that the use of polar 
                                                          
182
 For an informative review on the types of cycloaddition reactions tested here, see: L. M. Stanley and M. K. Sibi, 
Chem. Rev., 2008, 108, 2887-2902.  
183
 D. M. Sedgwick and G. B. Hammond, J. Fluorine Chem., 2018, 207, 45-58. 
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protic solvents is the most effective at removing the halide from the final product.184 In this context, we 
ran a small optimisation of more common solvents in order to achieve a higher selectivity and less 
hydrodefluorination (entries 10-20, Table 3.8). In the end, we found that the reaction was more 
sluggish in the non-polar toluene, which proved useful in terms of controlling the selectivity. In this 
way, we managed to obtain full conversion of 3.126a to 3.143a with an acceptable selectivity of 12:1, 
by increasing the reaction time (entries 18-20, Table 3.8). Unfortunately, we were unable to purify the 
resulting crude mixture through standard column chromatography—all three species involved 
(fluorovinyl sulfone 3.126, saturated fluoroalkyl sulfone 3.143 and the corresponding 
hydrodefluorination product 3.144) had very similar RF values and were not easily seen in UV light, nor 
with standard TLC stains—meaning it was preferable to reach full conversion despite a slightly higher 
degree of the non-fluorinated product. Nevertheless, separation via HPLC was possible. 
 
  
                                                          
184
 a) M. Hudlicky, J. Fluorine Chem., 1979, 14, 189-199. b) K. J. Stranger, R. J. Angelici, J. Mol. Catal. A Chem., 
2004, 207, 59-68. 
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Table 3.8. Hydrogenation of fluorovinyl sulfones. 
 
Entry [H] [cat.]c Solvent T (˚C) Time (h) Conv. (%)g 3.143:3.144g 
1 H2 (1 atm) Pd/C MeOH r.t. 1 100 2:1 
2 NH4·HCO2 - MeOH r.t. 24 - - 
3a NH4·HCO2 Pd/C MeOH r.t. 24 - - 
4 NH4·HCO2 - EtOH 110 8 N.D.
h - 
5 N2H4/H2O2 CuSO4 EtOH r.t. 24 - - 
6b TsNHNH2 - Toluene 150
 8 N.D.i N.D. 
7b TsNHNH2 - Toluene 160
f 3 N.D.j N.D. 
8 NaBH4 - MeOH r.t. 24 - - 
9 PhSiH3 CuOt-Bu
d Toluene/H2O r.t. 24 - - 
10 H2 (1 atm) Pd(OH)2/C MeOH r.t. 1 100 1:1 
11 H2 (1 atm) PtO2 MeOH r.t. 24 - - 
12 H2 (1 atm) Pd/C EtOAc r.t. 1 100 3:1 
13 H2 (1 atm) Pd/C MTBE r.t. 1 100 6:1 
14 H2 (1 atm) Pd/C Et2O r.t. 1 100 3:1 
15 H2 (1 atm) Pd/C AcOH r.t. 1 100 1:10 
16 H2 (1 atm) Pd/C Dioxane r.t. 1 100 7:1 
17 H2 (1 atm) Pd/C Cyclohexane r.t. 1 100 7:1 
18 H2 (1 atm) Pd/C Toluene r.t. 1 30 >25:1 
19 H2 (1 atm) Pd/C
e Toluene r.t. 1.5 80 >25:1 
20 H2 (1atm) Pd/C
e Toluene r.t. 2 100 12:1 
a 




4 Å MS added to the reaction mixture. 
c 
Catalyst loading 10 mol% 
unless stated otherwise. 
d 




Catalyst loading 15 mol%. 
f 
Reaction 




H NMR unless stated otherwise. N.D. = Not determined. 
h 
Target compound not detected; evidence of addition-elimination by EtOH. 
i 
Traces of 3.143a detected in a 
complex mixture. 
j 
Complex mixture, partial isomerisation of (Z)- to (E)-3.126a.  
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 B. C. Ranu, S. K. Guchhait and K. Ghosh, J. Org. Chem., 1998, 63, 5250-5251. 
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 D. H. Appella, Y. Moritani, R. Shintani, E. M. Ferreira and S. L. Buchwald, J. Am. Chem. Soc., 1999, 121, 9473-
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We also carried out some control experiments to determine the manner in which the 
hydrodefluorination reaction occurred. There are generally three speculated mechanisms for this: 1) 
hydrogenation of the C—C double bond to give the desired 3.143, followed by the elimination of HF 
and hydrogenation of the resulting defluorinated vinyl sulfone 3.145; 2) a concerted mechanism 
directly resulting in 3.144 as proposed by Hudlicky via a carbene intermediate;184a and 3) direct cleavage 
of the C—F bond in 3.143 promoted by the palladium catalyst. Vinyl sulfone 3.145 was not observed at 
any point and, in contrast to Andersson187 and Hudlicky’s work with α-fluorovinyl carbonyls, we 
observed that fluoroalkyl sulfone 3.143 reacted further in the same reaction conditions resulting in 
further loss of fluorine. These observations led us to believe that direct cleavage of the C(sp3)—F bond 
was responsible for hydrodefluorination (Scheme 3.48). 
 
 
Scheme 3.48. Control experiments to determine the mechanism of hydrodefluorination. 
 
Having determined the best conditions for the hydrogenation of (Z)-β-fluorovinyl sulfones to β-
fluoroalkyl sulfones, we evaluated the scope of the reaction. The conversions and selectivities were 
determined via 1H NMR spectroscopy, given that the fluorinated 3.143 and non-fluorinated 3.144 could 
be easily distinguished (Figure 3.5). We found that β-fluorovinyl sulfones with electron-neutral aromatic 
rings (entries 1-5, Table 3.9), as well as those bearing electron-donating groups (entries 6-7, Table 3.9), 
all reacted well in similar time frames to give moderate to high selectivities. However, substrates 
bearing substituents positioned to withdraw electron density from the double bond reacted much more 
slowly (entries 8-11, Table 3.9). Interestingly, in the hydrogenation reaction the m-methoxy 
substituents in substrate 3.126i exerted a deactivating effect, similar to the difluorinated aromatic 
group in 3.126m. This is in accordance with the Hammett coefficient for methoxy groups in the meta 
position, in which their electron-withdrawing effect overrides their resonance effect (this was also seen 
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 M. Engman, J. S. Diesen, A. Paptchikhine and P. G. Andersson, J. Am. Chem. Soc., 2007, 129, 4536–4537. 
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in Chapter 2, refer to pages 103-104). The hydrogenation of thiophene-derived fluorovinyl sulfone 
3.126o failed to complete with 15 mol% catalyst loading, even after submitting the same mixture to the 
reaction conditions several times. We suspected that the catalyst was poisoned in some way by the 
thiophene product, which was confirmed when the reaction proceeded to completion in a normal time 
frame upon treating the substrate with a stoichiometric amount of palladium over charcoal under an 
atmosphere of hydrogen. 
The related α-fluorovinyl sulfone 3.146, β-fluoro acrylate 3.132, and aliphatic fluorovinyl sulfone 3.126u 
were also successfully hydrogenated in high selectivities and yields (entries 13, 15 and 16, Table 3.9). 
The higher selectivity resulting from the hydrogenation of α-fluorovinyl sulfone 3.146 suggests that the 
β-fluorine is more susceptible to hydrodefluorination, which is in accordance with Sauvetre and co-
workers’ results: with related α-fluoroalkenyl carbonyl compounds no loss of fluorine was observed, 
despite using methanol as the solvent.188 Methyl sulfone derivative 3.126s displayed less 
hydrodefluorination over a reaction time of three hours, once again suggesting that our problems had 
arisen from the more electron-withdrawing nature of the phenyl sulfone. 
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Table 3.9. Scope of the hydrogenation of fluorovinyl sulfones. 
 
Entry Substrate Product Time (h) Conv. (%) Yield (%)b 3.143:3.144e 
1 (Z)-3.126a 
 
2 100 96 12:1 
2 (Z)-3.126b 
 
2.5 100 97 7:1 
3 (Z)-3.126c 
 
3 100 94 8:1 
4 (Z)-3.126d 
 
2 100 92 32:1 
5 (Z)-3.126e 
 
3 95 96 24:1 
6 (Z)-3.126f 
 
3 100 96 13:1 
7 (Z)-3.126g 
 
2 100 95 24:1 
8 (Z)-3.126i 
 
60 100 95 19:1 
9 (Z)-3.126j 
 
16 40 0c - 





60 100 94 12:1 
11 (Z)-3.126n 
 
120 80 90d 4:1 
12a (Z)-3.126o 
 
2.5 100 85 13:1 
13 (Z)-3.126s 
 
3 80 96d >99:1f 
14 (Z)-3.126u 
 
1.5 100 94 13:1 
15 (Z)-3.146 
 
2 100 94 24:1 
16 (Z)-3.132 
 
1.5 100 90 10:1 
a
 Catalyst loading of 100 mol% used. 
b
 Yield refers to inseparable mixture of 3.143 and 3.144.
c
 The only product 
detected was 3.126a resulting from the cleavage of the aromatic C—Br bond. 
d 
Yield refers to the inseparable 
mixture of unreacted 3.126, 3.143, and 3.144. 
e
 Ratio measured via 
1
H NMR spectrum of the crude mixture (refer 
to Figure 3.5). 
f
 No defluorinated product observed after three hours of reaction time. 
 
We also studied the hydrogenation of the corresponding E isomer of our model substrate (E)-3.126a. In 
this case, the substrate was less reactive and required a much longer reaction time to achieve full 
conversion (Table 3.10). This is somewhat different to what one would expect from this type of 
reaction.  
Generally speaking, the reaction rate of catalytic heterogeneous hydrogenation correlates directly to 
the stability of the olefin in question. Therefore, less stable alkenes generally react faster under 
hydrogenation conditions, and generally cis alkenes are less stable due to steric effects.189 In our case, 
strictly speaking the E isomers are in the trans configuration, although sterically speaking this is not the 
case; sterically, our substrate (E)-3.126a is comparable to a more traditional cis alkene. Moreover, the 
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isomerisation seen upon submitting the E isomers to high temperatures suggests that the Z isomers are 
more thermodynamically stable. Therefore, one would expect the reaction rate of the E isomers to be 
higher than for the corresponding Z isomers.  
In this sense, we expect that the difference has more to do with electronic rather than steric effects.  
Furthermore, the hydrogenation of the E isomer resulted in a higher degree of defluorinated product. 
This result reinforces our previous observations that the hydrodefluorination process takes place on the 
resulting β-fluoroalkyl sulfone product 3.143, rather than taking place directly from the vinyl fluoride 
starting material with the double bond intact (refer to Scheme 3.47). The hydrogenation process of the 
E isomer is slower, while the resulting product is the same and therefore fluorine would be lost from 
the product at the same rate, resulting in a greater amount of defluorinated 3.144a. 
 
Table 3.10. Hydrogenation of the related E isomer, (E)-3.126a 
 
Entry Substrate Time (h) Conv. (%) 3.143a:3.144a 
1 (Z)-3.126a 2 100 12:1 
2 (E)-3.126a 2 0 - 
3 (E)-3.126a 4 10 1:1 
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3.3.3. Preliminary studies of the homogeneous hydrogenation of vinyl 
fluorides. 
 
Hydrogenation is fundamental process in organic chemistry and has been used for over a century to 
add elemental hydrogen across unsaturated bonds.150 Many advances have been made in the area of 
hydrogenation since early examples in the 19th century; perhaps the most important came in the mid-
20th century when Wilkinson developed the first homogeneous rhodium complex to rival the reactivity 
of well-established heterogeneous catalysts, as mentioned earlier. Following this, Knowles and Noyori 
were able to further develop the homogeneous version of the reaction to allow enantioselective 
hydrogenation. They later shared the Nobel Prize in Chemistry in 2001 “for their work on chirally 
catalysed hydrogenation reactions”, which has now been successfully applied to a wide range of 
substrates and industrial processes—the first example of asymmetric hydrogenation was swiftly applied 
to the industrial synthesis of L-DOPA (Scheme 3.49).151, 190 
 
 
Scheme 3.49. Nobel prizes in 2001 for developments in asymmetric hydrogenation: Knowles’ DiPAMP ligand 
and its immediate application in the industrial synthesis of L-DOPA; and Noyori’s Ru-BINAP catalyst. 
 
However, the field still faces many challenges, particularly in the asymmetric area; the earlier examples 
were almost exclusively carried out using specific substrates bearing functional groups in proximity to 
the alkene able to coordinate to the metal centre and help in directing the selectivity. Recently, more 
substrates have become amenable to the transformation following further advances in the 
development of chiral ligands and catalysts, although many classes of substrates remain 
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underrepresented in the field: vinyl halides are one such class. As discussed previously, vinyl halides are 
generally considered poor substrates for hydrogenation reactions, since they present the additional 
challenge of dehalogenation. Examples of selectively reducing alkenyl halides to alkyl halides are 
extremely scarce, although a few do exist. Amongst these transformations, it is perhaps most common 
to start with vinyl fluorides given that the C—F bond is the strongest of the carbon-halide bonds, thus 
making them the most resistant to dehalogenation. In recent years, vinyl fluorides have seen an 
increased interest as substrates for hydrogenation, possibly due to the increasing demand for new 
methodologies of introducing fluorine into organic molecules.183, 191 
Since the hydrogenation of fluorovinyl sulfones was unknown in the literature, after carrying out the 
work in the previous section we set our sights on something far more ambitious: the homogeneous, 
and therefore potentially asymmetric, hydrogenation of these substrates. The following work was 
carried out partly during a short stay (July-October 2017) in the University of Louisville, Kentucky (USA), 
in the research group of Prof. G. B. Hammond. The structures of some representative ligands and 
catalyst complexes used throughout this study are summarised in Figure 3.6. 
 
 
Figure 3.6. Selection of representative ligands and catalyst complexes used in this study. 
                                                          
191
 For some representative examples, see: a) M. Saburi, L. Shao, T. Sakurai and Y. Uchida, Tetrahedron Lett., 1992, 
33, 7877–7880. b) S. W. Krska, J. V. Mitten, P. G. Dormer, D. Mowrey, F. Machrouhi, Y. Sun and T. D. Nelson, 
Tetrahedron, 2009, 65, 8987–8994. c) M. Engman, J. S. Diesen, A. Paptchikhine and P. G. Andersson,  J. Am. Chem. 
Soc., 2007,129, 4536–4537. 
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Aromatic β-fluorovinyl sulfone 3.126a and aliphatic derivative 3.126q were first tested as the model 
substrates, and we found immediately that the aromatic group hindered the hydrogenation reaction, in 
accordance with Saburi’s work dealing with acrylic acids.192 Our initial screenings showed that 
hydrodefluorination also took place here, comparative to that seen with the heterogeneous 
hydrogenation described previously (Table 3.11). However, a recent report from Krska and co-workers 
at Merck suggested that the fluorine loss in homogeneous hydrogenation differed slightly from the 
heterogeneous scenario. The authors found that rather than the solvent, the ligand had a much more 
dramatic effect on the hydrodefluorination and used methanol for all the reactions, and claim that 
other solvents greatly improved neither the chemo- nor the enantioselectivity.191b 
 
Table 3.11. Initial screenings with fluorovinyl sulfones. 
 
Entry R [cat.] Ligand Solvent Conv. (%)a 3.143:3.144a 
1 n-Hex [Rh(COD)2]BF4 BINAP EtOAc 99% 7:1 
2 n-Hex [Rh(COD)2]BF4 Tol-BINAP EtOAc 73% 3:1 
3 n-Hex [Ru(BINAP)(cymene)Cl]Cl - MeOH 0% - 
4 Ph [Rh(COD)2]BF4 BINAP EtOAc 0% - 
5 Ph [Rh(COD)2]BF4 BINAP DCM 30% 3:1 
6 Ph [Ru(BINAP)(cymene)Cl]Cl - MeOH 0% - 






With regards to the aromatic fluorovinyl sulfone 3.126a, we found that the reaction was sensitive to a 
number of factors, including hydrogen pressure: when using 20 atmospheres of hydrogen, the reaction 
failed to proceed, even in methanol, and the starting fluorovinyl sulfone was recovered. At atmospheric 
pressure, however, with a combination of [Rh(COD)2]BF4 and Segphos in methanol produced the 
reaction to 60% conversion resulting in a low selectivity of 2:1. We reasoned this could be due to the 
poor coordinating ability of such an electron-deficient double bond, meaning at higher hydrogen 
                                                          
192
 a) M. Saburi, L. Shao, T. Sakurai and Y. Uchida, Tetrahedron Lett., 1992, 33, 7877–7880. b) M. Saburi, H. 
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pressures the coordination of the double bond could not compete with hydrogen. Other reports have 
carried out similar hydrogenations at very high pressures (50-100 atm), although this is usually 
accompanied with heating the reaction mixture for good results;191b-c, 193 unfortunately, we lacked the 
facilities to use such conditions. 
We also attempted the asymmetric hydrogenation of an “unfunctionalised” vinyl fluoride 3.149; an 
ambitious transformation given the small size of the fluorine atom as a substituent. Although the 
reaction was carried out successfully, initially there was a large degree of hydrodefluorination; 
especially when using methanol as the solvent. Protic solvents seemed to promote the reaction the 
most, and coordinating solvents such as dioxane and acetone showed some conversion and better 
chemoselectivity, whereas non-coordinating solvents were unsuccessful. The solvent that gave the best 
results in terms of conversion and chemoselectivity was a mixture of dioxane and isopropanol, inspired 
by Zhou et al.193 Rhodium-based catalyst systems showed the most promise early on, however, all of 
the conditions tested gave rise to racemic products (Table 3.12). 
 
Table 3.12. Solvent effects and initial screenings of other catalyst systems. 
 
Entry [cat.] Ligand Solvent Conv. (%)b 3.150:3.151b eec 
1 [Rh(COD)Cl]2 Walphos i-PrOH 100% 3:1 <5% 
2 [Rh(COD)Cl]2 Walphos MeOH 100% 1:1 <5% 
3 [Rh(COD)Cl]2 Walphos Acetone 30% >15:1 <5% 
4 [Rh(COD)Cl]2 Walphos Dioxane 60% >15:1 <5% 
5 [Rh(COD)Cl]2 Walphos Toluene 0% - - 
6 [Rh(COD)Cl]2 Walphos DCM 0% - - 
7 [Rh(COD)Cl]2 Walphos D-IP
a 100% 12:1 <5% 
8 [Ir(COD)Cl]2 Walphos DCM 0% - - 
9 [(Ph2-Ubaphox)Ir(COD)]BARF - DCM 0% - - 
10 [Ru(BINAP)(cymene)Cl]Cl - MeOH 0% - - 
a 
D-IP = Dioxane:i-PrOH (3:1). 
b




 Determined by HPLC in an IC Chiralpak column. 
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We also tried varying other conditions, since existing examples of enantioselective hydrogenation of 
vinyl halides have used higher temperatures and pressures. Furthermore, given the difficulty in 
enantioselectively hydrogenating 3.149, we decided to try other fluorinated substrates with different 
functional groups proximal to the C=C double bond, such as fluoroacrylates or allylic alcohols (Table 
3.13). TaniaPhos (refer to Figure 3.6 for the structure) was also tested due to the tertiary amine group 
present: we envisioned that an acidic additive could protonate this group, and potentially form a 
hydrogen bond with the fluorine atom of the substrates (Figure 3.7). Unfortunately, this mixture also 
failed to give any enantioselectivity, although the chemoselectivity was good.  
 
 
Figure 3.7. Transition state for the envisioned H-bond directed enantioselective reaction with Taniaphos. 
 
Despite the lack of enantioselectivity observed in these reactions, this study shows that the 
homogenous hydrogenation of a variety of vinyl fluorides can be carried out in a selective manner. 
Some representative examples from this study are summarised in Table 3.13. 
 




Table 3.13. Representative reactions carried out into the search for enantioselectivity. 





We have successfully and selectively synthesised a family of (E)- and (Z)-β-fluorovinyl sulfones starting 
from the corresponding alkynyl sulfones for the first time. The E isomers were obtained via copper-
catalysed addition of 3HF·Et3N, whereas the Z isomers were achieved using a simple and practical 
metal-free addition of TBAF. 
The reactivity of the resulting fluorovinyl sulfones was studied, and their selective hydrogenation to 
saturated fluoroalkyl sulfones was carried out; an unprecedented reaction in the chemical literature. 
This was done in both a heterogeneous and homogeneous manner. Although the homogeneous 
reaction was unfruitful in the search for an asymmetric version, this study proves that these challenging 
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3.5. Experimental section. 
 
Reactions were carried out under a nitrogen atmosphere unless otherwise indicated. Solvents were 
purified prior to use: THF was distilled from sodium and DCM from calcium hydride. Reagents were 
used as received from the suppliers without further purification, unless stated otherwise. The reactions 
were monitored by TLC on 0.25mm precoated silica-gel plates, which were revealed with UV light and 
aqueous ceric ammonium molybdate or potassium permanganate stains. Flash column chromatography 
was performed with the indicated solvents on silica gel 60 (particle size: 0.040−0.063 mm). 1H, 13C and 
19F NMR spectra were recorded by a 300 MHz spectrometer. Chemical shifts are given in ppm (δ), 
referenced to the residual proton resonances of the solvents. Coupling constants (J) are given in Hertz 
(Hz). The letters s, d, t, q and m stand for singlet, doublet, triplet, quartet and multiplet respectively. 
The letters br indicate that the signal is broad. A QTOF mass analysis system was used for the HRMS 
measurements. 
 




i. Dibromomethylenation reaction. The corresponding aldehyde (1 equiv) and carbon 
tetrabromide (2 equiv) were dissolved in anhydrous DCM (0.3M), and triphenylphosphine (4 equiv) was 
added portion-wise over 20 minutes at 0 °C. The resulting brown solution was allowed to slowly warm 
to room temperature and was stirred until the reaction completed (analysed via TLC, approximately 2 
hours). Water was then added to quench the reaction, and the mixture was extracted with DCM (2 x 20 
ml). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo. The resulting crude mixture was purified via flash column chromatography [n-
hexane:ethyl acetate (15:1)]. 
ii. DBU-mediated elimination. DBU (4 equiv) was added to a solution of 1,1-dibromoalkene 
3.134 at room temperature over a period of 30 minutes, and the reaction was stirred for a further 16 
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hours. Following this, HCl (6M in water, 50 equiv) was added over a period of 30 minutes at 0 °C, and 
the biphasic mixture was left for a further 30 minutes. The resulting was extracted with hexane:AcOEt 
(1:1) and the combined organic layers washed with brine, dried over K2CO3, and concentrated in vacuo. 
No further purification was necessary and all spectroscopic data coincided with those given in the 
literature. 
Compounds 3.134p-q and 3.133p-q have been previously described by Pelter, Ward et al.,194 whereas 
compounds 3.134r and 3.133r have been described by Doddi et al.195 
 




Ceric ammonium nitrate (2.5 equiv) was added portion-wise to a mixture of the corresponding 
acetylene (1 equiv), sodium p-toluenesulfinate (1.2 equiv) and NaI (1.2 equiv) in MeCN (0.08 M) under a 
nitrogen atmosphere. After the completion of the reaction (1-3h approx.), water was added and the 
reaction mixture was extracted with DCM. The organic layer was separated, washed with brine, dried 
over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was then redissolved in 
anhydrous acetone (0.1 M) and heated at 60-75 °C with K2CO3 (3 equiv) for 16 h. After the completion 
of the reaction, water was added and the reaction mixture was extracted once again with DCM. The 
combined organic extracts were washed with brine and dried over anhydrous Na2SO4. The solvent was 
removed in vacuo using a rotary evaporator and the residue was purified by column chromatography to 
afford the desired product. Compounds 3.125d and 3.125f have been previously described by Nair et 
al.171; compounds 3.125a and 3.125e by Zhu, Jiang et al.196; compounds 3.125b, 3.125i-j, and 3.125n by 
Kuhakarn et al.197; compound 3.125c and 3.125o by Wei, Wang et al.198; and compounds 3.125h, 3.125l 
and 3.125v by Schwarz and König.199 
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Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded 3.125k as a 
white solid (44%, 340 mg), with a melting point of 130–132 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.50 (s, 3H), 7.26 (dd, J= 9.9, 6.0 Hz, 1H), 7.42 (d, J= 9.0 Hz, 2H), 7.45–7.49 
(m, 1H), 7.59–7.63 (m, 1H), 7.67 (dd, J= 3.0, 3.0 Hz, 1H), 7.97 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.8 (CH3), 86.5 (C), 90.6 (C), 120.0 (C), 122.4 (C), 127.6 (CH), 130.0 (CH), 
130.1 (CH), 131.2 (CH), 134.5 (CH), 135.2 (CH), 138.6 (C), 145.6 (C) ppm.  
HRMS (EI) calcd. for C15H12BrO2S [M+H




Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded 3.125m as a 
white solid (67%, 150 mg), with a melting point of 105–107 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.50 (s, 3H), 6.93–6.99 (m, 1H), 7.04-7.08 (m, 2H), 7.43 (dd, J= 9.0, 0.6 Hz, 
2H), 7.96 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.8 (CH3), 86.9 (C), 89.2 (C), 107.8 (dd, J= 25.0, 25.0 Hz, CH), 115.7 (dd, J= 
28.0, 9.0 Hz, CH), 120.0 (dd, J= 120, 12.0 Hz, C), 127.7 (CH), 130.1 (CH), 138.3 (C), 145.9 (C), 162.1 (d, J= 
252.2 Hz, CF), 163.7 (d, J= 252.2 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −107.3-(-107.4) (m, 2F) ppm.  
HRMS (EI) calcd. for C15H11F2O2S [M+H
+]: 293.0442, found: 293.0434. 
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The terminal alkyne starting material (1 equiv) was dissolved in THF (0.1 M) and cooled to -78 °C, and n-
BuLi (2.5 M in hexanes, 1.1 equiv) was added slowly. The resulting mixture was stirred at this 
temperature for an hour, and then removed from the acetone/dry ice bath and stirred for a further 30 
minutes whilst slowly warming to room temperature. Phenyl or methyl disulfide (1.2 equiv) and 
iodomethane (1.2 equiv, unnecessary when using methyl disulphide) were then added, and the mixture 
was stirred for 6h at room temperature. After this time, a saturated aqueous NH4Cl solution was added 
to quench the reaction, and the resulting biphasic mixture was extracted with diethyl ether. The 
combined organic layers were dried over anhydrous Na2SO4, concentrated in vacuo, and the resulting 
residue was submitted to high vacuum to remove the phenyl methyl sulphide side-product. The crude 
mixture was dissolved in DCM (0.1 M) and cooled to 0 °C. m-CPBA (3 equiv) was then added portion-
wise, ensuring that the reaction mixture didn’t heat up excessively—if this is uncontrolled and the m-
CPBA is added at room temperature or higher a vigorous reaction can take place by which the reaction 
mixture can overflow. The resulting mixture was stirred at 0 °C for one hour and then a further 12h at 
room temperature. After this time, a saturated aqueous solution of sodium bisulphite was added, along 
with further water. The organic phase was washed successively with further sodium bisulphite solution, 
saturated aqueous sodium bicarbonate solution, and brine. The resulting organic layer was dried over 
anhydrous Na2SO4, concentrated in vacuo and purified by flash column chromatography. Compound 
3.125g has been previously described by Nair et al.,171 compounds 3.125p and 3.125q have been 










Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded 3.125r as a white 
solid (61%, 566 mg), with a melting point of 114-116 °C. 
1H NMR (CDCl3, 300 MHz): δ 3.85 (s, 6H), 3.88 (s, 3H), 6.78 (s, 2H), 7.57-7.65 (m, 2H), 7.69-7.74 (m, 1H), 
8.06-8.17 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 56.3 (CH3), 61.0 (CH3), 84.5 (C), 94.0 (C), 110.1 (CH), 112.3 (C), 127.4 (CH), 
129.4 (CH), 134.1 (CH), 141.7 (C), 141.8 (C), 153.2 (C) ppm.  
HRMS (EI) calcd. for C17H20NO5S [M+NH4
+]: 350.1057, found: 350.1057. 
 
 
 1,2-Dimethoxy-4-((methylsulfonyl)ethynyl)benzene, 3.125s 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (3:1)] afforded 3.125s as a white 
solid (46%, 35 mg), with a melting point of 105–107 °C. 
1H NMR (CDCl3, 300 MHz): δ 3.28 (s, 3H), 3.87 (s, 3H), 3.90 (s, 3H), 6.85 (d, J=8.4 Hz, 1H), 7.03 (d, J=1.9 
Hz, 1H), 7.22 (dd, J=8.3, 1.9 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 46.9 (CH3), 56.1 (2CH3), 83.5 (C), 92.7 (C), 109.1 (C), 111.2 (CH), 114.8 
(CH), 127.3 (CH), 148.9 (C), 152.3 (C) ppm.  
HRMS (EI) calcd. for C11H16NO4S [M+NH4
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i. Aluminium chloride-mediated tosylation. Tosyl chloride (2.52 g, 13.2 mmol) and aluminium 
chloride (1.77 g, 13.2 mmol) were dissolved in anhydrous DCM (50 ml) and stirred for 30 minutes at 
room temperature. The mixture was then cooled to 0 °C, and bis(trimethylsilyl)acetylene (1.88 g, 11.0 
mmol) was added slowly as a solution in anhydrous DCM (50 ml), and the reaction was allowed to stir 
for 30 minutes at 0 °C, and then for a further 14h at room temperature. After this time, the reaction 
mixture was once again cooled to 0 °C, and HCl (3M in water) was added slowly to quench the reaction. 
If the addition is fast or at room temperature, a violent reaction can take place by which the reaction 
mixture can overflow. Following this, the mixture was transferred to a separatory funnel and the 
organic layer was washed successively with water (20 ml), aqueous sodium bicarbonate (20 ml), and 
brine (20 ml). The resulting organic layer was then dried over anhydrous Na2SO4, concentrated in vacuo, 
and recrystallised from hot hexanes to afford 3.135 (42%, 1.17 g). No further purification was 
necessary. 
ii. Elimination of the TMS protecting group. Previously synthesised 3.135 (80 mg, 0.32 mmol) 
was dissolved in methanol (3 ml) and cooled to 0 °C. The resulting solution was stirred and maintained 
at 0 °C during the dropwise addition of an aqueous solution of sodium fluoride (0.1M) (4.8 ml, 0.48 
mmol). The reaction mixture was stirred for 90 minutes at the same temperature and subsequently 
diluted with water. The mixture was extracted with Et2O (3 x 15 ml), washed with water (2 x 15 ml), 
saturated NaHCO3 (2 x 15 ml), and brine (2 x 15 ml), dried over anhydrous Na2SO4 and concentrated to 
dryness. The crude product was recrystallised from hot hexanes to afford the pure product as 
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TBAF (1 M in THF) (1.5 equiv) was added to a solution of the corresponding alkynyl sulfone (1 equiv) 
and NH4Cl (1 equiv) in THF (0.1 M) under a nitrogen atmosphere at room temperature. After 
completion of the reaction (TLC analysis, typically 1-3h), the reaction mixture was quenched with 
aqueous NH4Cl (sat.) and extracted with ethyl acetate. The organic layer was separated and dried over 
anhydrous Na2SO4. The solvent was removed in vacuo and the residue was purified by flash 
chromatography using mixtures of hexane and ethyl acetate as the eluent. Compound 3.126a has been 
previously described by Hammond, Bo et al.105 Ethyl (Z)-3-fluoro-3-phenylacrylate (3.132) has been 




Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126b as a 
white solid (69%, 28 mg), with a melting point of 130–132 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.46 (s, 3H), 6.69 (d, J= 33.0 Hz, 1H), 7.39 (d, J= 9.0 Hz, 2H), 7.52 (d, J= 9.0 
Hz, 1H), 7.57–7.62 (m, 2H), 7.84–7.89 (m, 3H), 8.00 (d, J= 9.0 Hz, 2H), 8.12 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 110.0 (d, J= 12.8 Hz, CH), 121.5 (d, J= 7.6 Hz, CH), 125.8 (d, J= 
25.7 Hz, C), 127.1 (d, J= 7.6 Hz, CH), 127.3 (CH), 127.7 (CH), 127.8 (CH), 128.5 (CH), 129.0 (CH), 129.8 
(CH), 132.5 (C), 134.8 (C), 139.3 (C), 144.6 (C), 164.0 (d, J= 273.3 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −93.9 (d, J= 31.0, 1F) ppm.  
HRMS (EI) calcd. for C19H16FO2S [M+H
+]: 327.0850, found: 327.0852. 
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Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126c as a 
white solid (72%, 27 mg), with a melting point of 196–198 °C.  
1H NMR (CDCl3, 300 MHz) δ 2.47 (s, 3H), 6.60 (d, J= 33.0 Hz, 1H), 7.37–7.50 (m, 5H), 7.59-7.65 (m, 6H), 
7.98 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz) δ 21.7 (CH3), 109.5 (d, J= 13.6 Hz, CH), 126.4 (d, J= 8.3, 2CH), 127.1 (CH), 
127.2 (C), 127.7 (CH), 128.4 (CH), 129.0 (CH), 129.8 (CH), 139.3 (d, J= 8.3 Hz, C), 144.6 (C), 145.2 (C), 
163.3 (d, J= 273.3 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −93.8 (d, J= 32.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C21H18FO2S [M+H




Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126d as a 
white solid (67%, 28 mg), with a melting point of 100–102 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.39 (s, 3H), 2.46 (s, 3H), 6.52 (d, J= 33.0 Hz, 1H), 7.23 (d, J= 9.0 Hz, 2H), 
7.37 (d, J= 9.0 Hz, 2H), 7.46 (d, J= 9.0 Hz, 2H), 7.95 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.5 (CH3), 21.6 (CH3), 108.7 (d, J= 13.6 Hz, CH), 125.8 (CH), 125.9 (CH), 
126.1 (C), 127.6 (CH), 129.7 (CH), 139.4 (C), 143.2 (C), 144.4 (C), 164.5 (d, J= 274.0 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −93.4 (d, J= 31.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H16FO2S [M+H
+]: 291.0850, found: 291.0858. 
 





Flash chromatography of the crude reaction product [n-hexane-EtOAc (15:1)] afforded (Z)-3.126e as a 
white solid (67%, 28 mg), with a melting point of 122-124 °C.  
1H NMR (CDCl3, 300 MHz): δ 1.32 (s, 9H), 2.46 (s, 3H), 6.52 (d, J= 33 Hz, 1H), 7.37 (d, J= 9.0 Hz, 2H), 7.44 
(d, J= 9.0 Hz, 2H), 7.51 (d, J= 9.0 Hz, 2H), 7.95 (d, J= 9.0 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 30.9 (CH3), 35.1 (C), 108.8 (d, J= 13.6 Hz, CH), 125.8 (d, J= 7.5 
Hz, CH), 126.0 (d J= 2.3 Hz, CH), 127.6 (CH), 129.7 (CH), 139.4 (C), 144.4 (C), 156.3 (C), 164.2 (d, J= 273.3 
Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -93.4 (d, J= 31.1 Hz, 1F) ppm.  
HRMS (EI) calcd. for C19H22FO2S [M+H




Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded (Z)-3.126f as a 
white solid (71%, 45 mg), with a melting point of 74-75 °C.  
1H NMR (CDCl3, 300 MHz):δ 2.45 (s, 3H), 3.84 (s, 3H), 6.43 (d, J= 32.8 Hz, 1H), 6.92 (d, J= 9.1 Hz, 1H), 
7.36 (d, J= 9.0 Hz, 1H), 7.51 (d, J= 9.0 Hz, 1H), 7.94 (d, J= 9.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz):δ 21.6 (CH3), 55.2 (CH3), 107.4 (d, J= 13.4 Hz, CH), 114.5 (CH), 120.9 (d, J= 
25.6 Hz, C), 127.5 (CH), 127.8 (d, J= 8.2 Hz, CH), 129.7 (CH), 139.5 (C), 144.3 (C), 162.9 (C), 164.2 (d, J= 
272.2 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -93.3 (d, J= 33.9 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H16O3S [M+H
+]: 307.0799, found: 307.0800. 
 




 (Z)-1-(1-Fluoro-2-(phenylsulfonyl)vinyl)-4-methoxybenzene, (Z)-3.126g 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126g as a 
white solid (72%, 40 mg), with a melting point of 78-80 °C.  
1H NMR (CDCl3, 300 MHz): δ 3.86 (s, 3H), 6.45 (d, J= 33.0 Hz, 1H), 6.93 (d, J= 9.0 Hz, 2H), 7.51-7.65 (m, 
5H), 8.07 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 55.5 (CH3), 107.1 (d, J= 13.6 Hz, CH), 114.5 (CH), 120.8 (d, J= 25.6 Hz, C), 
127.5 (CH), 127.9 (J= 8.3 Hz, 2CH), 129.1 (CH), 133.3 (CH), 142.4 (C), 163.0 (C), 164.5 (d, J= 273.0 Hz, C) 
ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -92.7 (d, J= 33.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H13FO3S [M+H
+]: 293.0642, found: 293.0642. 
 
 
 (Z)-1-(1-Fluoro-2-tosylvinyl)-3,5-dimethoxybenzene, (Z)-3.126i 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126i as a 
white solid (70%, 30 mg), with a melting point of 158-160 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.47 (s, 3H), 3.80 (s, 6H), 6.53 (d, J= 33.0 Hz, 1H), 6.57-6.59 (m, 1H), 6.67 (d, 
J= 3.0 Hz, 2H), 7.38 (d, J= 9.0 Hz, 2H), 7.94 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz):δ 21.7 (CH3), 55.6 (CH3), 103.9 (CH), 104.3 (d, J= 52.1 Hz, CH), 110.2 (d, J= 
13.6 Hz, CH), 127.7 (2CH), 129.8 (2CH), 130.5 (d, J= 26.4 Hz, C), 139.1 (C), 144.6 (C), 161.1 (C), 163.7 (d, 
J= 274.0 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -92.3 (d, J= 31.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C17H18FO4S [M+H
+]: 337.0904, found: 337.0895. 




 (Z)-1-Bromo-4-(1-fluoro-2-tosylvinyl)benzene, (Z)-3.126j 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126j as a 
white solid (63%, 22 mg), with a melting point of 145-147 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.47 (s, 3H), 6.56 (d, J= 33.0 Hz, 1H), 7.38 (d, J= 9.0 Hz, 2H), 7.42 (d, J= 9.0 
Hz, 2H), 7.58 (d, J= 9.0 Hz, 2H), 7.95 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 110.3 (d, J= 13.6 Hz, CH), 127.2 (CH), 127.3 (CH), 127.6 (d, J= 
26.7 Hz, C), 127.7 (CH), 129.9 (CH), 132.3 (C), 144.8 (C), 163.5 (d, J= 273.3 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -94.2 (d, J= 31.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H13BrFO2S [M+H
+]: 354.9798, found: 354.9806. 
 
 
 (Z)-1-Bromo-3-(1-fluoro-2-tosylvinyl)benzene, (Z)-3.126k 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126k as a 
white solid (60%, 20 mg), with a melting point of 81-83 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.47 (s, 3H), 6.57 (d, J= 30.0 Hz, 1H), 7.33 (d, J= 9.0 Hz, 1H), 7.38 (d, J= 6.0 
Hz, 2H), 7.50 (d, J= 9.0 Hz, 1H), 7.61-7.64 (m, 1H), 7.69-7.70 (m, 1H), 7.95 (d, J= 9.0 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 111.2 (d, J= 13.6 Hz, CH), 123.1 (C), 124.4 (d, J= 7.5 Hz, CH), 
127.7 (CH), 128.8 (d J= 8.3 Hz, CH), 129.9 (CH), 130.5 (CH), 135.2 (CH), 138.8 (C), 144.8 (C), 162.0 (d, J= 
274.0 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -94.1 (d, J= 31.1 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H13BrFO2S [M+H
+]: 354.9798, found: 354.9793. 
 




 (Z)-1,3-Difluoro-5-(1-fluoro-2-tosylvinyl)benzene, (Z)-3.126m 
Flash chromatography of the crude reaction product [n-hexane-EtOAc (10:1)] afforded (Z)-3.126m as a 
white solid (30%, 21 mg), with a melting point of 158-160 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.48 (s, 3H), 6.57 (d, J= 30.0 Hz, 1H), 6.92-7.00 (m, 1H), 7.08-7.11 (m, 2H), 
7.40 (d, J= 9.0 Hz, 2H), 7.95 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 107.7 (dd, J= 24.8, 24.9 Hz, CH), 109.0 (dd, J= 27.1, 27.2 Hz, 
CH), 112.1 (d, J= 12.8 Hz, CH), 127.8 (CH), 129.9 (CH), 131.9 (d, J= 28.7 Hz, C), 138.5 (C), 145.1 (C), 161.1 
(d, J= 274.0 Hz, CF), 163.0 (d, J= 251.4 Hz, CF), 163.2 (d, J= 251.5 Hz, CF) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -106.7 (s, 2F), -94.2 (d, J= 31.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H12F3O2S [M+H




Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded (Z)-3.126n as a 
white solid (28%, 20 mg), with a melting point of 129-131 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.45 (s, 3H), 6.64 (d, J= 32.0 Hz, 1H), 7.37 (dd, J= 8.6, 0.7 Hz, 1H), 7.68 (s, 
2H), 7.94 (d, J= 8.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 111.9 (d, J= 13.1 Hz, C), 111.9 (d, J= 13.1 Hz, C), 125.9 (q, J= 2.4 
Hz, CH), 126.2 (d, J= 7.6 Hz, CH), 127.8 (CH), 129.9 (CH), 132.2 (d, J= 27.4 Hz, C), 133.8 (d, J= 33.1 Hz, C), 
138.6 (C), 144.9 (C), 162.1 (d, J= 274.0 Hz, C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -94.84 (d, J = 31.9 Hz, CF), -63.71 (s, CF3) ppm.  
HRMS (EI) calcd. for C16H16F4NO2S [M+NH4
+]: 362.0832, found: 362.0825. 
 





Flash chromatography of the crude reaction product [n-hexane-EtOAc (5:1)] afforded (Z)-3.126o as a 
white solid (70%, 65 mg), with a melting point of 121-123 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.46 (s, 3H), 6.39 (d, J= 33.2 Hz, 1H), 7.15 (d, J= 6.0 Hz, 1H), 7.35-7.38 (m, 
3H), 7.74 (d, J= 3.0 Hz, 1H), 7.94 (d, J= 9.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 109.0 (d, J= 12.5 Hz, CH), 124.4 (d, J= 7.5 Hz, CH), 127.6 (CH), 
128.0 (CH), 128.2 (d, J= 6.0 Hz, CH), 129.8 (2CH), 131.0 (d, J= 27.9 Hz, C), 139.3 (C), 144.5 (C), 160.0 (d, 
J= 270.9 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -92.7 (d, J= 32.1 Hz, 1F) ppm.  
HRMS (EI) calcd. for C13H12FO2S2 [M+H
+]: 283.0257, found: 283.0254. 
 
 
(Z)-4-(1-Fluoro-2-(methylsulfonyl)vinyl)-1,2-dimethoxybenzene, (Z)-3.126s  
Flash chromatography of the crude reaction product [n-hexane-EtOAc (1:1)] afforded (Z)-3.126s as a 
white solid (86%, 21 mg), with a melting point of 110-112 °C.  
1H NMR (CDCl3, 300 MHz): δ 3.19 (s, 3H), 3.92 (s, 3H), 3.94 (s, 3H), 6.35 (d, J= 33.6 Hz, 1H), 6.92 (d, J= 8.6 
Hz, 1H), 7.04 (d, J= 1.8 Hz, 1H), 7.27 (dd, J= 8.5, 1.7 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 44.7 (CH3), 56.1 (CH3), 56.2 (CH3), 106.7 (d, J= 13.8 Hz, CH), 108.2 (d, J= 8.9 
Hz, CH), 111.1 (CH), 120.1 (d, J= 10.4 Hz, CH), 120.6 (d, J= 27.8 Hz, C), 149.3 (C), 152.9 (C), 165.1 (d, J= 
269.4 Hz, C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −92.8 (d, J= 33.8 Hz, 1F) ppm. 
HRMS (EI) calcd. for C11H14FO4S [M+H
+]: 261.0591, found: 289.0589. 
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A screw-top eppendorf tube was charged with alkynyl sulfone (1 equiv) and (Ph3P)3CuF (10 mol%), and 
purged with nitrogen. Toluene (0.05 M) was then added, followed by 3HF·Et3N (3 equiv), and the 
resulting mixture was heated at 70 °C for 20h in an oil bath. When the reaction was complete, the crude 
mixture was concentrated and purified by flash column chromatography using mixtures of hexane and 
ethyl acetate as the eluent (assuming the reaction was complete; if not, mixtures of hexane and DCM 




Flash chromatography of the crude reaction product [n-hexane:EtOAc (4:1)] afforded (E)-3.126a as a 
colourless oil (35%, 65 mg). 
1H NMR (CDCl3, 300 MHz): δ 2.32 (s, 3H), 6.38 (d, J= 18.4 Hz, 1H), 7.13-7.21 (m, 2H), 7.32-7.39 (m, 2H), 
7.42-7.47 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): 22.0 (CH3), 114.9 (d, J= 31.8 Hz, C), 127.8 (CH), 128.2 (d, J= 16.3 Hz, C), 128.5 
(CH), 130.0 (d, J= 5.0 Hz, CH), 130.1 (CH), 132.4 (d, J= 2.2 Hz, CH), 138.9 (d, J= 2.9 Hz, C), 144.9 (C), 168.0 
(d, J= 276.4 Hz, C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -72.19 (d, J= 18.4 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H14FO2S [M+H
+]: 277.0693, found: 277.0698. 
 





Flash chromatography of the crude reaction product [n-hexane:EtOAc (5:1)] afforded (E)-3.126b as a 
pale yellow solid (38%, 16 mg) with a melting point of 42-43 °C.  
1H NMR (CDCl3, 300 MHz): δ 2.39 (s, 3H), 6.56 (d, J= 18.4 Hz, 1H), 7.21 (d, J= 8.0 Hz, 2H), 7.52-7.69 (m, 
5H), 7.84–7.98 (m, 3H), 8.24 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.5, 114.7 (d, J= 32.0 Hz), 124.9 (d, J= 3.8 Hz), 125.6 (d, J= 25.7 Hz), 
126.9, 127.3, 127.4, 127.8 (d, J= 8.2 Hz), 128.3, 128.7, 129.1, 129.6, 131.2 (d, J= 6.5 Hz), 132.0, 134.7, 
138.5, 144.5, 167.7 (d, J= 276.6 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −71.9 (d, J= 18.4 Hz, 1F) ppm. 
HRMS (EI) calcd. for C19H19FNO2S [M+NH4




Flash chromatography of the crude reaction product [n-hexane:EtOAc (4:1)] afforded (E)-3.126d as a 
colourless oil (43%, 18 mg).  
1H NMR (CDCl3, 300 MHz): δ 2.41 (s, 6H), 6.39 (d, J= 18.5 Hz, 1H), 7.22-7.29 (m, 4H), 7.57 (d, J= 8.0 Hz, 
2H), 7.66 (d, J= 8.3 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 21.7 (CH3), 113.7 (d, J= 32.6 Hz, CH), 125.6 (d, J= 26.0 Hz, C), 
127.3 (CH), 127.9 (CH), 128.8 (CH), 129.1 (CH), 129.5 (CH), 129.6 (d, J= 5.6 Hz, CH), 129.7 (CH), 130.0 
(CH), 138.7 (d, J= 2.7 Hz, C), 142.7 (C), 144.4 (C), 167.8 (d, J= 275.7 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ −72.0 (d, J= 18.6 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H19FNO2S [M+NH4
+]: 308.1115, found: 308.1116. 
 




 (E)-1-((2-Fluoro-2-(4-methoxyphenyl)vinyl)sulfonyl)-4-methylbenzene, (E)-3.126f 
Flash chromatography of the crude reaction product [n-hexane:EtOAc (3:1)] afforded (E)-3.126f as a 
colourless oil (51%, 30 mg). 
1H NMR (CDCl3, 300 MHz): δ 2.41 (s, 3H), 3.87 (s, 3H), 6.33 (d, J= 18.8 Hz, 1H), 6.94 (dd, J= 9.1, 0.9 Hz, 
2H), 7.25 (t, J= 0.7 Hz, 1H), 7.27 (t, J= 0.7 Hz, 1H), 7.65 (s, 2H), 7.68 (s, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 55.4 (CH3), 112.6 (d, J= 33.5 Hz, C), 113.5 (CH), 120.6 (d, J= 26.6 
Hz, C), 127.3 (CH), 129.7 (CH), 131.5 (d, J= 5.6 Hz, CH), 138.8 (d, J= 3.1 Hz, C), 144.4 (C), 162.6 (C), 167.4 
(d, J= 274.4 Hz, C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -73.15 (d, J= 19.8 Hz, 1F) ppm. 
HRMS (EI) calcd. for C16H15FO3S [M+H




Flash chromatography of the crude reaction product [n-hexane:EtOAc (3:1)] afforded (E)-3.126g as a 
colourless oil (56%, 40 mg).  
1H NMR (CDCl3, 300 MHz): δ 3.86 (s, 3H), 6.35 (d, J= 18.6 Hz, 1H), 6.93 (d, J= 8.4 Hz, 2H), 7.38-7.50 (m, 
2H), 7.51-7.61 (m, 1H), 7.66 (d, J= 8.6 Hz, 2H), 7.78 (dd, J= 5.3, 3.3 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 55.5 (CH3), 112.4 (d, J= 33.6 Hz, CH), 113.6 (CH), 120.5 (d, J= 26.6 Hz, C), 
127.2 (CH), 129.1 (CH), 131.5 (d, J= 5.6 Hz, CH), 133.4 (CH), 141.7 (d, J= 2.5 Hz, C), 162.7 (C), 167.8 (d, J= 
275.1 Hz, C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -71.8 (d, J= 18.6 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H17FNO3S [M+NH4
+]: 310.0908, found: 310.0911. 
 





Flash chromatography of the crude reaction product [n-hexane:EtOAc (5:1)] afforded (E)-3.126i as a 
colourless oil (27%, 13mg).  
1H NMR (CDCl3, 300 MHz): δ 2.42 (s, 3H), 6.45 (d, J= 18.5 Hz, 1H), 7.28 (dd, J= 8.5, 0.6 Hz, 2H), 7.52-7.66 
(m, 6H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 114.9 (d, J= 31.3 Hz, CH), 127.0 (C), 127.1 (C), 127.4 (CH), 129.8 
(CH), 131.0 (d, J= 4.9 Hz, CH), 131.4 (CH), 138.3 (C), 144.8 (C), 166.27 (d, J= 275.7 Hz, C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -73.5 (d, J= 18.5 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H16BrFNO2S [M+NH4
+]: 372.0064, found: 372.0068. 
 
 
(E)-3-(1-Fluoro-2-tosylvinyl)thiophene, (E)-3.126o  
Flash chromatography of the crude reaction product [n-hexane:EtOAc (4:1)] afforded (E)-3.126o as a 
colourless oil (63%, 23 mg). 
1H NMR (CDCl3, 300 MHz): δ 2.41 (s, 3H), 6.36 (d, J= 20.4 Hz, 1H), 7.29–7,26 (m, 2H), 7.34 (ddd, J= 5.2, 
3.0, 1.4 Hz, 1H), 7.51 (dd, J= 5.2, 1.3 Hz, 1H), 7.71 (d, J= 8.3 Hz, 2H), 8.19 (ddd, J= 3.0, 1.3, 0.7 Hz, 1H) 
ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 112.7 (d, J= 33.1 Hz, C), 125.8 (CH), 127.1 (s, CH), 127.5 (d, J= 
5.0 Hz, CH), 129.8 (CH), 132.3 (d, J= 8.3 Hz, C), 138.7 (d, J= 2.8 Hz, C), 144.6 (C), 162.4 (d, J= 269.0 Hz, C) 
ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -77.8 (dd, J= 20.5, 1.3 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H13FO2S [M+H
+]: 283.0257, found: 283.0257. 
 





Flash chromatography of the crude reaction product [n-hexane:EtOAc (2:1)] afforded (E)-3.126p as a 
white solid (60%, 24 mg) with a melting point of 51-53 °C. 
1H NMR (CDCl3, 300 MHz): δ 3.89 (s, 3H), 3.93 (s, 3H), 6.37 (d, J= 18.8 Hz, 1H), 6.89 (d, J=8.4 Hz, 1H), 
7.25 (d, J=2.1 Hz, 1H), 7.34 (ddd, J= 8.4, 2.0, 0.6 Hz, 1H), 7.41-7.50 (m, 2H), 7.53-7.61 (m, 1H), 7.75-7.81 
(m, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 56.0 (2OCH3), 110.3 (CH), 112.2 (d, J= 5.4 Hz, CH), 112.7 (d, J= 33.7 Hz, 
CH), 120.5 (d, J= 26.8 Hz, C), 123.7 (d, J= 6.5 Hz, CH), 127.2 (CH), 129.1 (CH), 133.4 (CH), 141.6 (d, J= 2.5 
Hz, C), 148.4 (C), 152.4 (C), 167.5 (d, J= 275.0 Hz, C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -72.7 (d, J= 18.9 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H19FNO4S [M+NH4




Flash chromatography of the crude reaction product [n-hexane:EtOAc (2:1)] afforded (E)-3.126q as a 
colourless oil (53%, 19 mg). 
1H NMR (CDCl3, 300 MHz): δ 4.31 (dqd, J= 7.0, 3.3, 1.5 Hz, 4H), 6.37 (d, J= 18.6 Hz, 1H), 6.91 (dd, J= 8.4, 
0.8 Hz, 1H), 7.19-7.27 (m, 2H), 7.46-7.54 (m, 2H), 7.56-7.63 (m, 1H), 7.80-7.85 (m, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 64.1 (CH2), 64.6 (CH2), 112.8 (d, J= 33.5 Hz, CH), 117.1 (CH), 118.8 (d, J= 
5.5 Hz, CH), 121.2 (d, J= 26.6 Hz, C), 123.6 (d, J= 5.9 Hz, CH), 127.3 (CH), 129.0 (CH), 133.4 (CH), 141.6 
(C), 143.0 (C), 147.1 (C), 167.3 (d, J= 275.8 Hz, CF) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -71.8 (d, J= 18.6 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H17FNO4S [M+NH4
+]: 338.0857, found: 338.0866. 





Flash chromatography of the crude reaction product [n-hexane:EtOAc (2:1)] afforded (E)-3.126r as a 
colourless oil (58%, 23 mg). 
1H NMR (CDCl3, 300 MHz): δ 3.86 (s, 6H), 3.91 (s, 3H), 6.44 (d, J= 18.6 Hz, 1H), 7.42-7.49 (m, 2H), 7.52-
7.60 (m, 1H), 7.75-7.81 (m, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 56.3 (CH3), 61.0 (CH3), 107.1 (d, J= 5.6 Hz, CH), 113.9 (d, J= 32.9 Hz, CH), 
123.0 (d, J= 26.8 Hz, C), 127.2 (CH), 128.7 (d, J= 8.2 Hz, CH), 129.0 (CH), 129.9 (CH), 133.4 (CH), 133.8 (d, 
J= 13.9 Hz, CH), 141.4 (C), 152.7 (C), 167.4 (d, J= 276.5 Hz, C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -73.0 (d, J= 18.6 Hz, 1F) ppm.  
HRMS (EI) calcd. for C17H21FNO5S [M+NH4
+]: 370.1119, found: 370.1123. 
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Palladium over activated charcoal (15 mol%) was added to a solution of the corresponding β-fluorovinyl 
sulfone (1 equiv) in toluene (0.033 M), and the reaction flask was charged with hydrogen gas by purging 
several times, without stirring. The reaction was then stirred under H2 (atmospheric pressure) at room 
temperature for the required time. The mixture was then filtered to remove the catalyst, and the 
solvent was evaporated in vacuo. In most cases, compounds 3.143 contain small amounts of 
inseparable defluorinated sulfones 3.144. Compound 3.143a has been described by Liu et al.201 Both α-




Crude reaction product 3.143b (96%, 20 mg) was obtained as a viscous oil after 2.5h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 2.45 (s, 3H), 3.57 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.86-3.98 (m, 1H), 6.18 
(ddd, J= 45.0, 9.0, 3.0 Hz, 1H), 7.33-7.38 (m, 3H), 7.52-7.55 (m, 2H), 7.76-7.87 (m, 6H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 62.6 (d, J= 26.4 Hz, CH2), 88.8 (d, J= 177.4 Hz, CHF), 122.5 (d, J= 
5.3 Hz, CH), 125.3 (d, J= 7.5 Hz, CH), 126.8 (CH), 126.9 (CH), 127.7 (CH), 128.1 (CH), 128.3 (2CH), 128.9 
(CH), 129.8 (2CH), 132.9 (C), 133.5 (C), 134.1 (d, J= 20.4 Hz, C), 136.6 (C), 145.0 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -173.1 (ddd, J= 45.1, 28.2, 11.3 Hz, 1F) ppm.  
HRMS (EI) calcd. for C19H21FNO2S [M+NH4
+]: 346.1272, found: 346.1268. 
 
                                                          
201
 Z. Yuan, H.-Y. Wang, X. Mu, P. Chen, Y.-L. Guo and G. Liu,  J. Am. Chem. Soc., 2015, 137, 2468−2471. 





Crude reaction product 3.143c (94%, 16 mg) was obtained as a viscous oil after 3h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 2.47 (s, 3H), 3.52 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.81-3.93 (m, 1H), 6.08 
(ddd, J= 45.0, 9.0, 3.0 Hz, 1H), 7.36-7.61 (m, 11H), 7.87 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 62.7 (d, J= 25.7 Hz, CH2), 88.5 (d, J= 177.4 Hz, CHF), 126.0 (d, J= 
6.8 Hz, 2CH), 127.1 (CH), 127.6 (CH), 127.7 (CH), 128.3 (CH), 128.8 (CH), 129.9 (CH), 135.7 (d, J= 19.6 Hz, 
C), 136.7 (C), 140.2 (C), 142.4 (C), 145.0 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -173.1 (ddd, J= 45.1, 31.1, 11.3 Hz, 1F) ppm.  
HRMS (EI) calcd. for C21H23FNO2S [M+NH4




Crude reaction product 3.143d (92%, 23 mg) was obtained as a viscous oil after 2h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 2.36 (s, 3H), 2.48 (s, 3H), 3.45 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.76-3.89 (m, 
1H), 7.18 (s, 4H), 7.38 (d, J= 9.0 Hz, 2H), 7.86 (d, J= 9.0 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.2 (CH3), 21.7 (CH3), 62.7 (d, J= 26.4 Hz, CH2), 88.5 (d, J= 176.0 Hz, CHF), 
125.6 (d, J= 6.0 Hz, CH), 128.3 (CH), 129.5 (CH), 129.8 (CH), 133.9 (d, J= 20.4 Hz, C), 136.7 (C), 139.4 (C), 
144.9 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -171.7 (ddd, J= 48.0, 31.0, 14.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H21FNO2S [M+NH4
+]: 310.1272, found: 310.1269. 
 





Crude reaction product 3.143e (96%, 16 mg) was obtained as a viscous oil after 3h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 1.32 (s, 9H), 2.47 (s, 3H), 3.43 (ddd, J= 33.0, 15.0, 3.0 Hz, 1H), 3.77-3.90 (m, 
1H), 5.99 (ddd, J= 45.0, 9.0, 3.0 Hz, 1H), 7.22 (d, J= 9.0 Hz, 2H), 7.35-7.40 (m, 4H), 7.85 (d, J= 9.0 Hz, 2H) 
ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 31.2 (CH3), 34.7 (C), 62.7 (d, J= 26.4 Hz, CH2), 88.5 (d, J= 176.7 
Hz, CHF), 125.4 (d, J= 6.0 Hz, CH), 125.8 (CH), 128.3 (CH), 129.8 (CH), 133.8 (d, J= 13.6 Hz, C), 136.7 (C), 
144.9 (C), 152.6 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -171.9 (ddd, J= 48.0, 31.1, 14.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C19H27FNO2S [M+NH4




Crude reaction product 3.143f (96%, 21 mg) was obtained as a viscous oil after 3h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 2.47 (s, 3H), 3.45 (ddd, J= 30.0, 15.0 3.0 Hz, 1H), 3.81 (s, 3H), 3.78-3.90 (m, 
1H), 5.95 (ddd, J= 48.0, 9.0, 3.0 Hz, 1H), 6.89 (d, J= 9.0 Hz, 2H), 7.22 (d, J= 9.0 Hz, 2H), 7.37 (d, J= 9.0 Hz, 
2H), 7.84 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 55.3 (CH3), 62.5 (d, J= 27.2 Hz, CH2), 88.4 (d, J= 175.9 Hz, CHF), 
114.2 (CH), 127.3 (d, J= 6.0 Hz, CH), 128.3 (CH), 128.9 (d, J= 20.4 Hz, C), 129.8 (CH), 136.7 (C), 144.9 (C), 
160.4 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -168.0 (ddd, J= 45.2, 28.2, 11.3 Hz, 1F) ppm.  
HRMS (EI) calcd. for C16H21FNO3S [M+NH4
+]: 326.1221, found: 326.1215. 
 





Crude reaction product 3.143g (95%, 19 mg) was obtained as a viscous oil after 2h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 3.47 (ddd, J= 33.0, 15.0, 3.0 Hz, 1H), 3.81 (s, 3H), 3.78-3.93 (m, 1H), 5.97 
(ddd, J= 48.0, 9.0, 3.0 Hz, 1H), 6.88 (d, J= 9.0 Hz, 2H), 7.22 (d, J= 9.0 Hz, 2H), 7.55-7.60 (m, 2H), 7.65-7.70 
(m, 1H), 7.97 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 55.3 (OCH3), 62.5 (d, J= 27.2 Hz, CH2), 88.3 (d, J= 175.2 Hz, CHF), 114.3 
(2CH), 127.3 (d, J= 5.3 Hz, CH), 128.3 (CH), 128.7 (d, J= 20.4 Hz, C), 129.2 (CH), 133.9 (CH), 139.7 (C), 
160.4 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -167.8 (ddd, J= 48.0, 31.1, 14.1 Hz, 1F) ppm.  
HRMS (EI) calcd. for C15H19FO3S [M+NH4
+]: 312.1064, found: 312.1056. 
 
 
1-(1-Fluoro-2-tosylethyl)-3,5-dimethoxybenzene, 3.143i  
Crude reaction product 3.143i (95%, 12 mg) was obtained as a viscous oil after 60h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 2.48 (s, 3H), 3.45 (ddd, J= 33.5, 15.0, 3.1 Hz, 1H), 3.72-3.84 (m, 1H), 3.78 (s, 
6H), 5.90 (ddd, J= 48.1, 9.0, 3.1 Hz, 1H), 6.41 (s, 3H), 7.39 (d, J= 9.0 Hz, 2H), 7.86 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 55.4 (CH3), 62.4 (d, J= 25.7 Hz, CH2), 88.5 (d, J= 180.0 Hz, CHF), 
101.0 (CH), 103.2 (d, J= 6.8 Hz, CH), 128.3 (CH), 129.9 (CH), 136.7 (C), 139.3 (d, J= 20.4 Hz, C), 145.0 (C), 
161.2 (2C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -175.2 (ddd, J= 48.0, 33.5, 14.0 Hz, 1F) ppm.  
HRMS (EI) calcd. for C17H20FO4S [M+H
+]: 339.1061, found: 339.1050. 
 





Crude reaction product 3.143m (94%, 18 mg) was obtained as a viscous oil after 60h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 2.48 (s, 3H), 3.44 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.75 (ddd, J= 21.0, 15.0, 
9.0 Hz, 1H), 6.00 (ddd, J= 45.0, 9.0, 3.0 Hz, 1H), 6.77-6.85 (m, 3H), 7.40 (d, J= 9.0 Hz, 2H), 7.85 (d, J= 9.0 
Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 62.4 (d, J= 25.7 Hz, CH2), 87.4 (d, J= 180.4 Hz, CHF), 104.6 (dd, 
J= 25.7 Hz, CH), 108.5 (ddd, J= 25.6, 7.5 Hz, 2CH), 128.2 (CH), 129.9 (CH), 136.4 (C), 140.7 (C), 145.3 (C), 
163.1 (d, J= 252.4 Hz, CF), 163.1 (d, J= 252.4 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -176.6 (ddd, J= 45.1, 28.2, 14.0 Hz, 1H), -107.5-(-107.4) (m, 2F) ppm. 
HRMS (EI) calcd. for C15H17F3NO2S [M+NH4




Crude reaction product 3.143n (90%, 9 mg) was obtained as a viscous oil. Data taken from the crude 
mixture. Only the most characteristic signals for 3.143n are described in the following data, due to the 
difficulties in isolating this compound (see spectrum).  
1H NMR (CDCl3, 300 MHz): δ 2.48 (s, 3H), 3.48 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.80 (ddd, J= 24.0, 15.0, 
9.0 Hz, 1H), 6.09 (ddd, J= 48.0, 9.0, 3.0 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.6 (CH3), 62.5 (d, J= 24.9 Hz, CH2), 87.9 (d, J= 179.7 Hz, CHF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -177.0 (ddd, J= 46.0, 30.0, 14.2 Hz, 1F), -63.1 (s, 3F) ppm.  
HRMS (EI) calcd. for C16H18F4NO2S [M+NH4
+]: 364.0989, found: 364.0993. 
 





Crude reaction product 3.143o (85%, 10 mg) was obtained as a viscous oil after 2.5h reaction time. In 
this case, Pd/C (100 mol%) had to be used due to catalyst poisoning by the product. 
1H NMR (CDCl3, 300 MHz): δ 2.47 (s, 3H), 3.52 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.79-3.92 (m, 1H), 6.10 
(ddd, J= 6.0 Hz, 1H), 7.30-7.34 (m, 2H), 7.38 (d, J= 9.0 Hz, 2H), 7.84 (d, J= 9.0 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 21.7 (CH3), 62.0 (d, J= 25.7 Hz, CH2), 84.8 (d, J= 174.4 Hz, CHF), 123.6 (d, J= 
7.5 Hz, CH), 124.8 (d, J= 3.0 Hz, CH), 127.3 (CH), 128.3 (CH), 129.9 (CH), 136.6 (C), 137.8 (d, J= 21.9 Hz, 
C), 145.1 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -167.5 (ddd, J= 45.2, 28.2, 11.3 Hz, 1F) ppm.  
HRMS (EI) calcd. for C13H17FNO2S2 [M+NH4




Crude reaction product 3.143s (96%, 11 mg) was obtained as a viscous oil after 3h reaction time. Only 
the most characteristic signals for 3.143s are described in the following data, due to the difficulties in 
isolating this compound (see spectrum). An acceptable 13C spectrum was unobtainable due to the small 
quantity of product obtained as an inseparable mixture with a small amount of starting material 3.126s. 
1H NMR (CDCl3, 300 MHz): δ 3.06 (t, J= 1.1 Hz, 3H), 3.13-3.40 (m, 1H), 3.78 (ddd, J= 15.4, 12.2, 10.1 Hz, 
3H), 5.99 (ddd, J=47.3, 10.1, 2.0 Hz, 1H) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ −169.19 (ddd, J= 47.3, 34.9, 12.2 Hz, 1F) ppm. 
HRMS (EI) calcd. for C11H17FNO4S [M+NH4
+]: 278.0857, found: 278.0872. 
 





Crude reaction product 3.143u (94%, 14 mg) was obtained as a viscous oil after 1.5h reaction time.  
1H NMR (CDCl3, 300 MHz): δ 0.89-1.72 (m, 13H), 3.28 (ddd, J= 30.0, 15.0, 3.0 Hz, 1H), 3.54-3.60 (m, 1H), 
4.92-5.15 (m, 1H), 7.57-7.71 (m, 3H), 7.95-7.97 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 13.9 (CH3), 22.4 (CH2), 24.4 (d, J= 4.5 Hz, CH2), 28.7 (CH2), 31.5 (CH2), 34.8 
(d, J= 20.4 Hz, CH2), 61.0 (d, J= 23.4 Hz, CH2), 88.1 (d, J= 174.4 Hz, CHF), 128.2 (CH), 129.2 (CH), 133.9 
(CH), 139.7 (C) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -180.0 (m, 1F) ppm.  
HRMS (EI) calcd. for C14H25FNO2S [M+NH4
+]: 290.1585, found: 290.1578. 
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4.0. A brief introduction to drug development.  
 
The development of new pharmaceuticals implies a wide spectrum of procedures and research efforts, 
ranging from the discovery of new molecular entities (NMEs) that demonstrate certain favourable 
biological activities, all the way through to the optimisation of a lead compound and the large scale 
production and commercialisation of the resulting drug. In recent years, the process has become 
increasingly expensive, unstable and slow. Consequently, the cost invested in the discovery of new lead 
compounds has increased exponentially; a trend that has not been reflected in the number of new 
drugs reaching marketable status (Figure 4.1). 
 
 
Figure 4.1. New drugs approved by the FDA between 1996 and 2017.
202, 203 
 
In fact, as little as one NME in every 5,000-10,000 makes it through the rigorous development process, 
reaching marketable status after an average investment of 10-15 years of intensive research and a total 
of 2.8-3 billion USD (according to current estimates).204 Despite these somewhat foreboding data, the 
pharmaceutical industry continues to advance and offers hope to millions of people suffering from a 
wide variety of diseases around the globe. For example, in 2017 the American Food and Drugs 
Administration (FDA) approved 46 new drugs to treat a range of diseases, including but not limited to 
Parkinson’s disease, Chagas disease, hepatitis, and various forms of cancer.203 
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Currently, there are several approaches towards drug discovery. Of these, perhaps the most widely 
used is high-throughput screening, a technique that relies on the rapid screening of thousands of 
compounds with set biological targets in the search of a favourable response. This is often the fastest 
way by which pharmaceutical companies are able to identify a small library of hits to take forward for 
further tests. Research into practices such as diversity oriented synthesis is crucial for this approach to 
drug discovery, allowing the rapid synthesis of large libraries of compounds with varied 3D structures. 
Another method involves the rational design of a lead compound, combining the ideas and hypotheses 
of scientists with computational data in order to study 3D models of biological targets; a fact that 
represents both the main advantage and main limitation of this approach. Since this approach relies 
heavily on data and modes of action of biological targets that are already public knowledge, it is easier 
to later make changes to the structure and modify the compound’s activity if need be. Therefore, this 
approach can only provide a solution to problems that are already understood.205 In contrast, high-
throughput screening can provide answers without first knowing how or why a compound exerts a 
favourable biological response.  
In any case, once a hit is identified through high throughput screening, the mode of action must be 
elucidated and from there the modification and optimisation of the compound will include many 
computational models to understand the interactions formed between molecule and target.  
This chapter continues a long-term project within our research group, involving the rational design and 
lead optimisation of new small molecule peptidomimetics that show favourable therapeutic potential 
against some of the most dangerous diseases of our time. 
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This chapter forms part of an ongoing study within our research group, in collaboration with the groups 
of J. Gallego (Universidad Católica de Valencia) and J. Alcamí (Instituto de Salud Carlos III), dealing with 
the synthesis and biological activity of novel p-terphenyls as Rev protein mimics capable of inhibiting 
HIV replication.  
In this context, the main objectives of this work were the synthesis and biological evaluation of a new 
series of terphenyl structures. The present chapter should be considered together with the work 
presented in 2017 by L. Herrera in her doctoral thesis.206 Much of the work contained in Herrera’s 
doctoral thesis was carried out simultaneously to this work, and dealt with the synthesis and biological 
evaluation of p-terphenyls with a new substitution pattern, specifically with the side-chains in 1,4 
relative positions. This will also be discussed in the following sections, as applicable.  
Therefore, this project will include monolaterally-substituted derivatives, varying side-chain patterns, 
and other more complex structures specifically designed to further study the structure-activity 
relationship of our p-terphenyls—generally with side-chains in 1,3 relative positions—and their 
interaction with the RRE (Rev Response Element) of HIV-1.  
We will also begin to explore other interactions which could be targeted by our terphenyl 
peptidomimetics. One such example is the MTIP-MyoA interaction involved in the malaria infection, 
which will be discussed in turn. 
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4.2. Acquired immunodeficiency syndrome. 
4.2.1. Introduction. 
 
Acquired immune deficiency syndrome, or AIDS, has become one of the most dangerous pandemics of 
our time, with up to 37 million people living with HIV infection in 2016.207 Of these, around 25 million 
reside in sub-Saharan Africa—this is due to numerous factors, but perhaps mainly because the epidemic 
originated in this part of the world. Since the beginning of the epidemic in the early 1980s, more than 
80 million people are thought to have been infected with the virus, with approximately half that figure 
succumbing to an AIDS-related death.  
AIDS is the final result of HIV (Human Immunodeficiency Virus) infection and was first recognised as a 
disease in the 1980s. HIV infection does not kill directly, instead acting by compromising the patient’s 
immune system and rendering them susceptible to other opportunistic infections. HIV is not just one 
virus, but a set of viral strains. The main two types are HIV-1, which is responsible for the vast majority 
of global infections, and HIV-2, which is confined to western Africa.  
HIVs are generally accepted to have originated from Simian Immunodeficiency Viruses (SIVs) and 
evolved into strains capable of infecting humans (HIVs) through various interspecies contamination 
events. HIV-1, the much more infectious type, has been shown to have evolved from SIVs originating in 
chimpanzees, specifically SIVcpzPtt and SIVcpzPts from Central chimpanzees (Pan troglodytes 
troglodytes) and Eastern chimpanzees (Pan troglodytes schweinfurthii) respectively.208 Given the 
genetic similarities between humans and chimpanzees it’s clear to see why HIV-1 is the most infectious 
to humans; in fact, a single strain from this type is mostly responsible for the global pandemic. On the 
other hand, HIV-2 is thought to have originated in sooty mangabeys (Cercocebus atys), a different 
species of ape that carries another strain of simian immunodeficiency virus known as SIVsmm. These 
apes are rather less similar genetically to humans and as such their virus is less infectious to us; people 
infected with HIV-2 rarely even develop AIDS. Due to this, HIV-2 infection has remained largely confined 
to the West African countries—where the sooty mangabey’s habitat lies—and has not spread to other 
parts of the globe.  
The most plausible explanation for the cross-species contamination event is thought to be due to the 
tendency of communities in these areas to keep such species as pets, or to use them for so-called 
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“bush-meat” as a food source; an open cut or wound could easily come into contact with the blood of 
an infected primate whilst preparing a meal.209 
Despite the large number of people still living with HIV infection, the number of AIDS-related deaths 
has dropped significantly over the past decade. Peaking at 1.9 million deaths in 2005, the figure has 
dropped around 48% and in 2016 this figure stood at 1 million. Nevertheless, AIDS-related illnesses 
remain the leading cause of deaths among women of reproductive age globally. Similarly, new HIV 
infections have dropped by 16% since 2010, although over the past few years there has been an 
alarming rise in new infections in Eastern Europe and central Asia.  
These drops are due to massive global efforts to develop more effective treatments and to increase the 
coverage of people receiving the correct treatment—there is a clear inverse relationship between the 
number of people receiving treatment and the number of new infections. However, global coverage of 
patients receiving treatment remains one of the biggest challenges; excluding Western Europe and 
North America, in most areas less than 50% of the patients are receiving the proper treatment. 
It’s worth noting that, despite these advances, there is still no way to cure HIV infection—and we are 
still far from achieving such a feat. However, current therapies are capable of efficiently paralysing the 
replication and proliferation of the virus, both protecting the patient from AIDS-related illnesses and 
suppressing transmission to others. These advances have effectively ended the AIDS epidemic in certain 
parts of the world: people are instead living with chronic HIV infection.210 
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4.2.2. HIV infection. 
 
HIV is a species of Lentivirus, a genus of retrovirus characterised by long incubation periods—as the 
name suggests. HIV infection occurs in various stages, starting with an incubation period followed by 
acute infection (sometimes referred to as primary infection), then a latency period which can last for 
anywhere between months and many years before finally resulting in AIDS (Figure 4.2). 
 Upon transmission of the virus, it begins replicating in the mucosal and submucosal endothelial 
tissues around the area of transmission. At first the virus is not present in the plasma and as such is 
undetectable, until around 7-21 days have passed and the virus finally starts entering the plasma, at 
which point the virus is detectable at around 1-5 virions per millilitre of plasma via sensitive qualitative 
methods of nucleic acid amplification, although usually the infection is detected much later than this. 
This initial period is characterised by the appearance of various viral markers and antibodies in the 
blood, including inflammatory cytokines and the viral RNA.211 
 
 
Figure 4.2. Development of HIV infection over time. 
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 Symptoms can start to appear after this initial incubation period during the acute infection, and 
can take any number of forms since they aren’t directly caused by the virus. On the contrary, all 
symptoms associated to HIV/AIDS are indirect, and are due to the reduced capability of the host’s 
immune system to deal with foreign threats due to the decline in CD4+ T-cells (messengers that 
recognise pathogens in the system and trigger signalling pathways to recruit lymphocytes, often CD8 
cells, to eliminate the pathogen).212 The acute infection corresponds with a primary dip in the CD4+ T-
cell levels and a temporary maximum in the HIV RNA levels (Figure 4.2). In these first few weeks, the 
host is susceptible to the first onset of detectable symptoms which can vary from person to person but 
can take the form of joint aches and pains, nausea, diarrhoea, headaches, swollen lymph glands or 
fevers; all common symptoms for other milder illnesses such as influenza, leading to a possible HIV 
infection being overlooked.213  
The latency period on average lasts between 8-12 years, but this is increasing slowly over the years as 
more people are being treated with antiretroviral drugs, and as treatments become more effective. This 
treatment is capable of diminishing HIV presence to almost undetectable levels, but once the patient 
stops taking the treatment the virus bounces back to elevated levels in the plasma, and as such the 
patient regresses to a more infectious state (the risk of transmission is higher when the viral load is 
higher). Eventually at the end of this latency period, the CD4+ T-cell levels drop severely and AIDS 
develops, bringing with it a new onset of symptoms and opportunistic illnesses, which can lead to the 
death of the patient. 
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4.2.3. HIV pathogenesis and biological cycle. 
 
The mechanism of infection of HIV is similar to that of other viruses belonging to the family 
Retroviridae. The viruses of this family contain single-stranded positive-sense RNA, using their own 
reverse transcriptase to produce DNA once inside a host cell; this is the reverse of the usual DNA to 
RNA pattern, hence the name retrovirus (retro meaning backwards). Although the different virions 
belonging to this family of virus lead to very different infections, their structure and components are 
similar. 
The HIV virion measures roughly 120 nm in diameter and has an approximately spherical shape. The 
casing of each virion is made up of a lipid bilayer, originating from the host cell, adorned with 
glycoproteins gp120 which are anchored to the surface by transmembrane proteins gp41. This casing 
protects the important genetic information contained in the interior of each virion: two copies of viral 
RNA, bound to proteins p6 and p7, encapsulated in a truncate-conical capsid formed of p24 proteins. 
The capsid also contains viral enzymes—an inverse transcriptase, an integrase and a protease—vital in 
the replication and proliferation of the virus (Figure 4.3).214 
 
 
Figure 4.3. Structure of the HIV-1 virus. 
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The mechanism of infection can be divided into two distinct phases: 1) early stage, which constitutes 
everything from the binding of the virus to the formation of the provirus; and 2) late stage, which 
constitutes everything from the expression of viral genetic material to the liberation of new virions 
from the host cell.  
The virus first binds to the lipid membrane of the host cell, mediated by the glycoproteins gp120 on the 
surface of the virion—they are highly specific for the recognition of the CD4 receptors and either CCR5 
or CXCR4 chemokine receptors which are present on the membranes of macrophages and CD4+ T-
cells.215 This is the reason for the specific targeting of the immune system associated with HIV infection: 
the virus selectively enters and infects this type of cell, although in some cases the virus can enter other 
cells such as astrocytes or renal epithelial cells, causing HIV-associated neurocognitive disorder and 
nephropathy respectively (Figure 4.4).213a, 216  
Once the virus is bound to the host cell, a sequence of conformational changes takes place, leading to 
an interaction with a cellular co-receptor and the fusion of the viral lipid bilayer with the lipid 
membrane of the host cell, depositing the contents of the virus into the interior of the host cell. The 
viral protein capsid containing the viral RNA then breaks down, leaving it free and unprotected in the 
cytoplasm of the host cell. From there, the viral RNA is reverse-transcribed using the virus’ own reverse 
transcriptase, thereby producing a double-stranded section of complementary DNA—denominated the 
provirus—which is then transferred to the nucleus and inserted into the host’s own DNA through the 
action of the viral integrase enzyme. In this state, the provirus can remain latent for long periods of 
time (Figure 4.4).  
The HIV-1 provirus contains 9,800 nucleotide pairs and contains nine separate genes. The genes code 
for proteins very similar to other virus in the family Retroviridae: three genes that code for structural or 
functional proteins (in this case the glycoprotein gp120, polyproteins gag and pol); two that code for 
regulatory proteins (tat and rev); and four that code for accessory proteins (vpu, vpr, vif and nef).217 
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The late stage of the infection begins with transcription of the provirus, for which it relies on the host’s 
own transcription mechanism. This results in messenger RNA (mRNA), which can then be shuttled out 
of the cell nucleus and into the cytoplasm through the action of the regulatory protein Rev. Once in the 
cytoplasm, the mRNA provides all the genetic information necessary for the translation, or synthesis, of 
viral proteins. The result of the translation process, however, is a long chain of polyproteins which often 
must then be cleaved into functional fragments; the virus contains its own specific protease enzyme for 
this purpose. These proteins, along with two strands of viral RNA, then assemble the internal 
components of a new virus particle. Subsequently, the exposed viral components approach the cell 
membrane and, through a process known as budding, the cell membrane forms a lipid bilayer around 
the viral components, and allows the new virion to pass through into the extracellular medium. The 
virus subsequently undergoes a maturation process during which it gains its capacity to infect new host 
cells (Figure 4.4).219 
Strictly speaking, acquired immunodeficiency syndrome is not caused directly by HIV infection; the virus 
causes a sequence of harmful events that leads to what we know as AIDS. This simply refers to the 
dangerously low levels of CD4+ T-cells per millilitre of plasma observed in HIV-infected patients. This 
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syndrome usually develops in the late stage of infection after the latent period associated to lentivirus. 
This period can last anywhere from months to years, but with current treatments it’s not uncommon 
for this period to take 8-12 years, although it can vary greatly between patients.220 The pathway causing 
the death of the infected CD4+ T-cells, along with their abrupt depletion during the primary infection, is 
still poorly understood. This was highlighted by Thomas in 2009, and is thought to be one of the biggest 
mysteries of the disease—we still don’t know the mechanisms by which HIV infection causes AIDS.221 
However, in 2014 a series of reports surfaced describing several mechanisms to explain this 
phenomenon, and all coincided that the main mechanism is a form of apoptosis (programmed cell 
death).212, 222 For example, Greene et al. detailed how HIV causes the death of host quiescent T-cells 
through pyroptosis, a chronic inflammatory form of apoptosis designed to recruit new immune cells to 
the site in order to continue fighting the infection based on the activation of caspase-1 (Figure 4.5).222a 
 
 
Figure 4.5. Cycle detailed by Greene et al. describing how HIV could cause the rapid depletion of CD4
+
 T-cells by 
pyroptosis, leading to AIDS. 
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4.2.4. Regulatory protein Rev. 
 
The regulatory HIV-1 Rev protein plays a fundamental role in the replication cycle of the virus, given 
that it is responsible for the transport of the viral RNA from the host cell nucleus to the cytoplasm, 
where the packaging and encapsulation of new virions takes place—hence the name Rev, an 
abbreviation of regulator of expression of virion proteins.223 This protein recognises a specific part of the 
mRNA, known as the RRE (an acronym of Rev Response Element), through an α-helix rich in arginine 
residues (Figure 4.6, a-b).224  
The RRE is a highly structured section of RNA, made up of several hairpin-type motifs around a central 
hub, characterised for containing certain anomalous base pairs. The most important of these is found in 
the IIB stem, which presents consecutive G-G and G-A mismatches,225 resulting in an internal loop 
approximately 5 Å wider than the rest of the stem.226 This internal loop is a perfect fit for the arginine-
rich α-helix of Rev (also known as Rev34-50 to refer to the residues forming the α-helix), allowing for the 
selective formation of a Rev-RRE ribonucleoprotein complex; the first step in the process of nuclear 
export (Figure 4.6, c-d).227 
It is worth noting that nuclear RNA export is a highly regulated process. There are many membrane-
bound receptors that aid the crossing of large molecules, such as nucleic acids or proteins, since alone 
they are usually unable to pass the lipid membrane. These receptors facilitate the exchange of proteins 
from one side of the cell membrane to the other, although the situation is more difficult for nucleic 
acids. In past years, it was believed that RNAs were able to cross the membrane using these receptors 
as a free strand, although this has since been proven inaccurate—for the transport of this class of 
biological molecules, it’s necessary to first construct a protein-RNA complex. 
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Figure 4.6. a) and b) The arginine-rich α-helix of Rev responsible for binding to the RRE viewed from different 
angles (Arg residues highlighted in orange). c) The Rev34-50-IIB loop complex. d) A schematic showing the 
mismatching base-pairs in the IIB hairpin in the RRE, forming the Rev binding site. 
 
In the early stage of HIV infection, the proviral DNA is integrated into the host DNA, and transcribed to 
form viral mRNA. Inside the nucleus, the mRNA is split into smaller fragments that code for each gene. 
The smaller fragments are able to cross the nuclear membrane, while the whole mRNA strands remain 
in the nucleus. Therefore, in this phase, the virus is unable to replicate since the strand of RNA never 
reaches the cytoplasm, where the encapsulation process of new virions takes place. 
However, the fragment containing the rev gene is indeed able to reach the cytoplasm, where it is 
translated into the Rev protein.223c This protein is capable of crossing the nuclear membrane and, once 
back inside the nucleus, the Rev protein binds to the RRE of the full mRNA strand to form the Rev-RRE 
complex as described earlier. After the formation of this primary complex between the α-helix of Rev 
and the high-affinity bulge in the RRE, it is thought that the other loops present in the RRE show an 
increased affinity to Rev. In 2010, Frankel et al. proposed that this leads to up to six molecules of Rev 
binding to the same RNA strand, and that Rev actually oligomerises—through hydrophobic interactions 
built around a core of Leu22 and Ile59—upon binding, resulting in a “jellyfish-type” structure (Figure 
4.7).228 The Rev protein also contains a short leucine-rich nuclear export signal that directly interacts 
with a nuclear Ran-GTP bound karyopherin (proteins involved in transporting molecules across the 
nuclear membrane of eukaryotic cells) RNA export factor called Crm1, which is essential to the actual 
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transport of the RNA complex across the nuclear membrane. In this way, the Crm1-bound 
ribonucleoprotein Rev-RRE “jellyfish-type” complex is able to pass the nuclear membrane, allowing for 
the replication cycle of the virus to continue.229 
 
 
Figure 4.7. “Jellyfish-type” structure proposed by Frankel et al.
228 
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4.2.5. Current treatments against HIV infection. 
 
Although there is still no cure to HIV infection, we are now able to prevent the replication and 
proliferation of the virus, making it less infectious and protecting the patient’s immune system to a 
certain degree. Various biological processes represent viable targets throughout the virus replication 
cycle, but the most common targets for current treatments are the following: 1) viral recognition and 
binding to the CD4+ T-cell to prevent the virus ever entering the cell (entry inhibitors); 2) transcription 
of viral RNA to form proviral DNA (reverse transcriptase inhibitors); 3) integration of viral DNA into the 
host DNA (integrase inhibitors); and 4) production of vital viral proteins (protease inhibitors). HIV 
infection is typically treated with a mixture of drugs from several of these classes in order to halt the 
spread of the virus as much as possible—this type of treatment is commonly referred to as highly active 
antiretroviral therapy (abbreviated to HAART). These mixtures generally consist of two different 
nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor, 
protease inhibitor or integrase inhibitor which will all be discussed in turn.  
It’s worth noting that, at present, there are no antiretroviral drugs on the market that exploit the Rev-
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4.2.5.1. Entry inhibitors. 
 
The entry of HIV-1 to the host CD4-expressing cells (T-cells or macrophages) involves a complex cascade 
of events and interactions between the viral envelope protein (Env) and the surface proteins of the host 
cell (Figure 4.8).230 Env is the name given to the homotrimeric structure made up of three surface 
glycoproteins gp120 non-covalently bound to three membrane-bound glycoproteins gp41. Firstly, as 
mentioned previously, the virus glycoproteins gp120 bind to the CD4 receptors on the surface of the 
host cell. However, this interaction alone is not enough for the virus to enter the host cell; for that, 
another membrane-bound co-receptor is necessary. This can be either CCR5 or CXCR4, depending on 
the virus tropism—the tropism refers to exactly which type of cell the virus infects, and can be either R5 
or X4 for those that infect cells using the CCR5 or CXCR4 co-receptors respectively. The primary union of 
gp120 and CD4 therefore causes a conformational change in Env which opens up an otherwise buried 
pocket of gp120, and interaction of this region with the corresponding co-receptor produces further 
structural rearrangements. In this way, a helical region of the three gp41 proteins (denominated the 
HR1 trimer) are pushed forwards into the host cell membrane, causing a further change by which a 
second helical region of gp41 (denominated HR2) moves to bind with the first HR1 trimer. This change 
essentially contracts the gp41 glycoprotein and pulls the virus into close proximity to the host cell 
membrane. A second Env-CD4 complex reinforces the interaction and allows the two membranes to 
fuse, leading to the liberation of the virus contents in the interior of the host cell. 
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Entry inhibitors represent a relatively new class of antiretroviral drugs against HIV; there are only a few 
entry inhibitors currently on the market for use in HAART, all approved within the last 15 years. The first 
of these was Enfuvirtide—a peptide marketed by Roche under the trade name Fuzeon—which was 
approved by the FDA in 2003.231 This drug is commonly referred to a fusion inhibitor, referring to its 
specific role in inhibiting the final membrane fusion step in the entry cascade. In terms of structure, 
Enfuvirtide is homologous to a 36 amino acid segment of the HR2 region of gp41, thereby binding to 
HR1 and preventing the contraction of gp41 which approximates the virus to the host cell membrane.232  
Maraviroc was the second entry inhibitor to be approved by the FDA in 2007, marketed by Pfizer under 
the trade names Selzentry or Celsentri.233 This entry inhibitor acts by binding to the CCR5 co-receptor, 
thus blocking its interaction with gp120 and preventing viral entry. The compound was discovered using 
a high-throughput screening method which identified imidazopyridine-based structure UK-107,543 as 
the most potent ligand for the CCR5 receptor. Subsequent optimisation in terms of potency, 
pharmacokinetics, absorption and interactions with other important targets resulted in Maraviroc 
(Scheme 4.1).234 The downside of this mode of action is that although Maraviroc is effective for viruses 
that use CCR5 to enter the cell (the R5 strains), those that use CXCR4 to enter are unaffected. This 
means the drug is useless for patients expressing CRCX40-tropic viruses, and that over time it is likely 
that the virus will switch to the other strain due to natural selection—only X4 viruses will continue to 
infect new cells and replicate. 
 
 
Scheme 4.1. Structures of lead compound UK-106,543 and optimised marketable drug Maraviroc. 
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A third example, this time a monoclonal antibody by the name of Ibalizumab (trade name Trogarzo), 
was developed by TaiMed Biologics and gained FDA approval earlier this year in March 2018.235 The 
mechanism of action is different to those previously described, this time binding directly to a region of 
CD4 present on the host cell surface. In this way, the drug avoids any differences in virus tropism; all 
HIV-1 viral strains must first bind to CD4 receptors to enter the host cell.236  
Besides these scarce examples of entry inhibitors actually on the market, there are several others in 
various stages of development. One such example is the small molecule Fostemsavir (BMS-663068), an 
investigational drug currently being studied in phase III clinical trials by Bristol-Myers Squibb.237 
Furthermore, another monoclonal antibody by the name of PRO 140 is currently under development by 
Cytodyn Inc., and has recently completed a primary endpoint of phase II/III clinical trials in February 
2018.238  
Entry inhibitors represent an upcoming and promising class of antiretroviral therapy, given their 
extracellular site of action avoiding contact with many potential problematic secondary interactions 
inside the host cell.230a 
 
  
                                                          
235





 J. M. Jacobson, D. R. Kuritzkes, E. Godofsky, E. DeJesus, J. A. Larson, S. P. Weinheimer and S. T. Lewis, 
Antimicrob. Agents Chemother., 2009, 53, 450-457. 
237
 a) https://aidsinfo.nih.gov/drugs/508/fostemsavir/0/patient (Accessed 5
th
 July 2018). b) Z. Li, N. Zhou, Y. Sun, 





 July 2018). b) AIDS Patient Care ST., 2008, 22, 159-160. 
Chapter 4  D. M. Sedgwick, Tesis Doctoral 
235 
 
4.2.5.2. Reverse transcriptase inhibitors. 
 
This class of antiretroviral drugs is the most widely used at present, most likely because they were the 
first to be researched and commercialised. 3'-Azido-2',3'-dideoxythymidine (AZT or Zidovudine), a 
thymidine analogue, was the first drug of its kind to reach commercial status in 1987 and was also one 
of the fastest drugs to make it through the pipeline in recent years; AZT was first proven to be active 
against HIV in the laboratory in 1985 and was approved by the FDA just 25 months later.239 The 
nucleoside structure must first be phosphorylated by various kinases in vivo to be active, after which it 
bears a strong resemblance to thymidine triphosphate which is the natural substrate for the viral 
reverse transcriptase—the only difference is the replacement of the 3’-hydroxyl group in the 
endogenous substrate with an azide group (Figure 4.9).240 Hence, in the phosphorylated form, the drug 
acts as a competitive inhibitor for viral reverse transcriptase, with AZT being incorporated into the 
proviral DNA strand. The next nucleotide is then rendered unable to form a bond between the 3’ group 
and the phosphate group in 5’ of the next nucleotide in the sequence, ultimately hindering viral DNA 
production and consequently viral replication.  
 
 
Figure 4.9. Structural similarities between AZT-triphosphate and TTP. 
 
In the years following the introduction of AZT there were many developments in the area of reverse 
transcriptase inhibitors, and currently there are three different classes of these inhibitors on the 
market. These are nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase 
inhibitors (NtRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Both NRTIs and NtRTIs 
                                                          
239
 H. Mitsuya, R. Yarchoan and S. Broder, Science, 1990, 249, 1533-1544. 
240
 A. R. Van Rompey, M. Johansson and A. Karlsson, Pharmacol. Ther., 2000, 87, 189-198. 
Chapter 4  D. M. Sedgwick, Tesis Doctoral 
236 
 
have the same mode of action—as their name suggests, they are based on endogenous DNA bases and 
competitively inhibit the reverse transcriptase enzyme to hinder viral DNA production—but NNRTIs are 
more chemically diverse and act via a slightly different mechanism, since they are not based on the 
nucleotide substrate.  
 NNRTIs are generally more well suited to the task in hand, achieving better selectivities and 
binding affinities than N(t)RTIs, as well as having other pharmacokinetic and pharmacodynamic 
differences. For example, N(t)RTIs need metabolising in vivo to the active triphosphate form whereas 
NNRTIs can interact directly with the target and do not necessarily require prior activation. NNRTIs act 
by binding to an allosteric site on the reverse transcriptase enzyme roughly 10 Å away from the 
substrate binding site that is both structurally and functionally associated with the substrate binding 
site.241 This binding pocket lies between the three-stranded β-sheet containing catalytic aspartic acid 
residues D110, D185 and D186, which changes conformation once bound to the NNRTI. Therefore, it is 
believed that the inhibitory effect is due to an inactive conformation at the substrate binding site when 
this allosteric pocket is occupied (Figure 4.10).   
 
 
Figure 4.10. Mechanisms leading to reverse transcriptase inhibition by NNRTIs. 
 
Although NNRTIs usually exert their inhibitory activity through binding to the same allosteric pocket, 
not all of these exploit the same interactions to induce the conformational changes leading to inhibition 
of DNA synthesis. This is somewhat due to the emergence of NNRTI-resistant strains of HIV; the rapid 
replication of the HIV-1 virus often results in a mutation around the NNRTI binding pocket, and 
therefore removes certain possible interactions. Since a mutation in the allosteric binding pocket does 
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not necessarily influence the catalytic ability and function of the enzyme, virus viability does not suffer 
from these mutations, resulting in various NNRTI-resistant strains.  
The exact reasons for these mutations and the mechanisms of resistance are still poorly understood. 
Having said that, it has been shown that the Y181C and Y188L mutations confer resistance due to the 
elimination of favourable interactions formed between the drug and the enzyme, whereas the K103N 
mutation is thought to reduce the rate of NNRTI binding due to slightly altered structure of the binding 
pocket.242  
For this reason, we must continue to develop structurally diverse drugs of this kind; there are currently 
over 30 different structural subgroups within this class of inhibitors (Figure 4.11). The first NNRTI, 
Nevirapine (marketed under the trade name Viramune and developed by Boehringer Ingelheim), was 
approved by the FDA in 1996. Nevirapine contains a tricyclic dipyridodiazepinone core, and interacts 
with residues Tyr-181 and Tyr-188.243 This makes it susceptible to the K103N mutation, similar to the 
structurally different NNRTI Efavirenz.244 This second drug was approved in 1998 by the FDA, and is one 
of the most important antiretroviral drugs on the market; it is included in the World Health 
Organisation’s List of Essential Medicines, the safest and most effective drugs necessary for a 
functioning health system.245  
Lersivirine was an investigational drug in development by ViiV Healthcare, but was recently 
discontinued since phase III results demonstrated that this drug was not as effective at inhibiting viral 
replication as other drugs currently on the market such as Efavirenz. Interestingly, this compound 
showed a different binding mode to other NNRTIs—forming interactions with Trp-229 with the 3,5-
dicyanophenoxy ring—making its resistance profile somewhat different also. In this way, Lersivirine 
could have proved useful for patients presenting K103N or Y181C viral mutants.246 A second drug, 
Fosderivine, was also in development by ViiV Healthcare, but was discontinued when a phase II study 
resulted in 5 of 35 patients suffering seizures.247 Nevertheless, these studies could provide useful 
insights for the development of a new generation of NNRTIs.248 
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Figure 4.11. Varying structures of approved and discontinued NNRTIs. 
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4.2.5.3. Integrase Inhibitors. 
 
Integrase is the enzyme responsible for the integration of the proviral DNA into the host DNA, hence 
the name integrase. The functional enzyme is produced via proteolytic cleavage of the Gag-Pol 
polypeptide coded by the pol gene.249 Despite its vital importance in the replication cycle of HIV-1, 
compounds targeting the integrase enzyme represent a relatively new class of antiretroviral drugs. This 
has been attributed to the complexity of the integration process—although once we understood the 
reaction and in vitro models were available, the first integrase inhibitors were developed fairly rapidly. 
Raltegravir (marketed by Merck as its potassium salt under the trade name Isentress), the first small-
molecule integrase inhibitor, was approved for use in 2007 (Figure 4.12).250 Originally it was only 
approved for use in patients in which other first-line treatments had no effect, but in 2009 it was 
approved for use as a first-line treatment in all patients and is now included in the World Health 
Organisation’s List of Essential Medicines, just like Efavirenz.244, 245 Since then, several more examples of 
integrase inhibitors have been approved, such as Elvitegravir (trade name Stribild, developed by Gilead 




Figure 4.12. Chemical structure of some integrase inhibitors showing common features. 
 
Integrase is made up of three separate sections, and all three are necessary for its catalytic activity: the 
N-terminal domain; the catalytic core domain; and the C-terminal domain. The N-terminal domain 
contains an essential His-His-Cys-Cys sequence (specifically His-12, His-16, Cys-40 and Cys-43), which 
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together chelate a zinc ion (Zn2+) to form a zinc-finger motif. The core catalytic domain contains three 
completely conserved residues responsible for the activity, which are Asp64, Asp116 and Glu152—also 
known as the DDE triad. Between them these residues chelate two positive ions, Mg2+ or Mn2+, which 
act as a guide for the viral DNA. The final C-terminal domain contains non specific DNA binding sites, 
and is responsible for binding the viral DNA which is then pulled through to the core catalytic domain in 
order for strand transfer to occur.251 Current integrase inhibitors block this process, and therefore they 
are termed INSTIs (INtegrase Strand Transfer Inhibitors). 
The INSTI mechanism of action has been studied in detail; for example, in 2008 Chen et al.252 used 
computational modelling to show how this class of molecules binds to the enzyme and therefore blocks 
integrase activity, using an investigational drug denominated L-870,810 that was discontinued after 
liver and kidney toxicity was discovered in dog models.253 This compound is structurally similar to both 
Raltegravir and Elvitegravir, and contains similar motifs that allow it to exert an inhibitory effect on the 
HIV-1 integrase enzyme (Figure 4.12). The mode of action of these INSTIs is based on the competitive 
chelation of the divalent metal ions in the catalytic core domain used to guide the viral DNA into the 
host DNA, preventing the continuation of the integration process (Figure 4.13). This is augmented by 
the benzyl residue favourably interacting with a hydrophobic pocket which opens up only at certain 
points of the integration process—when the inhibitor binds to this site and chelates the metal ion, the 
integrase structure is rendered more rigid and the integration reaction is inhibited.  
Despite these advances, we now know that integrase is important for more than this pivotal role in the 
replication cycle of HIV-1, such that future integrase inhibitors may not inhibit the actual integration 
process itself, but other important processes that may be mediated by integrase.254 
 
                                                          
251
 M. Thomas and L. Brady, Trends Biotechnol., 1997, 15, 167-172. 
252
 X. Chen, M. Tsiang, F. Yu, M. Hung, G. S. Jones, A. Zeynalzadegan, X. Qi, H. Jin, C. U. Kim, S. Swaminathan and J. 
M. Chen, J. Mol. Biol., 2008, 380, 504-519. 
253
 F. W. N. M. Wit, J. M. A. Lange and P. A. Volberding, in Global HIV/AIDS Medicine, ed. P. A. Volberding, M. A. 
Sande, W. C. Greene, J. M. A. Lange and J. E. Gallant, Elsevier, Amsterdam, 1
st
 edn., 2008, ch. 12, pp. 123-135. 
254
 T. Masuda, Front. Microbiol., 2011, 2, 1-5. 




Figure 4.13. a) Coordination of L-870,810 (white stick model) to the catalytic core domain of HIV-1 integrase 
(yellow surface) showing the 3D structure of the hydrophobic pocket (Site 1). b) Model with key residues 
highlighted; the hydrophobic pocket in blue and the DDE triad chelating the Mg
2+
 ions in red (Site 2). Taken 
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4.2.5.4. Protease inhibitors. 
 
This class of drugs inhibits the action of viral protease, and represents the second class of antiretroviral 
therapy to be approved for use. Protease is responsible for the cleavage of polypeptides resulting from 
the translation of viral mRNA, thereby producing important viral proteins necessary for the formation 
of new virions. Saquinavir, the first example of a protease inhibitor, was developed by Hoffman-La 
Roche and approved for use in 1995 after another incredibly short application process lasting just 97 
days. The rapid clinical phases seen in some antoretroviral therapies, such as AZT and Saquinavir, is a 
testament to the desperation of the AIDS epidemic in early years; between 1980 and 1987 when AZT 
was first approved there was absolutely no way of treating HIV infection, and a positive diagnosis was 
essentially a death sentence.  
Protease inhibitors are now widely used in HAART, along with reverse transcriptase and integrase 
inhibitors, and generally present a peptidomimetic structure mimicking the native substrate. For 
example, Saquinavir contains a hydroxyethylamine moiety in place of a peptide bond, granting it a 3D 
structure similar to an intermediate transition-state stabilised by the enzyme during peptide cleavage 
(Figure 4.14). However, a common problem with drugs with peptide-based structures of this type is 
that the oral availability is hampered due to affinity for efflux pumps, decreasing its oral availability—
something that could have been detected earlier, had more detailed clinical trails been carried out.255 




Figure 4.14. Structural basis of the first protease inhibitor Saquinavir. 
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Since then, there has been a trend in new protease inhibitors to contain fewer peptide bonds, in an 
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The identification of small-molecule peptidomimetics is key in the development of new molecular 
entities that are able to interfere with biological processes mediated by peptides or proteins. The idea 
behind peptidomimetics, as the name suggests, is to mimic the 3D structure of a peptide; a premise 
that has gained increasing interest recently as the scientific community unravels the mysteries of 
cellular processes, due to emerging areas such as proteomics.257 Protein-protein interactions are 
ubiquitous in biological systems, regulating a plethora of processes from recognition and signal 
transmission to apoptosis, and therefore interfering with this type of interactions could give rise to 
pharmaceuticals with unprecedented activities and novel modes of action. However, traditional 
methods of interfering with these interactions—logically, through the use of peptide drugs—present 
certain problems. Nevertheless, there are still several examples of peptide drugs such as insulin or 
oxytocin, although they represent just 2% of the global market. 
Peptide drugs face many challenges with absorption, distribution, metabolism and excretion (ADME).258 
Firstly, the low lipophilia of the peptide bond and ability to form many hydrogen bonds render most 
peptides incapable of passing lipid membranes, and therefore they generally demonstrate very low 
bioavailability (<1%), although there are some exceptions such as cyclosporine A (a cyclic peptide used 
as an orally active immunosuppressive drug).259 Secondly, peptides are susceptible to cleavage and 
elimination by endogenous proteases. Due to the fundamental role that proteins and peptides play in 
biological systems, there are also many ways of removing them from the body quickly and efficiently, in 
order to effectively control the levels of hormones and other peptides. Consequently, the amount of 
peptide drugs that are finally approved for use is very low: a recent study of 484 peptide drug 
candidates found that eventually 54% were discontinued, and only 12% were approved.260 
For these reasons, Lipinski famously described a series of drug-like qualities—generally known as 
Lipinski’s rule of 5—that new drug candidates should present to have the best chance of success during 
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clinical trials.261 These guidelines state that an orally administered drug should violate no more than one 
of the following rules: 
 
 No more than five hydrogen-bond donors (N—H or O—H bonds) 
 No more than ten hydrogen bond acceptors (N or O atoms) 
 A molecular mass less than 500 gmol-1 
 A logP value not greater than 5 
 
The great majority of drugs follow these rules, although as with any general rule, there are plenty of 
exceptions. Oral administration of drugs is far preferred to any other method as it is non-intrusive, most 
convenient for both medical professionals and the patient, and presents the best patient compliance. 
However, the oral administration of drugs presents certain challenges. For a drug to be well absorbed 
via oral administration, it must have high membrane permeability in order to pass through the walls of 
the intestine into the blood stream. Furthermore, it must first survive in the acidic conditions and 
metabolism of the stomach and to a certain extent that of the liver, to remain in the plasma for the 
time necessary to exert the desired effect. Peptides therefore must be injected directly into the 
patient’s blood stream in order to avoid metabolism in the stomach and to bypass membrane 
permeability issues; although this means patients must either inject themselves or visit the doctor for 
each injection, neither of which is an ideal situation.  
The use of peptidomimetics provides a solution to this problem. By using small molecules that mimic 
just the active fragment of the peptide—often referred to as the pharmacophore—the compound is 
much more likely to fall within Lipinski’s guidelines, and ultimately more likely to reach marketable 
status. Peptidomimetics can be classified into several distinct groups, as seen in the following sections. 
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4.3.2. Classification of peptidomimetics. 
 
Historically, peptidomimetics have been classified into type-I, type-II and type-III mimics. This 
classification can often be fairly blurred at the edges, especially between type-I and type-II 
peptidomimetics.262 The first class is generally referred to as containing peptidomimetics directly based 
on the peptide backbone, often matching atom-for-atom the backbone of the native peptide agonist. 
Consequently, these compounds rely heavily on mimicking the same interactions that the native 
peptide would make with the receptor. On the other hand, type-II mimetics originally emerged as 
functional mimetics—compounds found to interact with a certain peptide receptor. Initially, these 
compounds were therefore presumed to contain a structure similar to the native peptide, although this 
was later proved incorrect. Type-II peptidomimetics do not necessarily bind to exactly the same site as 
the native peptide. On the contrary, they often act as allosteric inhibitors. The classification of type-III 
peptidomimetics, however, is much more straightforward; type-III peptidomimetics are non-peptide 
small molecules that contain structural motifs capable of projecting certain functional groups into the 
correct 3D space in order to interact favourably with the receptor. 
Recently, Grossmann et al. described a similar classification system based on the actual structure of the 
peptidomimetic, removing the element of doubt between certain classes.263 
 
 Class A. Small peptide-based structures with a peptide backbone and slight modifications to 
side chain structure. 
 Class B. Small peptide-based structures with a modified peptide backbone, and perhaps more 
modifications to side chain structure. 
 Class C. Non-peptide small molecules that are capable of projecting substituents into a 
configuration analogous to the peptide. 
 Class D. Non-peptide small molecules that have an unrelated structure but mimic the mode of 
action. 
 
Of these, class C structures will be the most important to this project, representing the “ideal” within 
the concept of peptidomimetics. 
                                                          
262
 A. S. Ripka and D. H. Rich, Curr. Opin. Chem. Biol., 1998, 2, 441-452. 
263
 M. Pelay-Gimeno, A. Glas, O. Koch and T. N. Grossmann, Angew. Chem. Int. Ed., 2015, 54, 8896-8927. 
Chapter 4  D. M. Sedgwick, Tesis Doctoral 
247 
 
4.3.3. Strategies in peptidomimetic design. 
 
Many strategies exist for the design of peptidomimetics. Traditionally, these were generally peptide-
based modifications to side chains in order to lock certain conformations; the shift from a full-length 
peptide chain to just the pharmacophore can remove important structural features.264 Some common 
class A and B modifications can be seen in Figure 4.15 using an example peptide.  
 
 
Figure 4.15. Class A and B modifications using an example Trp-Tyr-Ala-Arg sequence. 
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In modern times, with more knowledge of structural biology and chemistry we have shifted more 
towards the use of class C peptidomimetics. In this sense, certain privileged structures present the 
necessary conformations to properly mimic various peptide structural motifs.  
Class C mimics are somewhat more complex since they generally focus on the secondary structures of 
proteins and are not based on peptide backbones, although they can generally be grouped into three 
distinct types depending on the motif they mimic: turns, β-sheets, or α-helices (Figure 4.16). 
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4.3.3.1. Turn mimics. 
 
Turn structures are extremely common in nature; without this class of structural motif proteins would 
not be able to adopt the folded and globular forms we so often encounter in protein structure. 
Although there are many forms of turn structure, depending on the number of amino acid residues 
between the key C=O---HN hydrogen bond, the most common are β-turns (also denominated β-hairpins 
or reverse turns) and γ-turns (Figure 4.17).266 Given that γ-turns are fairly similar to the open chain 
conformation, in this section we will focus on the related β-turns.  
 
 
Figure 4.17. γ- and β-turns. 
 
Among the first small-molecule β-turn mimics was thiazolidinone 4.1, found to mimic the structure of 
the D-Ala-L-Pro turn.267 It’s worth mentioning that proline plays a unique role in these situations; being 
the only natural amino acid containing a cyclic structure, it lacks an N—H hydrogen bond donor and 
provides rigidity and conformational bias towards a turn-like structure (Figure 4.18).263 Although 4.1 is a 
peptide-based structure, this discovery paved the way to other class C small molecules that successfully 
mimic the structure of a β-turn without the need for peptide bonds. Of these, perhaps the most 
common is the benzodiazepine structure 4.2, which was first demonstrated to mimic a Pro-Ala junction 
by Ripka and De Lucca in 1993, just like the thiazolidinone structure described previously.268 In addition, 
carbohydrate-based structures 4.3 have been found to mimic the β-turn conformation found in 
Somatostatin (based on existing cyclic class A peptidomimetic 4.4).269 More recently, in 2011 Boger et 
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al. designed a library of trans-pyrrolidine-3,4-carboxamides 4.5 that were proven to be efficient 
inhibitors of various opioid receptors that recognise a β-turn motif in their endogenous ligands.270  
 
 
Figure 4.18. Selected β-turn structural mimics. 
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4.3.3.2. β-Sheet mimics. 
 
This type of structure is in some ways an extension of the previously mentioned β-turns, in that the turn 
allows the peptide to fold over onto itself in such a way that the two chains are aligned in parallel, held 
together by hydrogen bonds between them. This conformation forces the side chain residues to adopt 
an alternating up-down configuration, and prevents same-chain hydrogen bonding.271 Therefore, 
structural mimics of β-sheets and β-hairpins began with the corresponding β-turn mimics discussed 
previously, with early studies focusing on the same Pro-Ala turn formation and ways to stabilise small β-
hairpin type formations.272 This was achieved using several specifically designed structures—including 
epindolidiones,273 5-amino-2-methoxybenzamide derivatives,274 1,2-dihydro-3(6H)-pyridinone units,275 
and diphenylacetylenes,276 among others—to force a small peptide to adopt the desired conformation 
(Figure 4.19). 
Due to the complexity of β-sheet conformations—they rely heavily on hydrogen-bond stabilisation and 
contain large spaces between each set—there are relatively few class C examples of this type (Figure 
4.20).263 One of the first examples of a structural mimetic was the 1,3-disubstituted triazole backbone, 
which adopts a zig-zag conformation reminiscent of the β-sheet structure in solution.277 An elegant 
example came from Hamilton and Wyrembak in 2009 with the disclosure of 2,2-disubstituted indolin-3-
ones as β-sheet mimetics.278 This class of compound was found to be the same length as five peptide 
residues, with the substituents in the 2 positions of each subsequent indolinone lining up almost exactly 
with the residues in the i, i + 2, and i + 4 positions respectively. More recently, Burgess et al. 
demonstrated how subtle changes in the building blocks of a sequence can dramatically change the 3D 
structure of the whole compound.279 These authors used either piperidine-piperidinone or pyrrolidine-
pyrrolidinone to produce peptidomimetics, and found that the pentamer based on 6-membered rings 
mimicked a β-sheet structure, whereas the related compound constructed of 5-membered rings 
mimicked an α-helix. 
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Figure 4.19. Selected β-sheet mimetics based on stabilisation and conformation locking of peptides. 
 
 
Figure 4.20. Selected structural class C mimics of β-sheets. 
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4.3.3.3. α-Helix mimics. 
 
α-Helices are abundant in nature, regulating uncountable biological processes through protein-protein, 
protein-RNA or protein-DNA interactions, among others. The previously discussed HIV-1 Rev protein 
(see Section 4.2.4. Regulatory protein Rev) is just one example of a protein presenting this structure, but 
there are many more—in fact, it is estimated that helices make up 30-40% of structured protein 
domains.263 Much like the related β-hairpin mimics, early examples focused on the stabilisation of short 
peptide chains into helical conformations via one of two ways. The first of these is through covalent 
bonds between adjacent side chains: the formation of disulfides,280 lactams,281 and the ring-closing 
metathesis of olefins282 have all been used to this end. The second is through non-covalent interactions 




Figure 4.21. Schematic depiction of the different methods employed to stabilise α-helices. 
 
Many advances have been made over the past decade towards improved class C mimics of the α-helix 
structure, starting with the pioneering work by Howson et al. involving 1,6-disubstituted indanes which 
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mimicked the positions i and i + 1 of an α-helical dipeptide fragment.286a Although this work cannot fully 
be considered an α-helix mimetic—given that at least 5 residues are required to form an α-helix—it 
paved the way to more structurally diverse and complex studies. The same group also extended this to 
the 1,1,6-trisubstituted indanes—mimics of the i - 1, i, and i + 1 residues—that were shown to have 




Figure 4.22. Pioneering work by Howson et al. into the use of indanes as α-helix mimics. 
 
Following this, in the year 2001 Hamilton and co-workers described a backbone that would 
revolutionise the area of α-helix mimics; the p-terphenyl.287 This was the first report to tackle the 
mimicry of a large area of an α-helix, over more than two turns. In their seminal report, the authors 
described how the three substituents on each ring of the p-terphenyl mimicked almost perfectly the 
residues i, i + 3 (or i + 4) and i + 7 of an α-helix (Figure 4.23). This is due to the staggered conformation 
of the terphenyl rings, produced by the steric repulsion between the substituent in ortho with the 
hydrogen of the adjoining ring. This strategy was then used to design inhibitors for the interaction 
between calmodulin (a protein that serves as the primary receptor for intracellular Ca2+ and contains an 
α-helix crucial for target binding) with smooth muscle myosin light chain kinase (a calmodulin 
receptor),288 resulting in several terphenyl derivatives with potent inhibitory activity (Figure 4.23). This 
was taken further and the same compounds were used to inhibit the interaction between calmodulin 
and 3’-5’-cyclic nucleotide phosphodiesterase, an enzyme whose function it is to degrade the 
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phosphodiester bond in cyclic adenosine monophosphate (cAMP),289 with IC50 values in the nanomolar 
range. The same authors went on to develop terphenyl inhibitors for a number of biological processes, 
such as the Bak/Bcl-XL anti-apoptotic protein-protein interaction (which has previously been inhibited 
through the use of covalently stabilised short peptide chains)290 and even HIV-1 cell entry (Figure 
4.23).291 The latter is based on the disruption of the gp41 core complex within the Env core (refer to 
Figure 4.8), preventing the virus fusion process. This is achieved by interfering with the folding of the 
gp41 proteins into the six-helix bundle to approximate the virus to the cell membrane; the hydrophobic 
terphenyl successfully mimics a region of the C- or N-terminal rich in Leu and Ile residues. Furthermore, 
in 2006 the authors elucidated how the substitution of the central phenyl ring for an indane could 
mimic both the i + 3 and i + 4 residues, along with the standard i and i + 7.292 
 
 
Figure 4.23. p-Terphenyls as α-helix mimics; note the similar distances between the three residues. 
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Since then, various new scaffolds have been designed based on the original terphenyl design disclosed 
by Hamilton, often accompanying the introduction of heteroatoms in the backbone in order to 
augment aqueous solubility, such as p-terpyridine 4.7 (Figure 4.24).257, 293 Moreover, these new 
additions to the class C α-helix mimetics have focused on mimicking a growing number of side chains on 
more than one face of the helix. The major drawback with Hamilton’s design was that his terphenyls 
were only able to mimic one face of the helix (for example those seen in Figure 4.23, or p-terpyridine 
4.7), meaning that only superficial interactions could be mimicked effectively. This has since been 
addressed in a number of ways. Firstly, with the development of next generation peptidomimetics such 
as those based on benzamide structures able to mimic many more side chains than the standard p-
terphenyl (4.6a-d, Figure 4.24). On the other hand, in 2012 Zhang et al. demonstrated how an 
anthracene-based could mimic two opposite sides of the BH3 α-helix to inhibit its interaction with Blc-1 
and Mlc-1, which are also involved in the regulation of apoptosis (4.8, Figure 4.24).294 
 
 
Figure 4.24. Further terphenyl-derived bifacial α-helix mimics. 
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Curiously, β-hairpins have also been used to mimic the projection of side chains in an α-helical 
arrangement (Figure 4.25, a). Robinson and co-workers first proved this in 2004, when they used a β-
hairpin based on a D-Pro-L-Pro turn to mimic the structure of the p53 tumour suppressor α-helix,295 and 
by doing so inhibited the interaction of this protein with HDM2—an attractive biological target in 
emerging cancer therapies.296 The same authors also applied this to the inhibition of the formation of 
the Rev-RRE complex.297 By mimicking the arginine residues present in Rev they achieved a high affinity 
for the RRE (Kd = 2 nM), although their Rev mimic had a low specificity towards other similar RNA 
targets. These results proved that it is possible to achieve very potent inhibition of the Rev-RRE 
interaction by using synthetic and non-endogenous ligands (Figure 4.25, b). 
 
 
Figure 4.25. a) Superposition of synthetic β-hairpin (yellow) and the p53 α-helix (red). b) Superposition of 
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4.4. The Suzuki-Miyaura cross-coupling reaction. 
 
Palladium is known to most people as a component in the catalytic converters of automobiles, or even 
as a precious metal used in jewellery, but most remain unaware of the essential role of palladium in 
modern organic synthesis.298 As a testament to its wide utility, in 2010 the Nobel Prize in Chemistry was 
awarded to Richard Heck, Ei-ichi Negishi and Akira Suzuki for “the development of palladium-catalysed 
cross couplings in organic synthesis.”299 
Although the area of metal-catalysed cross couplings emerged during the 1970s, it wasn’t until the 
1990s that the area started to gain interest and, by the 2000s, a great variety of cross-coupling 
reactions had been developed—including carbon(sp2)-heteroatom, carbon(sp2)-carbon(sp2), and 
carbon(sp2)-carbon(sp) among others. Over the past decade, the number of patents and publications 
involving such cross-coupling reactions has grown exponentially, by far the most popular of these being 
the Suzuki coupling, followed by the related Heck and Sonogashira couplings.300 This trend has also 
been seen in industrial processes, and nowadays many pharmaceuticals and agrochemicals contain a 
cross-coupling reaction in their synthesis.  
In general terms, the Suzuki-Miyaura reaction can be defined as the cross coupling between an 
organoborane compound and an organic halide (or pseudo-halide), catalysed by a palladium metal 
complex in basic media (Scheme 4.2). The Suzuki reaction has several advantages over other related 
cross couplings: 1) the organoboronate coupling partners are bench-stable and non-toxic; 2) the 




Scheme 4.2. The Suzuki-Miyaura cross coupling reaction. 
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 X.-F. Wu, P. Anbarasan, H. Neumann and M. Beller, Angew. Chem. Int. Ed., 2010, 49, 9047-9050. 
299
 a) A. Suzuki, Angew. Chem. Int. Ed., 2011, 50, 6723-6737. b) E. Negishi, Angew. Chem. Int. Ed., 2011, 50, 6738-
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The mechanism of the reaction follows an analogous catalytic cycle to other metal-catalysed cross 
couplings (Scheme 4.3).301 These reactions take place in three key steps: oxidative addition, 
transmetallation, and reductive elimination. 
 
 
Scheme 4.3. Catalytic cycle for cross-coupling reactions. 
 
Oxidative addition of aryl, benzyl, alkenyl, alkynyl and allyl halides or pseudo-halides to palladium(0) 
complexes results in stable trans-σ-palladium(II) species I. This step usually represents the rate-
determining step in the reaction; the weaker the C—X bond the faster the reaction, usually in the order 
I > Br > OTf >> Cl. On the other hand, aryl or alkenyl halides bearing electron-withdrawing groups 
activate the C—X bond and the reaction takes place faster. From there, complex I undergoes a ligand 
exchange with the base, forming complex II.302  
The transmetallation step involves reaction of this intermediate with the organoboronate coupling 
partner—which requires prior base-mediated activation—and subsequent isomerisation from the trans 
complex to cis-σ-palladium(II) species III. Of the three key steps, the transmetallation is the least 
                                                          
301
 a) J. K. Kochi, Organometallic Mechanisms and Catalysis, Academic, New York, 1978. b) R. F. Heck, Palladium 
Reagents in Organic Syntheses, Academic, New York, 1985. c) F. R. Hartley and S. Patai, The Chemistry of 
Metal‐Carbon Bond, Wiley, New York, 1985, Vol. 3. d) F. J. McQuillin, D. G. Parker and G. R. Stephenson, Transition 
Metal Organometallics for Organic Synthesis, Cambridge University Press, Cambridge, 1991. 
302
 a) C. Amatore, A. Jutand and A. Suarez, J. Am. Chem. Soc., 1993, 115, 9531-9541. b) C. Amatore, A. Jutand and 
M. A. M’Barki, Organometallics, 1992, 11, 3009-3013. 
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understood; there are many factors to consider, as it relies heavily on the organometallic species in 
question and the specific reaction conditions.303 
Finally, the cross-coupling product is liberated from intermediate III, re-establishing the catalytic 
palladium(0) species. For this to occur, intermediate III must be in the cis conformation for the two aryl 
groups to interact and form the new C—C bond.304 
It’s worth noting that the Suzuki cross coupling is generally accepted as the most important method for 
the synthesis of biaryls.298 This can be seen in the synthesis of several pharmaceutically relevant biaryls, 
such as the alternative synthesis of Losartan (a potent nonpeptide angiotensin II receptor antagonist) 
by Merck in 1994,305 or the industrial scale-up of biaryl 4.9 (a key intermediate in the synthesis of ONU-
6162, a potential CNS agent) developed by Pharmacia Corporation (Scheme 4.4).306 
 
Scheme 4.4. Representative examples of the Suzuki-Miyaura coupling in industrial processes. 
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Advances in ligand functionality have also contributed to the superiority of the Suzuki coupling over 
related cross-coupling reactions in the synthesis of biaryls 4.10; essentially any biaryl can be achieved 
through the use of the Suzuki cross-coupling reaction. The work by Buchwald and co-workers over the 
years highlight the use of biphenyl-based phosphines in order to obtain highly sterically hindered 
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In 2013, our research group first described how the p-terphenyl scaffold could be used in the rational 
design of mimics of the HIV-1 Rev34-50 α-helix, together with the groups of J. Gallego (Universidad 
Católica de Valencia) and J. Alcamí (Instituto de Salud Carlos III).308 The early terphenyl structures 
described by Hamilton and co-workers (see Section 4.3.3.3. α-Helix mimics)283, 290-292 bearing a 
monolateral substitution pattern were limited to mimicking just one face of a peptide structure, or an 
angle of 180°, and were consequentially limited to mimicking superficial interactions. The authors 
therefore reasoned that the use of hexasubstituted terphenyls instead of the aforementioned 
trisubstituted terphenyls could open up more possibilities for this class of peptidomimetics, given that 
more residues could be mimicked in this way.  
This way, the authors hypothesised that the resulting bilateral terphenyls would be able to mimic 
residues in the i, i + 1, i + 4, i + 5, i + 7, and i + 8 positions (Figure 4.26). With the possibility of mimicking 
a larger 360° angle, we thought that this new terphenyl structure would have a greater potential to 




Figure 4.26. Design of novel bilaterally substituted terphenyls.  
 
The terphenyl structures tested contained two ethylamine chains on both terminal phenyl rings, along 
with various substitutions on the central rings. This was due to the structure of the native Rev protein; 
                                                          
308
 a) L. González-Bulnes, I. Ibáñez, L. M. Bedoya, M. Beltrán, S. Catalán, J. Alcamí, S. Fustero and J. Gallego, 
Angew. Chem. Int. Ed., 2013, 52, 13405-13409. b) L. González-Bulnes, I. Ibáñez, S. Catalán, P. Barrio, S. Prado, A. 
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as previously discussed, the Rev α-helix that binds to the RRE is rich in arginine residues, a basic residue 
capable of establishing ionic interactions, as well as being both a donor and acceptor of hydrogen 
bonds. However, the introduction of guanidine groups into a bilaterally substituted terphenyl would be 
difficult due to their high polarity and challenging purification (the Rev helix contains various, and a 
terphenyl structure containing several guanidine groups would presumably be difficult to isolate in the 
required purity for biological assays). Therefore, the authors opted for primary amine side chains given 
their similar basicity and hydrogen bonding capabilities. 
A sequential Suzuki-Miyaura cross-coupling strategy was employed for the synthesis of the terphenyl 
scaffolds, using previously functionalised synthons (Scheme 4.6).  
 
 
Scheme 4.6. Retrosynthesis of bilateral terphenyl structures tested by Fustero, Gallego and Alcamí et al. 
 
In this way, the synthesis of the desired terphenyls passed through intermediate biphenyl structures, 
some of which were also tested for affinity for the HIV-1 RRE. However, these compounds showed a 
much weaker union to the RRE than the corresponding terphenyls. These results showed that the 
staggered conformation of the terphenyl scaffold, as well as the extra interactions established with a 
third phenyl ring, were important for the binding to the receptor. The best of the terphenyls tested was 
Ter.0, which presents hydroxy and methoxy groups in the terminal positions, and two methyl groups in 
the central phenyl ring (Figure 4.27, a). 
The binding site of the terphenyls was confirmed via NMR TOCSY experiments. The ppm shifts in the 
signals corresponding to the nucleotides within the RRE when exposed to 0, 1, or 2 equivalents of the 
terphenyl ligand can give information about exactly where the terphenyl binds—and the greatest shifts 
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were observed in the signals arising from the nucleotides inside the widened loop of the RRE, which is 
the binding site of the endogenous Rev protein (Figure 4.27, b-c). 
 
Figure 4.27. a) Structure of lead compound Ter.0. b) Modelling of Ter.0 inside the RRE, showing the nucleotides 




Furthermore, the bilaterally-substituted terphenyl Ter.0 inhibited the formation of the Rev-RRE 
complex (IC50 = 7.0 μM) and displayed moderate selectivity for the RRE over other similar RNA strands. 
In addition, the compound showed high in vivo activity (EC50 = 3.4 μM) and, most importantly, showed 
very little cyctotoxicity even at the maximum concentration tested (CC50 = >100 μM). 
More recently, within the same collaboration between our research group, J. Gallego (UCV) and J. 
Alcamí (ISCIII), a second generation of p-terphenyls was developed and tested for inhibition of the Rev-
RRE complex formation. These results featured in the doctoral thesis of Dr. L. Herrera in 2017206 and, at 
the time of writing, the corresponding manuscript is in preparation.309 Despite building on the idea that 
a bilateral substitution pattern should be beneficial for their inhibitory activity, this new series of 
terphenyl scaffolds contained a major structural difference: the alkylamine chains were positioned in a 
relative 1,4-substitution pattern. In this way, the residues expected to be mimicked were those in the i, 
i + 2, i + 4, i + 6, i + 7, and i + 9 positions of Rev34-50 (Figure 4.28).  
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Figure 4.28. New terphenyl derivatives bearing a relative 1,4-substitution pattern overlaying an α-helix. 
 
Several of these derivatives were also found to successfully inhibit the Rev-RRE interaction in the 
micromolar range in fluorescence polarisation anisotropy assays310 (e.g. compound 4.12 demonstrated 
an IC50 value of 27.0 μM). The in vivo experiments were similarly successful, with compound 4.12 
showing an EC50 value of just 10.4 μM. Again, these compounds generally showed very little cytotoxicity 
(Figure 4.29). Some representative examples from the two studies can be seen below, including Ter.0 
(the best performing terphenyl of the 1,3 relatively substituted series) and 4.12 (the best performing 
terphenyl of the 1,4 relatively substituted series). 
 
 
Figure 4.29. Selected examples of the most active terphenyl derivatives from past studies in the group. 
 
                                                          
310
 N. W. Luedtke and Y. Tor, Biopolymers, 2003, 70, 103-119. 
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In addition, an electrophoretic mobility shift assay was carried out in this study. The purpose of this test 
was to determine whether the compounds inhibited the formation of full length Rev-RRE 
ribonucleoprotein complexes; since the association of Rev to the RRE is not one-to-one (refer to Figure 
4.7), the binding of more Rev units to a single strand of free RRE can be observed via electrophoresis, a 
technique used to separate macromolecules based on their size (Figure 4.30).  
 
 
Figure 4.30. The structure of the most active terphenyl of the second series, 4.12, along with the electrophoretic 
mobility shift assay showing the inhibition of high-order Rev-RRE complex formation.
309 
 
The same NMR TOCSY studies were also carried out on 4.12, with somewhat similar results to those of 
the lead compound Ter.0 (Figure 4.31).  
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 These results proved that other terphenyl structures are also capable of mimicking the Rev34-50 α-helix, 
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4.6. Results and discussion. 
4.6.1. Monolateral p-terphenyls. 
 
According to our hypothesis, bilaterally-substituted terphenyls should better mimic a biological 
interaction given the 360° projection of the substituents. However, the terphenyl structures disclosed 
by Hamilton in his seminal report regarding terphenyls as peptidomimetics had just one substitution on 
each aromatic ring. Therefore, we decided to synthesise a small library of monolaterally-substituted 
terphenyls in order to prove that the bilateral substitution was key to the observed activity of the 
previously discussed terphenyls. Furthermore, if we were incorrect and the following monolateral 
derivatives proved just as effective as the aforementioned bilateral terphenyls, we reasoned that the 
synthesis would be much simpler, faster, and less expensive, given that less complex starting materials 
would be required for less complex target structures. 
Therefore, in collaboration with J. Gallego, we designed three monolaterally-substituted p-terphenyls in 
order to test this hypothesis (Figure 4.32). Ter.1 and Ter.2 are direct monolateral analogues of Ter.0, 
the lead compound from previous studies in our group, whereas Ter.3-5 are simplifications designed to 
explore the necessity of the oxygen-based substituents in positions 1 and 4’’. 
 
 
Figure 4.32. Target unilaterally-substituted terphenyl structures. 
 
The synthesis of these compounds would follow the example previously established in the group; the 
terphenyls would be constructed via a series of Suzuki-Miyaura coupling reactions between specially 
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designed synthons, identified by retrosynthetic analysis of the target compounds (Scheme 4.7). In turn, 
the necessary alkylamine chains would be accessed via reduction of the corresponding nitrile 
incorporated into each synthon before coupling. Ter.2 and Ter.4 would be obtained through the 
hydrogenolysis of the benzyl ethers present in Ter.1 and Ter.3 respectively. 
 
Scheme 4.7. Retrosynthetic analysis and identification of the necessary synthons. 
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4.6.1.1. Synthesis of monolateral terphenyl derivatives. 
 
Synthesis of monolateral synthons Syn.1-5. 
We first reasoned that the synthesis of these synthons would be more straightforward than those 
described previously in the group, given that these derivatives only presented one side chain rather 
than two. Therefore, we first thought that a radical bromination of 4.15 would provide quick and easy 
access to the bromomethyl intermediate 4.16 (Scheme 4.8). A simple SN2 reaction with a cyanide 
source and subsequent borylation would afford desired synthons Syn.1 and Syn.2 in just three steps. 
 
 
Scheme 4.8. Retrosynthetic analysis of Syn.1-2. 
 
However, benzylic bromination of 4.15a with NBS failed to produce 4.16a as we first planned; most 
likely due to the competing benzylic position on the benzyl ether, something we had initially 
overlooked. Unfortunately, this meant we had to resort to changing the protecting group—adding 
several extra steps to the sequence, since we specifically wanted the benzyl ether substituent to be 
present in Ter.1 and Ter.3, given the favourable activity demonstrated in previous studies in our group. 
We therefore attempted the reaction both with the methyl- and TBS-protected substrates 4.15c and 
4.15d, respectively. Only methyl-protected 4.15c gave rise to the desired product, but we were unable 
to remove the methyl substituent afterwards. The demethylation of methoxy groups is somewhat 
difficult and generally requires strongly acidic conditions. In this context, the treatment of both 4.16c 
and 4.17c—obtained via subsequent treatment of bromomethyl derivative 4.15c with sodium 
cyanide—with HBr and BBr3 proved unsuccessful (Scheme 4.9).  
 




Scheme 4.9. Attempted synthetic routes towards benzylated synthon Syn.1 and synthesis of 4.17b, the 
precursor of Syn.2. 
 
Following this, with regards of the synthesis of Syn.1 we resorted to a route analogous to that 
described previously in our group, starting from the corresponding aldehyde (Scheme 4.10). 
Commercial substrate 5-bromosalicylaldehyde 4.18 was benzylated with benzyl bromide and potassium 
triphosphate, and the resulting aldehyde was then reduced with sodium borohydride. Intermediate 
alcohol 4.19 was then converted into the desired benzyl bromide derivative 4.16a through the use of 
phosphorus tribromide, and subsequently treated with sodium cyanide in the presence of potassium 
iodide and 18-crown-6 to afford 4.17a in excellent overall yield (Scheme 4.10). It’s worth noting that all 
of these reactions were fairly clean and the crude mixture was used in each step; only 4.17a was 
isolated by column chromatography. 
 
 
Scheme 4.10. Final synthesis of key intermediate 4.17a on the route to Syn.1. 
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Once the final nitrile-bearing aryl bromides 4.17a and 4.17b were synthesised, both were subjected to 
Miyaura borylation in order to introduce the boronic ester groups in Syn.1 and Syn.2 respectively, 
required for the final Suzuki coupling. Syn.3 was also synthesised via Miyaura borylation of 
commercially available substrate 2-methyl-4-bromophenol 4.20 (Scheme 4.11). 
 
 
Scheme 4.11. Miyaura borylations to form the final synthons Syn.1-3. 
 
We then turned our attention to synthons Syn.4 and Syn.5. The synthesis of these compounds was 
relatively straightforward: Syn.4 was synthesised via an analogous route to that utilised for Syn.2, 
consisting of benzylic bromination and SN2 introduction of the nitrile; and Syn.5 was commercially 
available (Scheme 4.12). 
 
 
Scheme 4.12. Synthesis of Syn.4. 
 
Construction of terphenyl structures Ter.1-5. 
With the synthesis of all the necessary synthons complete, we turned our attention to constructing the 
terphenyl structures. This was carried out in a sequence already established in our research group, via 
sequential Suzuki couplings. Firstly, Syn.4 and Syn.5 were coupled with Syn.3 to give 1’-
hydroxybiphenyls 4.21. Subsequent formation of the corresponding triflates prepared these biphenyl 
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Scheme 4.13. Construction of the terphenyl scaffolds. 
 
Only moderate yields were observed in the cross-coupling reactions, though we suspect each coupling 
could be optimised to give a higher yield. However, these reactions were carried out using conditions 
previously used in the group without further optimisation, given that this project was based on 
achieving specific structures for preliminary in vitro and in vivo tests, which required only several 
milligrams each. 
From the terphenyl structures 4.23, the nitrile groups were reduced using borane in THF to give final 
terphenyls Ter.1, Ter.3 and Ter.5. A small amount of Ter.1 and Ter.3 was then subjected to 
hydrogenation conditions to remove the benzyl ether protecting group, affording Ter.2 and Ter.4 
respectively (Scheme 4.14). 
 




Scheme 4.14. Final steps towards Ter.1-5. Nitrile reduction affording the desired amine residues and 
hydrogenolysis of the benzyl ethers to form Ter.2 and Ter.4 respectively. 
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4.6.1.2. Biological evaluation of monolateral terphenyls Ter.1-5. 
 
With the aim of evaluating this small series of monolaterally-substituted p-terphenyls, analogous to 
those described by Hamilton, we carried out various biological assays both in vitro and in vivo. 
Throughout this project, the in vitro assays—more specifically, the fluorescence anisotropy assays, gel 
electrophoresis assays, and NMR experiments—were carried out by the group of José Gallego in the 
Universidad Católica de Valencia (UCV), whereas the in vivo studies were developed by the group of 
José Alcamí in the Instituto de Salud Carlos III (ISCIII) in Madrid.  
 
Fluorescence polarisation anisotropy studies 
The first studies of these compounds was always an in vitro technique, specifically fluorescence 
polarisation anisotropy.310 This experimental technique is based on the interaction between polarised 
light and a fluorophore-labelled analyte. When the fluorophore is excited with polarised light, the 
emission is also at least partially polarised; this is because the transition moments of absorption and 
emission lie among specific directions within the fluorophore structure.311 This depends both on the 
size of the molecule and the viscosity of the media; smaller molecules tumble faster than larger ones, 
and this occurs faster in less viscous media. Therefore, by exploiting this difference it’s possible to 
determine the degree of binding between a fluorophore-labelled ligand and its receptor using the 
variation of fluorescence anisotropy between the free ligand—which is considered to be free to rotate 
in solution, therefore negating any polarisation of emitted fluorescence—and the ligand-receptor 
complex (Figure 4.33). This type of assay has been used effectively in experiments to determine the 
inhibition constants of various aminoglycosides such as neomycin, which has a high affinity for the IIB 
loop in HIV-1 RRE.312 
To this end, we used a peptide chain with a structure analogous to Rev34-50 labelled with fluorescein 
isothiocyanate (FITC, the complex will from now on be referred to as RevpFITC). In this way it was 
possible to determine the dissociation constant of this ligand, as well as its displacement from the 
receptor upon the addition of an external inhibitor—in this case our terphenyl compounds.  
To validate any results observed with this method we also measured the Ki of neomycin, obtaining a 
value of 6.4 μM which is concordant with the relevant literature.313 
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Figure 4.33. Schematic representation of the fluorescence polarisation anisotropy assay. 
 
None of the monolaterally substituted terphenyls proved to have a high affinity for the RRE in this 
assay, although Ter.1 demonstrated an IC50 of 76.0 μM (Figure 4.34). Notably Ter.2, the monolaterally 
substituted analogue of Ter.0, also proved inactive here. We had expected results such as these; this 
meant that the bilateral substitution was in fact important for inhibiting the Rev-RRE interaction as we 
had first hypothesised. Since the union with Rev is deeply embedded in the RRE, we expected that 
mimicking all three faces of the α-helix would be important for the inhibitory activity, and these results 
show that this is the case.  
 
 
Figure 4.34. Fluorescence polarisation anisotropy inhibition data. 




Our terphenyl compounds were also tested against HIV-1 replication in vivo, in the group of J. Alcamí 
(Instituto de Salud Carlos III). For these assays, we employed MT-2 cells—a cell line containing the HIV-1 
genome. 
Interestingly, we found these compounds to be active in this assay—something we did not expect after 
the poor fluorescence polarisation anisotropy results. What’s more, they proved to be just as active as 
the previous lead compound, Ter.0. This indicated that these monolaterally substituted terphenyls 
were interacting with the cells in a different way, maintaining the anti-HIV activity. However, in contrast 
to Ter.0, the monolateral derivatives were also shown to be highly cytotoxic (Figure 4.35). 
A potential explanation for this could be non-specific binding to DNA rather than RNA; we observed that 
these monolaterally substituted terphenyls have a 3D structure fairly similar to the pyrrole-imidazole 
based polyamides developed by Dervan et al., which bind to the minor groove of DNA.314 
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In light of these unexpected results, we speculated that the in vivo activity could arise from binding to 
DNA. Specifically, the lower observed EC50, together with the higher cytotoxicity, could potentially be 
explained by binding to the long terminal repeat of the viral DNA genome, which acts as a promoter for 
viral RNA transcription. Therefore, we decided to evaluate the interaction between DNA and the 
monolaterally substituted terphenyl derivatives via 2D NMR TOCSY (Total Correlation Spectroscopy) 
experiments, carried out by J. Beltrán and J. Gallego.315  
To this end, we used an autocomplementary DNA sequence to explore if these terphenyls showed any 
affinity for DNA (Figure 4.36).  
 
 
Figure 4.36. Autocomplementary DNAd sequence used to evaluate terphenyl DNA affinity. 
 
We found that both Ter.2 and Ter.5 bound to DNA, and that Ter.2 induces a stronger perturbation in 
the DNA chemical shifts than Ter.5. This could be seen clearly in the TOCSY plot, with both terphenyls 
causing a displacement in the chemical shift of the C10 and C11 nucleotides (Figure 4.37, a and b). This 
was in contrast to Ter.0, that showed a weaker shift in just C10 (Figure 4.37, c).
308 
In conclusion, monolaterally-substituted terphenyls do not effectively bind to the IIB stem of the RRE, 
and therefore do not effectively mimic the Rev34-50 α-helix. Although they show activity in vivo, the 
mechanism of action is suspected to be somewhat different given the high toxicity and failure to 
produce a significant response in in vitro experiments, as well as showing a certain affinity for DNA. This 
is in stark contrast to the bilateral derivatives studied previously, which show a clear affinity for the RRE 
in vitro and are active in vivo without showing significant cytotoxicity. 
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Figure 4.37. TOCSY plots to determine DNA binding. 
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4.6.2. Bilateral p-terphenyls: effect of substituents in positions 1 and 4’’. 
 
In addition to exploring the possibility of going forward with simplified monolaterally-substituted 
terphenyls, we aimed to further explore the structure-activity relationship of the related bilateral 
derivatives, such as those previously described in our group. Taking the lead Ter.0 as a starting point, 
we first looked at the oxygen-based substituents in the 1 and 4’’ positions.  
During the in silico analysis of these compounds carried out in the group of J. Gallego (Universidad 
Católica de Valencia), no major interactions were identified between these groups and the biological 
target. Therefore, it should be possible to remove these groups and maintain the activity. Doing so 
would potentially simplify the synthesis of new terphenyl derivatives, allowing a much faster turnover 
for new compounds for biological testing. 
In this context, we first designed a series of terphenyls bearing different combinations of 1 and 4’’ 
substitutions, Ter.6-9, to gain an insight into the effects of such substitutions on the biological activity 
(Scheme 4.15). The synthesis of these terphenyls would again require the prior synthesis of several 
synthons, identified via retrosynthetic analysis of each terphenyl as seen previously, taking into account 
the same synthetic steps to construct the terphenyl scaffold: that is, a series of Suzuki couplings 
between specially designed synthons to construct the terphenyl structure; nitrile reduction to access 
the alkylamine chains; and possible removal of benzyl ether protecting groups by hydrogenolysis.  
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4.6.2.1. Synthesis of bilateral terphenyls Ter.6-9. 
 
Synthesis of synthons Syn.6-10. 
Fortunately, Syn.8 was commercially available, and was used as received from the commercial source.  
Both Syn.6 and Syn.10 had been synthesised previously in the group, during the synthesis of Ter.0.308 
Therefore, we followed the same synthetic route towards these synthons as previously described. In 
this context, Syn.6 was synthesised starting with the Duff formylation of 4-bromophenol (Scheme 4.16). 
The phenol group of dialdehyde intermediate 4.24 was then protected as a benzyl ether for the 
remainder of the synthesis, and the aldehyde groups were reduced with sodium borohydride. The 
resulting diol was then subject to a modified Appel reaction with triphenylphosphine and N-
bromosuccinimide to introduce the bromine atoms in 4.27, which were then replaced with nitrile 
groups through SN2 reaction with sodium cyanide. Finally, Miyaura borylation of the resulting dinitrile 
compound 4.28 completed the synthesis of Syn.6.  
 
 
Scheme 4.16. Synthesis of Syn.6. 
 
On the other hand, Syn.10 was synthesised starting with the methylation of commercially available 3,5-
dimethyl-4-bromophenol (Scheme 4.17). Following this, the two benzylic methyl groups were oxidised 
through reaction with potassium permanganate, and the resulting carboxylic acids in 4.30 were 
converted into the corresponding methyl esters via Fischer esterification with methanol and sulphuric 
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acid. A simple reduction of the ester groups in 4.31 and subsequent Appel reaction furnished the 
dibromo intermediate 4.33, which was then treated with sodium cyanide to afford the final Syn.10.  
 
 
Scheme 4.17. Synthesis of Syn.10. 
 
With regards to Syn.7, we chose 5-bromo-m-xylene as a starting point, with the idea of introducing the 
bromine atoms directly through benzylic bromination, as seen previously in the synthesis of Syn.2. 
However, when using the conditions used in the synthesis of Syn.2, the desired 3,5-bis 
(bromomethyl)bromobenzene 4.34 was not obtained. Instead, the major product was 4.35, resulting 
from dibromination of a single methyl substituent. The addition of fewer equivalents of NBS did not 
significantly improve the results, nor did the use of lower temperatures or concentrations. Eventually, a 
literature search revealed that by using a different activator for the reaction, AIBN, and adding the NBS 
portion-wise over three days, we would be able to achieve the desired compound in a moderate yield 
of 68% (Scheme 4.18).316  
From there, the remaining steps (nucleophilic substitution of bromine atoms with sodium cyanide and 
borylation) took place uneventfully and in moderate to high yields. 
 
                                                          
316
 O. H. Omar, F. Babudri, G. M. Farinola, F. Naso and A. Operamolla, Eur. J. Org. Chem., 2011, 529-537. 




Scheme 4.18. Benzylic bromination of 5-bromo-m-xylene and synthesis of Syn.7. 
 
We then focused on obtaining Syn.9, and identified commercially available 2,6-
bis(bromomethyl)bromobenzene as an ideal starting point; the desired synthon would be accessible in 
just one step. Therefore, we submitted this starting material to our standard SN2 conditions with 
sodium cyanide in the presence of potassium iodide and 18-crown-6, and obtained Syn.9 in excellent 
yield (Scheme 4.19). 
 
 
Scheme 4.19. Synthesis of Syn.9 in just one step from commercial 2,6-bis(bromomethyl)bromobenzene. 
 
The real differences in the synthesis of these terphenyls derivatives lie in the synthesis of the required 
synthons. In this case, when comparing Ter.9 (which requires the synthesis of Syn.7 and Syn.9) to the 
original lead compound Ter.0 (which requires the synthesis of Syn.6 and Syn.10), there are 8 steps 
difference in the synthesis of the synthons, which translates to over a week’s work in the laboratory 
(Scheme 4.20). This means that the synthesis of new derivatives lacking the extra groups in positions 1 
and 4’’ could be much faster, allowing for much faster testing and turnover in the search for improved 
activity. Also, fewer steps meant that we were able to stockpile each intermediate to a certain degree 
in order to repeat the synthesis of certain terphenyls for further biological assays. 
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Furthermore, the shorter synthetic route for the synthons means much fewer reagents wasted, as well 
as saving the waste of over 10 chromatographic columns: all of this meaning that the shorter synthetic 
route works out much cheaper and more efficient in the long run. Of course, this would ultimately all 
depend on the biological results of these terphenyl derivatives—if they had no effect on the RRE-Rev 
interaction, we would have no option but to include the substituents in the 1 and 4’’ positions, despite 
the longer synthesis. 
 
 
Scheme 4.20. Comparison of total yields and time required for synthetic routes with and without substituents 
in positions 1 and 4’’. 
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Construction of terphenyl structures Ter.6-9 
Once again, after the synthesis of the necessary synthons, we addressed the synthesis of the terphenyl 
structures, via the same method previously discussed; Suzuki coupling to obtain the hydroxybiphenyl, 
followed by the formation of the corresponding triflate and a second Suzuki coupling to obtain the final 
terphenyl scaffold. The nitrile groups were then reduced with borane in THF and the benzyl ether 
protecting group removed where necessary (Scheme 4.21). 
 
 
Scheme 4.21. Final steps towards the synthesis of Ter.6-9; Suzuki couplings and reduction of the nitrile groups. 
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4.6.2.2. Biological evaluation of bilateral terphenyls Ter.6-9. 
 
With regards to the biological evaluation of this terphenyl series, we carried out both in vitro and in vivo 
experiments, analogous to the experiments described previously for the evaluation of the 
corresponding monolateral derivatives (refer to section 4.6.1.2. Biological evaluation of monolateral 
terphenyls Ter.1-5).  
In this case, comparing the biological results for Ter.6-9 to the previously studied Ter.0, we can deduce 
that neither the hydroxy nor methoxy groups have a significant effect on the interaction of the 
terphenyl compounds with the IIB stem of the RRE. Although Ter.0 remains the most active, Ter.9 
shows only slightly less affinity for the IIB stem in the fluorescence polarisation anisotropy experiments 
(Figure 4.38). Several interesting details arose from this series. 
 
 In terms of the in vitro assays, the order of inhibition capacity of the RRE IIB-Rev34-50 complex 
formation was Ter.0 ≈ Ter.9 > Ter.8 ≈ Ter.7. This indicated that the best interaction with the 
RRE was achieved with either both groups or neither, whereas the presence of just one group 
hindered this interaction. 
 Ter.6 resulted more active in all assays than Ter.7, whereas this trend was reversed in the 
original Ter.0. The improved in vivo activity of Ter.6 compared to Ter.7 could be related to the 
improved lipophilicity of the benzyl ether compared to the free phenol, although presumably 
the significant difference of the IC50 values is also important. 
 
This had major implications in the design and synthesis of new terphenyl derivatives, as it allowed us to 
remove the two substituents in the 1 and 4’’ positions, thereby significantly shortening the synthetic 
route towards new compounds (refer to Scheme 4.20). Therefore, from this point on, new terphenyl 
derivatives did not generally contain these two groups. 
 




Figure 4.38. Biological results obtained for Ter.6-9. 
 
Given the favourable results obtained for the benzyl ether Ter.6 compared to the corresponding free 
phenol, which we reasoned could be due to the increased lipophilia, we also tested the 
pharmacokinetics of this compound in mice. These studies were performed in GVK Bio, a Contract and 
Research Development Organisation based in Hyderabad (India). This was carried out using cassette 
dosing—meaning that all four compounds were injected simultaneously—and initially the mice 
perished at a dose of 1 mg/kg. The dose was therefore lowered to 0.5 mg/kg, and in this way the study 
could be concluded with the mice in a healthy state. 
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In this context, Ter.6 was tested alongside several other analogues from the series with relative 1,4 
substitution, specifically 4.14 and 4.12. A further compound, 114g5, was used as a reference in this 
assay. This compound belongs to the MyriaScreen Diversity Library, a commercially available collection 
of compounds specifically designed for high-throughput screening and which follow Lipinski’s rule of 5, 
therefore featuring desirable pharmacokinetic characteristics. 
The three terphenyl compounds gave favourable results in this assay: 1) elevated values observed for 
the AUC0-∞ (the area under curve, a parameter used in pharmacokinetic studies to represent the total 
drug exposure extrapolated to time = infinity, with the extrapolated amount shown by the AUCExtra); 2) 
long half times t1/2; and 3) a much lower clearance CLobs compared to reference 114g5, presumably due 
to higher bioavailability and higher metabolic stability (Table 4.1).  
 







0.63 0.50 0.50 0.50 
C0 
(ng/ml) 
1553.35 878.20 871.04 101.34 
t1/2 (h) 9.94 2.69 11.96 0.66 
AUC0-inf 
(ng·h/ml) 
1636.24 573.88 681.92 65.98 
AUCExtra 
(%) 
34.97 12.86 18.31 2.28 
Vobs 
(ml/kg) 
5.50 3.38 12.65 7.18 
CLobs 
(ml/h/kg) 
6.39 14.52 12.22 126.30 
MRT0-last (h) 9.42 1.84 4.37 0.72 
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4.6.3. Bilateral p-terphenyls: effects of varying inter-amine distance. 
 
Another possibility in the search for a better terphenyl-RRE interaction was the elongation of the 
alkylamine chains in positions 2 and 6, since the docking studies had shown that a terphenyl with a 
greater inter-amine distance in these positions could fit the target better. More specifically, in silico 
studies revealed that a longer chain could improve the contacts between the ligand and the opposite 
strands in the RNA binding site. This was also the premise of the study into terphenyls with the 
alkylamine chains in a relative 1,4 substitution pattern (with substitutions in 2, 5, 2’, 5’, 2’’, and 5’’), 
covered in a previous section.206, 309 Although no significant advantages were observed in that work, 
these tests were carried out simultaneously. Furthermore, this would render the compounds slightly 
less symmetrical; the target could therefore better differentiate the alkylamine chains in 2 and 6, and 
those in 2’’ and 6’’. 
In this sense, several of the new terphenyl structures in this section therefore present an extra CH2 in 
the alkylamine chains on aromatic ring A. In this small series, the biphenyls containing rings B and C 
were the same as previously described during the synthesis of terphenyls Ter.6, Ter.7 and Ter.9, and so 
the only new synthons that were required were generally those corresponding to upper phenyl ring A 
(Scheme 4.22). 
Similarly, we decided to vary the substitution pattern of the terphenyl structures as a way of modifying 
the number of amino groups and the distance between them. Therefore, some structures in this section 
contain just one alkylamine chain in the meta position of phenyl C, after the observation that related 
triaminoterphenyls in the 1,4 series gave favourable results in both in vitro and in vivo assays (refer to 
Figure 4.29, section 4.5. Background.).309 This could also be linked to the diminished positive charge on 
such compounds, since they only contain three amine groups rather than four; previously we had 
observed that in some in vivo assays, the benzyl protected terphenyls gave higher activities than their 
corresponding phenols, potentially due to the higher lipophilicity. A similar effect could be observed 
when dealing with less amine groups, despite the poor interaction observed with the monolaterally-
substituted terphenyls in Section 4.6.1.2.  
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4.6.3.1. Synthesis of bilateral terphenyls Ter.10-14. 
 
Synthesis of synthons Syn.11-13. 
Synthons Syn.5 and Syn.7-9 had all been used previously; therefore, we focused our attention on the 
synthesis of the remaining synthons corresponding to phenyl ring A of the terphenyls in this series, in 
order to elongate the two alkylamine chains present. Syn.13, which now represents a synthon towards 
Ter.14, was used as intermediate 4.17b during the synthesis of Ter.5 (refer to Scheme 4.9). 
Taking advantage of the previously synthesised dialdehyde 4.25, we prepared Syn.11 starting with a 
Wittig reaction using commercially available stabilised phosphine ylide to afford intermediate 4.40, 
which was then reduced with sodium borohydride to form 4.41 with the desired saturated 
propanenitrile chains in positions 2 and 6 (Scheme 4.23). The Wittig reaction to form 4.40 was very 
clean and no purification was necessary before the subsequent reduction reaction, just a simple 
aqueous work up and change of solvent. 
 
 
Scheme 4.23. Synthesis of dipropanenitrile derivative 4.41 towards the synthesis of Syn.11. 
 
On the other hand, we found that 5-bromoisophthalaldehyde 4.43 was relatively expensive to use as a 
starting material, so we opted instead for the much cheaper dicarboxylic acid 4.42 as a starting point in 
the synthesis of Syn.12. To achieve the dialdehyde from the dicarboxylic acid, we identified three 
potential pathways: 1) formation of the corresponding Weinreb amide and subsequent reduction to the 
dialdehyde; 2) direct reduction to the corresponding diol and oxidation to dialdehyde 4.43; or 3) 
formation of the diester, reduction and subsequent oxidation to the dialdehyde (Scheme 4.24).  
The formation of the Weinreb amide before reduction gave rise to complex mixtures, and failed to give 
significant yields of the desired product.  The other two routes, however, resulted in the dialdehyde in 
similar yields. Several conditions were tested for the oxidation step, such as Jones’ reagent and 
manganese dioxide, but the best yield was obtained using pyridinium chlorochromate (PCC). 
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Dialdehyde 4.43 was then subjected to the same synthetic sequence as 4.25—Wittig reaction and 
subsequent reduction with NaBH4—to afford dinitrile compound 4.44. 
 
 
Scheme 4.24. Synthetic route towards dialdehyde 4.43 and subsequent Wittig reaction to form 4.44. 
 
From there, dinitrile compounds 4.41 and 4.44 were subject to the previously established borylation 
conditions, although this was unsuccessful. This was attributed to the longer alkanenitrile chain being 
able to position itself in such a way as to coordinate with either the palladium or the boronate species. 
After several attempts at changing the reaction conditions, such as the temperature or the reaction 
time, we found that the addition of 1% DMSO to the reaction mixture and conventional heating steered 
the reaction to the desired synthons Syn.11 and Syn.12 (Scheme 4.25).317 
  
                                                          
317
 S. C. Goodacre, L. J. Street, D. J. Hallett, J. M. Crawforth, S. Kelly, A. P. Owens, W. P. Blackaby, R. T. Lewis, J. 
Stanley, A. J. Smith, P. Ferris, B. Sohal, S. M. Cook, A. Pike, N. Brown, K. A. Wafford, G. Marshall, J. L. Castro and J. 
R. Atack, J. Med. Chem., 2006, 49, 35-38. 




Scheme 4.25. Synthesis of Syn.11 and Syn.12 via borylation of dinitrile aryl bromides 4.41 and 4.44 respectively. 
 
Construction of terphenyl structures Ter.10-12 
The terphenyl structures were then constructed via the same Suzuki cross-coupling sequence. Since 
Ter.10-12 share phenyl rings B and C with previously synthesised terphenyls Ter.6, Ter.7 and Ter.9, the 
beginning of the synthetic sequences coincide until biphenyl triflate 4.38a, though terphenyls Ter.13 
and Ter.14 required newly synthesised triflates in order to construct the final terphenyl structure 
(Scheme 4.26).  
 
 
Scheme 4.26. Preparation of new triflates in the synthetic route towards terphenyls Ter.13 and Ter.14. 
 
From there, the path towards the construction of the majority of the terphenyl structures was 
equivalent to that already seen. Once the terphenyl structures had been prepared (Scheme 4.27), the 
nitrile groups were reduced to the corresponding primary amines to afford the final terphenyl targets, 
and the benzyl ether protecting group removed via hydrogenolysis in the case of Ter.11 (Scheme 4.28). 
 




Scheme 4.27. Construction of terphenyl structures 4.47, precursors of Ter.10-14 respectively. 
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4.6.3.2. Biological evaluation of bilateral terphenyls Ter.10-14. 
 
With regards to the biological evaluation of this terphenyl series, we again carried out both in vitro and 
in vivo experiments, analogous to those experiments described previously for the evaluation of the 
corresponding monolateral derivatives (refer to section 4.6.1.2. Biological evaluation of monolateral 
terphenyls Ter.1-5).  
In this series, we found that the elongation of the alkylamine chains of phenyl ring A did not drastically 
affect the biological activity of this class of compounds, as we had envisioned from the in silico analysis 
previously discussed. However, with regard to the differences between benzyl ethers and free phenols, 
the results here mirrored the results of the original report in which Ter.0 was studied (Figure 4.39). 
 
 
Figure 4.39. Biological results obtained for Ter.10-12, with past results for comparison. 
 
Secondly, the differences in the varied substitution patterns seen in this series were striking. Ter.13, 
bearing a single ethylamine chain in the 2’’ position, was inactive (much like 4.48, see Figure 4.40).309 
When the single ethylamine chain was shifted to the 3’’ position in Ter.14, however, the biological 
activity was dramatically enhanced, demonstrating a moderate IC50 and a potent EC50. These results 
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followed the same trend seen in other terphenyls that had been previously synthesised in our research 
group, within the study into the terphenyls with the relative 1,4 substitution pattern (Figure 4.40).206, 309 
More importantly, Ter.14 was found to be more cytotoxic than other active bilateral derivatives. This 
reinforces previous observations that the bilateral substitution pattern is important for the safety of 
these compounds; since the monolaterally substituted compounds containing two alkylamine chains 
displayed higher affinity for DNA than the target RNA and exerted their antiviral and cytotoxic activities 
via this mechanism, perhaps these mixed derivatives containing three alkylamine chains have a certain 
affinity for both.  
 
 
Figure 4.40. Biological results obtained for the Ter.13 and Ter.14. 
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We also tested the role of the counteranion in several of these compounds, since we assumed we 
would be able to better control the stoichiometry of the salt formation; using HCl an excess was always 
added, under the assumption that the remaining HCl would be removed from the mixture in vacuo, 
leaving the hydrochloride salt in perfect balance with the number of amine groups present. However, 
the hydrochloride salt was invisible to both NMR analysis and mass spectrometry, and so we had no 
way to test this. We therefore formed the mesylate and tosylate salts of Ter.9, Ter.13 and Ter.14 since 
these salts could be observed easily through 1H NMR analysis, and are used widely in other 
pharmaceutical formulations.318 
However, this was discontinued given that no significant difference was observed in any of the assays 
observed for these derivatives.  
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4.6.4. Bilateral p-terphenyls: effects of varying functional group. 
 
In light of the unpromising results obtained in the biological assays for the previous terphenyls, we 




Scheme 4.29. New terphenyls to study the introduction of new functional groups, and the synthons required for 
their synthesis. 
 
In this context, we first envisioned a fluorinated analogue of Ter.6-7, in an attempt to increase the 
lipophilicity. However, we decided that a direct exchange of the methyl groups in ring B for 
trifluoromethyl groups would be synthetically challenging, and the identification of commercial 
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compound 4.49 led us to modify this target to Ter.15-16, with simple fluorine substituents in positions 
2’ and 6’ (Scheme 4.30). 
 
 
Scheme 4.30. Identification of 4.49 as the precursor for Syn.14 towards fluorinated derivatives Ter.15-16. 
 
Ter.17-19 were steps towards the real challenge in this project; mimicking the active α-helix of the HIV-
1 Rev protein using the 360° projection of substituents attached to a terphenyl scaffold. Hence, given 
the arginine-rich structure of the endogenous Rev protein, we wanted to test some guanidine-
containing terphenyls. We knew that the alkylamine chains were capable of mimicking the interaction 
somewhat, but using the same guanidine functional group as the native Rev protein could potentially 
forge more interactions with the target RRE, thereby increasing the inhibitory activity. Ter.20 would 
contain ureas, similar functional groups with the possibility of forming more interactions with the 
biological target than the simple amines that we had been working with thus far. Ter.21 was a 
somewhat capricious option due to the common use of the aminoalcohol moiety in RNA-binding 
compounds.  
In terms of their synthesis, both Ter.19 and Ter.21 would require a new synthon in order to selectively 
functionalise the amine chains in positions 2 and 6. Therefore, we decided that we would be able to 
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4.6.4.1. Synthesis of bilateral terphenyls Ter.15-21. 
 
Synthesis of terphenyls Ter.15-16. 
In theory, the only new synthon necessary for this terphenyl was Syn.14, which was synthesised via 
Miyaura borylation using the same conditions as had been used throughout this project (Scheme 4.31). 
 
 
Scheme 4.31. Synthesis of Syn.14 from commercially available 4.49. 
 
From there, the terphenyl was constructed as seen in the rest of the cases (Scheme 4.32). However, the 
final reduction of the nitrile groups was unsuccessful. The resulting crude product was difficult to purify 
and all identified fractions lacked fluorine; most likely due to the increased ability of aromatic fluoride 
substituents to undergo nucleophilic substitution, thereby being replaced by hydrogen during the 
prolonged treatment with borane.  
 




Scheme 4.32. So close yet so far. 
 
Therefore, we resorted to an alternative route relying on the prior reduction of the nitrile groups, thus 
proceeding with protected amines. We identified different synthons for this cause, making use of the N-
Boc protecting group due to its facile introduction (Scheme 4.33). We also removed the benzyl ether 
group in the 1 position for simplicity, since we had to synthesise the synthons from scratch, hence 
designing a new terphenyl which lacked this substituent, Ter.22. 
 
 
Scheme 4.33. Use of previously reduced synthons avoiding the exposure of aromatic fluorides to borane 
reduction towards a new target, Ter.22. 
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These synthons were synthesised easily from the corresponding nitriles 4.36 and Syn.9 via borane 
reduction and subsequent Boc-protection and, in the case of Syn.15, a final borylation reaction. The 
conditions used here were somewhat different for this synthon, since a short bibliographic search 
revealed that substrates bearing similar aminoethyl chains reacted well under microwave irradiation in 
acetonitrile at high temperatures. This methodology resulted in high yields after just 15 minutes of 




Scheme 4.34. Synthesis of synthons Syn.15-16. 
 
Upon the successful synthesis of these new synthons, the route towards fluorinated terphenyl Ter.22 
was attempted once again, with the Suzuki couplings taking place in decent yields just as with the nitrile 
derivatives (Scheme 4.35). 
This time, the deprotection of the Boc protecting groups proved problematic, most likely due to the 
purification of the product. We first utilised a standard deprotection procedure, an excess of 
trifluoroacetic acid (TFA) in dichloromethane, but we were unable to isolate the desired Ter.22. In 
terms of the reaction mechanism, after deprotection of the Boc groups, more trifluoroacetic acid would 
remain in the reaction media. Given that the resulting product contains four primary amines, the final 
result would be the trifluoroacetate salt. Therefore in the typical reaction work-up involving liquid-
liquid extraction, the desired product would presumably remain in the aqueous phase. Even after 
basification of the aqueous phase, we were unable to detect the product in the organic phase; the final 
terphenyl structures are generally water-soluble. Hence, we were unable to separate the desired 
product from trifluoroacetate salts, and therefore were unable to acceptably purify the final terphenyl. 
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Scheme 4.35. Synthesis of second Ter.22 precursor 4.56, and failed attempt at N-Boc deprotection. 
 
Synthesis of terphenyls Ter.17-19. 
Turning to the more promising guanidine-bearing terphenyls Ter.17-19, we identified Goodman’s 
reagent as a suitable choice for the introduction of the guanidine groups, which can be used to 
guanidinylate both primary and secondary amines in high yields under mild conditions (Scheme 4.36).320 
The original report even details the use of this reagent to introduce multiple guanidine groups into 
polypeptide-based amine substrates, showcasing the efficiency of this procedure. 
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Scheme 4.36. Goodman’s guanidinylation reagent. 
 
Firstly, the terphenyl scaffold for Ter.19 was synthesised, starting from biphenyl triflate 4.38a. 
Subsequent Boc deprotection rendered the free amines which would then be suitable substrates for 
the guanidinylation reaction (Scheme 4.37). It’s worth noting that in this case, with just two amines and 
two nitriles, the deprotection reaction proceeded smoothly in the mixture of trifluoroacetic acid/DCM, 
as well as the isolation. 
 
 
Scheme 4.37. Synthesis  of terphenyl 4.58, precursor to the guanidinylation reaction towards Ter.19. 
 
On the other hand, Ter.17 and Ter.18 were synthesised starting from Ter.9 and Ter.12 respectively. We 
first attempted to introduce the guanidine group following Goodman’s reaction conditions, which 
involved adding the amine to a solution of the guanidinylation reagent and triethylamine in 
dichloromethane. This was successful in the case of 4.58, however, for the other tetramine substrates 
the reaction failed to take place. This was most likely due to solubility issues; neither Ter.9 nor Ter.12 
was soluble in dichloromethane. Similarly disappointing results were obtained when using a mixture of 
THF:DCM, although we found that adding a minimum of methanol to the reaction mixture—just 
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enough to dissolve all the reactants—gave much better results. In this way, guanidine-bearing 
terphenyls 4.59a-c were obtained (Scheme 4.38). 
 
 
Scheme 4.38. Synthesis of guanidine-bearing terphenyls. 
 
Once these terphenyls had been obtained, we proceeded to carry out the final steps. In the case of 
Ter.17 and Ter.18, the only remaining step was the deprotection of the guanidines, whereas Ter.19 
required both a reduction of the nitrile groups and subsequent deprotection. Deprotection of the four 
guanidine groups in 4.59b using TFA/DCM gave results similar to those in the previous section in the 
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attempt to synthesise fluorinated Ter.22—we were unable to purify Ter.18 in this way. However, we 
found that treatment with a 1:1 mixture of HCl (4N in dioxane) and HCl (4N in water) successfully 
removed the Boc protecting groups when heated at 40 °C for 20h. Furthermore, these conditions 
required neither extraction nor further purification: all Boc groups were successfully removed, and 
simple concentration of the reaction mixture afforded Ter.18·4HCl in good yield (Boc removal leaves no 




Scheme 4.39. Boc deprotection to afford Ter.17 and Ter.18. 
 
Finally, the synthesis of Ter.19 proved to be more troublesome than we had first expected, due to a 
problem we had initially overlooked. The borane reduction of the nitrile groups requires subsequent 
hydrolysis of the boron adducts that form during the reduction process, which we had usually carried 
out with aqueous hydrochloric acid. However, the Boc group is unstable in acidic conditions, and even 
using equimolar amounts of HCl and BH3, the reaction was unsuccessful. The borane reduction of 
nitriles throughout this project had never been a “clean” reaction, and had always required purification 
by flash column chromatography afterwards. This also meant that we couldn’t carry out the 
transformations in a one-pot manner, using HCl both to quench the borane in the reduction step and 
simultaneously carry out the Boc removal, since we would be unable to purify the resulting mixture. 
Due to this, Ter.19 was also abandoned and the synthesis was not finalised. 
 
Synthesis of terphenyl Ter.20 
The synthesis of this urea-bearing terphenyl also used Ter.9 as a starting point. Here, we envisioned 
using benzyl isocyanate to introduce the urea. This had the advantage of containing more hydrophobic 
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phenyl rings in an attempt to increase the solubility of the resulting tetraurea; ureas tend to be fairly 
insoluble in many organic solvents. Furthermore, this way we would be able to purify the benzylated 
intermediate before subjecting it to hydrogenolysis of the benzyl groups.  
We therefore treated Ter.9 with benzyl isocyanate in dichloromethane, and despite expected solubility 
issues we obtained the corresponding product in good yield and high purity (Scheme 4.40). However, 
4.60 proved to be insoluble in almost every solvent tested, including water, although it was partly 
soluble in DMSO (just enough to obtain an acceptable 1H NMR spectrum). These solubility problems 
hindered any advances and the subsequent hydrogenation reaction failed to proceed in all solvents 
tested. We therefore also abandoned the synthesis of this terphenyl derivative. 
 
 
Scheme 4.40. Attempted synthesis of Ter.20. 
 
Synthesis of terphenyl Ter.21. 
The synthesis of this terphenyl was similar to that of Ter.19, in that ring A contained functionalised 
amines whereas ring C did not; an orthogonal protection strategy was also necessary in this case. In 
order to add the hydroxyethyl group onto the aminoethyl chains in positions 2 and 6, we identified 2-
iodoethanol as a suitable substrate. We first tested the reaction with benzylamine, and obtained the 
desired product in almost quantitative yield (Scheme 4.41). What’s more, liberation of the acid HI 
during the reaction meant that product 4.61 precipitated as the corresponding HI salt. 
 
 
Scheme 4.41. Initial tests towards the introduction of the hydroxyethyl group. 
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With this in mind, terphenyl intermediate 4.58 was treated with 2-iodoethanol in acetonitrile as the 
solvent, giving rise to the corresponding product 4.62 in moderate yield. From there, we reduced the 
nitrile groups using borane-THF complex as we had done throughout this project—although we 
employed a greater excess of borane in this reaction due to the presence of the aminoalcohol 
substituents on ring A (Scheme 4.42).  
 
 
Scheme 4.42. Synthesis of Ter.21. 
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4.6.4.2. Biological evaluation. 
 
Unfortunately, we only have preliminary results for in vitro studies relating to Ter.17 and Ter.18. 
However, the results are promising. Ter.17 and Ter.18 are active in both the fluorescence anisotropy 
and electrophoresis assays, approximately at the same level as 4.12 (Figure 4.41). However, these 
experiments need to be replicated and the results confirmed. At the time of writing we do not have in 
vivo values (EC50 and CC50) for these derivatives. 
On the other hand, Ter.21 was inactive at the maximum concentration employed in all assays (100 μM). 
 
 
Figure 4.41. Biological results obtained for derivatives containing different functional groups. 
  






Malaria is the most widespread parasitic infection that affects humans. According to the WHO, in 2016 
a total of 216 million new cases of malaria and 445,000 deaths were reported by 91 countries 
worldwide.321 However, others argue that since the WHO relies on countries to report these infections, 
and since up to 90% of global infections are in Africa and other such underdeveloped areas, the real 
figures could be up to double this amount, with most estimates placing annual deaths around the 1 
million mark.322 A large percentage of malaria-related deaths correspond to Sub-Saharan African 
children under the age of 15. Although there are antimalarial treatments available, parasitic resistance 
and the high cost of dealing with the sheer number of infections in poor communities means that there 
is an urgent need for the development of cheaper medicines that are less susceptible to resistance 
phenomena. 
Malaria is caused by protozoan parasites belonging to the Plasmodium genus. Four species of parasite 
account for nearly all global infections: P. falciparum, P.vivax, P. malariae and P. ovale. Of these, P. 
falciparum produces the most severe disease and is the cause of the majority of malaria-related deaths. 
The areas that suffer most from malaria correlate fairly well with those that also have the highest rates 
of HIV infection, and the two are thought to interact in several ways: 1) malaria could increase HIV viral 
load in infected people; 2) the compromised immune system of HIV patients worsens the fevers 
associated to malaria; and 3) the HIV virus interacts adversely with malaria during pregnancy.323 
The parasitic life cycle begins with a bite from the vector—usually female mosquitoes from the 
Anopheles genus—during which sporozoites are injected into the host (Figure 4.42). Sporozoites are 
motile and once inside the body they migrate to the liver, where they infect liver hepatocytes and 
produce merozoites. These cells then burst free from the liver cells and infect red blood cells; this is the 
most severe stage of the infection, and can result in anaemia, fevers and vomiting. The cells continue to 
develop in the red blood cells and eventually produce gametocytes, the sexual stage of the parasite. 
The life cycle is complete when another vector bites the patient and consumes the gametocytes in the 
red blood cells.324  
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325
 M. K. Jones and M. F. Good, Nat. Med., 2006, 12, 170-171. 
Chapter 4  D. M. Sedgwick, Tesis Doctoral 
314 
 
4.7.2. Specific target and mimic design. 
 
A key part of this cycle is the infection of red blood cells by the merozoite life-stage, during which the 
parasite attaches itself to the red blood cell surface via the apical complex—a defining feature of 
apicomplexan parasites that mediates host penetration and invasion.326 Once attached, it passes 
through the erythrocyte (red blood cell) membrane and occupies a parasitophorous vacuole in which it 
replicates, effectively “hidden” from the host’s immune system. Invasion takes just 30-60 seconds and 
is driven by a multi-protein motor complex located between the inner-membrane complex and the 
merozoite cell membrane (Figure 4.43).327  
 
 
Figure 4.43. Plasmodium spp. motor complex structure. 
 
This motor complex is highly conserved throughout the Plasmodium genus, both in sporozoites and 
merozoites, and features a myosin A (MyoA) protein that is anchored to the inner membrane via 
binding of an α-helical tail domain to the membrane-bound myosin-tail domain interacting protein 
(MTIP). This interaction is key in coupling MyoA ATP hydrolysis to the production of motive force, which 
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is necessary for invasion of host red blood cells. This interaction currently remains an unexploited 
target in current antimalarial drugs, but represents an important possibility given the highly conserved 
nature of the structures of both MyoA and MTIP across similar parasitic species, which means that the 
inhibition of this interaction should be less susceptible to resistance phenomena.328 Furthermore, 
antimalarial treatment based on the inhibition of this interaction would avoid all invasion processes, 
essentially preventing the disease rather than curing it. 
Interestingly, the X-ray crystal structure of the MTIP-MyoA complex, available in the protein database 
(PDB), reveals that the α-helix of MyoA is deeply embedded in the MTIP protein, making it a suitable 
target to be mimicked by a bilaterally substituted terphenyl.329 Using database searches,330 the group of 
J. Gallego identified this protein-protein contact as a suitable target and was able to model some initial 
terphenyl designs, mimicking residues i, i + 1, i + 4, i + 5, i + 7, and i + 8 just like in the previously 
discussed bilaterally substituted terphenyls used in studies to inhibit the Rev-RRE interaction (Figure 
4.44, a). Most importantly, several of the MyoA α-helix residues amenable to be mimicked by the 
terphenyl side chains, specifically R806 (i + 1), R812 (i + 7) and K813 (i + 8), had been identified as 
hotspots for this interaction,330 and a good overlap was detected by molecular modelling between the 
butylamine side chains of terphenyl compounds designed to inhibit the MTIP-MyoA interaction and the 
charged hotspots of the protein. In terms of the new target, the residues within the MyoA α-helix to be 
mimicked would be the following: M805(i)R(i + 1)VQA(i + 4)H(i + 5)IR(i + 7)K813(i + 8) (Figure 4.44, b).  
 
 
Figure 4.44. a) Structures of initial terphenyl designs. b) MyoA α-helix tail structure and the residues to mimic.  
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The presence of positively-charged residues, i.e. Arg-812 and Lys-813, was important to our decision; 
given our previous experience working with Rev mimetics, we knew that alkylamine chains were 
capable of mimicking arginine residues resulting in active terphenyl compounds. Ter.23 would contain 
an n-butyl chain in the 6’’ position in an attempt to more efficiently mimic the methionine residue in 
the native helix. However, since we had less experience in the synthesis of asymmetrical terphenyls of 
this type containing aliphatic hydrocarbon chains, Ter.24 was also explored—which contained a fourth 
butylamine chain in place of the n-butyl in the 6’’ position (Figure 4.44). This terphenyl was found to 
have a strong overlap with the residues of the native MyoA within the MTIP binding site during in silico 
analysis (Figure 4.45). 
 
 
Figure 4.45. Overlap of Ter.24 (magenta) with MyoA (green side chains) within the MTIP (white) binding site. 
 
Nevertheless, despite the synthetic challenge that it would likely present, we decided that Ter.23 would 
be a better option. This study was based on protein-protein interactions, rather than protein-RNA 
interactions involved in the binding of Rev to the RRE region, and so we reasoned that excessive 
positive charge would be less beneficial in this case. Therefore Ter.23, which contains only positive 
charges in the same locations as the native MyoA protein should, in theory, provide a better imitation 
of the endogenous protein. Furthermore, methionine residue M805 is more similar to the n-butyl chain 
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4.7.3. Retrosynthetic analysis of Ter.23. 
 
This structure, in contrast with the previously seen examples, was somewhat less symmetrical and only 
contained three alkylamine substituents, the fourth being replaced by a simple alkyl chain (Figure 4.46).  
 
 
Figure 4.46. Structure and retrosynthesis of Ter.23.   
 
When designing the synthetic route to Ter.23, we came across some problems. With regards to Syn.17, 
we imagined that perhaps the simplest way to carry this reaction out would be the synthesis of 3,5-
diallylbromobenzene—which was described in the literature331—followed by a double cross metathesis 
with acrylonitrile and subsequent hydrogenation to obtain the aryl bromide precursor. However, this 
reaction was unsuccessful, and we decided that we could substitute the butylamine side chains on 
phenyl ring A with propylamine chains instead, given that we had seen previously that both ethyl- and 
propylamine chains were able to mimic arginine residues. This would simplify the synthesis greatly, 
since we could use previously synthesised Syn.12 to access the required ring A. We would therefore 
focus on a terphenyl with a slightly different structure (vide infra). 
Syn.18 would also be somewhat of a challenge due to the unsymmetrical substitutions on either side of 
the central terphenyl axis. Therefore, we decided that a Wittig reaction would be the easiest method to 
introduce the butyl substituent, starting from the corresponding aldehyde, which in turn could be 
installed using the Duff formylation used previously in the synthesis of 4.24 (Scheme 4.43). 
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Scheme 4.43. Retrosynthesis of Syn.18. 
 
With regards to Syn.19, we originally envisioned a cross-metathesis reaction between propene and 2-
allylphenol—a cheap and commercially available reagent—to construct the butyl chain. However, we 
reasoned that as an initial structure to test the hypothesis, we could use a shorter propyl chain and 
save the cross-metathesis step (as well as possible protection/deprotection) (Scheme 4.44, a). 
Therefore, we set out to synthesise an analogous structure with a propyl chain on the lower synthon 
(Scheme 4.44, b). 
 
 
Scheme 4.44. a) Retrosynthetic analysis of Syn.19 and Syn.20; comparison of the butyl- vs. propyl-containing 
aromatic ring. b) New target structure after retrosynthetic analysis, Ter.25, and the required synthons. 
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4.7.4. Synthesis of terphenyl Ter.25. 
 
Given that Syn.12 had already been prepared (refer to Scheme 4.25), we first turned our attention to 
Syn.18. Starting from 2-methyl-4-bromophenol 4.20, a Duff formylation gave rise to the desired 
aldehyde 4.63, as planned (Scheme 4.45).  
 
 
Scheme 4.45. Synthesis of 4.63 by Duff formylation. 
 
The subsequent Wittig reaction with triphenylpropylphosphonium bromide gave certain problems; 
some bases were unsuccessful in promoting the reaction, and when the free phenol was used the 
reaction did not proceed (Table 4.2). Therefore, phenol 4.63 had to be protected—we chose to use a 
benzyl protecting group since this could be removed simultaneously to the hydrogenation of the double 
bond resulting from the Wittig reaction. Once the phenol was protected, reaction with 
triphenylpropylphosphonium bromide and sodium hexamethyldisilazane (NaHMDS) successfully 
formed the desired product, but the reaction failed to complete. No reaction was observed when using 
other bases such as sodium hydride and potassium tert-butoxide, given that the phosphonium ylide did 
not form (this particular ylide has a deep orange colour, which was absent when using these bases). 
Finally, the use of n-BuLi gave much better results, pushing the reaction to completion and drastically 
improving the yield. The result was an inseparable 2:1 mixture of the cis and trans isomers, although 
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Table 4.2. Optimisation of the Wittig reaction to form intermediate 4.65. 
 
Entry R Base Yield 4.65 (%)b  Entry R Base Yield 4.65 (%)b 
1 H NaHMDS 0  4 Bn t-BuOK 0 
2 Bn NaHMDS 36  5 Bn NaH 0 
3 Bn NaHMDSa 24  6 Bn n-BuLi 78 
a 
More base was added (2 equivalents with respect to the phosphonium salt). 
b
 Yield refers to isolated yield of 
inseparable cis/trans mixture. 
 
It was assumed that the boronic ester would be more stable in the hydrogenation step when compared 
to the aryl bromide given our previous experience in hydrogenation reactions. Therefore the borylation 
reaction was carried out using the cis/trans mixture of 4.65 obtained from the Wittig reaction, in order 
to prevent loss of the aromatic bromine substituent during the hydrogenation step, resulting in 4.66 in 
a high yield. Subsequent hydrogenation simultaneously removed the benzyl protecting group and 
reduced the double bond (Scheme 4.46). 
 
 
Scheme 4.46. Borylation and hydrogenation steps resulting in the final Syn.18. 
 
With Syn.18 in hand, we began working towards the synthesis of Syn.20. As stated in the previous 
section, we decided to prepare this synthon with a propyl chain rather than the initially designed butyl, 
in order to save a step in the synthetic route. The hydrogenation of starting 2-allylphenol took place 
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without complications, resulting in 2-propylphenol in a high yield. The allylation of this intermediate 
also took place in high yield to form the Claisen rearrangement precursor, 4.67 (Scheme 4.47).  
 
 
Scheme 4.47. Preparation of Claisen rearrangement precursor 4.67. 
 
The following reaction was somewhat problematic, requiring high temperatures and resulting in 
moderate yields, with fairly complex crude mixtures that were sometimes difficult to separate by flash 
column chromatography. A basic literature search for reaction conditions revealed that the best 
conditions were often using basic solvents such as various aniline derivatives, pyridine or other amines. 
Therefore, we first attempted the reaction in these solvents at high temperatures, both in the 
microwave reactor and using conventional heating (Table 4.3). In the end, we found that the best 
results were obtained using DMF as a solvent in the microwave at 200 °C (entry 6, Table 4.3), although 
these conditions still only afforded a moderate 57% yield of 4.68.  
 
Table 4.3. Optimisation of the Claisen rearrangement. 
 
Entry Solvent Temp. (°C) Time (h) Yield 4.68 (%)a 
1 Aniline 165 20 41 
2 DMF 165 20 30 
3 DMF:Pyridine (5:1) 165 20 32 
4 Aniline 185 20 49 
5 Aniline 185 40 52 
6 DMF 200 20 57 
a
 Isolated yield.  
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From there, we attempted a cross-metathesis reaction with acrylonitrile in order to lengthen the 
carbon chain and introduce the nitrile group. However, when we attempted the reaction with 4.68, the 
desired product was not detected in any of the conditions tested (Table 4.4). Once again, the reaction 
was much more successful after protecting the free phenol as benzyl ether 4.69. We found that we had 
to force the reaction with high temperatures, and the reaction worked best when carried out in the 
microwave. In addition, in order to achieve the best results we found it necessary to add several 
portions of catalyst, possibly due to catalyst inactivation or degradation.  
 
Table 4.4. Optimisation of the cross-metathesis reaction with acrylonitrile. 
 
Entry Solvent Cat. load Temp. (°C) Time  Yield 4.70 (%)a 
1 DCM 5 mol% r.t. 24h 0 
2 Toluene 5 mol% r.t. 24h 0 
3 Toluene 5 mol% 100 (mw) 1h 30 
4 Toluene 2 x 5 mol% 100 (mw) 2 x 1h 57 
5 Toluene 2 x 5 mol% 120 8h then 16h 55 
6 Toluene 3 x 5 mol% 120 (mw) 3 x 1h 62 
a 
Yield refers to the isolated yield of the inseparable mixture of cis/trans isomers. 
 
Again, 4.70 was taken forward as a cis/trans mixture given its irrelevance in the following 
hydrogenation step. Both the hydrogenation and the formation of the final triflate Syn.20 were 
straightforward and resulted in a high yields (Scheme 4.48).  
 




Scheme 4.48. Hydrogenation and trifluoromethylsulfonylation to finalise the synthesis of Syn.20. 
 
Following this, the construction of terphenyl 4.74 took place uneventfully using the same conditions as 
throughout this study: Syn.18 and Syn.20 were coupled in a Suzuki-Miyaura coupling, the resulting 
biphenyl converted into triflate, and coupled with Syn.12 via further Suzuki-Miyaura coupling. The 




Scheme 4.49. Synthesis of final terphenyl Ter.25.  
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4.7.5. Biological evaluation. 
 
The preliminary biological results of Ter.25 are very promising. The group of J. Gallego (Universidad 
Católica de Valencia) have determined that Ter.25 inhibits the formation of the MTIP-MyoA complex of 
Plasmodium knowlesi with an IC50 of 4 μM (Figure 4.47). For comparison, control experiments with 
Ter.5 were carried out; this derivative displayed no affinity for the target, even at the highest 
concentration tested (100 μM). At the time of writing, no in vivo data was available. 
 
 









We have designed and synthesised a library of p-terphenyls capable of mimicking the 3D structure of 
the native HIV-1 Rev protein. Unfortunately, both the in vitro affinity for the target RNA region (the 
RRE) and the in vivo antiviral activities of the new series of compounds has failed to improve on 
previously reported values.  
However, we have observed that the oxygen-based substituents in the 1 and 4’’ positions make little 
difference with regards to the Rev-mimicking potential of this type of scaffold. This has allowed us to 
significantly shorten the synthetic sequence, decreasing the turnover time for the synthesis and 
biological testing of new derivatives. 
Furthermore, we have successfully produced guanidine-bearing terphenyl derivatives which should be 
able to more accurately mimic the structure of the native Rev protein, which presents an α-helix rich in 
arginine residues. Preliminary in vitro experiments indicate that this is the case. 
On the other hand, we have successfully described the first p-terphenyl capable of mimicking the 
protein-protein interaction MyoA-MTIP, present in P. falciparum, the parasite responsible for malaria. 
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4.9. Experimental section. 
 
Reactions were carried out under a nitrogen atmosphere unless otherwise indicated. Solvents were 
purified prior to use: THF was distilled from sodium and DCM from calcium hydride. Reagents were 
used as received from the suppliers without further purification, unless stated otherwise. The reactions 
were monitored by TLC on 0.25mm precoated silica-gel plates, which were revealed with UV light and 
aqueous ceric ammonium molybdate or potassium permanganate stains. Flash column chromatography 
was performed with the indicated solvents on silica gel 60 (particle size: 0.040−0.063 mm). 1H, 13C and 
19F NMR spectra were recorded by a 300 MHz spectrometer. Chemical shifts are given in ppm (δ), 
referenced to the residual proton resonances of the solvents. Coupling constants (J) are given in Hertz 
(Hz). The letters s, d, t, q and m stand for singlet, doublet, triplet, quartet and multiplet respectively. 
The letters br indicate that the signal is broad. A QTOF mass analysis system was used for the HRMS 
measurements. 
 
4.9.1. Synthesis of the required synthons. 




i. O-Benzylation. Commercially available 5-bromosalicylaldehyde 4.18 (1.00 g, 4.97 mmol) and 
potassium phosphate tribasic (2.11 g, 9.94 mmol) were dissolved in DMF (10 ml), and the resulting 
solution was stirred for 15 minutes at room temperature. After this time, benzyl bromide (1.8 ml, 14.91 
mmol) was added and the mixture was left to stir at room temperature for a further 18 hours. 
Subsequently, the mixture was diluted with water (20 ml) and extracted with ethyl acetate (15 ml). The 
organic layer was washed with water (3 x 20 ml), saturated sodium bicarbonate solution (20 ml) and 
brine (20 ml). The organic layer was then dried over anhydrous sodium sulphate, filtered and 
concentrated to dryness. The crude mixture was purified by flash column chromatography using n-
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hexane:EtOAc (10:1) as the eluent, to afford the corresponding benzyl ether as a white solid (1.32 g, 
91%). The spectroscopic data were concordant with those reported in the literature.332 
ii. Aldehyde reduction. The product of the previous step, 2-(benzyloxy)-5-bromobenzaldehyde 
(1.32 g, 4.53 mmol), was suspended in ethanol (45 ml) and the resulting mixture was cooled in an ice 
bath. Sodium borohydride (343 mg, 9.07 mmol) was then added portion-wise, and the reaction was left 
to stir for 2 hours at the same temperature. After this time, the reaction was carefully quenched with 
aqueous HCl (1M, 10 ml) and left for a further 10 minutes. The resulting mixture was then concentrated 
to remove the ethanol, and the concentrated mixture was extracted with ethyl acetate (3 x 20 ml). The 
combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to 
dryness. The resulting crude 4.19 was used in the next step without need for further purification. 
iii. Phosphorus tribromide-mediated bromination. The crude 4.19 (1.31 g, 4.53 mmol) was 
dissolved in anhydrous DCM (20 ml) and cooled in an ice bath. Once cooled, phosphorus tribromide 
(1M in DCM) (5.4 ml, 5.4 mmol) was added slowly and the reaction was stirred until no starting material 
remained (TLC analysis, typically 4h). After the reaction had finished, the brown solution was added to 
an extraction funnel and the organic layer washed with water (2 x 15 ml) and brine (15 ml). The organic 
layer was then dried over anhydrous sodium sulphate, filtered and concentrated to dryness. The 
resulting crude 4.16a was used in the next step without need for further purification. 
iv. Introduction of nitrile groups. The crude 4.16a (1.47 g, 4.13 mmol), potassium iodide (34 
mg, 0.21 mmol), 18-crown-6 (272 mg, 1.03 mmol) and sodium cyanide (303 mg, 6.19 mmol) were 
dissolved in MeCN:H2O (8:1) (40 ml) and left to stir at room temperature for 24h. After this time, the 
mixture was diluted with water and extracted with ethyl acetate (3 x 20 ml). The combined organic 
layers were washed with brine (20 ml), dried with anhydrous sodium sulphate, filtered, and 
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Flash column chromatography using n-hexane:EtOAc (4:1) as the eluent afforded 4.17a as a yellow solid 
(1.14 g, 82% from 4.18 benzyl ether) with a melting point of 54-55 °C. 
1H NMR (CDCl3, 300 MHz): δ 3.71 (s, 2H), 5.12 (s, 2H), 6.86 (d, J= 8.8 Hz, 1H), 7.34-7.47 (m, 6H), 7.53 (d, 
J= 2.4 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 18.7 (CH2), 70.6 (CH2), 113.2 (C), 113.5 (CH), 117.3 (C), 121.2 (C), 127.4 
(CH), 128.4 (CH), 128.8 (CH), 132.1 (CH), 132.3 (CH), 135.9 (C), 155.0 (C) ppm.  
HRMS (EI) calcd. for C15H16BrN2O [M+NH4
+]: 319.0441, found: 319.0427. 
 
v. Miyaura borylation (Version 1). A microwave vial was charged with 2-(2-(benzyloxy)-5-
bromophenyl)acetonitrile 4.17a (230 mg, 0.76 mmol), bis(pinacolato)diboron (231 mg, 0.91 mmol), and 
potassium acetate (223 mg, 2.28 mmol), and anhydrous dimethoxyethane was added (5 ml). Nitrogen 
gas was then bubbled through the solution for 5 minutes before adding PdCl2(dppf) (56 mg, 0.076 
mmol). The resulting mixture was heated in a microwave oven for 90 minutes at 120 °C. After this time, 
the reaction mixture was cooled and filtered through a pad of Celite, washing with DCM, and the filtrate 




Flash column chromatography using n-hexane:EtOAc (4:1) as the eluent afforded Syn.1 as a pale yellow 
oil (1.14 g, 82%). 
1H NMR (CDCl3, 300 MHz): δ 1.34 (s, 12H), 3.71 (s, 2H), 5.16 (s, 2H), 6.96 (d, J= 8.2 Hz, 1H), 7.30-7.48 (m, 
5H), 7.76 (dd, J= 8.2, 1.6 Hz, 1H), 7.79 (s, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 19.2 (CH2), 20.3 (CH3), 70.6 (CH2), 84.3 (C), 111.5 (C), 118.4 (C), 118.9 (C), 
127.8 (CH), 128.1 (CH), 128.6 (CH), 129.1 (CH), 135.1 (CH), 136.6 (C), 137.2 (CH), 158.9 (C) ppm.  
HRMS (EI) calcd. for C21H25NO3B [M+H
+]: 350.1922, found: 350.1916. 
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 i. Benzylic bromination. Commercially available 3-bromotoluene 4.15b (1 ml, 8.19 mmol) was 
dissolved in carbon tetrachloride, along with N-bromosuccinimide (1.60g, 9.01 mmol) and benzoyl 
peroxide (198 mg, 0.82 mmol). The mixture was heated at reflux for 3h and then cooled to room 
temperature. The resulting suspension was then filtered to remove the succinimide precipitate, and the 
filtrate was concentrated to dryness. The crude mixture was purified by flash column chromatography 
using n-hexane:EtOAc (20:1) as the eluent, to afford pure 4.16b as a colourless oil (1.99 g, 97%). The 
spectroscopic data were concordant with those reported in the literature.333 
 ii. Introduction of nitrile groups. The product of the previous step was subject to the same 
conditions described previously (see iv. Introduction of nitrile groups, Section 4.9.1.1). The crude 
mixture was purified by flash column chromatography using n-hexane:EtOAc (5:1) as the eluent, to 
afford pure 4.17b as a colourless oil (1.45 g, 93%). The spectroscopic data were concordant with those 
reported in the literature.334 
 iii. Miyaura borylation (Version 1). The product of the previous step was subject to the same 
conditions described previously (see v. Miyaura borylation (Version 1), Section 4.9.1.1). The crude 
mixture was purified by flash column chromatography using n-hexane:EtOAc (10:1) as the eluent, to 
afford Syn.2 as a colourless oil (283 mg, 76%). The spectroscopic data were concordant with those 
reported in the literature.335 
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Commercially available 4-bromo-2-methylphenol 4.20 was subject to the same conditions described 
previously (see v. Miyaura borylation (Version 1), Section 4.9.1.1). The crude mixture was purified by 
flash column chromatography using n-hexane:EtOAc (10:1) as the eluent, to afford Syn.3 as a pale 
yellow solid (413 mg, 68%). The spectroscopic data were concordant with those reported in the 
literature.336 
 




 i. Benzylic bromination. Commercially available 4-bromo-2-methylanisole was subject to the 
same conditions described previously (see i. Benzylic bromination, section 4.9.1.2). The crude mixture 
was purified by flash column chromatography using n-hexane:EtOAc (15:1) as the eluent, to afford 
bromomethyl intermediate as a pale yellow solid (490 mg, 81%). The spectroscopic data were 
concordant with those reported in the literature.337 
 ii. Introduction of nitrile groups. The product of the previous step was subjected to the same 
conditions described previously (see iv. Introduction of nitrile groups, Section 4.9.1.1). The crude 
mixture was purified by flash column chromatography using n-hexane:EtOAc (5:1) as the eluent, to 
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afford Syn.4 as a yellow solid (277 mg, 70%). The spectroscopic data were concordant with those 
reported in the literature.338 
 
4.9.1.5. Synthesis of Syn.6. 
  
 
This very compound had been previously synthesised in our research group, hence we followed the 
same synthetic procedure as we reported in 2013.308 
 




i. Double benzylic bromination. Commercially available 5-bromo-m-xylene (1 ml, 7.36 mmol) 
was dissolved in anhydrous chloroform, and N-bromosuccinimide (2.88 g, 16.19 mmol) was added in 6 
portions over 3 days (1 portion every 12 hours). Whenever N-bromosuccinimide was added, 
azobisisobutyronitrile (AIBN) (5 mg) was added straight after. After the first addition, the mixture was 
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heated to reflux and maintained at that temperature during the 3 days of reaction time, although the 
reaction was cooled before adding each portion of N-bromosuccinimide and AIBN. The resulting 
mixture was then cooled to room temperature and concentrated to dryness. The crude mixture was 
purified by flash column chromatography using n-hexane:EtOAc (20:1) as the eluent, to afford pure 4.34 
as a white solid (1.72 g, 68%). The spectroscopic data were concordant with those reported in the 
literature.339 
 ii. Introduction of nitrile groups. Previously synthesised 4.34 (1.72 g, 5.00 mmol), potassium 
iodide (41 mg, 0.25 mmol), 18-crown-6 (330 mg, 1.25 mmol) and sodium cyanide (735 mg, 15 mmol) 
were dissolved in MeCN:H2O (8:1) (50 ml) and left to stir at room temperature for 24h. After this time, 
the mixture was diluted with water and extracted with ethyl acetate (3 x 20 ml). The combined organic 
layers were washed with brine (20 ml), dried with anhydrous sodium sulphate, filtered, and 
concentrated to dryness. The crude mixture was purified by flash column chromatography using n-
hexane:EtOAc (5:1) as the eluent, to afford pure 4.36 as a pale yellow solid (764 mg, 65%). The 
spectroscopic data were concordant with those reported in the literature.336 
 iii. Miyaura borylation (Version 1). The product of the previous step was subject to the same 




Flash column chromatography using n-hexane:EtOAc (5:1) as the eluent afforded Syn.7 as a white solid 
(1.14 g, 75%) with a melting point of 96-97 °C. 
1H NMR (CDCl3, 300 MHz): δ 1.37 (s, 12H), 3.78 (s, 4H), 7.43 (s, 1H), 7.73 (s, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 23.4, 24.9, 84.4, 117.4, 130.1, 130.5, 134.0 ppm.  
HRMS (EI) calcd. for C16H23N3O2B [M+NH4
+]: 300.1878, found: 300.1883. 
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Commercially available 2,6-bis(bromomethyl)bromobenzene was subject to the same conditions 
described previously (see ii. Introduction of nitrile groups, Section 4.9.1.6). The crude mixture was 
purified by flash column chromatography using n-hexane:EtOAc (3:1) as the eluent, to afford Syn.9 as a 
pale yellow solid (1.42 g, 93%). The spectroscopic data were concordant with those reported in the 
literature.340 
 
4.9.1.8. Synthesis of Syn.10. 
 
 
This very compound had been previously synthesised in our research group, hence we followed the 
same synthetic procedure as we reported in 2013.308 
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 i. Wittig reaction and conjugate reduction. Previously synthesised 4.25 (1.00 g, 3.13 mmol) was 
dissolved in anhydrous THF (15 ml), and (triphenylphosphoranylidene)acetonitrile (2.36 g, 7.83 mmol) 
was added. The mixture was allowed to stir until the starting material had been consumed (TLC 
analysis, typically 5h), and after this time water was added and the products were extracted with ethyl 
acetate (3 x 20 ml). The combined organic layers were washed with brine (20 ml), dried over anhydrous 
sodium sulphate, filtered and concentrated to dryness. The residue was then dissolved in anhydrous 
ethanol (30 ml), and sodium borohydride (473 mg, 12.52 mmol) was added portion-wise. The reaction 
was stirred under reflux for 16h. After this time, the resulting mixture was cooled to room temperature 
and quenched with water. The solution was concentrated to remove the ethanol and the product was 
extracted from the resulting aqueous slurry with ethyl acetate (3 x 20 ml). The combined organic layers 




 3,3'-(2-(Benzyloxy)-5-bromo-1,3-phenylene)dipropanenitrile, 4.41 
Flash column chromatography using n-hexane:EtOAc (4:1) as the eluent afforded 4.41 as a pale yellow 
solid (740 mg, 64%) with a melting point of 49-50 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.62 (t, J= 7.5 Hz, 4H), 2.93 (t, J= 7.5 Hz, 4H), 4.88 (s, 2H), 7.33 (s, 2H), 7.36-
7.51 (m, 5H) ppm.  
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13C NMR (CDCl3, 75.5 MHz): δ 17.8 (CH2), 26.4 (CH2), 76.5 (CH2), 117.9 (C), 118.7 (C), 127.6 (CH), 128.8 
(CH), 129.0 (CH), 132.2 (CH), 134.3 (C), 136.1 (C), 154.6 (C) ppm.  
HRMS (EI) calcd. for C19H21N3OBr [M+NH4
+]: 386.0863, found: 386.0875. 
 
 ii. Miyaura borylation (Version 2). Previously synthesised 4.41 (500 mg, 1.35 mmol), 
bis(pinacolato)diboron (536 mg, 2.03 mmol), and potassium acetate (397 mg, 4.05 mmol) were 
dissolved in 1,4-dioxane:DMSO (100:1) (5 ml) in a sealable reaction vessel. Nitrogen gas was then 
bubbled through the solution for 5 minutes before adding PdCl2(dppf) (102.4 mg, 0.14 mmol). The 
reaction vessel was subsequently sealed and heated to 100 °C for 20h. After this time, the mixture was 





Flash column chromatography using n-hexane:EtOAc (3:1) as the eluent afforded Syn.11 as a pale 
yellow solid (433 mg, 77%) with a melting point of 97-99 °C. 
1H NMR (CDCl3, 300 MHz): δ 1.36 (s, 12H), 2.62 (t, J= 7.7 Hz, 4H), 2.97 (t, J= 7.7 Hz, 4H), 4.89 (s, 2H), 
7.36-7.48 (m, 5H), 7.62 (s, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 17.9 (CH2), 24.9 (CH3), 26.6 (CH2), 76.3 (CH2), 84.1 (C), 119.2 (C), 126.0 (br, 
C), 127.7 (CH), 127.6 (CH), 128.6 (CH), 128.9 (CH), 131.5 (C), 136.0 (CH), 136.4 (C), 158.1 (C) ppm.  
HRMS (EI) calcd. for C25H33N3O3B [M+NH4
+]: 434.2609, found: 434.2626. 
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 i. Carboxylic acid reduction and reoxidation to aldehyde level. Commercially available 5-
bromoisophthalic acid 4.42 (1.00 g, 4.08 mmol) was dissolved in anhydrous THF (20 ml), and BH3-THF 
(1M in THF) (20.4 ml, 20.4 mmol) was added slowly whilst stirring. Following this, the reaction mixture 
was refluxed for 4h. After this time, the reaction mixture was cooled in an ice bath, carefully quenched 
with aqueous HCl (3N) (10 ml), and stirred for 30 minutes in the ice bath and a further 30 minutes at 
room temperature. The mixture was then concentrated to remove the THF, and the resulting aqueous 
slurry extracted with ethyl acetate (5 x 20 ml). The combined organic layers were washed with brine (20 
ml), dried over sodium sulphate, filtered and concentrated to dryness. The residue was then dissolved 
in anhydrous DCM (20 ml), and both 4 Å molecular sieves (500 mg) and pyridinium chlorochromate 
(2.20g, 10.2 mmol) were added. The resulting orange-brown mixture was stirred for 4h at room 
temperature, after which time the mixture was filtered through a pad of Celite, washing with DCM. The 
filtrate was then concentrated and purified through flash column chromatography using n-
hexane:EtOAc (10:1) as the eluent, affording pure 4.43 as a white solid (530 mg, 61% from 4.42). The 
spectroscopic data were concordant with those reported in the literature.341 
 ii. Wittig reaction and conjugate reduction. The dialdehyde product of the previous step was 
subject to the same conditions described previously (see i. Wittig reaction and conjugate reduction, 
Section 4.9.1.9). The resulting 4.44 was used in the next step without further purification. 
 ii. Miyaura borylation (Version 2). The product of the previous step was subject to the same 
conditions described previously (see ii. Miyaura borylation (Version 2), Section 4.9.1.9).  
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Flash column chromatography using n-hexane:EtOAc (2:1) as the eluent afforded Syn.12 as a pale 
yellow solid (567 mg, 83%) with a melting point of 41-42 °C. 
1H NMR (CDCl3, 300 MHz): δ 1.32 (s, 12H), 2.61 (t, J= 7.4 Hz, 4H), 2.93 (t, J= 7.4 Hz, 4H), 7.20 (s, 1H), 7.54 
(s, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 19.2 (CH2), 24.8 (CH3), 31.3 (CH2), 84.1 (C), 130.1 (br, C), 131.3 (CH), 133.4 
(CH), 138.0 (C) ppm.  
HRMS (EI) calcd. for C18H27N3O2B [M+NH4
+]: 328.2191, found: 328.2187. 
 




Commercially available 4-bromo-2,6-difluorophenol 4.49 was subject to the same conditions described 
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Flash column chromatography using n-hexane:EtOAc (10:1) as the eluent afforded Syn.14 as a 
colourless solid (264 mg, 58%) with a melting point of 106-108 °C. 
1H NMR (CDCl3, 300 MHz): δ 1.35 (s, 12H), 5.82 (br s, 1H), 7.28-7.36 (m, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 24.8 (CH3), 84.3 (C), 117.5 (dd, J= 12.8, 6.7 Hz, CH), 120.3 (br, C), 135.5 (t, 
J= 16.0 Hz, CH), 151.4 (dd, J= 243.8, 4.3 Hz, CF) ppm.  
19F NMR (CDCl3, 282.4 MHz): δ -136.43 (s, 2F) ppm. 
HRMS (EI) calcd. for C12H19NO3BF2 [M+NH4
+]: 274.1421, found: 274.1415. 
 




 i. Nitrile reduction and amine protection. Previously synthesised 4.36 (500 mg, 2.13 mmol) was 
dissolved in anhydrous THF (8 ml) in a sealable reaction vessel and BH3·THF (1M in THF) (22 ml, 22.0 
mmol). The vessel was then sealed and the mixture was stirred at 70 °C for two days, after which time 
the reaction was cooled to room temperature, quenched with aqueous HCl (3N, 10 ml) and stirred for a 
further 2 hours open to air. The reaction was then concentrated to dryness and redissolved in 
anhydrous DCM (20 ml). Triethylamine (1.46 ml, 10.6 mmol) was added, followed by di-tert-butyl 
dicarbonate (2.31g, 10.6 mmol), and the mixture was stirred at room temperature for 18h. Following 
this, the reaction was quenched with saturated ammonium chloride solution (10 ml) and the organic 
layer was washed subsequently with saturated ammonium chloride solution (10 ml), saturated sodium 
bicarbonate solution (10 ml), water (2 x 10 ml), and brine (10 ml). The organic layer was dried over 
anhydrous sodium sulphate, filtered, and concentrated to dryness to afford a white solid 4.53 (652 mg, 
69% from 4.36), which was used in the next step without further purification. 
 ii. Miyaura borylation (Version 3). The crude product from the previous step (652 mg, 1.47 
mmol) was added to a microwaveable reaction vial and dissolved in anhydrous acetonitrile (7.5 ml), 
along with bis(pinacolato)diboron (575 mg, 2.21 mmol) and potassium acetate (432 mg, 4.41 mmol). 
Nitrogen gas was then bubbled through the solution for 5 minutes before adding PdCl2(dppf) (110 mg, 
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0.15 mmol). The reaction vessel was subsequently sealed and heated under microwave irradiation at 
160 °C for 15 minutes. After this time, the mixture was cooled to room temperature and passed 





Flash column chromatography using n-hexane:EtOAc (5:1) as the eluent afforded Syn.15 as a dense 
yellow oil (548 mg, 76%). 
1H NMR (CDCl3, 300 MHz): δ 1.36 (s, 12H), 1.45 (s, 18H), 2.80 (t, J= 7.0 Hz, 4H), 3.39 (dd, J= 13.1, 6.7 Hz, 
4H), 4.58 (br s, 2H), 7.28 (s, 1H), 7.52 (d, J= 1.7 Hz, 2H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 24.9, 28.4, 36.1, 79.2, 83.8, 113.9, 132.3, 133.3, 138.6, 155.9 ppm. 
HRMS (EI) calcd. for C26H45BN2O6 [M+H
+]: 491.3287, found: 491.3271. 
 




Previously synthesised 2,6-bis(acetonitrile)bromobenzene Syn.9 was subject to the same conditions 
described previously (see i. Nitrile reduction and amine protection, section 4.9.1.12).  
 
 




 Di-tert-butyl ((2-bromo-1,3-phenylene)bis(ethane-2,1-diyl))dicarbamate, Syn.16 
The crude mixture was purified by flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, to afford Syn.16 as a white solid (674 g, 60%) with a melting point of 96-98 °C.  
1H NMR (CDCl3, 300 MHz): δ 1.44 (s, 18H), 2.99 (t, J=7.0 Hz, 4H), 3.4 (br s, 4H), 4.63 (br s, 2H), 7.07-7.13 
(m, 2H), 7.19 (dd, J= 8.1, 6.6 Hz, 1H) ppm.  
13C NMR (CDCl3, 75.5 MHz): δ 28.4 (CH3), 37.3 (CH2), 40.2 (CH2), 79.2 (C), 126.9 (C), 127.2 (CH), 129.3 
(CH), 139.2 (C), 155.9 (C) ppm.  
HRMS (EI) calcd. for C20H32BrN2O4 [M+H
+]: 443.1540, found: 443.1537. 
 




 i. Duff formylation. Commercially available 4.20 (1.0 g, 5.35 mmol) was added to a 
microwaveable reaction vial, along with hexamethylenetetramine (HMTA) (1.12 g, 8.02 mmol) and 
trifluoroacetic acid (TFA) (10 ml). Care should be taken upon addition of the TFA since the mixture heats 
up considerably. Following this, the vessel was sealed and the reaction heated by microwave irradiation 
at 120 °C for 90 minutes. Subsequently, the mixture was transferred to a round-bottomed flask and 
concentrated H2SO4 (6 ml) and water (10 ml) was added and the mixture was stirred for a further 2 
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hours. Following this, the mixture was diluted with water and extracted with ethyl acetate (3 x 20 ml). 
The combined organic layers were washed with saturated aqueous sodium bicarbonate solution (3 x 20 
ml) and brine (20 ml), dried over anhydrous sodium sulphate, filtered and concentrated to dryness. 
Flash chromatography using n-hexane:EtOAc (10:1) afforded the desired 4.63 as a yellow solid (771 mg, 
67%). The spectroscopic data were concordant with those reported in the literature.342 
 ii. O-Benzylation. The product of the previous step was subject to the same conditions 
described previously (see i. O-Benzylation, Section 4.9.1.1). The crude mixture was used in the next step 
without further purification. 
 iii. Wittig reaction. A round-bottomed flask was charged with propyltriphenylphosphonium 
bromide (1.43 g, 3.70 mmol), purged with nitrogen, and THF was added (20 ml). The mixture was 
cooled in an ice bath, and n-butyllithium (2.5M in hexanes) (1.52 ml, 3.80 mmol) was added dropwise. 
The solution turned a dark orange colour that was crucial to the success of the reaction. This mixture 
was stirred at the same temperature for 15 minutes, and crude 4.64 (940 mg, 3.08 mmol) was then 
added and the reaction was stirred for 16 hours. After this time, saturated aqueous ammonium chloride 
solution (10 ml) was added carefully to quench the reaction, and the mixture was extracted with ethyl 
acetate (3 x 20 ml). The combined organic layers were then washed subsequently with water (2 x 10 ml) 




The crude mixture was purified by flash column chromatography using n-hexane:EtOAc (15:1) as the 
eluent, to afford a 3:2 mixture of (Z)- and (E)-4.65 as a white solid (796 g, 78%). 4.65 was characterised 
as a mixture, given the irrelevance of this isomerism to the synthetic sequence (the double bond will be 
later hydrogenated and the two isomers will converge into one saturated product).   
1H NMR (CDCl3, 300 MHz): δ 1.00-1.15 (m, 2 x 3H), 2.17-2.39 (m, 2 x (3H + 2H)), 4.81 (s, 2 x 2H), 5.79 (dt, 
J= 11.5, 7.3 Hz, 1H, Z (major)), 6.30 (dt, J= 15.9, 6.4 Hz, 1H, E (minor)), 6.52 (d, J= 11.6, 1H, Z (major)), 
6.63 (dt, J= 15.9, 1.5 Hz, 1H, E (minor)), 7.24-7.54 (m, 2 x 7H) ppm. 
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13C NMR (CDCl3, 75.5 MHz): δ 13.5, 14.2, 16.2, 22.1, 26.3, 74.7, 75.0, 116.1, 117.1, 122.7, 123.2, 126.9, 
128.0, 128.1, 128.2, 128.5, 128.6, 130.7, 132.0, 132.3, 133.1, 133.5, 133.6, 133.8, 133.9, 135.2, 136.3, 
137.1, 137.2, 153.4, 154.3 ppm. 
 
  iv. Miyaura borylation (Version 1). The product of the previous step was subject to the same 





The crude mixture was purified by flash column chromatography using n-hexane:EtOAc (15:1) as the 
eluent, to afford a 2:1 mixture of (Z)- and (E)-4.66 as a colourless oil (773 mg, 85%). 4.66 was 
characterised as a mixture, given the irrelevance of this isomerism to the synthetic sequence (the 
double bond will be later hydrogenated and the two isomers will converge into one saturated product).   
1H NMR (CDCl3, 300 MHz): δ 1.02-1.15 (m, 2 x 3H), 1.38 (s, 2 x 18H), 2.21-2.38 (m, 2 x (2H + 3H)), 4.84 (s, 
2 x 2H), 5.75 (dt, J= 11.5, 7.3 Hz, 1H, Z (major)), 6.40 (dt, J= 15.9, 6.4 Hz, 1H, E (minor)), 6.57 (d, J= 11.5, 
1H, Z (major)), 6.70 (dt, J= 16.0, 1.4 Hz, 1H, E (minor)), 7.29-7.88 (m, 2 x 7H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 13.7, 14.3, 16.2, 22.1, 24.9, 26.4, 74.4, 74.8, 83.6, 83.7, 123.5, 124.3, 
127.3, 128.1, 128.4, 128.5, 130.6, 130.7, 131.2, 134.1, 134.7, 135.1, 135.3, 136.2, 136.5, 137.5, 137.6, 
157.2, 157.9 ppm. 
HRMS (EI) calcd. for C24H34BNO3 [M+NH4
+]: 396.2705, found: 396.2706. 
 
 v. Hydrogenation and phenol deprotection. The 2:1 isomeric mixture (500 mg, 1.32 mmol) 
from the previous step was added to a round-bottomed flask, along with palladium over charcoal (10-
20% w/w) (140 mg, 0.13 mmol), and the mixture was dissolved in anhydrous ethanol (10 ml). The flask 
was purged 5 times with hydrogen gas using a gas bag, and the reaction mixture was stirred vigorously 
for 8 hours. After this time, the mixture was filtered through a pad of Celite, washing with DCM, and the 
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filtrate was concentrated to dryness. No further purification was needed, and Syn.18 was obtained as a 
pale yellow oil (299 mg, 78%). 
 
 
 2-Butyl-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, Syn.18 
1H NMR (CDCl3, 300 MHz): δ 0.94 (t, J= 7.3 Hz, 3H), 1.27-1.45 (m, 14H), 1.53-1.68 (m, 2H), 2.25 (s, 3H), 
2.55-2.65 (m, 2H), 4.89 (br s, 1H), 7.45 (d, J= 2.6 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 13.98, 15.62, 22.8, 24.8, 29.8, 32.1, 83.5, 120.4 (br, C), 122.4, 127.3, 
134.8, 135.5, 154.8 ppm. 
HRMS (EI) calcd. for C17H28BO3 [M+H
+]: 291.2126, found: 291.2132. 
 




 i. Hydrogenation and O-allylation. Commercially available 2-allylphenol (2.0 g, 14.9 mmol) and 
palladium over charcoal (10-20% w/w) (316 mg, 0.298 mmol) were placed in a round-bottomed flask 
and suspended in anhydrous methanol (30 ml). The flask was purged with hydrogen gas 5 times using a 
gas bag, and the mixture was stirred vigorously for 16h. After this time, the mixture was filtered 
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through Celite, washing with DCM, and the filtrate was concentrated to dryness. No further purification 
was needed and the residue was dissolved in anhydrous DMF (30ml). To this mixture, potassium iodide 
(123 mg, 0.75 mmol), 18-crown-6 (396 mg, 1.5 mmol), and allyl bromide (3.9 ml, 44.7 mmol) were 
added and the reaction was stirred at room temperature for 20h. After this time the mixture was 
diluted with water (20 ml) and extracted with diethyl ether (3 x 20 ml). The combined organic layers 
were then washed with water (5 x 20 ml), saturated aqueous sodium bicarbonate solution (2 x 20 ml) 
and brine (20 ml). The final ethereal phase was dried over anhydrous sodium sulphate, filtered and 
concentrated to dryness to afford 4.67 as a colourless oil (2.26 g, 86% from 2-allylphenol). No further 
purification was necessary, and spectroscopic data were concordant with those reported in the 
literature.343 
 ii. Claisen Rearrangement. O-allyl-2-propylphenol 4.67 (500 mg, 2.84 mmol) was dissolved in 
DMF (3 ml) in a sealable reaction vessel. The mixture was then sealed and heated at 200 °C for 20h, 
after which time the mixture was diluted with water and extracted with diethyl ether (2 x 10 ml). The 
combined ethereal layers were washed with water (3 x 15 ml), dried over anhydrous sodium sulphate, 
filtered and concentrated to dryness. The crude mixture was purified by flash column chromatography 
using n-hexane:EtOAc (30:1) as the eluent to afford pure 4.68 as a colourless oil (285 mg, 57%). The 
spectroscopic data of 4.68 were concordant with those reported in the literature.343 
iii. O-Benzylation. The product of the previous step was subject to the same conditions 
described previously (see i. O-Benzylation, Section 4.9.1.1). The crude mixture was used in the next step 
without further purification. 
iv. Cross metathesis. Crude 4.69 (200 mg, 0.75 mmol) was introduced into a microwaveable 
reaction vial and dissolved in anhydrous toluene (5 ml). Acrylonitrile (0.25 ml, 0.38 mmol) was added, 
followed by Hoveyda-Grubbs 2nd generation catalyst (23 mg, 0.038 mmol). The flask was sealed and 
heated to 120 °C under microwave irradiation for 1 hour. After this time, the reaction was cooled and a 
second portion of the catalyst (23 mg, 0.038 mmol) was added, and the reaction was once again heated 
to 120 °C under microwave irradiation for 1 hour. This was repeated once more, and then the reaction 
cooled to room temperature and concentrated to dryness.  
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The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (8:1) as the 
eluent, affording the pure product as a 4:1 mixture of (Z)- and (E)-4.69 as a pale yellow oil (136 mg, 
62%). 4.69 was characterised as a mixture, given the irrelevance of this isomerism to the synthetic 
sequence (the double bond will be later hydrogenated and the two isomers will converge into one 
saturated product).   
1H NMR (CDCl3, 300 MHz): δ 0.97 (t, J= 7.3 Hz, 2 x 3H), 1.59-1.79 (m, 2 x 2H), 2.61-2.72 (m, 2 x 2H), 3.52 
(dd, J= 6.4, 1.8 Hz, 2H, E (minor)), 3.77 (dd, J= 7.5, 1.4 Hz, 2H, Z (major)), 4.81 (s, 2H, E (minor)), 4.85 (s, 
2H, Z (major)), 5.21 (dt, J= 16.3, 1.8 Hz, 1H, E (minor)), 5.36 (dt, J= 10.8, 1.5 Hz, 1H, Z (major)), 6.59 (dt, 
J= 10.8, 7.5 Hz, 1H, Z (major)), 6.82 (dt, J= 16.3, 6.4 Hz, 1H, E (minor)), 7.01-7.51 (m, 2 x 8H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 14.2, 23.8, 32.1, 32.8, 34.0, 75.6, 99.7, 100.6, 116.0, 124.7, 127.4, 127.7, 
127.8, 128.1, 128.2, 128.6, 129.4, 129.6, 130.4, 136.3, 137.1, 153.1, 154.1, 155.1 ppm. 
HRMS (EI) calcd. for C20H25N2O [M+NH4
+]: 309.1961, found: 309.1966. 
 
v. Hydrogenation and phenol deprotection. The product of the previous step was subject to the 
same conditions described previously (see v. Hydrogenation and phenol deprotection, Section 4.9.1.14). 




1H NMR (CDCl3, 300 MHz): δ 1.02 (t, J= 7.3 Hz, 3H), 1.67 (dq, J= 14.8, 7.4 Hz, 2H), 1.94-2.12 (m, 2H), 2.36 
(t, J=7.2 Hz, 2H), 2.51-2.63 (m, 2H), 2.81 (t, J= 7.3 Hz, 2H), 4.78 (br s, 1H), 6.84 (t, J= 7.5 Hz, 1H), 6.94-
7.09 (m, 2H) ppm. 
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13C NMR (CDCl3, 75.5 MHz): δ 14.0, 16.6, 22.8, 25.5, 29.3, 32.0, 119.9, 120.5, 126.0, 127.4, 128.2, 128.4, 
151.6 ppm. 
HRMS (EI) calcd. for C13H21N2O [M+NH4
+]: 221.1648, found: 221.1648. 
 
 vi. Triflate formation. Previously synthesised 4.71 (200 mg, 0.98 mmol) was dissolved in 
anhydrous DCM (10 ml) and the solution was cooled in an ice bath. Pyridine (0.2 ml, 2.46 mmol) was 
added and the reaction was stirred for 15 minutes in the ice bath, after which trifluoromethanesulfonic 
anhydride (1M in DCM) (1.5 ml, 1.5 mmol) was added slowly. The reaction was stirred for 20 minutes 
and a further 90 minutes at room temperature. Following this, the reaction was diluted with diethyl 
ether (10 ml) and quenched with aqueous HCl (1M, 5 ml). The mixture was extracted with diethyl ether 
(2 x 10 ml), and the combined ethereal phase was washed with water (2 x 15 ml) and brine (15 ml). The 
organic phase was dried over anhydrous sodium sulphate, filtered and concentrated to dryness.  
 
 
 2-(3-Cyanopropyl)-6-propylphenyl trifluoromethanesulfonate, Syn.20 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (6:1) as the 
eluent, affording pure Syn.20 as a colourless oil (286 mg, 87%). 
1H NMR (CDCl3, 300 MHz): δ 0.98 (t, J= 7.3 Hz, 3H), 1.58-1.73 (m, 2H), 1.96-2.07 (m, 2H), 2.38 (t, J= 7.2 
Hz, 2H), 2.67-2.77 (m, 2H), 2.87-2.96 (m, 2H), 7.11-7.34 (m, 3H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 13.8 (CH3), 16.7 (CH2), 23.2 (CH2), 25.7 (CH2), 29.6 (CH2), 32.4 (CH2), 118.6 
(q, J= 320.5 Hz, CF3), 119.1 (C), 128.6 (CH), 128.9 (CH), 129.9 (CH), 133.5 (C), 136.7 (C), 145.6 (C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -73.49 (s, 3F) ppm. 
HRMS (EI) calcd. for C14H20F3N2O3S [M+NH4
+]: 353.1141, found: 353.1143. 
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4.9.2. Synthesis of biphenyls. 




The required aryl bromide (or triflate) (1 equiv) was placed in a microwaveable vial along with the 
corresponding phenylboronic acid pinacol ester (1.1 equiv), and the mixture was dissolved in 
acetonitrile (0.3 M). Nitrogen gas was then bubbled through the solution for 5 minutes. Meanwhile, a 
solution of potassium phosphate tribasic (3 equiv) in degassed water (35% v/v of the required 
acetonitrile) was prepared. The aqueous solution was then added to the acetonitrile solution, followed 
by the addition of PdCl2(dppf) (10 mol%), and the reaction vessel was sealed. The reaction was heated 
to 120 °C under microwave irradiation for 90 minutes, after which time the mixture was cooled to room 
temperature and extracted with ethyl acetate. The combined organic layers were dried over anhydrous 
sodium sulphate, filtered and concentrated. The crude mixture was purified via flash column 




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (4:1) as the 
eluent, affording pure 4.21a as a white solid (213 mg, 57%) with a melting point of 108-110 °C. 
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1H NMR (CDCl3, 300 MHz): δ 2.29 (s, 3H), 3.61 (s, 2H), 3.86 (s, 3H), 4.75 (br s, 1H), 6.82 (d, J= 8.1 Hz, 1H), 
6.90 (dd, J= 8.5, 2.6 Hz, 1H), 6.97 (dd, J= 8.1, 2.3 Hz, 1H), 7.02 (d, J= 2.1 Hz, 1H), 7.05 (d, J= 2.6 Hz, 1H), 
7.18 (d, J= 8.5 Hz, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.3, 22.7, 55.9, 114.2, 114.6, 115.4, 118.8, 124.6, 128.2, 129.3, 132.1, 
132.2, 132.3, 134.6, 153.9, 159.5 ppm. 
HRMS (EI) calcd. for C16H16NO2 [M+H




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (4:1) as the 
eluent, affording pure 4.21b as a pale brown oil (169 mg, 62%). 
1H NMR (CDCl3, 300 MHz): δ 2.22 (s, 3H), 3.57 (s, 2H), 4.96 (br s, 1H), 6.77 (d, J=6.5 Hz, 1H), 6.92 (dd, J= 
6.5, 1.8 Hz, 1H), 6.98 (d, J=1.8 Hz, 1H), 7.14-7.22 (m, 1H), 7.24-7.34 (m, 2H), 7.42-7.47 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.3, 22.5, 115.4, 118.9, 124.7, 128.0, 128.2, 128.3, 128.6, 129.3, 131.0, 
132.0, 132.6, 142.2, 154.2 ppm. 
HRMS (EI) calcd. for C15H14NO [M+H
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The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.37a as a white to pink solid (312 mg, 75%) with a melting point of 129-131 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.31 (s, 6H), 3.46 (s, 4H), 4.80 (s, 1H), 6.79 (s, 2H), 7.45 (dd, J= 8.7, 6.6 Hz, 
1H), 7.55 (d, J= 7.2 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.5, 22.9, 118.4, 124.9, 128.5, 128.7, 129.0, 129.1, 130.4, 141.7, 153.0 
ppm. 
HRMS (EI) calcd. for C18H20N3O [M+NH4




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.37b as a white solid (114 mg, 71%). The spectroscopic data were concordant 




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (4:1) as the 
eluent, affording pure 4.45a as a pale brown solid (254 mg, 73%) with a melting point of 114-115 °C. 
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1H NMR (CDCl3, 300 MHz): δ 2.30 (t, J= 0.6 Hz, 6H), 3.66 (s, 2H), 4.78 (s, 1H), 6.89-6.92 (m, 2H), 7.24-7.28 
(m, 1H), 7.34-7.39 (m, 2H), 7.50-7.54 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.4 (CH3), 22.5 (CH2), 118.9 (C), 123.7 (C), 128.2 (CH), 128.3 (C), 128.5 
(CH), 129.2 (CH), 129.5 (CH), 131.0 (CH), 132.3 (C), 142.3 (C), 152.3 (C) ppm. 
HRMS (EI) calcd. for C16H19N2O [M+NH4




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (4:1) as the 
eluent, affording pure 4.45b as a white solid (263 mg, 78%) with a melting point of 97-99 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.32 (s, 6H), 3.80 (s, 2H), 4.76 (s, 1H), 7.21 (s, 2H), 7.22-7.25 (m, 1H), 7.37-
7.44 (m, 1H), 7.47-7.52 (m, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.5 (CH3), 24.1 (CH2), 118.4 (C), 123.9 (C), 126.3 (CH), 126.7 (CH), 126.9 
(CH), 127.4 (C), 127.8 (CH), 129.8 (CH), 130.6 (C), 132.7 (C), 142.6 (C), 152.7 (C) ppm. 
HRMS (EI) calcd. for C16H19N2O [M+NH4




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (5:1) as the 
eluent, affording pure 4.50 as a white solid (142 mg, 57%) with a melting point of 142-143 °C. 
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1H NMR (CDCl3, 300 MHz): δ 3.38 (s, 4H), 6.70 (dd, J= 6.6, 1.6 Hz, 2H), 7.36-7.51 (m, 3H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 22.8 (CH2), 113.0 (dd, J= 14.0, 8.2 Hz, CH), 117.6 (C), 127.9 (t, J= 8.0 Hz, C), 
129.3 (CH), 130.1 (CH), 130.3 (C), 134.0 (t, J= 15.6 Hz, C), 139.1 (C), 152.7 (dd, J= 247.2, 6.4, CF) ppm. 
19F NMR (CDCl3, 282.4 MHz): -131.79 (s, 2F) ppm. 
HRMS (EI) calcd. for C16H16FN3O [M-F+H2+NH4





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (5:1) as the 
eluent, affording pure 4.54 as a dense orange oil (131 mg, 49%). 
1H NMR (CDCl3, 300 MHz): δ 1.37 (s, 18H), 2.51 (t, J= 7.0 Hz, 4H), 3.15 (d, J= 5.7 Hz, 4H), 4.59 (t, J= 5.7 
Hz, 2H), 6.68 (d, J= 8.2 Hz, 2H), 7.13 (d, J= 7.5 Hz, 2H), 7.20-7.29 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 28.3, 33.8, 41.2, 79.4, 112.8 (dd, J= 13.6, 7.9), 127.4, 128.0, 130.2 (t, J= 7.8 
Hz), 132.8 (t, J= 15.7 Hz), 137.5, 139.9, 152.1 (dd, J= 224.8, 6.7 Hz), 155.9 ppm. 
19F NMR (CDCl3, 282.4 MHz): -133.15 ppm. 
HRMS (EI) calcd. for C26H35F2N2O5 [M+H
+]: 493.2509, found: 493.2508. 
 
 





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (5:1) as the 
eluent, affording pure 4.72 as a dense brown oil (98 mg, 41%). 
1H NMR (CDCl3, 300 MHz): δ 0.78 (t, J= 7.3 Hz, 3H), 0.94 (t, J= 7.3 Hz, 3H), 1.32-1.49 (m, 4H), 1.52-1.65 
(m, 2H), 1.66-1.79 (m, 2H), 2.15 (t, J= 7.5 Hz, 2H), 2.25-2.34 (m, 5H), 2.46-2.54 (m, 2H), 2.63 (td, J= 7.2, 
1.6 Hz, 2H), 4.66 (br s, 1H), 6.72 (s, 2H), 7.07 (dd, J= 7.4, 1.4 Hz, 1H), 7.14 (dd, J= 7.6, 1.4 Hz, 1H), 7.21 (d, 
J= 7.5 Hz, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 14.0 (CH3), 14.1 (CH3), 16.1 (CH3), 16.6 (CH2), 22.4 (CH2), 24.5 (CH2), 26.7 
(CH2), 29.7 (CH2), 31.8 (CH2), 32.7 (CH2), 35.8 (CH2), 119.6 (C), 122.8 (C), 126.3 (CH), 127.0 (CH), 127.1 
(CH), 127.4 (C), 128.9 (CH), 129.3 (CH), 131.4 (C), 138.3 (C), 141.4 (C), 141.7 (C), 150.6 (C) ppm. 
HRMS (EI) calcd. for C24H35N2O [M+NH4
+]: 367.2744, found: 367.2747. 
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The activation of the previously synthesised biphenyls was carried out by the formation of the 
corresponding triflates, using the general procedure as described in the previous section (see vi. Triflate 
formation, Section 4.9.1.15). 
 
 
2'-(Cyanomethyl)-4'-methoxy-3-methyl-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate, 4.22a 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (6:1) as the 
eluent, affording pure 4.22a as a pale green oil (281 mg, 87%). 
1H NMR (CDCl3, 300 MHz): δ 2.43 (s, 3H), 3.58 (s, 2H), 3.87 (s, 3H), 6.93 (dd, J= 8.5, 2.6 Hz, 1H), 7.07 (d, 
J= 2.6 Hz, 1H), 7.14-7.24 (m, 3H), 7.31 (d, J= 8.4 Hz, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.9 (CH3), 22.7 (CH2), 55.9 (CH3), 114.4 (CH), 115.0 (CH), 118.3 (C), 119.0 
(q, J= 321.2 Hz, CF3), 121.9 (CH), 128.8 (CH), 129.3 (C), 131.7 (C), 131.9 (CH), 132.8 (C), 133.4 (CH), 140.4 
(C), 148.2 (C), 160.2 (C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -74.21 (s, 3F) ppm. 
HRMS (EI) calcd. for C17H18F3N2O4S [M+NH4
+]: 403.0934, found: 403.0924. 
 




2'-(Cyanomethyl)-3-methyl-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate, 4.22b 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (7:1) as the 
eluent, affording pure 4.22b as a pale yellow oil (220 mg, 92%). 
1H NMR (CDCl3, 300 MHz): δ 2.44 (s, 3H), 3.60 (s, 2H), 7.20 (ddd, J= 8.4, 2.3, 0.4 Hz, 1H), 7.26-7.29 (m, 
2H), 7.34 (d, J= 8.4 Hz, 1H), 7.38-7.48 (m, 2H), 7.53-7.58 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 16.9 (CH3), 22.5 (CH2), 118.4 (C), 119.0 (q, J= 318.1 Hz, CF3), 122.0 (CH), 
128.1 (C), 128.6 (CH), 128.9 (CH), 129.3 (C), 129.6 (CH), 130.8 (CH), 131.9 (C), 133.2 (CH), 140.4 (C), 
140.5 (C), 148.4 (C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -74.20 (s, 3F) ppm. 
HRMS (EI) calcd. for C16H16F3N2O3S [M+NH4
+]: 373.0828, found: 373.0822. 
 
 
2',6'-Bis(cyanomethyl)-3,5-dimethyl-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate, 4.38a 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (6:1) as the 
eluent, affording pure 4.38a as a colourless solid (405 mg, 91%) with a melting point of 110-112 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.38 (s, 6H), 3.34 (s, 4H), 6.92 (s, 2H), 7.42 (dd, J= 9.0, 6.1 Hz, 1H), 7.47-7.51 
(m, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 17.3 (CH3), 22.5 (CH2), 117.4 (C), 118.6 (q, J= 319.9 Hz, CF3), 128.7 (CH), 
129.5 (CH), 129.6 (C), 130.2 (CH), 133.4 (C), 136.7 (C), 139.4 (C), 146.8 (C) ppm. 
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19F NMR (CDCl3, 282.4 MHz): δ -73.72 (s, 3F) ppm. 
HRMS (EI) calcd. for C19H16F3N2O3S [M+H





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (6:1) as the 
eluent, affording pure 4.38b as a white solid (145 mg, 86%). The spectroscopic data were concordant 
with those reported in the literature.308 
 
 
2'-(Cyanomethyl)-3,5-dimethyl-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate, 4.46a 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (7:1) as the 
eluent, affording pure 4.46a as a dense colourless oil (318 mg, 84%). 
1H NMR (CDCl3, 300 MHz): δ 2.35 (s, 6H), 3.52 (s, 2H), 6.98 (s, 2H), 7.14-7.18 (m, 1H), 7.27-7.36 (m, 2H), 
7.43-7.47 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 17.6 (CH3), 22.5 (CH2), 118.5 (C), 119.0 (q, J= 319.4 Hz, CF3), 128.1 (C), 
128.8 (CH), 129.1 (CH), 129.5 (CH), 130.7 (CH), 130.8 (CH), 132.4 (C), 140.2 (C), 140.6 (C), 146.8 (C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -73.86 (s, 3F) ppm. 
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HRMS (EI) calcd. for C17H18F3N2O3S [M+NH4
+]: 387.0985, found: 387.0989. 
 
 
3'-(Cyanomethyl)-3,5-dimethyl-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate, 4.46b 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (7:1) as the 
eluent, affording pure 4.46b as a colourless oil (342 mg, 93%). 
1H NMR (CDCl3, 300 MHz): δ 2.46 (s, 6H), 3.82 (s, 2H), 7.36-7.29 (m, 3H), 7.40-7.54 (m, 3H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 17.7 (CH3), 24.0 (CH2), 118.1 (C), 119.0 (q, J= 319.6 Hz, CF3), 127.1 (CH), 
127.3 (CH), 127.7 (CH), 129.0 (CH), 130.1 (CH), 131.0 (C), 132.4 (C), 140.5 (C), 141.1 (C), 147.0 (C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -73.87 (s, 3F) ppm. 
HRMS (EI) calcd. for C17H18F3N2O3S [M+NH4
+]: 387.0985, found: 387.0984. 
 
 
2',6'-Bis(cyanomethyl)-3,5-difluoro-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate, 4.51 
The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (9:1) as the 
eluent, affording pure 4.51 as a yellow solid (170 mg, 76%) with a melting point of 96-98 °C. 
1H NMR (CDCl3, 300 MHz): δ 3.43 (s, 4H), 6.97-7.05 (m, 2H), 7.50-7.63 (m, 3H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 22.8 (CH2), 114.0-114.7 (m, CH), 117.2 (C), 119.0 (q, J= 321.7Hz, C), 129.7 
(CH, C), 130.9 (CH), 137.6 (C), 138.5 (t, J= 8.3 Hz, C), 155.7 (d, J= 259.8 Hz, C) ppm. 
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19F NMR (CDCl3, 282.4 MHz): δ -73.30 (t, J= 6.4 Hz, 3F), -120.46 (q, J= 6.4 Hz, 2F) ppm. 
HRMS (EI) calcd. for C17H13F5N3O3S [M+NH4





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (10:1) as the 
eluent, affording pure 4.55 as a colourless oil (166 mg, 86%). 
1H NMR (CDCl3, 300 MHz): δ 1.41 (s, 18H), 2.51 (t, J= 7.1 Hz, 4H), 3.21 (dd, J= 13.5, 6.7 Hz, 4H), 4.46 (br 
s, 2H), 6.99 (d, J= 7.9 Hz, 2H), 7.20 (d, J= 7.6 Hz, 2H), 7.30-7.38 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 28.3, 34.0, 41.1, 79.4, 114.3 (d, J= 20.8 Hz, CH), 118.6 (q, J= 321.2 Hz, CF3), 
124.9, 127.8, 128.8, 136.8, 138.4, 141.9, 154.4 (d, J= 257.3 Hz, CF), 155.6 ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -72.99 (t, J= 6.4 Hz, 3F), -123.15 (br s, 2F) ppm. 
HRMS (EI) calcd. for C27H34F5N2O7S [M+H





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (10:1) as the 
eluent, affording pure 4.73 as a colourless oil (128 mg, 89%). 
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1H NMR (CDCl3, 300 MHz): δ 0.78 (t, J= 7.3 Hz, 3H), 0.93 (t, J= 7.3 Hz, 3H), 1.29-1.50 (m, 4H), 1.59 (ddd, 
J= 11.5, 10.4, 5.0 Hz, 2H), 1.67-1.78 (m, 2H), 2.17 (t, J= 7.2 Hz, 3H), 2.21-2.30 (m, 2H), 2.43 (s, 3H), 2.45-
2.52 (m, 2H), 2.77 (td, J= 7.3, 3.1 Hz, 2H), 6.93 (dd, J= 7.1, 1.9 Hz, 2H), 7.10 (dd, J= 7.5, 1.2 Hz, 1H), 7.16 
(dd, J= 7.6, 1.2 Hz, 1H), 7.27 (t, J= 7.6 Hz, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 13.8 (CH3), 14.0 (CH3), 16.7 (CH2), 17.4 (CH3), 22.3 (CH2), 24.4 (CH2), 26.6 
(CH2), 30.0 (CH2), 32.1 (CH2), 32.5 (CH2), 35.7 (CH2), 118.7 (q, J= 320.0 Hz, CF3), 119.3 (C), 126.4 (CH), 
127.3 (CH), 127.8 (CH), 129.9 (CH), 130.8 (CH), 131.6 (C), 136.1 (C), 137.7 (C), 139.7 (C), 139.9 (C), 141.1 
(C), 145.3 (C) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -73.44 (s, 3F) ppm. 
HRMS (EI) calcd. for C25H34F3N2O3S [M+NH4
+]: 499.2211, found: 499.2218. 
 
  
Chapter 4  D. M. Sedgwick, Tesis Doctoral 
359 
 
4.9.3. Synthesis of terphenyls. 




The required aryl bromide (or triflate) (1 equiv) was placed in a microwaveable vial along with the 
corresponding phenylboronic acid pinacol ester (1.1 equiv), and the mixture was dissolved in 
acetonitrile (0.2 M). Nitrogen gas was then bubbled through the solution for 5 minutes. Meanwhile, a 
solution of potassium phosphate tribasic (3 equiv) in degassed water (20% v/v of the required 
acetonitrile) was prepared. The aqueous solution was then added to the acetonitrile solution, followed 
by the addition of Pd(OAc)2 (10 mol%) and triphenylphosphine (25 mol%), and the reaction vessel was 
sealed. The reaction was heated to 120 °C under microwave irradiation for 90 minutes, after which time 
the mixture was cooled to room temperature and extracted with ethyl acetate. The combined organic 
layers were dried over anhydrous sodium sulphate, filtered and concentrated. The crude mixture was 
purified via flash column chromatography using mixtures of n-hexane and ethyl acetate as the eluent. 
In some cases, it was necessary to use mixtures of toluene and ethyl acetate for the flash column 
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The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.23a as a pale brown solid (106 mg, 38%) with a melting point of 172-173 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.24 (s, 3H), 3.61 (s, 2H), 3.72 (s, 2H), 3.81 (s, 3H), 5.10 (s, 2H), 6.86 (dd, J= 
8.5, 2.6 Hz, 1H), 6.96 (d, J= 8.4 Hz, 1H), 7.02 (d, J= 2.6 Hz, 1H), 7.03-7.07 (m, 1H), 7.09 (s, 1H), 7.16-7.19 
(m, 2H), 7.23 (dd, J= 5.9, 2.7 Hz, 1H), 7.28-7.43 (m, 6H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 19.4, 21.0, 22.7, 55.9, 70.9, 111.9, 114.3, 114.6, 118.4, 118.7, 119.2, 
127.1, 127.8, 128.6, 129.2, 129.3, 130.4, 130.5, 130.6, 131.7, 132.0, 134.4, 134.8, 136.2, 136.8, 139.1, 
140.3, 155.4, 159.8 ppm. 
HRMS (EI) calcd. for C31H30N3O2 [M+NH4




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.23b as a yellow solid (69 mg, 46%) with a melting point of 129-131 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.34 (s, 3H), 3.71 (s, 2H), 3.81 (s, 2H), 5.19 (s, 2H), 7.05 (d, J= 8.5 Hz, 1H), 
7.16 (dd, J= 7.7, 1.5 Hz, 1H), 7.19-7.22 (m, 1H), 7.29 (d, J= 7.9 Hz, 1H), 7.31-7.52 (m, 10H), 7.56-7.60 (m, 
1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 19.4 (CH2), 21.0 (CH3), 22.5 (CH2), 70.9 (CH2), 111.9 (CH), 118.4 (C), 118.8 
(C), 119.2 (C), 126.8 (CH), 127.8 (CH), 128.2 (C, C), 128.6 (2CH), 128.7 (CH), 129.15 (CH), 129.3 (CH), 
130.5 (CH), 130.6 (CH), 130.9 (C, CH), 131.4 (CH), 134.7 (C), 136.3 (C), 136.8 (C), 139.3 (C), 140.6 (C), 
142.0 (C), 155.5 (C) ppm. 
HRMS (EI) calcd. for C30H28N3O [M+NH4
+]: 446.2227, found: 446.2229. 
 





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (4:1) as the 
eluent, affording pure 4.23c as a white solid (57 mg, 31%) with a melting point of 107-109 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.24 (s, 3H), 3.63 (s, 2H), 3.75 (s, 2H), 7.07-7.12 (m, 1H), 7.14 (dd, J= 1.2, 
0.6 Hz, 1H), 7.21 (d, J= 7.7 Hz, 1H), 7.24-7.30 (m, 4H), 7.33-7.42 (m, 3H), 7.48-7.52 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 19.5, 21.1, 22.6, 116.8, 117.3, 125.4, 125.6, 126.8, 127.2, 127.7, 127.9, 
127.9, 128.0, 128.9, 129.0, 129.4, 130.0, 134.7, 138.2, 139.4, 140.5, 141.4 ppm. 
HRMS (EI) calcd. for C23H22N3 [M+NH4





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.39a as a white solid (117 mg, 54%) with a melting point of 173-176 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.02 (s, 6H), 3.45 (s, 4H), 3.67 (s, 4H), 4.94 (s, 2H), 6.86 (s, 2H), 7.27 (S, 2H), 
7.33-7.44 (m, 6H), 7.51 (d, J= 7.3 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 19.3, 21.4, 23.0, 117.9, 118.2, 125.7, 128.1, 128.5, 128.8, 129.4, 129.5, 
130.1, 130.9, 135.9, 136.5, 137.9, 138.4, 140.3, 141.2, 153.5 ppm. 
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HRMS (EI) calcd. for C35H32N5O [M+NH4





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (2:1) as the 
eluent, affording pure 4.39b as a white solid (78 mg, 61%) with a melting point of 171-173 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.04 (s, 6H), 3.48 (s, 4H), 3.86 (s, 4H), 3.91 (s, 3H), 6.90 (s, 2H), 7.09 (s, 2H), 
7.22 (d, J= 1.6 Hz, 2H), 7.31 (s, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 19.9, 21.7, 22.5, 54.6, 112.9, 116.3, 116.7, 125.2, 127.3, 129.8, 130.6, 
132.0, 135.0, 136.2, 139.1, 141.6, 158.6 ppm. 
HRMS (EI) calcd. for C29H28N5O [M+NH4




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (2:1) as the 
eluent, affording pure 4.39c as a white solid (312 mg, 65%) with a melting point of 176-178 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.05 (s, 6H), 3.51 (s, 4H), 3.86 (s, 4H), 6.93 (s, 2H), 7.22 (s, 2H), 7.32 (s, 1H), 
7.46 (dd, J= 8.7, 6.7 Hz, 1H), 7.57 (d, J= 7.6 Hz, 2H) ppm. 
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13C NMR (CDCl3, 75.5 MHz): δ 20.9 (CH3), 22.6 (CH2), 23.5 (CH2), 117.4 (C), 117.8 (C), 126.3 (CH), 127.7 
(CH), 128.3 (CH), 128.4 (CH), 128.9 (CH), 129.6 (C), 131.7 (C), 136.1 (C), 137.3 (C), 140.2 (C), 140.8 (C), 
142.5 (C) ppm. 
HRMS (EI) calcd. for C28H23N4 [M+H





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (2:1) as the 
eluent, affording pure 4.47a as a white solid (75 mg, 46%) with a melting point of 110-112 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.11 (s, 6H), 2.69 (t, J= 7.2 Hz, 4H), 3.02 (t, J= 7.2 Hz, 4H), 3.51 (s, 4H), 4.98 
(s, 2H), 6.90 (s, 2H), 7.07 (s, 2H), 7.39-7.49 (m, 6H), 7.57 (d, J= 7.7 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 18.1 (CH2), 21.0 (CH3), 22.6 (CH2), 26.6 (CH2), 76.2 (CH2), 117.9 (C), 119.0 
(C), 127.5 (CH), 127.6 (CH), 128.4 (CH), 128.6 (CH), 128.9 (CH), 129.7 (CH), 130.1 (CH), 132.3 (C), 132.9 
(C), 135.6 (C), 136.6 (C), 137.3 (C), 137.7 (C), 140.9 (C), 141.0 (C), 154.3 (C) ppm. 
HRMS (EI) calcd. for C37H36N5O [M+NH4
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The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.47b as a dense pale yellow oil (121 mg, 67%). 
1H NMR (CDCl3, 300 MHz): δ 2.09 (s, 6H), 2.71 (t, J= 7.1 Hz, 4H), 3.04 (t, J= 7.1 Hz, 4H), 3.53 (s 4H), 6.92 
(s, 2H), 7.06 (d, J= 1.5 Hz, 2H), 7.15 (s, 1H), 7.48 (dd, J= 8.6, 6.7 Hz, 1H), 7.59 (d, J= 7.6 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 19.5, 20.9, 22.5, 31.4, 117.8, 118.9, 127.1, 127.5, 127.9, 128.4, 128.8, 
129.6, 135.6, 137.5, 139.2, 141.0, 141.3, 141.6 ppm. 
HRMS (EI) calcd. for C30H30N5 [M+NH4




The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.47c as a white solid (127 mg, 61%) with a melting point of 139-140 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.06 (s, 6H), 3.71 (s, 2H), 3.85 (s, 4H), 7.04 (s, 2H), 7.20 (dd, J= 1.1, 0.6 Hz, 
2H), 7.30-7.35 (m, 2H), 3.27-7.45 (m, 2H), 7.54-7.59 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.3 (CH3), 22.5 (CH2), 24.0 (CH2), 117.8 (C), 118.8 (C), 126.5 (CH), 128.2 
(C), 128.5 (CH), 128.6 (CH), 128.8 (CH), 129.3 (CH), 130.8 (CH), 131.9 (C), 136.6 (C), 139.7 (C), 139.8 (C), 
142.0 (C), 143.4 (C) ppm. 
HRMS (EI) calcd. for C26H25N4 [M+NH4
+]: 393.2074, found: 393.2072. 
 
 





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.47d as a white solid (101 mg, 58%) with a melting point of 98-100 °C. 
1H NMR (CDCl3, 300 MHz): δ 2.08 (s, 6H), 3.84 (s, 6H), 7.16 (d, J= 1.3 Hz, 2H), 7.30-7.35 (m, 4H), 7.43-
7.49 (m, 1H), 7.59 (dd, J= 7.2, 1.0 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 20.0 (CH3), 22.5 (CH2), 22.7 (CH2), 116.3 (C), 116.8 (C), 125.0 (CH), 125.3 
(CH), 125.6 (CH), 125.8 (CH), 125.9 (CH), 127.5 (CH), 128.6 (CH), 129.4 (C), 130.5 (C), 135.4 (C), 138.4 (C), 
138.7 (C), 140.9 (C), 142.0 (C) ppm. 
HRMS (EI) calcd. for C26H25N4 [M+NH4





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (3:1) as the 
eluent, affording pure 4.52 as a pale brown solid (31 mg, 38%). Unfortunately due to the small 
quantities obtained in this preliminary reaction and the failure of the subsequent reduction, we were 
unable to obtain an acceptable 13C spectrum. 
1H NMR (CDCl3, 300 MHz): δ 3.53 (s, 4H), 3.75 (s, 4H), 5.01 (s, 2H), 6.87-6.97 (m, 2H), 7.42-7.48 (m, 5H), 
7.56 (d, J= 6.1 Hz, 1H), 7.59-7.65 (m, 4H) ppm. 
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19F NMR (CDCl3, 282.4 MHz): δ -111.17 (s, 2F) ppm. 
HRMS (EI) calcd. for C33H26F2N5O [M+NH4





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (5:1) as the 
eluent, affording pure 4.56 as a dense colourless oil (47 mg, 40%). Unfortunately due to the small 
quantities obtained in this preliminary reaction and the failure of the subsequent deprotection, we 
were unable to obtain an acceptable 13C spectrum. 
1H NMR (CDCl3, 300 MHz): δ 1.42 (s, 18H), 1.46 (s, 18H), 2.60 (t, J= 7.1 Hz, 4H), 2.87 (t, J= 7.1 Hz, 4H), 
3.25 (dd, J= 12.4, 6.0 Hz, 4H), 3.45 (dd, J= 13.6, 7.8 Hz, 4H), 4.49 (br s, 2H), 4.66 (br s, 2H), 6.85 (d, J= 7.8 
Hz, 2H), 7.11 (s, 1H), 7.18-7.28 (m, 4H), 7.30-7.41 (m, 1H) ppm. 
19F NMR (CDCl3, 282.4 MHz): δ -113.39 (s, 2F) ppm. 
HRMS (EI) calcd. for C46H68F2N5O8 [M+NH4
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The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (4:1) as the 
eluent, affording pure 4.57 as a colourless solid (154 mg, 62%) with a melting point of 145-147 °C. 
1H NMR (CDCl3, 300 MHz): δ 1.42 (s, 18H), 2.06 (s, 6H), 2.83 (t, J= 7.1 Hz, 4H), 3.40 (t, J= 6.6 Hz, 4H), 3.50 
(s, 4H), 4.59 (br s, 2H), 6.84-6.96 (m, 4H), 7.03 (s, 1H), 7.46 (dd, J= 8.6, 6.8 Hz, 1H), 7.57 (d, J= 7.6 Hz, 2H)  
ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.0, 22.5, 28.4, 29.7, 36.2, 42.0, 79.3, 117.8, 127.3, 127.5, 127.9, 128.3, 
128.8, 129.7, 135.3, 137.4, 139.6, 140.6, 141.1, 142.0, 155.8 ppm. 
HRMS (EI) calcd. for C38H47N4O4 [M+H





The crude mixture was purified via flash column chromatography using n-hexane:EtOAc (5:1) as the 
eluent, affording pure 4.74 as a pale brown oil (79 mg, 57%). 
1H NMR (CDCl3, 300 MHz): δ 0.75 (t, J= 7.3 Hz, 3H), 0.83 (t, J= 7.3 Hz, 3H), 0.75 (t, J= 7.3 Hz, 2H), 1.15-
1.20 (m, 2H), 1.31-1.43 (m, 2H), 1.44-1.54 (m, 2H), 1.70-1.83 (m, 2H), 2.03 (s, 3H), 2.21 (t, J= 7.1 Hz, 2H), 
2.31-2.41 (m, 4H), 2.51-2.59 (m, 2H), 2.68 (t, J= 7.5 Hz, 4H), 3.02 (t, J= 7.4 Hz, 4H), 6.87 (d, J= 5.2 Hz, 2H), 
7.06 (d, J= 1.6 Hz, 2H), 7.08-7.13 (m, 2H), 7.17 (dd, J= 7.6, 1.3 Hz, 1H), 7.22-7.28 (m, 1H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 13.9 (CH3), 14.1 (CH3), 16.8 (CH2), 19.4 (CH2), 19.5 (CH2), 21.1 (CH3), 22.3 
(CH2), 24.5 (CH2), 26.8 (CH2), 31.4 (CH2), 31.5 (CH2), 32.7 (CH2), 33.1 (CH2), 33.4 (CH2), 35.7 (CH2), 118.9 
(C), 119.0 (C), 119.5 (C), 126.4 (CH), 126.7 (CH), 127.2 (CH), 127.3 (CH), 127.6 (CH), 128.2 (CH), 128.4 
(CH), 128.6 (CH), 129.0 (CH), 135.7 (C), 138.0 (C), 138.6 (C), 138.7 (C), 139.2 (C), 140.3 (C), 141.3 (C), 
141.5 (C), 142.2 (C) ppm. 
HRMS (EI) calcd. for C36H45N4 [M+NH4
+]: 533.3639, found: 533.3622. 
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 Nitrile reduction. The corresponding nitrile-bearing terphenyl (1 equiv) was placed in a sealable 
reaction vessel and dissolved in anhydrous THF (0.1 M). To this solution, BH3·THF (1 M in THF) (5 
equivalents for each nitrile group) was added and the reaction vessel was sealed and allowed to stir at 
80 °C for 5 days. Subsequently, the reaction mixture was cooled to room temperature and aqueous HCl 
(3 M, 6 equivalents for each nitrile) was added carefully and the reaction was stirred for a further 2 
hours open to air. Following this, the mixture was transferred to a round-bottomed flask washing with 
methanol and concentrated to dryness. The crude mixture was purified via flash column 
chromatography using mixtures of DCM and ammonia solution (7N in methanol) as eluents. The 
product was immediately dissolved in methanol (0.05 M) and treated with HCl (2N in Et2O) to form the 
corresponding hydrochloride salt, and the solvent evaporated. The resulting residue was dissolved in 
the minimum amount of methanol and precipitated by adding diethyl ether. The supernatant was then 
decanted off to leave the pure products. In some cases the free amine was treated instead with 
methanesulfonic acid (1 equivalent for each amine) or p-toluenesulfonic acid to form the corresponding 
mesylate or tosylate salts. 
 O-Benzyl hydrogenolysis. The amine hydrochloride salt (1 equiv) was dissolved in anhydrous 
methanol (0.05 M) and palladium over charcoal (10-20% w/w) (10 mol%) was added. The reaction flask 
was purged 5 times with hydrogen gas from a gas bag and subsequently stirred vigorously for 18 hours. 
Following this, the reaction was filtered through a standard HPLC filter and concentrated to dryness, 
washing with extra methanol. No further purification was necessary. 
 





hydrochloride salt, Ter.1 
4.23a was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7 N in MeOH) 
(10:1) as the eluent, affording pure Ter.1 as a pale brown solid (23 mg, 48%) with a melting point of 
255-257 °C. 
1H NMR (CD3OD, 300 MHz): δ 2.29 (s, 3H), 2.67-2.74 (m, 2H), 2.75-2.83 (m, 2H), 2.90 (h, J= 7.1 Hz, 4H), 
3.82 (s, 3H), 6.80-6.89 (m, 2H), 7.09-7.22 (m, 7H), 7.32-7.43 (m, 3H), 7.49 (d, J= 7.3 Hz, 2H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.3 (CH3), 35.5 (CH2), 38.2 (CH2), 43.2 (CH2), 44.2 (CH2), 56.1 (CH3), 71.6 
(CH2), 113.0 (CH), 113.3 (CH), 116.6 (CH), 128.4 (CH), 128.9 (CH), 129.3 (CH), 129.4 (C), 129.9 (CH), 130.0 
(CH), 131.1 (CH), 132.7 (CH), 132.9 (CH), 133.0 (CH), 136.0 (C), 136.4 (C), 136.7 (C), 139.3 (C), 139.9 (C), 
141.8 (C), 142.1 (C), 157.6 (C), 160.9 (C) ppm. 
HRMS (EI) calcd. for C31H35N2O2 [M+H
+]: 467.2693, found: 467.2671. 
 
 
2'',3-Bis(2-aminoethyl)-4''-methoxy-2'-methyl-[1,1':4',1''-terphenyl]-4-ol hydrochloride salt, 
Ter.2 
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Ter.1 was subject to the previously described procedure for O-benzyl hydrogenolysis, affording pure 
Ter.2 as a hygroscopic, dense brown oil (11 mg, 89%). 
1H NMR (CD3OD, 300 MHz): δ 2.30 (s, 3H), 2.93-3.08 (m, 6H), 3.22 (t, J= 7.1 Hz, 2H), 3.84 (s, 3H), 6.90 (d, 
J= 8.3 Hz, 3H), 7.06-7.20 (m, 5H), 7.24 (d, J= 7.7 Hz, 1H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.3 (CH3), 30.5 (CH2), 32.8 (CH2), 41.3 (CH2), 41.7 (CH2), 56.2 (CH3), 113.9 
(CH), 116.3 (CH), 116.6 (CH), 124.5 (C), 128.3 (CH), 130.8 (CH), 131.4 (CH), 132.7 (CH), 133.0 (CH), 133.2 
(CH), 134.5 (C), 136.4 (C), 136.7 (C), 137.1 (C), 141.3 (C), 142.2 (C), 156.4 (C), 161.2 (C) ppm. 
HRMS (EI) calcd. for C24H29N2O2 [M+H




hydrochloride salt, Ter.3 
4.23b was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(10:1) as the eluent, affording pure Ter.3 as a pale brown solid (22 mg, 41%) with a melting point of 
248-249 °C. 
1H NMR (CD3OD, 300 MHz): δ 2.34 (s, 3H), 2.96-3.13 (m, 6H), 3.17-3.25 (m, 2H), 5.22 (s, 2H), 7.17-7.45 
(m, 13H), 7.52 (d, J= 7.1 Hz, 2H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.3 (CH3), 30.6 (CH2),  32.6 (CH2),  41.1 (CH2),  41.8 (CH2),  71.8 (CH2), 
113.6 (CH), 126.5 (C), 128.1 (CH), 128.7 (CH), 129.3 (CH), 129.5 (CH), 129.6 (CH), 130.2 (CH), 131.0 (CH), 
131.1 (CH), 131.5 (CH), 132.0 (CH), 132.5 (CH), 133.1 (CH), 135.6 (C), 136.1 (C), 137.2 (C), 138.9 (C), 
141.8 (C), 142.1 (C), 144.0 (C), 157.7 (C) ppm. 
HRMS (EI) calcd. for C30H33N2O [M+H
+]: 437.2587, found: 437.2585. 
 




2'',3-Bis(2-aminoethyl)-2'-methyl-[1,1':4',1''-terphenyl]-4-ol hydrochloride salt, Ter.4 
Ter.3 was subject to the previously described procedure for O-benzyl hydrogenolysis, affording pure 
Ter.4 as a pale yellow solid (10 mg, 96%) with a melting point of 218-220 °C. 
1H NMR (CD3OD, 300 MHz): δ 2.34 (s, 3H), 2.96-3.10 (m, 6H), 3.25 (t, J= 7.4 Hz, 2H), 6.94 (d, J= 8.2 Hz, 
1H), 7.12-7.41 (m, 9H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 19.5, 28.7, 30.8, 39.5, 40.0, 114.5, 122.8, 126.2, 126.9, 127.6, 129.0, 
129.2, 129.6, 130.2, 130.6, 131.2, 133.0, 133.7, 135.4, 139.7, 140.7, 142.2, 154.6 ppm. 
HRMS (EI) calcd. for C23H27N2O [M+H
+]: 347.2118, found: 347.2122. 
 
 
2,2'-(3'-Methyl-[1,1':4',1''-terphenyl]-2,3''-diyl)bis(ethan-1-amine) hydrochloride salt, Ter.5 
4.23c was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(10:1) as the eluent, affording pure Ter.5 as a pale yellow solid (18 mg, 54%) with a melting point of 
171-175 °C. 
1H NMR (CD3OD, 300 MHz): δ 2.31 (s, 3H), 2.91-3.11 (m, 6H), 3.20-3.26 (m, 2H), 7.20-7.49 (m, 11H) 
ppm. 
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13C NMR (CD3OD, 75.5 MHz): δ 21.1 (CH3), 32.6 (CH2), 35.0 (CH2), 41.8 (CH2), 42.4 (CH2), 128.1 (CH), 
128.8 (CH), 128.9 (CH), 129.5 (C), 129.6 (CH), 130.4 (CH), 131.1 (CH), 131.3 (CH), 132.0 (CH), 132.5 (CH), 
135.5 (C), 137.1 (C), 138.5 (C), 142.1 (C), 142.4 (C), 143.9 (C), 144.0 (C) ppm. 
HRMS (EI) calcd. for C23H27N2 [M+H




tetrayl)tetrakis(ethan-1-amine) hydrochloride salt, Ter.6 
4.39a was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(10:1) as the eluent, affording pure Ter.6 as a white solid (17 mg, 34%) with a melting point of >300 °C. 
1H NMR (CD3OD, 400 MHz): δ 2.08 (s, 6H), 2.61-2.68 (m, 8H), 2.68-2.76 (m, 4H), 2.76-2.80 (m, 4H), 4.96 
(s, 2H), 6.93 (d, J= 10.3 Hz, 4H), 7.15-7.20 (m, 2H), 7.26 (dd, J= 8.5, 6.5 Hz, 1H), 7.34-7.47 (m, 3H), 7.52-
7.56 (m, 2H) ppm. 
13C NMR (CD3OD, 101 MHz): δ 20.1, 28.3, 32.3, 39.7, 40.1, 75.9, 127.9, 128.1, 128.1, 128.3, 130.6, 131.0, 
135.4, 136.8, 136.9, 137.5, 137.6, 140.2, 142.1, 154.5 ppm. 
HRMS (EI) calcd. for C35H45N4O [M+H








2'',3,5,6''-Tetrakis(2-aminoethyl)-2',6'-dimethyl-[1,1':4',1''-terphenyl]-4-ol hydrochloride salt, 
Ter.7 
Ter.6 was subject to the previously described procedure for O-benzyl hydrogenolysis, affording pure 
Ter.7 as a pale yellow solid (9 mg, 92%) with a melting point of >300 °C. 
1H NMR (CD3OD, 300 MHz): δ 2.12 (s, 6H), 2.77-2.87 (m, 4H), 2.94-3.03 (m, 4H), 3.06-3.16 (m, 4H), 3.18-
3.28 (m, 4H), 6.94-7.03 (m, 4H), 7.30-7.40 (m, 3H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.9 (CH3), 30.4 (CH2), 33.2 (CH2), 41.3 (CH2), 41.9 (CH2), 127.1 (C), 129.7 
(CH), 129.9 (CH), 130.0 (CH), 132.2 (CH), 135.1 (C), 137.2 (C), 138.8 (C), 139.0 (C), 142.4 (C), 144.0 (C), 
153.8 (C) ppm. 
HRMS (EI) calcd. for C28H39N4O [M+H




amine) hydrochloride salt, Ter.8 
4.39b was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(8:1) as the eluent, affording pure Ter.8 as a white solid (21 mg, 52%) with a melting point of >300 °C. 
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1H NMR (CD3OD, 300 MHz): δ 2.09 (s, 6H), 2.75-2.83 (m, 4H), 2.91-3.01 (m, 4H), 3.02-3.11 (m, 4H), 3.20-
3.29 (m, 4H), 3.87 (s, 3H), 6.91 (s, 2H), 6.99 (s, 2H), 7.09 (s, 2H), 7.30 (s, 1H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.7 (CH3), 33.4 (CH2), 34.9 (CH2), 41.8 (CH2), 42.4 (CH2), 56.3 (CH3), 115.3 
(CH), 129.3 (CH), 130.0 (CH), 130.4 (CH), 138.3 (C), 138.4 (C), 139.3 (C), 139.7 (C), 142.3 (C), 143.7 (C), 
161.2 (C) ppm. 
HRMS (EI) calcd. for NaC29H40N4O [M+Na




hydrochloride salt, Ter.9·Cl 
4.39c was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(8:1) as the eluent, affording pure Ter.9·Cl as a white solid (153 mg, 51%) with a melting point of >300 
°C. 
1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 2.78-2.87 (m, 4H), 2.93-3.03 (m, 4H), 3.03-3.12 (m, 4H), 3.21-
3.30 (m, 4H), 7.01 (s, 2H), 7.11 (s, 2H), 7.28-7.43 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.7 (CH3), 33.2 (CH2), 34.9 (CH2), 41.9 (CH2), 42.4 (CH2), 129.3 (CH), 
129.8 (CH), 129.9 (CH), 130.0 (CH), 130.1 (CH), 137.1 (C), 138.4 (C), 139.4 (C), 139.7 (C), 142.4 (C), 143.6 
(C), 143.9 (C) ppm. 
MALDI (TOF) calcd. for C28H39N4 [M+H
+]: 431.32, found 431.32. This sample failed to give the desired 
mass in HRMS electrospray ionisation sampling, although the major peak observed using MALDI 
coincided with the expected [M+H+] value. 
 





mesylate salt, Ter.9·Mes 
Melting point = >300 °C 
1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 2.70 (s, 12H), 2.81 (dd, J= 10.0, 5.9 Hz, 4H), 2.99 (dd, J= 10.0, 
6.2 Hz, 4H), 3.06 (dd, J= 9.7, 6.4 Hz, 4H), 3.25 (dd, J= 9.6, 6.5 Hz, 4H), 7.01 (s, 2H), 7.08 (d, J= 1.6 Hz, 2H), 
7.28-7.44 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 33.2 (CH2), 34.9 (CH2), 40.0 (CH3), 41.8 (CH2), 42.4 (CH2), 129.3 
(CH), 129.7 (CH), 129.8 (CH), 129.9 (CH), 130.0 (CH), 137.1 (C), 138.4 (C), 139.4 (C), 139.8 (C), 142.4 (C), 




tosylate salt, Ter.9·Tos 
Melting point = >300 °C 
1H NMR (CD3OD, 300 MHz): δ 2.08 (s, 6H), 2.36 (s, 12H), 2.79 (dd, J= 9.9, 5.7 Hz, 4H), 2.97 (dd, J= 10.0, 
6.2 Hz, 4H), 3.05 (dd, J= 9.6, 6.4 Hz, 4H), 3.23 (dd, J= 9.6, 6.3 Hz, 4H), 6.99 (s, 2H), 7.08 (d, J= 7.9 Hz, 2H), 
7.22 (d, J= 7.9 Hz, 8H), 7.28-7.41 (m, 4H), 7.69 (d, J= 8.2 Hz, 8H) ppm. 
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13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 21.7 (CH3), 33.2 (CH2), 34.9 (CH2), 41.9 (CH2), 42.4 (CH2), 127.3 
(CH), 129.3 (CH), 129.7 (CH), 129.8 (CH), 129.9 (CH), 130.0 (CH), 130.3 (CH), 137.1 (C), 138.4 (C), 139.4 




diyl)bis(propan-1-amine) hydrochloride salt, Ter.10 
4.47a was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(8:1) as the eluent, affording pure Ter.10 as a white solid (31 mg, 37%) with a melting point of 251-252 
°C. 
1H NMR (CD3OD, 300 MHz): δ 1.78-1.89 (m, 4H), 2.07 (s, 6H), 2.52-2.67 (m, 8H), 2.68-2.73 (m, 4H), 2.74-
2.83 (m, 4H), 4.95 (s, 2H), 6.91 (d, J= 10.3 Hz, 4H), 7.18 (d, J= 7.2 Hz, 2H), 7.25 (d, J= 6.5 Hz, 1H), 7.30-
7.45 (m, 3H), 7.52 (d, J= 7.0 Hz, 2H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.2, 28.5, 35.0, 38.2, 42.1, 44.0, 77.0, 128.4, 128.5, 128.9, 129.1, 129.6, 
129.7, 130.1, 136.7, 137.0, 137.1, 138.3, 139.1, 140.0, 141.8, 143.3, 155.5 ppm. 
HRMS (EI) calcd. for C37H50N4O [M+2H









hydrochloride salt, Ter.11 
Ter.10 was subject to the previously described procedure for O-benzyl hydrogenolysis, affording pure 
Ter.11 as a hygroscopic, dense pale yellow oil (14 mg, 90%). 
1H NMR (CD3OD, 300 MHz): δ 1.97-2.08 (m, 4H), 2.11 (s, 6H), 2.77-2.87 (m, 8H), 2.93-3.04 (m, 8H), 6.87 
(s, 2H), 6.98 (s, 2H), 7.29-7.44 (m, 3H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.8 (CH3), 28.9 (CH2), 29.5 (CH2), 33.2 (CH2), 41.0 (CH2), 41.9 (CH2), 129.6 
(CH), 129.9 (CH), 130.7 (CH), 134.2 (C), 137.1 (C), 138.7 (C), 138.9 (C), 143.0 (C), 144.0 (C), 153.1 (C) 
ppm. 
HRMS (EI) calcd. for C30H43N4O [M+H




amine) hydrochloride salt, Ter.12 
4.47b was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(8:1) as the eluent, affording pure Ter.12 as a pale yellow solid (41 mg, 57%) with a melting point of 
221-222 °C. 
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1H NMR (CD3OD, 300 MHz): δ 2.00-2.12 (m, 10H), 2.75-2.88 (m, 8H), 2.95-3.04 (m, 8H), 6.95-7.02 (m, 
4H), 7.20 (s, 1H), 7.31-7.43 (m, 3H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 19.8 (CH3), 29.0 (CH2), 31.4 (CH2), 32.1 (CH2), 39.0 (CH2), 40.1 (CH2), 126.8 
(CH), 126.9 (CH), 127.9 (CH), 128.0 (CH), 128.1 (CH), 135.3 (C), 136.5 (C), 137.4 (C), 141.1 (C), 141.2 (C), 
141.3 (C), 142.1 (C) ppm. 
HRMS (EI) calcd. for C30H42N4 [M+H





4.47c was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(8:1) as the eluent, affording pure Ter.13 as a dense colourless oil (24 mg, 43%). 
1H NMR (CD3OD, 300 MHz): δ 2.08 (s, 6H), 2.97-3.10 (m, 8H), 3.25 (dd, J= 9.4, 6.2 Hz, 4H), 7.03-7.09 (m, 
4H), 7.23 (dd, J= 5.9, 2.3 Hz, 1H), 7.29-7.40 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 32.6 (CH2), 34.9 (CH2), 41.8 (CH2), 42.3 (CH2), 128.7 (CH), 
129.2 (CH), 129.4 (CH), 129.6 (CH), 130.0 (CH), 131.0 (CH), 132.0 (CH), 135.5 (C), 137.7 (C), 139.7 (C), 
141.9 (C), 142.0 (C), 143.9 (C), 144.1 (C) ppm. 
HRMS (EI) calcd. for C26H33N3 [M+H
+]: 388.2747, found: 388.2737. 
 




2,2',2''-(3',5'-Dimethyl-[1,1':4',1''-terphenyl]-2,3'',5''-triyl)tris(ethan-1-amine) mesylate salt, 
Ter.13·Mes 
1H NMR (CD3OD, 300 MHz): δ 2.08 (s, 6H), 2.70 (s, 9H), 2.98-3.09 (m, 8H), 3.18-3.29 (m, 4H), 7.03-7.09 
(m, 4H), 7.23 (dd, J= 6.0, 2.2 Hz, 1H), 7.29-7.40 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 32.6 (CH2), 34.9 (CH2), 40.0 (CH3), 41.8 (CH2), 42.3 (CH2), 128.7 
(CH), 129.2 (CH), 129.4 (CH), 129.6 (CH), 130.0 (CH), 131.0 (CH), 132.0 (CH), 135.5 (C), 137.7 (C), 139.7 
(C), 141.9 (C), 142.0 (C), 143.8 (C), 144.1 (C) ppm. 
 
 
2,2',2''-(3',5'-Dimethyl-[1,1':4',1''-terphenyl]-2,3'',5''-triyl)tris(ethan-1-amine) tosylate salt, 
Ter.13·Tos 
1H NMR (CD3OD, 300 MHz): δ 2.07 (s, 6H), 2.35 (s, 9H), 3.02 (dd, J= 10.1, 6.4 Hz, 8H), 3.17-3.27 (m, 4H), 
7.00 (d, J= 1.4 Hz, 2H), 7.18-7.37 (m, 11H), 7.64-7.73 (m, 6H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 21.7 (CH3), 32.6 (CH2), 34.9 (CH2), 41.8 (CH2), 42.4 (CH2), 127.4 
(CH), 128.7 (CH), 129.2 (CH), 129.4 (CH), 129.6 (CH), 130.0 (CH), 130.3 (CH), 131.1 (CH), 132.0 (CH), 
135.6 (C), 137.7 (C), 139.7 (C), 141.9 (C), 142.0 (C), 142.3 (C), 143.8 (C), 143.9 (C), 144.1 (C)  ppm. 
 






4.47d was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(8:1) as the eluent, affording pure Ter.14 as a dense colourless oil (27 mg, 48%). 
1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 3.04 (dd, J= 9.4, 6.5 Hz, 6H), 3.24 (dd, J= 10.1, 5.6 Hz, 6H), 
7.04 (d, J= 1.3 Hz, 2H), 7.28 (d, J= 6.2 Hz, 2H), 7.39 (s, 2H), 7.44 (t, J= 7.4 Hz, 1H), 7.56 (d, J= 7.2 Hz, 2H) 
ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 34.9 (CH2), 35.1 (CH2), 42.3 (CH2), 42.4 (CH2), 127.3 (CH), 
127.5 (CH), 128.8 (CH), 129.0 (CH), 129.1 (CH), 130.0 (CH), 130.9 (CH), 137.9 (C), 138.6 (C), 138.9 (C), 
139.6 (C), 141.4 (C), 143.5 (C), 144.0 (C) ppm. 
LRMS (EI) calcd. for C26H34N3 [M+H
+]: 388.2, found: 388.2. This sample failed to give the desired mass in 
HRMS electrospray ionisation sampling, although the major peak observed using LRMS coincided with 
the expected [M+H+] value. 
 
 
2,2',2''-(2',6'-Dimethyl-[1,1':4',1''-terphenyl]-3,3'',5-triyl)tris(ethan-1-amine) mesylate salt, 
Ter.14·Mes 
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1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 2.71 (s, 9H), 3.04 (dd, J= 9.6, 6.3 Hz, 6H), 3.19-3.27 (m, 6H), 
7.03 (d, J= 1.4 Hz, 2H), 7.27 (d, J= 5.7 Hz, 2H), 7.39 (s, 2H), 7.44 (t, J= 8.0 Hz, 1H), 7.56 (d, J= 6.8 Hz, 2H) 
ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 34.9 (CH2), 35.1 (CH2), 39.9 (CH3), 42.3 (CH2), 42.4 (CH2), 127.3 
(CH), 127.5 (CH), 128.8 (CH), 129.0 (CH), 129.1 (CH), 130.0 (CH), 130.9 (CH), 137.9 (C), 138.6 (C), 138.9 
(C), 139.6 (C), 141.4 (C), 143.5 (C), 144.0 (C) ppm. 
 
 
2,2',2''-(2',6'-Dimethyl-[1,1':4',1''-terphenyl]-3,3'',5-triyl)tris(ethan-1-amine) tosylate salt, 
Ter.14·Tos 
1H NMR (CD3OD, 300 MHz): δ 2.08 (s, 6H), 2.35 (s, 9H), 3.03 (dt, J= 11.8, 5.8 Hz, 6H), 3.17-3.27 (m, 6H), 
6.99 (s, 2H), 7.21 (d, J= 7.9 Hz, 6H), 7.26 (d, J= 6.8 Hz, 2H), 7.39 (s, 2H), 7.44 (t, J= 7.9 Hz, 1H), 7.56 (d, J= 
1.8 Hz, 2H), 7.70 (d, J= 8.2 Hz, 6H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 21.6 (CH3), 21.7 (CH3), 34.9 (CH2), 35.1 (CH2), 42.3 (CH2), 42.4 (CH2), 127.3 
(CH), 127.4 (CH), 127.5 (CH), 128.8 (CH), 129.1 (CH), 130.0 (CH), 130.3 (CH), 130.9 (CH), 137.9 (C), 138.9 











diyl)bis(propan-1-amine) hydrochloride salt, Ter.25 
4.74 was subject to the previously described procedure for nitrile reduction. The crude mixture was 
purified via flash column chromatography using mixtures of DCM and ammonia solution (7N in MeOH) 
(10:1) as the eluent, affording pure Ter.25 as a dense pale brown oil (13 mg, 32%). 
1H NMR (CD3OD, 300 MHz): δ 0.76 (t, J= 7.4 Hz, 3H), 0.80 (td, J= 7.4, 4.2 Hz, 3H), 1.11-1.20 (m, 2H), 1.27-
1.52 (m, 9H), 1.67-1.76 (m, 1H), 1.89-1.98 (m, 3H), 2.04 (d, J= 5.5 Hz, 3H), 2.27-2.43 (m, 6H), 2.54 (td, J= 
7.5, 4.3 Hz, 1H), 2.66-2.70 (m, 1H), 2.72-2.87 (m, 6H), 2.99 (td, J= 7.0, 2.1 Hz, 1H), 6.88 (s, 2H), 6.95 (d, 
J= 1.3 Hz, 1H), 6.97-7.04 (m, 1H), 7.09-7.25 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 16.7, 17.0, 19.6, 23.8, 25.9, 27.6, 28.3, 30.7, 31.9, 35.6, 36.3, 36.8, 37.4, 
39.4, 43.8, 123.3, 130.0, 130.2, 130.3, 130.5, 130.7, 130.9, 131.2, 131.6, 131.8, 132.0, 132.1, 132.3, 
139.4, 139.6, 142.2, 142.5, 143.0, 143.6, 144.1, 144.4, 144.6, 144.9, 145.1, 145.3, 145.4, 145.8 ppm. 
HRMS (EI) calcd. for C36H50N3 [M-2H2+H
+]: 524.3999, found: 524.3975. 
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4.9.4. Further modifications. 




Guanidinylation. The corresponding amine hydrochloride salt (1 equiv) was suspended in 
anhydrous DCM (0.1 M) and dissolved with the minimum amount of anhydrous methanol. 
Triethylamine (1.5 equivalents for each amine) was added, followed by Goodman’s reagent (1.5 
equivalents for each amine). The mixture was stirred at room temperature for 16 hours, after which 
time water was added and the mixture transferred to a separating funnel. The organic phase was 
washed consecutively with water, saturated sodium bicarbonate solution and brine. The resulting 
organic phase was dried over anhydrous sodium sulphate, filtered and concentrated. The crude mixture 
was purified via flash column chromatography using mixtures of n-hexane and ethyl acetate as the 
eluent. 
Boc deprotection (Version 1). The Boc-protected terphenyl was dissolved in an aqueous 
solution containing HCl (4N in water: 4N in 1,4-dioxane, 1:1, 0.05 M) and stirred for 16h at 40 °C. After 
this time, the mixture was cooled to room temperature and concentrated to dryness. The resulting 
residue was dissolved in the minimum amount of methanol and precipitated by adding diethyl ether. 










Ter.9 was subject to the previously described procedure for guanidinylation. The crude mixture was 
purified via flash column chromatography using mixtures of n-hexane:ethyl acetate (7:1) as the eluent, 
affording pure 4.59a as a dense colourless oil (98 mg, 65%). 
1H NMR (CDCl3, 300 MHz): δ 1.43-1.49 (m, 72H), 2.03 (s, 6H), 2.65 (t, J= 7.1 Hz, 4H), 2.90 (t, J= 6.7 Hz, 
4H), 3.51 (dd, J= 11.6, 6.7 Hz, 4H), 3.74 (dd, J= 11.6, 6.4 Hz, 4H), 6.86 (s, 2H), 6.99 (d, J= 1.4 Hz, 2H), 7.09 
(s, 1H), 7.18-7.29 (m, 4H), 8.20 (br s, 2H), 8.42 (br s, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.0, 27.8, 28.0, 28.1, 28.3, 32.7, 35.2, 41.8, 42.2, 79.1, 127.4, 127.5, 
127.6, 128.0, 128.1, 136.0, 136.9, 137.9, 139.1, 140.4, 141.7, 142.2, 153.0, 153.1, 156.0, 156.2, 163.5 
ppm. 
HRMS (EI) calcd. for C72H112N12O16 [M+2H




hydrochloride salt, Ter.17 
4.59a was subject to the previously described procedure for Boc deprotection, affording pure Ter.17 as 
a hygroscopic, dense, colourless oil (32 mg, 65%). 
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1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 2.71 (t, J= 7.2 Hz, 4H), 2.98 (t, J= 6.8 Hz, 4H), 3.29 (t, J= 7.0 Hz, 
4H), 3.57 (t, J= 6.8 Hz, 4H), 6.98 (s, 2H), 7.07 (s, 2H), 7.25-7.40 (m, 5H), 7.51 (t, J= 5.5 Hz, 1H)  ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 19.9 (CH3), 32.4 (CH2), 34.6 (CH2), 42.0 (CH2), 42.5 (CH2), 127.5 (CH), 
127.6 (CH), 128.0 (CH), 128.1 (CH), 136.2 (C), 136.3 (C), 138.0 (C), 138.9 (C), 140.8 (C), 141.2 (C), 142.3 
(C), 157.0 (C), 157.1 (C), 157.2 (C), 157.3 (C) ppm. 
HRMS (EI) calcd. for C32H48N12 [M+2H





Ter.12 was subject to the previously described procedure for guanidinylation. The crude mixture was 
purified via flash column chromatography using mixtures of n-hexane:ethyl acetate (7:1) as the eluent, 
affording pure 4.59b as a dense colourless oil (61 mg, 71%). 
1H NMR (CDCl3, 300 MHz): δ 1.42-1.52 (m, 72H), 1.90-2.10 (m, 10H), 2.61-2.74 (m, 8H), 3.44-3.57 (m, 
8H), 6.87 (s, 2H), 6.91 (d, J= 1.3 Hz, 2H), 7.00 (s, 1H), 7.18-7.29 (m, 3H), 8.19 (t, J= 4.3 Hz, 2H), 8.39 (t, J= 
4.9 Hz, 2H) ppm. 
13C NMR (CDCl3, 75.5 MHz): δ 21.1, 28.1, 28.3, 30.7, 32.7, 40.6, 41.8, 53.4, 79.1, 79.3, 82.9, 83.1, 126.7, 
126.9, 127.3, 127.5, 128.1, 135.9, 136.9, 137.8, 140.6, 141.2, 141.4, 142.2, 153.1, 153.3, 156.0, 156.2, 
163.5, 163.6 ppm. 
HRMS (EI) calcd. for C74H116N12O16 [M+2H
+]: 714.4311, found: 714.4314. 
 






4.59b was subject to the previously described procedure for Boc deprotection, affording pure Ter.18 as 
a hygroscopic, dense, colourless oil (18 mg, 59%). 
1H NMR (CD3OD, 300 MHz): δ 1.91-2.04 (m, 4H), 2.09 (s, 6H), 2.67-2.83 (m, 8H), 3.21-3.33 (m, 8H), 6.98 
(s, 4H), 7.16 (s, 1H), 7.27-7.38 (m, 3H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 19.9 (CH3), 30.4 (CH2), 32.2 (CH2), 32.4 (CH2), 40.6 (CH2), 41.9 (CH2), 126.8 
(CH), 126.9 (CH), 127.5 (CH), 127.6 (CH), 128.1 (CH), 136.2 (C), 136.3 (C), 137.9 (C), 140.9 (C), 141.1 (C), 
141.7 (C), 142.3 (C), 157.1 (C), 157.3 (C) ppm. 
HRMS (EI) calcd. for C34H52N12 [M+2H
+]: 314.2213, found: 314.2220. 
 




Boc deprotection (Version 2). Previously synthesised 4.57 (62 mg, 0.1 mmol) was dissolved in 
anhydrous DCM (4 ml) and trifluoroacetic acid (1 ml) was added slowly at room temperature. The 
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resulting mixture was stirred for 16h and, following this, the mixture was basified with saturated 
sodium bicarbonate solution, diluted with DCM (5 ml) and transferred to a separating funnel. The 
mixture was washed consecutively with saturated sodium bicarbonate solution (3 x 5 ml), and brine (5 
ml). The organic phase was then dried over anhydrous sodium sulphate, filtered and concentrated to 
dryness. The residue was then used directly in the next step without further purification. 
Guanidinylation. The crude product of the previous deprotection was subjected to the 





The crude mixture was purified via flash column chromatography using mixtures of n-hexane:EtOAc 
(5:1) as the eluent, affording 4.59c as a white solid (50 mg, 55% from 4.57). An unknown impurity was 
observed upon characterisation of this compound, and unfortunately we were unable to obtain an 
acceptable 13C spectrum. 
1H NMR (CDCl3, 300 MHz): δ 1.35-1.53 (m, 36H), 1.95-2.12 (m, 6H), 2.85-3.10 (m, 4H), 3.48-3.56 (m, 4H), 
3.70-3.95 (m, 4H), 6.82-7.01 (m, 4H), 7.48-7.63 (m, 4H) ppm. 
HRMS (EI) calcd. for C50H67N8O8 [M+H
+]: 907.5076, found: 907.5061. 
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Ter.9 (25 mg, 0.06 mmol) was suspended in anhydrous DCM (3 ml) and benzyl isocyanate (0.08 ml, 0.6 
mmol) was added at room temperature. The mixture was stirred for 16 hours at room temperature and 
after this time the solvent was decanted away, washing twice with methanol (2 x 3 ml). The resulting 
solid (44 mg, 77%) was difficult to handle and was insoluble in most common solvents, although we 
found it was slightly soluble in DMSO. For this reason, only the most characteristic NMR signals are 
listed below.  
1H NMR (DMSO-d6, 300 MHz): δ 1.98 (s, 6H), 2.35-2.49 (m, 4H), 2.61-2.79 (m, 4H), 3.04-3.17 (m, 4H), 
3.20-3.35 (m, 4H), 4.09-4.24 (m, 8H), 5.85 (t, J= 6.0 Hz, 1H), 5.97 (t, J= 6.0 Hz, 1H),  6.28 (t, J= 6.2 Hz, 
1H),  6.42 (t, J= 6.2 Hz, 1H), 6.88 (d, J= 12.0 Hz, 4H), 7.04 (s, 1H), 7.10-7.29 (m, 22H) ppm. 
HRMS (EI) calcd. for C60H67N8O4 [M+H
+]: 963.5280, found: 963.5298. 
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 Boc deprotection (Version 2). Terphenyl 4.57 (200 mg, 0.32 mmol) was subjected to the same 
conditions as described previously for the Boc deprotection (see Boc deprotection (Version 2), section 
4.9.4.2). The crude product was subject to the next step without further purification. 
 N-Alkylation. The crude product of the previous step was dissolved in acetonitrile (5 ml) in a 
sealable reaction vessel, and triethylamine (0.18 ml, 1.24 mmol) and 2-iodoethanol (0.12 ml, 1.6 mmol) 
were added. The reaction vessel was then sealed and the reaction was heated at 80 °C for 20h. After 
this time, the reaction was cooled to room temperature and the reaction was neutralised with 
saturated ammonium chloride solution. The mixture was transferred to a separating funnel and the 
mixture was extracted with ethyl acetate (2 x 10 ml). The combined organic layers were washed with 
saturated sodium bicarbonate solution (3 x 5 ml), dried over anhydrous sodium bicarbonate, filtered 
and concentrated to dryness. Further purification was unnecessary, and the desired 4.62 was obtained 
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1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 3.04-3.17 (m, 5H), 3.22-3.28 (m, 5H), 3.35-3.44 (m, 3H), 3.62 
(s, 4H), 3.82-3.88 (m, 3H), 6.92-7.18 (m, 4H), 7.35-7.59 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 19.8, 21.4, 27.6, 31.7, 33.1, 40.5, 49.4, 56.5, 118.0, 127.7, 128.1, 128.4, 
128.5, 130.2, 135.7, 136.3, 137.0, 137.7, 137.9, 141.3, 141.5, 141.7, 141.9 ppm. 
HRMS (EI) calcd. for C32H39N4O2 [M+H
+]: 511.3068, found: 511.3058. 
 
 Nitrile reduction. Hydroxyethylamine derivative 4.62 (51 mg, 0.1 mmol) was subjected to the 





The crude mixture was purified via flash column chromatography using mixtures of DCM and ammonia 
solution (7N in MeOH) (4:1-2:1) as the eluent, affording pure Ter.21 as a dense yellow oil (18 mg, 35%). 
1H NMR (CD3OD, 300 MHz): δ 2.10 (s, 6H), 2.83 (dd, J= 9.9, 5.8 Hz, 4H), 2.99 (dd, J= 10.0, 5.8 Hz, 4H), 
3.05-3.20 (m, 4H), 3.22-3.30 (m, 6H), 3.35-3.56 (m, 3H), 3.82-3.99 (3H), 7.00 (s, 2H), 7.12 (d, J= 7.3 Hz, 
2H), 7.30-7.44 (m, 4H) ppm. 
13C NMR (CD3OD, 75.5 MHz): δ 19.9, 31.3, 31.7, 33.0, 40.1, 40.6, 49.4, 56.6, 127.6, 127.9, 128.1, 128.2, 
135.3, 136.6, 137.5, 137.7, 137.9, 140.6, 141.8, 142.1 ppm. 
HRMS (EI) calcd. for C32H47N4O2 [M+H
+]: 519.3694, found: 519.3686. 
 
